$u^{\scriptscriptstyle b}$

^b UNIVERSITÄT BERN

Graduate School for Cellular and Biomedical Sciences University of Bern

Pulmonary disease, its risk factors and necessity for long-term follow-up care in childhood cancer survivors


PhD Thesis submitted by Maria Otth from Meiringen BE

for the degree of Doctor of Medicine and Philosophy (MD,PhD)

Supervisor Prof. Dr. Claudia E Kuehni Institute of Social and Preventive Medicine Faculty of Medicine of the University of Bern

Co-advisor Prof. Dr. Philipp Latzin Department of Pediatrics, Inselspital, University Hospital of Bern Faculty of Medicine of the University of Bern

Accepted by the Faculty of Medicine, the Faculty of Science and the Vetsuisse Faculty of the University of Bern at the request of the Graduate School for Cellular and Biomedical Sciences



To Ätti

Abstract

Treatment for childhood cancer puts the young patients at risk to develop adverse health outcomes. These adverse health outcomes can develop acute, already during treatment, or slowly over years to decades after completion of treatment. They can be of transient nature or long-lasting and chronic. Adverse health outcomes can potentially affect every organ system, including the lung. The term late effects is used to describe this heterogeneity of adverse health outcomes. Pulmonary late effects contribute to a higher morbidity and mortality in childhood cancer survivors compared to siblings or the general population.

Before starting this PhD project, knowledge on self-reported pulmonary symptoms, diseases and pulmonary function trajectories in Swiss childhood cancer survivors treated with hematopoietic stem cell transplantation (HSCT) was lacking. These survivors are often exposed to at least one known lung toxic treatment modality and additionally receive treatment of different intensity before HSCT. Therefore, this population is especially at risk to develop pulmonary late effects. Information on lung function trajectories was also lacking for Swiss childhood cancer survivors treated with known lung toxic chemotherapy or radiotherapy to the chest.

This PhD thesis primarily aimed to answer the open questions on frequency, severity, and risk factors for pulmonary late effects in childhood cancer survivors, especially in those treated with HSCT. To answer these questions data from the Swiss Childhood Cancer Registry (SCCR), the nested Swiss Childhood Cancer Survivor Study (SCCSS), and from medical records were used. The national, population-based SCCR registers all Swiss children and adolescents, who have been diagnosed with cancer since 1976 and below the age of 21 years. The SCCSS is a questionnaire-based survey including all \geq 5-year survivors registered in the SCCR and incorporates a section on pulmonary health. For information on exact treatment exposure, HSCT, and pulmonary function test results, I searched the medical records of all eligible survivors in all Swiss Pediatric Oncology centers. To answer the question on pulmonary function trajectories, I could only rely on retrospectively collected data, which is subject to some unavoidable limitations. Therefore, the second aim of this PhD project was to set up the "Swiss Childhood Cancer Survivor Study - Follow-up", a national, prospective, multicenter study to overcome the limitations of retrospective data collection in the future.

Four publications answer the main questions of my thesis. The following paragraphs summarize the methods used and the main findings of each publication.

Publication I: Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study (Chapter 4.1): I described changes in transplant characteristics in children and adolescents in Switzerland over the study period of 30 years. I compared self-reported pulmonary outcomes, including diseases and symptoms, in childhood cancer survivors exposed to HSCT to matched controls not exposed to HSCT by using data from the SCCSS. I additionally analyzed risk factors for pulmonary outcomes in the transplanted group. I collected the information on risk factors from the medical records. I could show that transplant characteristics changed over the study period with a reduced use of lung toxic treatment modalities, such as total body irradiation. Survivors exposed to HSCT reported pulmonary outcomes as frequent as not exposed survivors (20% versus 18%). Pneumonia was the most frequent pulmonary outcome in both groups. The risk factor analysis pointed to older age at diagnosis and thoracic surgery as possible risk factors for the reporting of pulmonary outcomes.

Publication II: Pulmonary function in long-term Swiss childhood cancer survivors after hematopoietic stem cell transplantation (Chapter 4.2) (preliminary data as this manuscript was in progress): I described pulmonary function in childhood cancer survivors who survived ≥ 5 years from diagnosis and were treated with HSCT. I searched all available pulmonary function test results in the medical records of eligible survivors. I reported the longitudinal trajectory of six selected pulmonary function parameters (forced expiratory volume in first second [FEV1], functional vital capacity [FVC], total lung capacity [TLC], vital capacity [VC], diffusion capacity for carbon monoxide [DLCO], resistance). With the exception of resistance, I converted the parameters into age, height, weight, and sex standardized z-scores. I described the longitudinal trajectory of each of these six parameters and performed risk factor analysis with a multivariable linear regression model, taking time since cancer diagnosis and clustering per survivor into account. In this model each risk factor was described in relation to a male reference patient not exposed to any of the risk factors. I could show that the mean value of each of the six selected parameters was wavelike over the observed 15 years but did visually not show a prominent decrease or increase. In the regression model FEV1, FVC, and TLC decreased continuously with every additional year from cancer diagnosis in the male reference patient (FEV1 zscore -0.06 [95%CI -0.09 - -0.03], FVC -0.06 [95%CI -0.09 - -0.02], TLC -0.092 [95%CI -0.22 - 0.04]). RV and DLCO showed a trend to increasing z-scores every year (RV z-score 0.11 [95%CI -0.02 - -0.23], DLCO 0.02 [95%CI -0.08 - 0.11]). Taking the risk factors into account, none had a significant effect on the annual change of FEV1, FVC, and DLCO z-score. Allogeneic HSCT led to a significant annual increase in TLC z-score (0.216 [95%CI 0.059-0.373]) compared to autologous HSCT and relapse to a significant annual reduction in RV z-score (-0.231[95%CI -0.405 - -0.055]). The starting point of the regression line, corresponding to the time of diagnosis, was significantly lower for FEV1 z-score in case of female gender and radiotherapy (gender: p=0.013; radiotherapy: p=0.001) and for FVC z-score in case of radiotherapy (p<0.001). The starting point for TLC, RV, and DLCO z-scores were not significantly influenced by any risk factor.

Publication III: Lung function in Swiss childhood cancer survivors – a retrospective study (Chapter 4.3): I assessed changes in lung function trajectories in survivors exposed to known lung toxic chemotherapy or thoracic radiotherapy. I used the Global Lung Function Initiative 2012 reference values to calculate the z-score for FEV1, FVC, and DLCO and the reference equations by Stocks/Quanier to calculate TLC z-scores. Besides plotting the parameters for FEV1 and FVC over time, I used a linear mixed effects regression model with random intercept and random slope to take the effect of each individual risk factor on the changes of FEV1 and FVC and clustered by survivor into account. FEV1 and FVC z-scores did not prominently change over the observed time after first exposure to the lung toxic treatment. However, the median z-score was constantly below the expected. In the regression analysis I could show that treatment with thoracic surgery was associated with a lower FVC z-score at time zero (=first exposure; z-score -1.19 [95%CI -2.03 - -0.36]). None of the risk factor s had a significant effect on FEV1 z-score (0.11 [95%CI 0.03 – 0.18]). None of the risk factors was significantly associated with a change in the annual FVC z-score.

Publication IV: The Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) – Protocol of a prospective, national, multicenter cohort study (Chapter 4.4): Clinical data generated and collected prospectively and in a standardized way can facilitate current and future research in the field on late effects in childhood cancer survivors. Therefore, I have designed the SCCSS-FollowUp. The SCCSS-FollowUp has an umbrella-like design, under which various projects can be performed. The important key feature to fall under the umbrella of SCCSS-FollowUp is, that only data generated during regular follow-up care visits of childhood cancer survivors can be collected and reused for research. For this study proposal I have written the study protocol, the study information and informed consent in four versions (children, parents, adolescents, and adults) and in two languages (German and French). To start the project on pulmonary late effects as the first one, I have developed a lung-specific questionnaire in three versions (parents, adolescents, and adults) and a clinical report form for clinicians. In addition, I have set up the RedCap database for the whole SCCSS-FollowUp project. All these steps are summarized in the manuscript of the study protocol and will be publicly available.

Within my PhD I could show that one fifths of \geq 5-year childhood cancer survivors exposed to HSCT reported at least one pulmonary disease or symptom at a median of 10 years from diagnosis, with pneumonia being the most frequent. This proportion was the same as in survivors not exposed to HSCT. In this cohort of long-term survivors exposed to HSCT, FEV1, FVC, and TLC z-scores showed a slight decrease with every additional year from diagnosis. This constant decrease over time was modified by additional risk factors, which either aggravated or slowed down the annual deterioration. For survivors exposed to lung toxic chemotherapy or radiotherapy to the chest, the picture was very similar with a steady decrease for FEV1 and increase for FVC z-scores in the linear model. These changes were modified by additional factors, which finally led to an overall deterioiration or improvement over time. Both studies highlighted that deterioration in selected pulmonary function parameters was multifactorial, as some factors tended to contribute to an annual deterioration of z-scores, others to an improvement. For example FVC decreased by -0.058 z-scores per year, independent of the additional risk factors. Female gender mitigated this decrease. Female gender was associated with an annual improvement of 0.04 FVC z-scores compared to males. Relapsed disease on the other hand led do an annual decrease (-0.021). Finally, a female patient who suffered from relapsed disease would show an annual decrease of -0.039 in the FVC z-score. Taking into account that these survivors have many years of life ahead, even a small annual decrease becomes highly relevant. These annual changes in pulmonary function parameters in both cohorts highlight the importance of long-term follow-up care in survivors at risk. The important clinical questions on who is at risk and needs surveillance, with which surveillance modality, and at what frequency are not answered conclusively today. We have started answering these questions within the framework of the International Guideline Harmonization Group (IGHG) (see Chapter 5.4.2), where I am involved as a co-coordinator.

Content

Abstract	Ι
Content	V
Abbreviations	VIII
Legend of figures and tables	IX

Chapter 1 – Introduction	1
1.1 History of childhood cancer and situation in Switzerland	3
1.2 Late effects in childhood cancer survivors	5
1.3 Pulmonary late effects in childhood cancer survivors	6
1.3.1 Anatomical structure of the lung	6
1.3.2 Risk factors for pulmonary diseases	6
1.3.2.1 Chemotherapeutic agents	8
1.3.2.2 Radiotherapy to the chest	9
1.3.2.3 Surgery of the lung and thorax	11
1.3.2.4 Hematopoietic stem cell transplantation (HSCT)	12
1.3.3 Pathomechanism of pulmonary damage	13
1.3.4 Pulmonary dysfunction	16
1.3.5 Methods to assess pulmonary function	16
1.4 Aftercare in childhood cancer survivors	20
1.4.1 Pulmonary long-term follow-up (LTFU) care	22
Chapter 2 – Aims of this PhD Thesis	23
2.1 General aim	25
2.2 Specific aims	26
2.2.1 Publication I: Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study	26
2.2.2 Publication II: Pulmonary function in long-term Swiss childhood cancer survivors after hematopoietic stem cell transplantation	26
2.2.3 Publication III: Lung function in Swiss childhood cancer survivors – a retrospective study	27
2.2.4 Publication IV: The Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS- FollowUp) – Protocol of a prospective, national, multicenter cohort study	27

Chapter 3 – Methods	29
3.1. Cohort description	31
3.1.1 Childhood Cancer Registry	31
3.1.2 Swiss Childhood Cancer Survivor Study (SCCSS)	31
3.1.3 SCCSS-FollowUp	32
3.2. Inclusion criteria for the publications in this thesis	32
3.3. Data collection	33
3.3.1 Questionnaire data (Publication I)	33
3.3.2 Medical data (Publication I, II, III)	34
3.3.3 Lung function data (Publication II, III)	34
Chapter 4 – Results	37
4.1. Publication I	39
4.2. Publication II	67
4.3. Publication III	105
4.4. Publication IV	149
Chapter 5 – Discussion and outlook	169
5.1. Summary of findings	. 171
5.2. Strength and limitations	. 172
5.3. Interpretation and implications for childhood cancer survivors and health care professionals	176
5.4. Outlook	178
5.4.1 Pilot Project SCCSS-FollowUp	178
5.4.2 International Guideline Harmonization Group – Pulmonary Dysfunction	180
5.5. Conclusion	191
Chapter 6 – References	193
Chapter 7 – Co-Author publications	201
7.1. Co-Author publication I	203
7.2. Co-Author publication II	221
7.3. Co-Author publication III	233
7.4. Co-Author publication IV	247
Chapter 8 – Other activities	279
8.1 Grant applications	281
8.2 Teaching activities	281
8.3 Peer review activity	281
8.4 International Guideline Harmonization Group – Metabolic Syndrome	281

8.5 Life After Childhood Cancer (LACC) research group	. 282
8.6 Young SIOPE – Essential Medicines project	. 282
Appendix A – Questions on pulmonary health and smoking from the SCCSS used in publication I	283
Appendix B – Data extraction sheet used for publication I and publication II	. 287
Appendix C – Documents for SCCSS-FollowUp	. 295
Appendix D – International Guideline Harmonization Group – Pulmonary Dysfunction	. 315
Appendix E – Acknowledgements	. 351
Appendix F – Curriculum vitae and list of publications	. 355
Appendix G – Declaration of originality	. 363

Abbreviations

Chronic Graft versus Host Disease
Childhood cancer survivor(s)
Childhood Cancer Registry
Confidence interval
Carbon monoxide
Diffusion Capacity of the lung for carbon monoxide
European Community of Coal and Steel
Forced expiratory volume in one second
Forced vital capacity
Gray
Human Leukocyte Antigen
Hematopoietic stem cell transplantation
International Classification of Childhood Cancer, version 3
International Guideline Harmonization Group
Long-term Follow-up
Odds ratio
Residual volume
Swiss Childhood Cancer Registry
Swiss Childhood Cancer Survivor Study
Swiss Childhood Cancer Survivor Study – Follow-up
Swiss Pediatric Oncology Group
Total body irradiation
Total lung capacity
Relative One-second-capacity (FEV1/FVC)
Vital capacity

Legend of figures and tables

Legend of figures

Figure 1: Dr. Sidney Farber Figure 2: Survival of patients diagnosed at age 0-14 years and registered in the Childhood Cancer Registry, stratified by period of diagnosis Figure 3: Structure of distal vasculature and airways Figure 4: Structure of the bronchial tree Figure 5: Radiation fields putting childhood cancer survivors at risk for pulmonary late effects Figure 6: Changes in irradiation fields for a patient with Hodgkin lymphoma over time Figure 7: Depth-dose curve of photon and proton radiation Figure 8: Comparison of proton radiation and Intensity Modulated Radiation Therapy (IMRT) with Photons Figure 9: Illustration of the different pulmonary structures, whose damage can lead to pulmonary late effects Figure 10: Volume-time graph Figure 11: Display formats of spirometry Figure 12: Spirometry Figure 13: Flow-pressure-curve Figure 14: Body plethysmography Figure 15: Recommendations from the COG LTFU guidelines (version 5.0) to screen for pulmonary fibrosis after exposure to chemotherapy Figure 16: Illustration of the normal distribution of the FEV1 z-score and the respective percentile Figure 17: Cohorts and data sources used with their respective inclusion criteria for the first author publications of this thesis Figure 18: Pictogram of the umbrella-structure of SCCSS-FollowUp study Figure 19: PRISMA flow diagram describing the selection of finally eligible publications for IGHG on pulmonary dysfunction Figure 20: Risk of bias assessment of observational studies, according to IGHG

Legend of tables

Table 1:	Summary of differences between autologous and allogeneic hematopoietic stem cell		
	transplantation		
Table 2:	List of risk factors for pulmonary late effects and resulting diseases		
Table 3:	Explanation of important lung volumes assessed during spirometry		
Table 4:	Recommended surveillance measurements and frequency by LTFU care guideline		
Table 5:	Recommended counseling for survivors at risk for pulmonary dysfunction by LTFU		
	care guideline		
Table 6:	Criteria included in the assessment of pulmonary function quality		
Table 7:	Eligible childhood cancer survivors for first phase of SCCSS-FollowUp		
Table 8:	GRADE quality assessment according to IGHG		
Table 9:	Overall conclusion of evidence on "Who needs surveillance" by PICO question and by		
	pulmonary outcome		

Chapter 1 - Introduction

1.1 History of childhood cancer and situation in Switzerland

Cancer in childhood and adolescence is a rare diseases with differences in frequency and types of cancer depending on the geographical area (1). The annual incidence rate in children and adolescents aged 0-19 years is 186.6 per 1 million children per year in the US (2), 13.4 per 100'000 children aged 0-14 years per year in Europe (3), and 17.3 per 100'000 children aged 0-14 years in Switzerland. This leads to 250-300 children and adolescents under the age of 18 newly diagnosed with cancer in Switzerland per year (4).

The first step in the treatment of childhood cancer was surgery in the 1940s in children diagnosed with solid tumors. Local control improved through the addition of radiotherapy in the following years and decades. It was recognized that preoperative irradiation reduces the risk of tumor dissemination during surgery, but distant metastasis remained a major problem. A milestone in pediatric oncology was the discovery of the anti-leukemic effect of aminopterin, an antifolic agent, introduced by Dr. Sidney Farber in 1948 (5). Until that time the diagnosis of leukemia, first described in a child in 1860 by Michael Anton Biermer, was inevitable lethal (6). Farber's discovery led to high activity in the development of other antineoplastic drugs and their use in solid tumors and leukemias. The introduction of chemotherapeutic agents gave the possibility to treat the distant metastasis. In the following years and decades, oncologists also started using combinations of antineoplastic drugs and in the 1980s bone marrow transplantation became feasible in children.



Figure 1: Dr. Sidney Farber (Photo from the National Institutes of Health)


Parallel to the progress in anti-cancer treatment, progress in supportive care contributed largely to increasing overall survival. Supportive care includes the management of anticipated toxicities, such as mesna for cyclophosphamide-toxicity to the urinary tract or folinic acid as rescue after high-dose methotrexate, management of emesis, management of pain during procedures, or antibacterial, antifungal, and antiviral prophylaxis in neutropenic patients.


From the very beginning it was evident, that treatment of pediatric cancer needs interdisciplinary care; in most cases neither the surgeon, the radiotherapist nor the oncologist alone can be successful. It was

also recognized that due to the rarity of pediatric cancer, relevant results and the required patient numbers can only be achieved through treatment within cooperative clinical trials internationally and at centers with experience.

Tumor-specific clinical trials/protocols guide oncologists through the whole cancer treatment. The protocols specify examinations and tests to confirm the diagnosis, to determine the extent of disease, to search for metastasis, and to assess organ function at baseline. This is followed by criteria to define the disease stage and to perform risk stratification. Then the protocol contains the detailed treatment plans for each risk group and time points and respective tests for the response assessment. Finally, the protocols also include a section on recommendations for follow-up care. These recommendations are normally outlined for 5-10 years following completen of treatment and mainly focus on relapsed disease or disease progression.

The improvements in diagnosing and treating childhood cancer and the management of toxicities has led to increased survival also in Swiss childhood cancer patients. One important reason might be, thet Switzerland, represented by the Swiss Pediatric Oncology Group (SPOG), also participates and treats children according to international treatment protocols. The 10-year survival rate over all diagnostic groups was 62% for patients diagnosed 1976 - 1988 and improved to 87% for those diagnosed 2009 - 2018 (**Figure 2**) (4). Even though the overall survival is high, it might be much lower for some diseases (e.g. DIPG or high-risk neuroblastoma) or even higher for others (e.g. standard-risk ALL, low grade glioma).





The treatment of children and adolescents diagnosed with cancer up to the age of 18 years takes place in one of nine pediatric oncology centers in Switzerland (Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, St. Gallen, Zurich).

1.2 Late effects in childhood cancer survivors

The term "childhood cancer survivor" (CCS) is used in most publications and research projects to describe former childhood cancer patients which are still alive five or more years after cancer diagnosis (7-9). This definition is also used in this thesis.

The term late effects refers to chronic medical conditions related to the cancer itself, its treatment, or treatment-related complications. Late effects can develop from acute toxicities or events during the treatment as chronification, or they develop newly years to decades after completion of treatment. Potentially every organ system can be affected by late effects and the severity range from asymptomatic and only detectable when specific tests are performed (e.g. pulmonary function testing, echocardiography, hormonal level in the blood) to mild, moderate, severe, life-threatening or even death (10, 11). The risk for each patient to develop late effects largely depends on the type of cancer, the age at diagnosis, and the treatment received, but also genetic factors or complications during the treatment are important factors.

The immense progress in pediatric oncology in the 1950s to 70s with rapidly rising survival rates, partly led to the motto "more treatment is better treatment". But Giulio d'Angio already raised concerns and worries about consequences and late effects of treatment given successfully to children and adolescents in 1974: "It is clear that the child cured of cancer must be followed for life, no so much because late recurrence of disease is feared as to permit early detection of the delayed consequences of radio- and chemotherapy". It is the non-targeted way of action of most chemotherapeutic agents and irradiation, which do not only destroy cancer cells but also cells of healthy tissue and thereby causes acute toxicities and late effects. In view of this, Giulio d'Angio stated that reduction of treatment intensity is necessary "to the minimum necessary to achieve cure" and that age, stage, site of origin, histologic type and grade have to be taken into account to stratify treatment intensity. Today, some of his considerations are reality:

- Where applicable, all treatment protocols include treatment stratification based on age, stage, biology and genetics, and treatment intensity varies by risk group.
- Randomized questions assess whether dose reduction of some chemotherapeutics is feasible without compromising the survival rate (e.g. randomization of 2 versus 4 doses of daunorubicine in AIEOP-BFM ALL 2009 trial).
- Most radiotherapeutic fields could be reduced and are more tailored to the initial tumor volume; in some cases irradiation can even be omitted completely (e.g. some low stages of Hodgkin's lymphoma).

But even today we have room for improvement and Giulio d'Angios statement "**Cure is not enough**" is still valid. This is because many drugs inevitable to treat cancer in childhood are still the same as in the very beginning and the toxic effects of these substances to the healthy tissues remain. In addition, new therapeutic approaches, such as checkpoint inhibitors and other targeted therapies, can potentially lead to late effects of which we are not yet aware of. Chapter 1.4 focusses on the consequences of late effects and long-term follow-up care.

1.3 Pulmonary late effects in childhood cancer survivors

Pulmonary late effects in CCSs are multifactorial with involvement of different parts of the lung itself and adjacent structures. As the structures involved, also the manifestation of pulmonary late effects is heterogeneous ranging from asymptomatic pulmonary function impairment to clinical symptoms of various degrees, such as dyspnea at exertion or at rest or chronic cough. The following chapters summarize the factors and mechanisms leading to pulmonary late effects, its detection and clinical manifestation.

1.3.1 Anatomical structure of the lung

The smallest units of the air-filled parts of the lung are the alveoli. The alveoli are surrounded by capillaries of the pulmonary vascular system. The gas exchange, the vital function of the lung, takes place at the alveolar-capillary membrane: oxygen diffuses from the alveolar lumen into the blood and carbon monoxide diffuses back in the alveoli which can then be exhaled (**Figure 3**). The alveoli are connected to the trachea through ever-widening airways (bronichioli, bronchioles) (**Figure 4**). Damage to the alveolar-capillary membrane, the bronchioles, the pulmonary vascular system, and the connective tissue surrounding all these structures causes pulmonary function impairment.

In addition, decreased pulmonary function in CCSs may not only result from damage of the lung tissue itself, but also from osseous chest wall abnormalities or deformities of the thoracic spine. Osseous changes of the chest wall, for example after resection of multiple ribs, or thoracic spine deformity can lead to a stiffness and reduced volume of the thoracic cage or to scoliosis (12, 13).

1.3.2 Risk factors for pulmonary diseases

Several important treatment modalities known to be pulmonary toxic cannot be omitted in the treatment of childhood cancer. The treatment modalities best described and also include in long-term follow-up (LTFU) guidelines are the chemotherapeutic agents bleomycin, busulfan,

lomustine, and carmustine, radiation to the thorax, thoracic surgery and hematopoietic stem cell transplantation.




Figure 3: Structure of distal pulmonary vasculature and airways. A) Bronchiolus with vascular tree; oxygenated blood red, deoxygenated blood blue; B) Alveolar-capillary membrane and its structure with Pneumocyte I, Pneumocyte II, and capillary endothelial cells (Figure from Prometheus, LernAtlas der Anatomie, 2005).




Figure 4: Structure of the bronchial tree (Figure from https://radiologykey.com).

1.3.2.1 Chemotherapeutic agents

Bleomycin

Bleomycin is a tumor-antibiotic and was an important component in the treatment of germ cell tumors and still is for relapsed or refractory Hodgkin's lymphoma. The lung toxicity of bleomycin results from a lack of the bleomycin-inactivating enzyme bleomycin hydrolase in the lung. This lack results in free radical formation and oxidative damage. Subsequent inflammatory processes lead to alveolar damage, hypersensitivity reaction, pneumonitis, and pulmonary fibrosis (14-16). The toxicity of bleomycin is dose dependent and more common with doses >400U/m2, which are rarely used in pediatrics (14, 17, 18). Simultaneous or subsequent radiotherapy to the lung, exposure to elevated oxygen concentrations, renal dysfunction, smoking, and higher age at treatment may exacerbate bleomycin toxicity (18). By knowing its pulmonary toxic effect, bleomycin could be reduced or even omitted for some indications during the last decades, such as in malignant germ cell tumors.

<u>Busulfan</u>

Busulfan is an alkylating agent mainly used in the conditioning of children and adolescents for autologous or allogeneic HSCT. The exact pathomechanism for pulmonary toxicity is unknown. It is unclear, whether a dose-response relationship exists in children. For adults it seems that cumulative doses lower than <500 mg do not cause pulmonary damage (14-16). In recent years, targeted dosing of busulfan has made it possible to individualize the absolute dose needed per patient. Dosing of busulfan is guided by a pharmacokinetic evaluation of the clearance and the resulting area under (AUC) the curve after the first dose. Patients with a fast clearance and a resulting lower AUC will receive a higher third dose than patients with a slow clearance. This allows to reduce toxicity while ensuring that patients receive the adequate busulfan dose to completely ablate the bone marrow.

Nitrosureas (Lomustine [CCNU], Carmustine [BCNU])

Nitrosureas are mainly used in the treatment brain tumors and to condition patients for autologous HSCT (BEAM conditioning). Nitrosureas predispose patients to the development of pneumonitis and pulmonary fibrosis (19, 20). Inflammatory reactions are the underlying mechanisms of nitrosureainduced pulmonary fibrosis. The inflammation causes depletion of Type I pneumocytes and following hyperplasia of Type II pneumocytes, which results in increased collagen deposition in the lung. Higher cumulative doses are associated with increasing risk of lung injury and patients additionally exposed to thoracic irradiation may develop lung injury at lower doses of nitrosureas than non-exposed (14-16).

1.3.2.2 Radiotherapy to the chest

Pulmonary damage can result from direct irradiation of the lung or chest wall or from scattered radiation during radiotherapy applied to the abdomen or spine. The COG LTFU guidelines Version 4.0 defined the following fields as potential pulmonary toxic: subtotal lymphoid irradiation, axilla, chest (thorax), extended mantle, mantle, mini-mantle, mediastinal, whole lung, total body irradiation (TBI), and total lymphoid irradiation (**Figure 5**) (21).

The mechanism of pulmonary toxicity starts with DNA strand breaks due to ionizing radiation. These breaks initiate a cascade of inflammatory reactions, with subsequent capillary leaks and alveolar and interstitial exudate. These changes are reversible to a certain degree but later organize into collagen, leading to fibrosis. Clinically, radiation pneumonitis is the acute disease and progresses to fibrosis in most survivors (14, 15).




Figure 5: Radiation fields putting childhood cancer survivors at risk for pulmonary late effects (Figure from COG LTFU guidelines, v4.0)

Besides the radiation field, the irradiated volume, total dose, dose per fraction, source of radiation, and the additional application of radiosensiziter play important roles in the development and extent of pulmonary damage. The irradiation fields became smaller and more focused on the primary tumor site over the course of time. These changes are shown in **Figure 6** with the example of Hodgkin's lymphoma (22). Also radiation doses decreased over time. In earlier Hodgkin protocols, such as the HD82 protocol, the patients received 25-35 gray (Gy) involved field radiation. In the most recent protocol (EuroNet-PHL-C2), also used in Switzerland, the radiation dose depends on the treatment group and the response after the first two cycles of chemotherapy. In those with low-stage disease and good response, radiotherapy is replaced by an additional block of chemotherapy, whereas in the HD82 protocol even patients with low stage disease received irradiation with 35Gy. In the current protocol, patients with higher stage disease or inadequate first response to treatment either receive 20Gy or 30Gy depending on the second response assessment to chemotherapy. Even those with high risk disease and poor response to chemotherapy receive lower doses today than those treated in the 1980's. The aim of the EuroNET-PHL-C2 protocol is, that only 20% of patients will need radiotherapy.




Figure 6: Changes in irradiation fields for a patient with Hodgkin lymphoma over time. Red dots represent involved lymph nodes, grey areas represent irradiated fields. (a) involved lymph nodes, (b) mantle field, (c) involved field radiation therapy, (d) involved nodal radiation therapy (Figure from Witkowska et al (22))

Using protons instead of photons may have an impact on pulmonary toxicity. Literature comparing both modalities in terms of pulmonary toxicity does not exist today. However, due to the physical properties of the protons, we can assume that they are less pulmonary toxic and cause less scattered radiation than photons. The most important general property of protons compared to photons is shown in **Figure 7**, where the radiation dose is shown on the y-axis and on the x-axis the depth in the water, representative for the body. The x-axis starts at zero, representing the surface of the water or the skin. In proton therapy, the peak of the proton beam is applied directly in the depth or at the tumor site respectively. The entry

dose is lower than in photon therapy and decelerates quicker behind the tumor, resulting in lower exit doses. In contrast, photon beam rises directly after entrance in the water or the body, and then declines exponentially as photons are absorbed. As tumor are not located at one single point, but have a given depth, the maximum dose range for proton irradiation must be expanded. This expansion is achieved through energy modulation, where the tumor is irradiated with different proton energies. The result of this energy modulation is a widening of the dose maximum at depth, which is called "spread out bragg peak" (SOBP).




Figure 7: Depth-dose curve of photon and proton radiation. SOBP, spread-out Bragg peak (Adapted from Mohan et al. (23))

Protons can thus be better targeted on the tumor volume. **Figure 8** shows the example of craniospinal irradiation of a child with medulloblastoma. When using Intensity Modulated Radiation Therapy (IMRT) with photons, the lung is involved, which is not the case if protons are used (24). The target dose, 3600cGy in this example, corresponds to the yellow line and is reached through the whole target volume (=spinal axis). The scattered radiation, lower than 3600cGy, is also limited to the spinal axis for proton radiation but not for IMRT, where it involves part of the lung and heart.

1.3.2.3 Surgery of the lung and thorax

In the COG LTFU guidelines Version 4.0 the following procedures have been defined as risk factors: thoracotomy, pulmonary lobectomy, pulmonary metastasectomy, pulmonary wedge resection, chest wall surgery, and rib resection (21). Mechanisms leading to pulmonary dysfunction include reduction of lung volume, reduced volume of the thoracic cage or stiffness of the thoracic cage (14, 25).




Figure 8: Comparison of proton radiation and Intensity Modulated Radiation Therapy (IMRT) with Photons. Sagittal (A) and axial (B) images with proton radiation in the upper image, IMRT in the bottom image. Doses in centiGray (cGy) listed to the left of each image (Figure Cotter at al. (24))

1.3.2.4 Hematopoietic stem cell transplantation (HSCT)

HSCT is divided into allogeneic and autologous. **Table 1** summarizes the most important features of both types and their differences. With some exception, allogeneic HSCT is not a first line treatment approach in pediatric oncology. Exceptions for allogeneic HSCT in the first line treatment are specific high riak and very-high risk acute lymphoblastic or acute myeloic leukemia and juvenile myelomonocytic leukemia (JMML). Allogeneic HSCT is most frequently indicated to treat refractory or relapsed leukemia. Autologous HSCT is included in the first line treatment of some high-risk diseases, such as high-risk neuroblastoma or high-risk sub-groups of medulloblastoma. Autologous HSCT is also a second line approach for refractory of relapsed solid tumors and lymphoma.

	Allogeneic HSCT	Autologous HSCT
Indications in oncology	Leukemia	Solid tumors (e.g. brain tumors, neuroblastoma), lymphoma
Aim	Replace patients bone marrow as the place of origin of the leukemic cells	Accelerate/ boost recovery of bone marrow which is depleted by high-dose chemotherapy needed to treat cancer outside of the bone marrow
Stem cell source	Stem cells of a (un-)related donor	Own stem cells
Risk of GvHD	Yes	Very rarely

 Table 1: Summary of differences between autologous and allogeneic hematopoietic stem cell transplantation

Abbreviation: GvHD, graft versus host disease

Some pulmonary complications and late effects can occur more frequently in children and adolescents treated with HSCT, but are not unique to the HSCT population. Other late effects are transplant-specific. Infectious complications, such as pulmonary aspergillosis or CMV pneumonitis, are mainly caused by the prolonged period of aplasia and are not unique to HSCT patients. In contrast, non-infectious complications are generally transplant-specific, such as Bronchiolitis Obliterans Syndrome (BOS), diffuse alveolar hemorrhage (DAH), and idiopathic pneumonia syndrome (IPS) (26, 27). DAH and IPS typically present with an acute onset of respiratory failure within the first 1 to 4 months after HSCT and are associated with a high mortality. BOS is typically diagnosed >100 days after transplantation, has a variable clinical course, but most patients present with slowly progressive airflow obstruction. Stabilization or improvement of lung function in patients with BOS are rare. BOS is a form of pulmonary manifestation of graft versus host disease (GvHD). GvHD is an immunological condition in patients after allogeneic HSCT. The immune cells, transferred from the donor to the recipient during HSCT, recognize the recipients' cells as foreign and attack them. Acute GvHD (aGvHD) presents within the first 100 days after HSCT and chronic GvHD (cGvHD) after day 100 (28). Between 9-32%of children and adolescents develop cGvHD, which has a higher impact on the development of late effects than aGvHD (29-33).

1.3.3 Pathomechanism of pulmonary damage

Lung damage is caused by various pathomechanisms and different pulmonary structures can be affected (**Figure 9**). Diffuse damage to alveolar cells (pneumocyte I and II) causes inflammation and leads to thickening of the alveolar wall. Additional thickening is caused by the injured and desquamated cells and the deposition of lipoprotein material within the alveoli, which leads to the formation of hyaline membranes (26). These hyaline membranes are the underlying cause of alveolar proteinosis. Thickening of the alveolar wall goes in line with thickening of the alveolo-capillary membrane and causes impaired gas exchange. Triggers for diffuse alveolar damage are bleomycin and busulfan (15). Acute respiratory syndrome is the acute clinical picture of diffuse alveolar damage, characterized by diffusion capacity impairment.

Damage to the bronchial epithelium induces inflammatory processes, which lead to narrowing and obstruction of the small bronchioles and larger bronchi. Triggers for damage to the bronchial epithelium are bleomycin and radiation(15). The acute clinical manifestation is bronchiolitis obliterans–organizing pneumonia (BOOP) with shortness of breath and dyspnea (26, 27). Pulmonary function tests are characterized by diffusion capacity impairment and obstruction.

Damage of pulmonary vessels with resulting inflammation and intima-thickening leads to progressive obstruction of the small pulmonary arteries, capillaries, and venules. Trigger for damage to the vascular system are bleomycin, carmustine and lomustine (15). The acute clinical picture is pulmonary venoocclusive disease with diffusion capacity impairment, reduced oxygenation of the blood, and a

ventilation-perfusion mismatch.

Interstitial diseases are also caused by inflammatory processes. Proliferation of inflammatory cells cause a thickening and higher density of the interstitium. Interstitial pneumonitis is the acute manifestation, leading to diffusion impairment and ventilation inhomogeneity (15, 26). The triggers, underlying pathomechanisms and affected structures are listed here separately, but in most patients several structures are simultaneously affected to different degrees.

Independent of the exact structure affected and the trigger, inflammatory reactions represent the main underlying pathomechanism for acute lung damage. Most pulmonary late effects and chronic pulmonary damage, develop from remodeling of these acute processes. In a second stage of the inflammatory processes not only the inflammatory cells proliferate but also fibroblasts with subsequent production of collagen. Collagen deposition in the alveolo-capillary membrane aggravates diffusion impairment, its desposition in the bronchial and vascular wall leads to a fixation of the narrowing, and deposition in the interstitium causes a general stiffening of the lungs. In addition to collagen production and deposition, long-term pulmonary damage can be caused by remodeling of pulmonary cells. Damage to type I pneumocytes, which line the alveoli and build part of the alveolo-capillary membrane, leads to a hyperplasia of type II cells, which normally produce surfactant. This remodeling causes a reduction in the alveolar surface participating in the gas exchange.

Radiation to the lung harbors an additional pathomechanisms to the inflammatory processes: impaired chest wall growth. In addition, some experts suggest, that the cancer diagnosis and its treatment negatively affects lung development, similar to severe malnutrition. Prenatal malnutrition, resulting in low birth weight at term, leads to reduced lung function in infancy and childhood compared to children born with appropriate weight (34, 35). To be comaprabel with childhood cancer survivors, not prenatal malnutrition may be important but malnutrition at a later time in a child's life. This has been evaluated in two publications by Lelijveld et al, describing the "Chronic disease outcomes after severe acute malnutrition" (ChroSAM) cohort in Malawi. The authors could not show an association between severe acute malnutrition in children and subsequent reduced lung function compared to local controls.

This paragraph highlights that pulmonary function impairment in childhood cancer survivors is multifactorial, involves different structures, and even though a lot of research has been done, not all mechanisms and are well known today. The different risk factors with their resulting pulmonary diseases are summarized in **Table 2**. The list is not exhaustive, as some factors might be associated with different presentations.




Figure 9: Illustration of the different pulmonary structures, whose damage can lead to pulmonary late effects: A) bronchioles and bronchi, B) vascular system, and C) alveoli

(Figure combined from different sources: https://www.pinterest.co.uk/pin/567523990533063737/, https://www.shutterstock.com/es/search/respiratory+membrane, https://erj.ersjournals.com/content/ 47/5/1518, https://www.normalbreathing.com/bronchoconstriction-natural-treat/)

Risk factors	Disease	
Chemotherapy		
Bleomycin	Acute respiratory distress syndrome	
	• Interstitial or hypersensitivity pneumonitis	
	• Bronchiolitis obliterans organizing pneumonia	
	Pulmonary veno-occlusive disease	
	Pulmonary fibrosis	
Busulfan	Acute respiratory distress syndrome	
	Alveolar proteinosis	
	Pulmonary fibrosis	
Nitrosureas	Hypersensitivity pneumonitis	
(Carmustine, Lomustine)	• Alveolitis	
	Pulmonary veno-occlusive disease	
	Pulmonary fibrosis	
Radiotherapy	Bronchiolitis obliterans organizing pneumonia	
	• Interstitial pneumonitis	
	• Impaired chest wall growth	
	Pulmonary fibrosis	
Surgery	Restrictive lung function impairment	
	• Scoliosis	
	• Chest wall deformity	

Table 2: List of risk factors for pulmonary late effects and resulting diseases (Visscher et al (36))

Risk factors	Disease	
Stem cell transplantation		
Lung toxic agents used for conditioning	See Busulfan and Nitrosureas	
Transplant-specific non-infectious pulmonary complications	 Idiopathic pneumonia syndrome Bronchiolitis obliterans syndrome Bronchiolitis obliterans organizing pneumonia Diffuse alwaster here are the set 	
1 I	• Diffuse alveolar hemorrhage	

Continuation Table 2

1.3.4 Pulmonary dysfunction

Childhood cancer survivors can suffer from different types of pulmonary dysfunction. Pulmonary dysfunction can broadly be categorized in obstructive, restrictive, diffusion capacity impairment, and mixed forms, based on results from pulmonary function tests. The main pathophysiological characteristic of obstructive dysfunction is a narrowing of the airways, leading to a reduction of respiratory flow. The obstruction in CCSs can affect different areas of the bronchial system, such as more distal or more proximal parts. Thickening of the bronchial wall due to inflammatory processes or fibrotic narrowing are pathomechanisms underling airway obstruction. Restrictive dysfunction results from a reduced elasticity and expandability of the lung tissue itself or the adjacent structures, such as the chest wall. The mechanisms behind restrictive dysfunction in CCSs include fibrotic changes of the lung parenchyma or resection of larger parts of the chest wall. The underlying condition in diffusion capacity impairment is thickening of the alveolar-capillary membrane. Thickening can result from damage to the alveoli, to the capillaries or from deposition of fibrotic tissue in the space between alveoli and capillaries.

Besides describing pulmonary dysfunction in CCSs in terms of PFT results, it can also be described in terms of specific clinical diagnoses, such as bronchiolitis, bronchiolitis obliterans (BO), bronchiolitis obliterans organizing pneumonia (BOOP), idiopathic pulmonary syndrome (IPS), pulmonary fibrosis, or emphysema.

1.3.5 Methods to assess pulmonary function

Pulmonary late effects can lead to impairment in airflow, lung volume or gas exchange. Different test methods are available to objectify these impairments. This section focusses on spirometry, body plethysmography and measurement of diffusion capacity for carbon monoxide (DLCO), as these are the widely used test methods today, are recommended in long-term follow-up guidelines, and I used them for the publications included in this thesis.

Physiologic breathing and volumes assessed during respiratory cycle

Breathing leads to air flow by displacement of air in the lungs. Tidal volume (TV) is the normal volume of air moved between in-and expiration during quiet tidal breathing when no additional effort is applied (**Figure 10**). In the volume-time graph, the curve goes up with each inspiration and down with each expiration. The volume of air which remains in the lungs after each normal exhalation during quiet tidal breathing is the functional residual capacity (FRC). In forced breathing maneuvers additional volumes of air are moved between maximal in- and expiration. The volume which can maximally be exhaled after full inspiration is the forced vital capacity (FVC). Physiologically not all air can be exhaled and the remaining volume is the residual volume (RV). Finally, the total volume of the lungs, as the sum of the FVC and RV, is called the total lung capacity (TLC).




Figure 10: Volume-time graph with breathing patterns and respective volumes with five normal breaths followed by one maximum breathing maneuver and five normal breaths (Figure adapted from https://www.bromleyemergency.com/frcem-primary/core-physiology-can-measured-spirometry/)

Spirometry

Spirometry is widely used to record static and dynamic lung function parameters. Lung volumes that are not affected by air flow are termed static lung volumes, such as FVC or TV. Lung volumes that are affected by air flow are termed dynamic lung volumes and are measured during spirometry with a forced expiration, e.g. forced expiratory volume in one second [FEV1], which is measured exactly 1 second after starting forced exhalation. **Table 3** gives a brief summary on four important lung parameters that are assessed during spirometry. The spirometry results can be displayed in three different ways: 1) as

numerical output with absolute numbers, as percentage of predicted value (%pred), and as z-score (Figure 11 a), 2) graphically as volume-time-curve (Figure 11 b), or 3) graphically as flow-volume-curve (Figure 11 c) (37, 38).

Parameter	Abbreviation	Explanation
Forced expiratory volume in	FEV1	Respiratory volume, which can be exhaled with
one second		force in the first second after maximum inspiration
Forced vital capacity	FVC	Respiratory volume, which can be maximally
		exhaled with force after complete inspiration
Relative one-second-capacity	FEV1/FVC	FEV1 expressed in % of the FVC
(Tiffenau-Index)		
Mid Forced Expiratory Flow	FEF25-75%	Forced expiratory flow between 25% and 75% of
Rates		the FVC

Table 3: Explanation of important lung volumes assessed during spirometry




Figure 11: Display formats of spirometry; a) numerical output, b) volume-time-curve, c) flow-volume-curve (Figures adapted: https://www.researchgate.net/publication/233912835_Guideline_for_office_spirometry_in_adults_2012, https://www.slideshare.net/ashrafeladawy/spirometry-basics-2)

In the <u>volume-time-curve</u>, the x-axis represents the time in seconds and the y-axis represents the volume of air breathed in and out in liters. The curve in **Figure 11 b** starts with two normal breaths, followed by a maximal inspiration until TLC. This is followed by a maximal forced expiration until RV is reached. The curve runs out towards the end, as the respiratory flow and the exhaled volume per second decreases. The <u>flow-volume-curve</u> plots the in- and exhaled volume on the x-axis in relation to the flow of the volume shift on the y-axis. In this example, the person could breathe in 4 liters with a maximal flow of 10 liter per second. The shape of the flow-volume-curve is especially important to assess the quality of the test result (see Section 3.3.3).

To perform spirometry, patients have to breathe through a mouthpiece connected to a software, which measures the in- and exhaled flow and volumes (Figure 12). The tight mouth closure around the mouthpiece limits the use of spirometry in small children but also in persons with disabilities, hindering

them to seal the mouthpiece (neurological impairment, facial paralysis) (37-39). Spirometry can usually be performed in children aged 6 years and older.



Figure 12: Spirometer (Figure from https://www.paediatricpulmonologist.co.za/lung-function-test.php)

Body plethysmography

Body plethysmography allows a more detailed assessment of pulmonary function than spirometry alone. Body plethysmography provides additional information, especially concerning static lung volumes and capacities, such as RV and TLC. It additionally allows to determine airway resistance based on the relationship of the flow to volume displacement (**Figure 13**). Flow and oral pressure are plotted against displacement of volume. The shape of the curve allows statements on quality of the test and pulmonary dysfunction. The flow-volume curve provided by body plethysmography is identical to the one provided by spirometry (39, 40).




Figure 13: Flow-pressure-curve




Figure 14: Body plethysmography

(Figures from http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/pulmonary/ and http://lungfunction.net/basics/body-plethysmography-flow-pressure-curve.htm)

For body plethysmography, the patients have to perform the breathing maneuvers in a sealed box with rigid walls (**Figure 14**). This setting allows to measure pressure changes in the box, which mirror the changes in the lung. The law of Boyle-Mariotte states that the product of pressure and volume stays constant for a gas. In other words, the pressure of a gas tends to increase as the volume of the box decreases. For body plethysmography, this means that during expiration the volume in the lung and the thoracic cage decreases and the volume in the box increases or is decompressed. This volume-shift in the box is measured during body plethysmography and allows to assess additional volumes which

cannot directly be measured. Compared to spirometry, body plethysmography is a more complex pulmonary function test which needs more time and might be more difficult in preschool children to perform.

Diffusion capacity for carbon monoxide (DLCO)

The diffusion capacity measures the ability of gas to diffuse from the air-filled alveoli into pulmonary capillaries. Carbon monoxide (CO) diffuses through the alveolar-capillary membrane in a very similar way as oxygen. As CO has a high affinity to hemoglobin and is simple to measure, it is used as a surrogate marker for the diffusion capacity of oxygen in the DLCO test.

DLCO measurement starts with normal breaths under room air, followed by a maximal expiration and a rapid and maximal inhalation. During rapid inhalation the test gas is switched on, consisting of carbon monoxide, a tracer gas (helium, methane or neon), and oxygen. After maximal inspiration the patient is asked to hold his breath for 10 seconds. Subsequently, the patient exhales completely and the exhaled gas is collected for analysis of the CO and tracer concentration. In case of diffusion capacity impairment less carbon monoxide can diffuse from the alveoli into the capillaries. This results in a higher concentration of test gas in the exhaled air than expected (39, 41).

1.4 Aftercare in childhood cancer survivors

As recognized in 1975 by Giulio D'Angio, late effects play an important role in childhood cancer survivors (42). First recommendations for follow-up care were introduced in the treatment protocols and are still included today. However, these recommendations are rather general, do not differentiate between risk groups and treatment intensity within the same protocol, and are vague ten years and more after completion of treatment. In addition, these recommendations mainly focus on the detection and monitoring of acute toxicities and disease relapse rather than screening for late effects.

The increasing knowledge on late effects and the importance of long-term follow-up care led to the development and formulation of different national long-term follow-up (LTFU) care guidelines. The most comprehensive LTFU care guideline today is the one from the Children's Oncology Group (COG LTFU). It consists of a separate section for chemotherapeutic agents, radiotherapy, surgery, and HSCT. Each of these sections includes a separate summary for each potential late effect. **Figure 15** shows the example for pulmonary fibrosis in the context of exposure to chemotherapy. Each of these sections states the therapeutic exposure associated with the late effect, the recommended periodic evaluations and the test frequency. In September 2003, the first COG LTFU guidelines have been published; today the 5th version, updated in October 2018, is available (43). The COG LTFU guidelines are starting from

two years after completion of treatment onwards. Other national guidelines exist in the Netherlands or the United Kingdom (44, 45). Current international efforts aim to harmonize these different national guidelines within the International Guideline Harmonization Group (IGHG) (46). Switzerland does not have its own LTFU guideline, and the practice of using guidelines is heterogeneous (47, 48). Some clinics use the recommendations from the treatment protocols, others the recommendations by the German Pediatric Oncology-Hematology Group (GPOH), and about half of the clinics use the COG LTFU guidelines.

With today's knowledge, LTFU care is a continuous and life-long process for most childhood cancer survivors and continuation in adulthood is crucial. This transition into adult medicine needs to be well planned together with the survivors and it is not feasible without committed health care professionals in adult medicine (49). To keep survivors engaged in LTFU care, education of the survivors themselves but also of health care professionals is needed. A good balance must also be found between the frequency and intensity of screening and its benefits for the survivors. This is especially true for pulmonary dysfunction, as treatment options are still limited today (section 5.4.2).




Figure 15: Recommendations from the COG LTFU guidelines (version 5.0) to screen for pulmonary fibrosis after exposure to chemotherapy (43)

1.4.1 Pulmonary long-term follow-up (LTFU) care

Current LTFU care guidelines are in agreement, that children exposed to bleomycin, busulfan, nitrosureas (BCNU and CCNU), radiotherapy to the chest, and thoracic surgery need surveillance. The COG guidelines and the recommendations from the UK also include a separate section for survivors treated with hematopoietic stem cell transplantation. The recommendations however differ in depth and detail, as shown in **Table 4** for surveillance modality and frequency. Also recommendations on how to advice and counsel survivors differ (**Table 5**). This highlights that harmonization is needed.

Table 4: Recommended surveillance measurements and frequen	ew hy L	TEL care	oundeline
Table 4. Recommended survemance measurements and nequen	CYUYL		guiucinic

Guideline	Measures	Frequency
COG	PFTs including DLCO and	
	spirometry	as clinically indicated in patients with abnormal
		results or progressive pulmonary dysfunction
DCOG	Flow-volume curve, diffusion	5 and 10 years after diagnosis; if no abnormalities
	capacity, lung volume (FVC and/or	(>75% predicted), then stop
	TLC by FV-curve and/or body pleth.)	
UK	Lung function test not specified	Perform baseline pulmonary function tests (PFTs)
		at end of treatment. If symptomatic or if abnormal
		PFTs (<2 SD below normal), repeat PFTs after 1
		year and/or consider referral to Respiratory
		specialist.

 Table 5: Recommended counseling for survivors at risk for pulmonary dysfunction by LTFU care

 guideline

Guideline	Counseling						
COG	Counsel regarding tobacco avoidance/smoking cessation. Patients who desire to scuba dive						
	should be advised to obtain medical clearance from a pulmonologist.						
	In patients with abnormal PFTs, consider repeat evaluation prior to general anesthesia.						
	Pulmonary consultation for symptomatic pulmonary dysfunction.						
	Influenza and pneumococcal vaccines.						
DCOG	Preventative measures (influenza vaccination, advice of career choice) if						
	- FEV1%VC, TLC and/or TLCOc/VA < 75% predicted, or if these parameters have at						
	least a 20% reduction from the baseline values.						
	- Recurrent respiratory infections/ chronic cough occur						
	If symptomatic consider referral to a pulmonologist.						
	No exposure to FiO2>30% following bleomycine > 400 mg/m2 or demonstrated damage						
	after bleomycine and/or radiotherapy to the thorax. This also applies to O2-inhalation in						
	sports such as scuba-diving. Do not smoke.						
UK	Advise patients and warn anaesthetists about previous bleomycin treatment. Consider						
	pneumococcal immunisation and annual influenza immunisation in patients with						
	established lung disease. Advise against smoking						

Abbreviations: COG, children's oncology group; DCOG, Dutch children's oncology group; UK, United kingdom

Chapter 2 - Aims of this PhD Thesis

2.1 General aim

The general aim of this PhD thesis is to contribute to the growing knowledge on pulmonary late effects in childhood cancer survivors, especially in those treated with hematopoietic stem cell transplantation.

Aim I: Describe transplant characteristics and self-reported pulmonary diseases and symptoms in Swiss childhood cancer survivors after hematopoietic stem cell transplantation (HSCT)

- How did transplant characteristics change in the observed three decades, especially in relation to pulmonary toxic exposure? (Publication I, Chapter 4.1)
- Do childhood cancer survivors treated with HSCT report more often pulmonary diseases and symptoms than childhood cancer survivors not treated with HSCT? (Publication I, Chapter 4.1)
- What are the treatment related risk factors associated with the reporting of pulmonary diseases and symptoms in childhood cancer survivors treated with HSCT? (Publication I, Chapter 4.1)

Aim II: Describe the longitudinal course of pulmonary function in Swiss long-term childhood cancer survivors after hematopoietic stem cell transplantation (HSCT)

- How does the longitudinal course of selected pulmonary function parameters in Swiss longterm childhood cancer survivors treated with HSCT look like? (Publication II, Chapter 4.2)
- How do pulmonary function parameters obtained before transplantation differ from parameters obtained in the first two years after transplantation and in the years three to five after transplantation (analysis in sub-cohort) (Publication II, Chapter 4.2)
- How do pulmonary function parameters obtained in the first two years after transplantation differ from pulmonary function parameters obtained in the 3rd to 5th year and 6th to 10th year? (analysis in sub-cohort) (Publication II, Chapter 4.2)
- What are treatment related risk factors associated with changes in pulmonary function over time? (Publication II, Chapter 4.2)

Aim III: Describe pulmonary function in Swiss childhood cancer survivors after exposure to lung toxic treatment modalities

- How does the longitudinal course of pulmonary function in Swiss childhood cancer survivors exposed to pulmonary toxic chemotherapy or radiotherapy to the chest look like? (Publication III, Chapter 4.3)
- What are treatment related risk factors associated with changes in pulmonary function over time? (Publication III, Chapter 4.3)

Aim IV: Set up a national prospective cohort study to assess late effects in Swiss childhood cancer survivors, including pulmonary late effects

• Describe the setup and logistics behind a prospective national multicenter cohort study (Publication IV, Chapter 4.5)

2.2 Specific aims

2.2.1 Publication I: Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study

The burden of pulmonary symptoms and diseases, summarized as pulmonary outcomes, in Swiss childhood cancer survivors treated with HSCT was unknown. International literature on this topic has been sparse. Therefore, I aimed to describe self-reported pulmonary outcomes in Swiss childhood cancer survivors, who survived at least 5 years from diagnosis and were treated with HSCT. I compared their outcomes to CCSs not treated with HSCT and investigated the effect of treatment- and transplant-related risk factors on the reporting of pulmonary outcomes. I additionally aimed to describe changes in transplant characteristics and procedures over the observed period of three decades.

2.2.2 Publication II: Pulmonary function in long-term Swiss childhood cancer survivors after hematopoietic stem cell transplantation

Most studies describing the longitudinal course of pulmonary function in childhood cancer survivors treated with HSCT were single center studies and with a follow-up period less than 5 years. Therefore, I aimed to describe pulmonary function trajectories in a national sample of childhood cancer survivors who survived at least 5 years since diagnosis and have been treated with HSCT. I additionally aimed do analyze changes and differences in pulmonary function z-scores between given time spans and in two sub-cohorts. The first sub-cohort consisted of childhood cancer survivors with a baseline test performed before HSCT. In these survivors I aimed to analyze changes in z-scores between baseline and the first two years from transplantation and between baseline and more than two years from transplantation. The second sub-cohort consisted of childhood cancer survivors who had at least one test performed within the first two years after HSCT and at least one test in the following years. In this sub-cohort I aimed to analyze early versus late changes in pulmonary function z-scores. I additionally aimed to assess patient- and treatment-related factors which predict a change, either as improvement or deterioration, in pulmonary function with increasing time from cancer diagnosis.

2.2.3 Publication III: Lung function in Swiss childhood cancer survivors - a retrospective study

Pulmonary function trajectories in childhood cancer survivors are often described as percentage of predicted value (%pred), above or below a certain cutoff. Using %pred inevitably leads to the use different reference equations for children and adults. This can lead to abrupt changes in calculated %pred when survivors grew older and reference equations change from pediatric to adult. Therefore, I aimed to describe pulmonary function (FEV1, FVC, TLC, and DLCO) in childhood cancer survivors treated with pulmonary toxic chemotherapy or radiotherapy to the chest in terms of z-scores by using reference equations which cover all age categories. Additionally, I aimed to evaluate the effect of different risk factors on longitudinal changes in FEV1 and FVC in this population.

2.2.4 Publication IV: The Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) – Protocol of a prospective, national, multicenter cohort study

Many studies on late effects and organ function in childhood cancer survivors, including pulmonary function, obtained their outcome data retrospectively. This type of data collection is often associated with limitations and harbors the risk to introduce bias. Therefore, I have designed the set up of the Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) to overcome the limitations of retrospective data collection. The SCCSS-FollowUp is a prospective, national multicenter cohort study, tailored to all late effects in childhood cancer survivors of all age categoris with the aim to

- 1) collect medical data prospectively and repeatedly,
- 2) collect medical data produced during regular follow-up care visits in a standardized way,
- 3) acquire information on subjective symptoms (e.g. through questionnaire) in parallel with objectifiable test results, and
- 4) collect retrospectively all information of initial cancer diagnosis and its treatment.

Chapter 3 - Methods

3.1. Cohort description

For all publications and projects within this thesis, I used childhood cancer survivors from two cohorts: the Childhood Cancer Registry and the Swiss Childhood Cancer Survivor Study (SCCSS).

3.1.1 Childhood Cancer Registry

Before describing the characteristics of the Childhood Cancer Registry, I have to specify a legal aspect, as there was a relevant change during this PhD project, which also affected setting up the SCCSS-FollowUp study. Due to a change in law, the former Swiss Childhood Cancer Registry (SCCR) became a federal registry from January 1st 2020 onwards and is now called Childhood Cancer Registry (ChCR). Before January 1st 2020, the SCCR felt under the human research law (Humanforschungsgesetz, HFG) and was not under the supervision of a federal agency. From January 1st 2020 onwards the new ChCR falls under the cancer registration law (Krebsregistrierungsgesetzt, KRG) and newly belongs to the federal Office of Public Health. This change in legal affiliation and becoming a federal registry led to initial uncertainties, if informed consents and data collected under the HFG can still be used under the KRG. This was particularly relevant for SCCSS-FollowUp, as we need the contact information of patients who consented under the HFG to future use of their data and to be able to recruit them in the SCCSS-FollowUp study. Mainly this aspect led to long delays in setting up the SCCSS-FollowUp and ethics approval is still pending. These changes in law did not affect the publications I-III, as they only relied on patients registered and data collected before January 1st 2020 and within the SCCR. Therefore, I will mainly use the term SCCR in this thesis.

The SCCR is a nationwide, population-based cancer registry including all Swiss children and adolescents who were diagnosed since 1976 and below the age of 21 years with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis (LCH). Diagnoses are classified according to the International Classification of Childhood Cancer, third edition (ICCC-3). The data collected in the SCCR include information on the cancer diagnosis, its treatment, long-term follow-up and patient's personal data (50). By December 2019, the SCCR include 11'879 cancers in 11'722 children and adolescents.

3.1.2 Swiss Childhood Cancer Survivor Study (SCCSS)

The Swiss Childhood Cancer Survivor Study (SCCSS) is a long-term, questionnaire-based, national cohort study of childhood cancer survivors registered in the SCCR who have been diagnosed since 1976, have survived \geq 5 years after initial diagnosis, and were alive at the time of study inclusion. The SCCSS questionnaire was sent to all eligible childhood cancer survivors in two waves: 2007 to 2013

and 2015 to 2017. For both waves the questionnaires were available in four versions (kids, parents, adolescents, and adults) and in three languages (German, French, Italian). For participants aged 5 to 15 years, the questionnaire was completed by their parents. Children aged between 8 and 15 years additionally completed a short questionnaire on their current well-being. Participants aged 16 to 19 years completed the version for adolescents and those aged ≥ 20 years received the adult version. The SCCSS aims to investigate physical and psychosocial health status and health behaviors in childhood cancer survivors. In addition, information on sociodemographic characteristics and cancer- and treatment related factors associated with health status or health behaviors is collected (9).

The Ethics Committee of the Canton of Bern approved the SCCR and SCCSS (KEK-BE: 166/2014). In addition, the SCCSS is registered at ClinicalTrials.gov (identifier: NCT03297034).

3.1.3 SCCSS-FollowUp

The Swiss Childhood Cancer Survivor Study Follow-up (SCCSS-FollowUp) is an extension of the SCCSS, which is questionnaire-based only. Every childhood cancer patient registered in the ChCR is eligible for SCCSS-FollowUp directly after completion of treatment. The recruitment however takes place in a project-specific approach. The SCCSS-FollowUp aims to collect medical data from regular follow-up care visits prospectively, repeatedly, and in a standardized way.

As the setup of this project is part of this thesis, it is described in more detail in chapter 4.4 and in the Appendix C.

3.2. Inclusion criteria for the publications in this thesis

Publication I: Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study

For this publication, all childhood cancer survivors who participated in the SCCSS, answered the questions on pulmonary diseases and symptoms, have been diagnosed with cancer between 1976 and 2010, and have been treated with autologous or allogeneic HSCT were eligible. For the matching process, I included participants of the SCCSS who fulfilled the same inclusion criteria but have not been treated with HSCT. I performed the matching by sex, diagnosis, age at diagnosis, and year of diagnosis. The age at diagnosis differed by ± 2 years and the year of diagnosis by ± 5 years between survivors treated with and without HSCT. With these ranges I targeted a 1:3 ratio.

Publication II: Pulmonary function in long-term Swiss childhood cancer survivors after hematopoietic stem cell transplantation

For this publication, the primary inclusion criteria were identical to the transplanted cohort from publication I. The additional inclusion criterion was, that at least two pulmonary function tests performed after the cancer diagnosis had to be available in the medical records.

Publication III: Lung function in Swiss childhood cancer survivors - a retrospective study

For this publication, I included all childhood cancer survivors registered in the SCCR, we have been treated in one of the nine Swiss pediatric oncology centers up to the age of 16 years and were diagnosed between 1990 and 2013. In addition, they had to be exposed to at least one lung toxic chemotherapeutic agent or chest radiotherapy, had at least one pulmonary function test available in their medical records, and were aged ≥ 6 years when starting the study.

Publication IV: The Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) – Protocol of a prospective, national, multicenter cohort study



The manuscript for this publication is the study protocol for the SCCSS-FollowUp. Ethics approval was still pending. Therefore, I have not recruited any patients. In the future, this study will allow to include all childhood cancer patients as soon as they finished their cancer treatment. As the SCCSS-FollowUp has an umbrella-like design, the final inclusion criteria into SCCSS-FollowUp are given by the included projects.

3.3. Data collection

3.3.1 Questionnaire data (Publication I)

For the first publication on self-reported pulmonary health, I could use two questions from the SCCSS questionnaire. Both questions were asked in the questionnaires for parents, adolescents, and adults. One question asked about different pulmonary diseases and symptoms and one about smoking habits (Appendix A). All questionnaire data have been entered in a RedCap® database by previous PhD students and were available in four different data sets: one dataset with all questionnaire versions from wave 1 and three separate datasets for the parent, adolescent and adult versions from wave 2. To further analyze the data, I extracted the relevant questions from all four datasets, combined them, and harmonize the answers options. This harmonization into yes/no categories was necessary, as the answer options slightly differed between the parent and adolescent/ adult version of the questionnaire.


3.3.2 Medical data (Publication I, II, III)

Exact treatment exposure and information on hematopoietic stem cell transplantation is not registered in the SCCR. The protocol name is available from the SCCR for most patients, but often without the respective treatment arm. As treatment exposure is crucial in evaluating late effects in childhood cancer survivors, I organized a retrospective review of medical records for all eligible survivors in all nine pediatric oncology clinics. I searched the paper archives of the pediatric oncology departments and the separate transplant archives for children transplanted in Zurich and in the adult oncology department in Basel (in the past children were transplanted in the adult hospital). The records of pediatric oncology patients include all results of consults, including lung function tests and interpretation. For publications I and II, the data collection was done by myself. I have defined the information which needed to be extracted from the medical records in advance and compiled it in a data extraction sheet (Appendix B). I searched the whole medical record of each childhood cancer patient. For publication III, the search for medical data has been performed by a previous PhD student. The search startegies differed slightly, as the previous PhD student did not search the specific transplant archives in Zurich and Basel but searched the archives of the pediatric respiratory medicine departments.

3.3.3 Lung function data (Publication II, III)

I collected the pulmonary function test (PFT) results at the same time as I searched the medical data in the pediatric oncology clinics (Chapter 3.3.2). I collected all test results independent of their quality. In a following step I assessed pulmonary function quality of all collected PFTs. A master student supported me for this task. Prior to starting the assessment, I defined important quality criteria to be judged on during the quality assessment (**Table 6**). During the definition of quality criteria I was supported by a pediatric pulmonologist (Dr. Sophie Yammine from the division of pediatric pulmonology, university chilren's hospital Bern). The master student and I assessed the quality of each PFT independently. In case of different conclusions we discussed the PFT curves together. If we could not find a consensus we approached Dr. Sophie Yammine.

Table 6: Criteria included in the assessment of pulmonary function quality. Green curves correspond to good quality, red curves to bad quality



Medical records report pulmonary function test results as raw data and percentage of predicted (%predicted). The %predicted derives from the comparison of the expected value based on the age, gender, and height of patients and the effective test result. The reference equations used to calculate %predicted are often either for children (e.g. Zapletal) or adults only (e.g. the European Community of Coal and Steel equations), or do not cover younger children (51-53). The switch from pediatric to adult reference equation during adolescence can cause relevant changes in the %predicted. Also cutoff values used to define pulmonary dysfunction (e.g. DLCO <75 %predicted (54)) are not always applicable to children. As an example, children can physiologically breathe out a larger volume in the first second (FEV1) in relation to the FVC, compared to adults.

Using z-score instead of %predicted can overcome some of these limitations. As %predicted, z-scores are adjusted for age, gender, and height. Reference equations covering all age categories, from age 3 - 95 years, exist from the Global Lung Initiative (GLI) (55). The use of equations covering all age

categories, overcomes the "jump" in adolescents and young adults. Basically the z-score describes how many standard deviations a PFT result differs from the predicted. The predicted corresponds to the mean of the normally distributed pulmonary function parameter in the reference population. (Figure 16).




Figure 16: Illustration of the normal distribution of the FEV1 z-score and the respective percentile (https://breathe.ersjournals.com/content/breathe/9/6/462.full.pdf)

A z-score of zero corresponds to the mean value of the reference population. The z-scores of $\pm 1,645$ correspond to the 5th and 95th percentile. As a result, 90% of healthy subjects have a z-score within this range. Z-scores of $\pm 1,645$ are most frequently used to define pulmonary function parameters as abnormal. By expressing PFT results as z-scores, age-inapropriate cutoff values can be avoided.

Figure 17 summerizes the cohorts and data sources used and the respective inclusion criteria for each of the four first-author publications and manuscripts of this thesis graphically.




Figure 17: Cohorts and data sources used with their respective inclusion criteria for the first author publications of this thesis.

Chapter 4 – Results

4.1. Publication I

Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study

Original article

Maria Otth, Christina Schindera, Tayfun Güngör, Marc Ansari, Katrin Scheinemann, Fabiën N. Belle, Philipp Latzin, Nicolas von der Weid, Claudia E. Kuehni

(Published, Bone Marrow Transplantation, 2020)

Own contribution to the project: Concept and design of the study, organization and conduct of data collection, data analysis, interpretation of the results, writing manuscript with integration of co-authors comments, manuscript submission, point-by-point reply to peer reviewers

ARTICLE





Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation—a cohort study

Maria Otth ()^{1,2,3} · Christina Schindera ()^{1,4} · Tayfun Güngör ()⁵ · Marc Ansari^{6,7} · Katrin Scheinemann ()^{2,8,9} · Fabiën N. Belle ()^{1,10} · Philipp Latzin¹¹ · Nicolas von der Weid⁴ · Claudia E. Kuehni ()^{1,12} · for the Swiss Pediatric Oncology Group (SPOG)

Received: 28 May 2020 / Revised: 16 October 2020 / Accepted: 3 November 2020 $\ensuremath{\textcircled{}}$ The Author(s) 2020. This article is published with open access

Abstract

Childhood cancer survivors treated with hematopoietic stem cell transplantation are at high risk for pulmonary morbidity and mortality. In this retrospective study we described transplant characteristics of pediatric patients who underwent hematopoietic stem cell transplantation in Switzerland and how these characteristics changed over time, compared self-reported pulmonary outcomes between transplanted and non-transplanted survivors, and investigated risk factors for the reported pulmonary outcomes. As part of the population-based Swiss Childhood Cancer Survivor Study, we sent questionnaires to all \geq 5-year childhood cancer survivors. During the study period transplant characteristics changed, with decreasing use of total body irradiation and increased use of peripheral blood stem cells and mismatched and unrelated donors as transplant source. One-fifth of transplanted survivors (20%, 95%CI 13–27%) and 18% of non-transplanted survivors (95%CI 13–21%) reported at least one pulmonary outcome. None of the analyzed factors was significantly associated with an increased risk of pulmonary outcomes in multivariable analysis. We found that pulmonary outcomes were frequently reported in transplanted and non-transplanted childhood cancer survivors, indicating a strong need for long-term pulmonary follow-up care.

Members of the Swiss Pediatric Oncology Group (SPOG) are listed below Acknowledgements.

Supplementary information The online version of this article (https:// doi.org/10.1038/s41409-020-01137-1) contains supplementary material, which is available to authorized users.

Claudia E. Kuehni claudia.kuehni@ispm.unibe.ch

- ¹ Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- ² Division of Oncology-Hematology, Department of Pediatrics, Kantonsspital Aarau, Aarau, Switzerland
- ³ Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
- ⁴ Division of Hematology and Oncology, University Children's Hospital Basel and University of Basel, Basel, Switzerland
- ⁵ Division of Hematology/Oncology/Immunology and SCT, Children's Research Center (CRC), University Children's Hospital Zurich-Eleonore Foundation, Zurich, Switzerland
- ⁶ Department of Women, Child and Adolescent, Oncology-Hematology Unit, Geneva University Hospital,

Published online: 25 November 2020

Introduction

Hematopoietic stem cell transplantation (HSCT) is an effective but intensive treatment for childhood cancer. HSCT can be performed as allogeneic or autologous

Geneva, Switzerland

- ⁷ CANSEARCH Research Laboratory, Medical Faculty, University of Geneva, Geneva, Switzerland
- ⁸ University of Basel, Basel, Switzerland
- ⁹ Department of Pediatrics, McMaster University Hamilton, Hamilton, ON, Canada
- ¹⁰ Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland
- ¹¹ Division of Respiratory Medicine, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland
- ¹² Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

transplantation and is used either as first line or salvage treatment [1–4]. The history of allogeneic HSCT goes back to the 1980s and indications, conditioning regimens, and donor sources have changed enormously since then [5, 6]. Pulmonary damage and late effects due to lung toxic treatments and complications prior to, during, or after transplantation can occur in childhood cancer survivors (CCS) [7-9]. Lung toxic treatments include the chemotherapeutics bleomycin, busulfan, carmustine (BCNU) or lomustine (CCNU), radiation involving the lung tissue, total body irradiation (TBI), and thoracic surgery [10-13]. Transplant-specific pulmonary complications include idiopathic pulmonary syndrome and complications from the spectrum of pulmonary graft versus host disease (GvHD), such as bronchiolitis obliterans or bronchiolitis obliterans organizing pneumonia [7, 14–16]. Severe pulmonary infections are additional complications due to long-lasting neutropenic episodes.

Pulmonary symptoms and diseases, summarized as pulmonary outcomes, are associated with high morbidity in survivors [17–19]. Cohort studies showed that survivors more often report pulmonary outcomes than siblings [20, 21]. To date, pulmonary outcomes in survivors after HSCT have only been reported by few single-center studies [22, 23]. Data based on national population-based assessments of pulmonary outcomes are lacking.

This nationwide retrospective study describes transplant characteristics, such as transplant indications and conditioning regimens, of pediatric patients who had HSCT in Switzerland and how these characteristics changed over time. Then, we compared self-reported pulmonary outcomes between transplanted and nontransplanted survivors and investigated risk factors for reporting pulmonary outcomes.

Methods

The Swiss Childhood Cancer Survivor Study

The Swiss Childhood Cancer Survivor Study (SCCSS) is a long-term national cohort study of all patients registered in the Swiss Childhood Cancer Registry (SCCR) who have been diagnosed since 1976, have survived ≥ 5 years after initial diagnosis, and were alive at the time of study inclusion [24]. The SCCR is a nationwide, population-based cancer registry including all patients diagnosed below age <21 years with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis [25]. From 2007 to 2017, we sent questionnaires to parents of children aged 5–15 years, adolescents aged 16–19 years, and adult CCS aged ≥ 20 years. The Ethics Committee of the Canton of Bern approved the SCCR and SCCSS (KEK-BE: 166/2014). The SCCSS is registered at ClinicalTrials.gov (identifier: NCT03297034).

Study population

We included all survivors who participated in the SCCSS and had been treated in a clinic affiliated to the Swiss Pediatric Oncology Group (SPOG) between 1976 and 2010. As the definition of 5-year survivors was based on the year of diagnosis and not the year of HSCT, some participants might have been transplanted <5 years before answering the questionnaire. As comparison group, we included survivors participating in the SCCSS who had not had a HSCT. Nontransplanted CCS were matched to transplanted CCS based on sex, diagnosis, age at diagnosis (range ± 2 years), and year of diagnosis (range ± 5 years) striving for a 1:3 ratio. Through this matching we wanted to achieve that CCS in both groups were as similar as possible in terms of sex, age at diagnosis and diagnosis, but did only differ by whether they had had HSCT or not. This matching did probably not eliminate all other differences between the groups since the reason for HSCT, such as high-risk status or relapse, already demands additional treatment for the HSCT patients.

Treatment and transplant characteristics

We collected treatment- and transplant-related characteristics of transplanted survivors from medical records. We calculated cumulative doses for eight known or suspected lung toxic agents: bleomycin, busulfan, carmustin (BCNU), cyclophosphamide, ifosfamide, lomustin (CCNU), melphalan, and thiotepa [11-13, 26]. We combined cumulative doses of alkylating agents (all chemotherapeutics except of bleomycin) by calculating the cyclophosphamide equivalent dose (CED) [27]. We categorized the cumulative CED as either lower/equal to or higher than 11,300 mg/m² with a median-split. We converted busulfan given orally to busulfan intravenously by multiplying it by factor 0.8 [28]. We categorized chest radiation as yes/no according to the Children's Oncology Group guidelines version 5.0 [13] and included irradiation of the upper abdomen. We recorded surgery to the thorax, lung, chest wall, mediastinum, and thoracic spine. Needle biopsies and implantation of venous devices were not coded as thoracic surgery. We collected date of transplantation, history of relapse, remission status, source of transplant, stem cell donor, cytomegalovirus (CMV) status, sex and blood group of donor and recipient, and information on graft versus host disease (GvHD). We categorized stem cell transplantation into autologous and allogeneic and further specified allogeneic transplantation into Human Leucocyte Antigen (HLA) matched (e.g., 12/ 12) and HLA-mismatched (e.g., 9/10) donors. As HLA

Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors...

typing and documentation changed substantially in the last decades, it was not possible to assess exact HLA matching [29, 30]. We categorized GvHD into acute and chronic according to information from medical records.

Pulmonary outcomes

We collected information on pulmonary symptoms (chronic cough defined as \geq 3 months) and diseases (pneumonia in last 2 years, lung fibrosis, emphysema, or chest wall abnormality) from the SCCSS questionnaires. We categorized the different pulmonary outcomes as yes/no (present/absent) variables. In addition to answering the questions, participants could describe other problems as free text. Responses we could not assign to one of the existing categories were coded as "other pulmonary problem". We had \leq 5% missings on pulmonary outcomes except for pneumonia (6% missings). We allocated missing information to "not having the pulmonary outcomes" assuming that survivors would mention pulmonary outcomes if they were clinically significant.

Clinical and lifestyle characteristics

We extracted the following clinical characteristics from the SCCR: sex, age at diagnosis, year of diagnosis, and cancer diagnoses according to the International Classification of Childhood Cancer, 3rd edition [31]. For analyses, we used the following four diagnostic categories: leukemia, where patients with relapsed and refractory disease often receive allogeneic HSCT, lymphoma, and neuroblastoma, where autologous HSCT is used for relapsed or high-risk disease, and other diagnoses, where HSCT is used less frequently. For lifestyle characteristics we extracted smoking status from the questionnaires (Supplementary Explanation E1).

Statistical analysis

We used descriptive statistics to describe sociodemographic, lifestyle, and clinical characteristics of transplanted and non-transplanted CCS. To assess trends in transplant characteristics across transplant eras we used the "nptrend" command in STATA software [32]. We compared the prevalence of pulmonary outcomes between transplanted and non-transplanted CCS using chi-square tests. We used logistic regression and likelihood ratio tests to quantify associations between sociodemographic, lifestyle, clinical, and transplant-related variables and pulmonary outcomes in transplanted CCS. We retained variables with a p value ≤ 0.1 in the univariable analysis for inclusion into the multivariable model and included radiotherapy as a priori confounder according to the literature. We compared sociodemographic and clinical characteristics of transplanted CCS who did or did not respond to the

questionnaire by using chi-square tests and student's *t*-tests. We used STATA software (Version 16.0, Stata Corporation, Austin, TX) to analyze the data.

Results

Characteristics of study population

We included 132 transplanted and 368 matched nontransplanted CCS (Supplementary Figs. F1 and F2). Transplanted responders and non-responders did not differ in sociodemographic, lifestyle, and clinical characteristics (Supplementary Table S1). The median age of transplanted CCS was 6.5 years (interquartile range, IQR 2.9–11.6 years) at cancer diagnosis and 8.8 years (IQR 4.8–13.6) at transplantation. Median follow-up time was 9.8 years (IQR 7.2–15.9). Leukemia was the most frequent cancer diagnosis (55%), followed by lymphoma (15%), and neuroblastoma (14%) (Table 1).

Transplant characteristics and change over time

The absolute number of transplanted CCS who participated in the SCCSS increased over time. Leukemia remained the most common underlying cancer diagnosis in all three eras (Table 2). Conditioning regimens changed with a relative but non-significant reduction in TBI-containing regimens from 61% in the first to 39% in the other two eras (p for trend = 0.083). Among chemotherapeutics, the proportion of CCS who received ifosfamide increased (p = 0.002) but the median cumulative dose decreased non-significantly (p = 0.477). Also cyclophosphamide dosage decreased (p < 0.001) with no significant reduction in the proportion of CCS receiving it (p = 0.186). For bleomycin there was a trend towards lower cumulative doses in more recent eras (p = 0.094). Two-thirds (65%) of CCS had radiotherapy involving the thorax with no significant change over time, and 9% had thoracic surgery with a trend to an increasing proportion of CCS in more recent years. Nearly half of transplanted CCS received autologous HSCT (46%) and in 57% HSCT was performed in first remission or refractory disease. The proportion of transplanted CCS receiving peripheral blood stem cells increased from 27% to 71% with a corresponding reduction in the proportion of those receiving bone marrow stem cells (p for trend <0.001). Eight CCS developed chronic GvHD (cGvHD) but none had pulmonary GvHD (Supplementary Table S2). Supplementary Tables S2 and S3 provide summaries of clinical, treatment, and transplant characteristics for CCS transplanted in autologous or allogeneic settings, stratified by era of transplantation. Differences in CCS exposed to allogeneic or autologous HSCT are shown in Supplementary Table S4.

age at diagnosis, diagnosis,	and year of diagnosis	(1:3 ratio).
	Transplanted CCS ($n = 132$) n (%)	Non-transplanted CCS $(n = 368)$ n (%)
Sociodemographic and lifes		
Sex, male	69 (52)	195 (53)
Age at questionnaire, median years (IQR)	18.4 (13.8–22.9)	18.5 (13.6–23.8)
Smoking status ^a		
Active smoking	7 (5)	27 (7)
Passive smoking	63 (48)	163 (44)
Former active smoking	9 (6)	20 (6)
Never smoking	54 (41)	158 (43)
Clinical characteristics		
Age at diagnosis, median years (IQR)	6.5 (2.9–11.6)	6.4 (2.7–11.4)
Age at transplantation, median years (IQR)	8.8 (4.8–13.6)	NA
Follow-up time ^b , median years (IQR)	9.8 (7.2–15.9)	10.1 (7.9–15.1)
Era of diagnosis		
1976–1995	40 (30)	120 (33)
1996–2005	60 (45)	156 (42)
2006-2010	32 (25)	92 (25)
Childhood cancer diagnosis	s according to ICCC	2-3
I: Leukemia	72 (55)	214 (58)
II: Lymphoma	20 (15)	60 (16)
IV: Neuroblastoma	19 (14)	44 (12)
Other ^c	21 (16)	50 (14)

Table 1 Characteristics of transplanted (N = 132) and non-

transplanted (N = 368) childhood cancer survivors, matched by sex,

CCS childhood cancer survivors, *ICCC-3* International Classification of Childhood Cancer, 3rd edition, *IQR* interquartile range.

^{au}Active" and "former active smoking" assessed in adolescents and adults; "passive smoking" in children corresponds to having parents who currently smoke or formerly smoked, "never smoking" in children corresponds to having both parents who never smoked.

^bTime from first diagnosis until date of answering the questionnaire.

^cOther tumors in transplanted survivors include: tumors of the central nervous system (n = 6), retinoblastoma (n = 1), malignant bone tumors (n = 7), soft tissue sarcomas (n = 4), malignant germ cell tumors (n = 3) Other tumors in non-transplanted survivors include: tumors of the central nervous system (n = 12), retinoblastoma (n = 1), malignant bone tumors (n = 9), soft tissue sarcomas (n = 4), malignant germ cell tumors (n = 3).

Prevalence of pulmonary outcomes

Any pulmonary outcome was reported as often in transplanted (20%) as in non-transplanted CCS (18%; p = 0.507). The occurrence of the listed pulmonary outcomes was not significantly different between transplanted and non-transplanted CCS. Pneumonia was the most frequently reported outcome (Fig. 1). The proportion of transplanted CCS reporting any pulmonary outcome did not change by era of transplantation (Table 2).

Risk factors for pulmonary outcomes

In univariable logistic regression analysis, we found associations between older age at cancer diagnosis (increase per year; odds ratio [OR] 1.2, 95% confidence interval [CI] 1.05-1.28), exposure to bleomycin (OR 4.63, 95%CI 1.08-19.97), and thoracic surgery (OR 7.44, 95%CI 2.13-25.92) with any pulmonary outcome (Table 3). We found no significant association with era of diagnosis, treatment with other chemotherapeutics, median CED, and thoracic radiotherapy, but numbers were small. Transplantrelated factors were also not significantly associated with reporting of pulmonary outcomes (Table 3). In multivariable logistic regression analysis, the effect of thoracic surgery was reduced to an OR of 3.91 (95%CI 0.95-16.02), suggesting that it has been confounded by other factors related to disease and treatment (Table 4). Most of the 12 CCS treated with thoracic surgery have been diagnosed with Ewing sarcoma (n = 7) or lymphoma (n = 4). All except one CCS have been transplanted autologous, most suffered from relapsed disease (n = 10), received radiotherapy to the chest (n = 10), were treated with open thoracic surgeries (n = 9), received at least one lung toxic chemotherapeutic agent (n = 7), or have been exposed to a combination of radiotherapy and thoracic surgery or resection of lung tissue (n = 9) (Supplementary Table S5).

Discussion

This nationwide population-based cohort study found that transplant characteristics changed over time with fewer HSCT recipients receiving TBI or lung toxic chemotherapeutics. One-fifth of \geq 5-year CCS reported at least one pulmonary outcome 10 years after cancer diagnosis irrespective of whether they had been transplanted or not. Our analyses point to older age at diagnosis and thoracic surgery as possible risk factors for self-reported pulmonary outcomes.

TBI is a crucial component of conditioning regimens for allogeneic HSCT, but known to be lung toxic. Even though TBI cannot completely be replaced by chemotherapy, such as in acute lymphoblastic leukemia [33], we found that the use of TBI has become less common in more recent eras. There was a non-significant trend towards lower cumulative doses of bleomycin and we found no evidence for a change in cumulative doses of carmustine, but numbers were small. The increasing use of peripheral blood stem cells in more recent eras is in line with literature [34–36] and the Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors...

	Total $(n = 132)$	1976-1995 (<i>n</i> = 33)	1996-2005 (<i>n</i> = 51)	2006-2015 (<i>n</i> = 48)	p value	
	(n = 132) n (%)	(n = 55) n (%)	(n = 51) n (%)	(n = +6) n (%)		
Clinical characteristics						
Cancer diagnosis according t	o ICCC-3				0.806	
I: Leukemia	72 (55)	18 (55)	26 (51)	28 (58)		
II: Lymphoma	20 (15)	8 (24)	7 (14)	5 (10)		
IV: Neuroblastoma	19 (14)	5 (15)	8 (16)	6 (13)		
Other ^a	21 (16)	2 (6)	10 (19)	9 (19)		
Treatment characteristics						
Conditioning containing TBI	59 (45)	20 (61)	20 (39)	19 (39)	0.083	
Conditioning regimens					0.003	
TBI + cyclophosphamide ± others	34 (26)	16 (48)	12 (23)	6 (13)		
TBI + others	25 (19)	4 (12)	8 (16)	13 (27)		
Busulfan + cyclophosphamide ± other	28 (21)	7 (21)	11 (21)	10 (21)		
Busulfan \pm others	8 (6)	1 (3)	4 (8)	3 (6)		
Carmustine ± others	9 (7)	3 (9)	3 (6)	3 (6)		
Cyclophosphamide ± others	9 (7)	1 (3)	6 (12)	2 (4)		
Melphalan \pm carboplatin \pm others	19 (14)	1 (3)	7 (14)	11 (23)		
Chemotherapeutic agents						
Alkylating agents combined ^b	131 (99)	33 (100)	50 (98)	48 (100)		
Busulfan	37 (28)	9 (27)	16 (31)	12 (25)	0.776	
Carmustine	9 (7)	4 (12)	3 (6)	2 (4)	0.180	
Cyclophosphamide	123 (93)	33 (100)	46 (90)	44 (92)	0.186	
Ifosfamide	62 (47)	9 (27)	23 (45)	30 (63)	0.002	
Lomustine	2 (2)	1 (3)	-	1 (2)	0.835	
Melphalan	44 (33)	9 (27)	17 (33)	18 (38)	0.342	
Thiotepa	14 (11)	3 (9)	8 (16)	3 (6)	0.563	
Bleomycin	8 (6)	3 (9)	3 (6)	2 (4)	0.371	
Chemotherapeutic agents, mg						
Alkylating agents combined ^b	11329 (5687–17164)	11658 (7924–17391)	11367 (5879–21425)	8546 (4447–16131)	0.199	
Busulfan	443 (324–480)	480 (470–587)	344 (297–480)	440 (374–449)	0.021	
Carmustine	300 (298-300)	300 (298-351)	300 (298-300)	300 (291-306)	0.737	
Cyclophosphamide	4200 (3021–7535)	7299 (4200–8684)	4247 (3090–8230)	3439 (2634–5258)	<0.001	
Ifosfamide	9941 (4032–22500)	11500 (5200–16032)	10227 (4032–22500)	8181 (4017–19767)	0.477	
Lomustine	395 (190-600)	190	-	600	0.317	
Melphalan	140 (139–169)	140 (140–142)	140 (140–140)	140 (139–180)	0.739	
Thiotepa	680 (588–900)	750 (168–900)	749 (591–900)	610 (307–900)	0.921	
Bleomycin	40 (40-46)	42 (40-80)	40 (40-50)	30 (20-40)	0.094	

SPRINGER NATURE

M. Otth et al.

Table 2 (continued)	m . 1	1076 1005	1006 2005	2006 2015	1 .4
		Total 1976–1995 $(n = 132)$ $(n = 33)$ n (%) n (%)	1996-2005 (<i>n</i> = 51)	2006–2015 (<i>n</i> = 48) <i>n</i> (%)	p value*
	· · · ·		(n = 51) n (%)		
Radiotherapy involving the thorax ^c	86 (65)	25 (76)	32 (63)	29 (60)	0.175
Thoracic surgery ^d	12 (9)	1 (3)	5 (10)	6 (13)	0.157
Transplant characteristics					
Remission status at transplant	ation				0.906
First remission	75 (57)	16 (48)	35 (69)	24 (50)	
Relapsed disease	57 (43)	17 (52)	16 (31)	24 (50)	
Stem cell donor					0.098
Autologous	61 (46)	17 (52)	25 (49)	19 (39)	
HLA identical sibling / HLA matched (un-) relative donor	56 (42)	16 (48)	19 (37)	21 (44)	
HLA mismatch (un-) related /haploidentical	15 (11)	0	7 (14)	8 (17)	
Source of transplant					< 0.001
Cord blood	6 (5)	-	1 (2)	5 (10)	
Peripheral blood	75 (57)	9 (27)	32 (63)	34 (71)	
Bone marrow	46 (35)	22 (67)	17 (33)	7 (15)	
Unknown	5 (4)	2 (6)	1 (2)	2 (4)	
Pulmonary outcome	26 (20)	7 (21)	11 (22)	8 (17)	0.582

HLA human leukocyte antigen, ICCC-3 International Classification of Childhood Cancer, 3rd edition, IQR interquartile range, N number, TBI total body irradiation.

*p value for trend.

^aOther tumors include: tumors of the central nervous system (n = 6), retinoblastoma (n = 1), malignant bone tumors (n = 7), soft tissue sarcoma (n = 4), malignant germ cell tumors (n = 3).

^bCombination according to Cyclophosphamide Equivalent Dose (CED) [27].

^cThoracic radiation fields according to COG guidelines, Version 4.0, Oct 2018, including radiation to the chest, whole lung, mediastinum, (mini-) mantle field, TBI and additionally upper abdomen and thoracic spine, including craniospinal irradiation.


^dThoracic surgery according to COG guidelines, Version 4.0, Oct 2018, including thoracotomy, chest wall surgery, rib resection, lobectomy, pulmonary metastasectomy and wedge resection.

increasing use of mismatched (un-) related donors reflects the overall progress in HSCT over time.

The proportion of transplanted CCS reporting any pulmonary outcome did not change during the three HSCT eras. Studies that compared self-reported pulmonary outcomes in transplanted CCS are few. Fanfulla et al. examined children during the first 18 months after allogeneic HSCT [22]. Cough was reported by 15–25% of children and pneumonia was diagnosed in the first 6 months in 19% of children. The occurrence of pneumonia in the first 6 months, is indicative of delayed immune reconstitution rather than late pulmonary outcomes. Since the follow-up (18 months) is shorter than in our population (10 years) direct comparison is difficult. Also in the entire cohort of Swiss CCS (N = 1 894) pneumonia was the most frequently reported pulmonary outcome (10%), and pulmonary fibrosis (0.8%) and emphysema (0.2%) were reported by few CCS [20]. CCS in the North American Childhood Cancer Survivor Study showed a different distribution of pulmonary outcomes with chronic cough being the most frequent outcome (7.8%), followed by pulmonary fibrosis (1.9%), and recurrent pneumonia (1.7%) [21]. We found no difference in the prevalence of pulmonary outcomes between transplanted and non-transplanted CCS in our study (20% vs. 18%). This could be explained by the high proportion of leukemia (58%) and lymphoma (16%) diagnoses in non-transplanted CCS due to the matching. A Danish cohort study included 94 leukemia survivors a median of 10 years from diagnosis, treated with chemotherapy only, and 11% suffered from pulmonary problems, mainly cough [37]. A

Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors...

Fig. 1 Prevalence of selfreported pulmonary diseases and symptoms in transplanted (N = 132) and nontransplanted matched childhood cancer survivors (N = 368). Error bars represent 95% confidence intervals. P value comparing prevalence between transplanted and nontransplanted survivors. *Total N reduced for pulmonary fibrosis and emphysema because question only asked in adolescents and adults: N = 85transplanted survivors, N = 195non-transplanted survivors. ** "Other pulmonary outcome" includes reduced lung function (n = 3) and pulmonary GvHD (n = 1).



US study including Hodgkin's lymphoma survivors treated with chest radiation but without HSCT showed that 17% had at least one episode of pneumonia and 9% reported dyspnea [38].

CCS who had undergone thoracic surgery in addition to HSCT reported more pulmonary outcomes than those without thoracic surgery. This might be because this group of CCS had received more often thoracic radiotherapy or lung toxic chemotherapeutics, had more often been diagnosed with relapsed disease, and underwent open thoracic surgeries in most cases, which goes along with a more intensive treatment. Residual confounding by these additional lung toxic treatment modalities probably leads to an overestimation of the association between thoracic surgery and pulmonary outcomes. Older age at diagnosis, resulting in older age at HSCT, was another risk factor for pulmonary outcomes in univariable analysis. No study has assessed self-reported pulmonary outcomes in the context of age at HSCT, but four studies showed an association between older age at HSCT and deterioration in selected pulmonary function parameters [23, 39–41]. In multivariable analysis, bleomycin was not a risk factor for pulmonary outcomes anymore, which is in line with findings from the whole Swiss CCS cohort [20]. In our cohort, we found no significant effect of other selected chemotherapeutics and transplant-related factors on the reporting of pulmonary outcomes. All studies that evaluated the impact of cGvHD on the lung, used pulmonary function tests as outcome measure [41-44]. They reported a negative effect of cGvHD on pulmonary function. We explain the missing effect of cGvHD, lomustine, and carmustine by the low number of survivors exposed to each of these factors. Also some CCS with severe pulmonary cGvHD might have died before receiving the SCCSS questionnaire and missing or non-detailed documentation in the medical records might have led to an underestimation of the effect of cGvHD on pulmonary outcomes.

We found no difference in pulmonary outcomes between CCS treated with autologous and allogeneic HSCT. Thoracic surgery was overrepresented in the autologous group because of the underlying diagnoses, mainly bone tumors. In contrast, CCS treated with allogeneic HSCT were more often exposed to chest radiotherapy, which can lead to radiation pneumonitis and an increased risk of interstitial pneumonitis due to infections such as CMV. Both factors have not been assessed in detail.

The strengths of this study include the population-based national design of the SCCSS, the high response rate of transplanted CCS (71%), and the comparability between responding and nonresponding transplanted survivors. This makes us confident, that our results can be extrapolated to \geq 5-year Swiss survivors who underwent HSCT. In addition, the completeness of exact treatment exposure, including cumulative doses of chemotherapeutics and detailed information on HSCT in transplanted CCS is another strength.

The reliance on self-reported outcome data is a limitation and our study did not include objective pulmonary function

M. Otth et a	al.
--------------	-----

Table 3 Association between sociodemographic, clinical, treatment, and	transplant characteristics on self-reported pulmonary outcomes.
--	---

	Reporting of any pulmonary outcome					
	noutcome	N _{total}	%	OR	95% CI	p value?
Sociodemographic and lifestyle characteristics						
Sex						0.795
Male	13	69	19	1		
Female	13	63	21	1.12	0.47-2.64	
Age at questionnaire, continuous (years)	26	132	20	1.05	0.99-1.11	0.088
Smoking status ^a						0.924
Never smoking	12	60	20	1		
Passive smoking	10	56	18	0.87	0.34-2.21	
Former active smoking	2	9	22	1.14	0.21-6.21	
Active smoking	2	7	29	1.60	0.27-9.28	
Clinical characteristics						
Age at diagnosis, continuous (years)	26	132	20	1.2	1.05-1.28	0.002
Follow-up time, continuous (years)	26	132	20	0.98	0.91-1.06	0.613
Era of diagnosis						0.800
1976–1990	5	20	25	1		
1991–2000	8	45	18	0.64	0.18-2.31	
2001–2010	13	67	19	0.72	0.22-2.35	
Cancer diagnosis according to ICCC-3						0.271
Leukemia	15	72	21	1		0.271
Lymphoma	5	20	25	1.27	0.39-4.04	
Neuroblastoma	1	19	5	0.21	0.03-1.71	
Other ^b	5	21	24	1.18	0.37–3.76	
Treatment characteristics	5	21	24	1.10	0.57-5.70	
Bleomycin						0.040
No	22	124	18	1		0.040
Yes	4	8	50	4.63	1.08-19.97	
Busulfan	+	0	50	4.05	1.06-19.97	0.190
No	16	95	17	1		0.190
Yes	10	93 37	27	1.83	0.74-4.51	
	10	57	27	1.65	0.74-4.31	0.107
Nitrosureas (BCNU and CCNU)	22	100	10	,		0.107
No	22	122	18	1	0.70 11.65	
Yes	4	10	40	3.03	0.79–11.65	0.044
Cyclophosphamide	2	0	22			0.844
No	2	9	22	1	0.16.4.04	
Yes	24	123	20	0.84	0.16-4.34	0.506
Ifosfamide	1.5	70				0.596
No	15	70	21	1		
Yes	11	62	18	0.79	0.33-1.88	
Melphalan						0.281
No	15	88	17	1		
Yes	11	44	25	1.62	0.67-3.91	
Treosulfan						0.400
No	24	126	19	1		
Yes	2	6	33	2.12	0.36-12.28	
Alkylating agents ^c						0.084
≤11,300 mg/m ²	9	66	14	1		
>11,300 mg/m ²	17	66	26	2.19	0.89-5.37	
Radiotherapy to chest (including TBI)						0.165
No	6	46	13	1		
Yes	20	86	23	2.02	0.75-5.45	
Thoracic surgery						< 0.001
No	19	120	16	1		
Yes	7	12	58	7.44	2.13-25.92	

Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors...

Table 3	(conti	nued)
Table 3	(conti	nucu)

	Reporting of	ng of any pulmonary outcome				
	noutcome	N _{total}	%	OR	95% CI	p value*
Transplant characteristics						
Remission status at transplantation						0.223
First remission/primary refractory	12	75	16	1		
Relapsed disease	14	57	24	1.71	0.72-4.05	
Type of transplantation						0.995
Allogeneic	14	71	20	1		
Autologous	12	61	20	0.99	0.42-2.35	
Stem cell donor						0.739
Autologous	12	61	20	1		
HLA ident. sibling, matched (un)related donor	11	56	20	0.99	0.40-2.48	
HLA mismatched (un)related, haploidentical	3	15	20	1.02	0.25-4.19	
Source of transplant $(n = 66)^d$						0.933
Bone marrow	7	34	21	1		
Peripheral blood	6	26	23	1.15	0.34-3.98	
Cord blood	1	6	17	0.77	0.08-7.71	
Graft versus host disease $(n = 71)^d$						0.449
No	4	15	27	1		
Yes	10	56	18	0.59	0.16-2.27	

Results from univariable logistic regression analysis. N = 132, median age at study 18.4 years.

BCNU Lomustine, CCNU Carmustine, HLA human leukocyte antigen, ICCC-3 International Classification of Childhood Cancer, 3rd edition, OR Odds ratio, TBI total body irradiation, CI confidence interval.

*p value calculate by logistic regression (Wald test) for continuous and binary independent variables and by likelihood ratio test for independent variables with >2 categories.

^aActive and former active smoking assessed in adolescents and adults. Passive and never smoking assessed in children, adolescent and adults.

^bOther diagnostic groups include: malignant bone tumors (n = 7), tumors of the central nervous system (n = 6), soft tissue sarcomas (n = 4), germ cell tumors (n = 3), retinoblastoma (n = 1).

^cCumulative alkylating dose according to cyclophosphamide equivalent dose (CED); categorized in smaller or equal to the median or larger as the median cumulative dose.

^dIn survivors undergone allogeneic transplantation only.

tests. CCS treated with open thoracic surgery are reminded by the scar of their history and thus may be more sensitive in dealing with their lung health, and may remember and report pulmonary outcomes better. However, Louie et al. reported a high agreement between self-reported pulmonary outcomes, such as chronic cough, pulmonary fibrosis, and emphysema, and their validation by extractions from medical records (sensitivity 96.2%; specificity 90.8%) [45]. The SCCSS has not been designed for survivors after HSCT specifically, neither for the assessment of pulmonary outcomes only and did not include specific questions on exertion-induced dyspnea or effort intolerance. This might have led to underreporting of pulmonary outcomes in our study. Also "pneumonia" might have been misunderstood by lay persons, as it was not defined in the questionnaire. Survival bias due to inclusion of ≥5-year survivors could have led to underestimation of pulmonary outcomes as more severely affected patients might have died. The small number of transplanted CCS who have been exposed to specific chemotherapeutics and

transplant-related exposures did not allow for a multivariable analysis of all exposures in a single model. Also the detailed information on treatment exposures, such as cumulative doses, was only available for transplanted CCS. Finally, the absolute numbers of CCS reporting pulmonary outcomes was small, because the study population was young with a relatively short follow-up time, and the incidence of pulmonary outcomes increases over lifetime [20, 21, 39, 46].

In summary, we found that one-fifth of CCS, including those who underwent HSCT and matched controls, developed long-term pulmonary outcomes. As we only assessed self-reported outcomes, using a limited number of questions, this proportion probably only represents the tip of the iceberg. This underlines that we should implement long-term pulmonary follow-up recommendations on a large scale [13, 47–49] using sensitive outcome measures, such as lung function tests, to assess the full spectrum of long-term pulmonary sequelae after childhood cancer at an early stage.

Table 4 Association between sociodemographic, clinical, treatment	,
and transplant characteristics on self-reported pulmonary outcomes.	

	OR	95% CI	p value
Age at diagnosis	1.13	0.99-1.28	0.055
Age at questionnaire	1.00	0.91 - 1.08	0.892
Bleomycin exposure	1.57	0.28-8.81	0.608
Median CED dose >11,300 mg/m ²	1.74	0.57-5.33	0.330
Thoracic surgery	3.91	0.95-16.02	0.058
Thoracic radiotherapy	1.58	0.49–5.14	0.446

Results from multivariable logistic regression analysis, adjusted for all factors in the table. N = 132, median 18.4 years at study.

CED cyclophosphamide equivalent dose, CI confidence interval, OR Odds ratio.

Acknowledgements We thank all childhood cancer patients and families for participating in our survey. We thank the study team of the SCCR (Luzius Mader, Sven Strebel, Nicolas Waespe), Marcel Zwahlen for statistical support, the data managers of the SPOG (Claudia Althaus, Nadine Assbichler, Pamela Balestra, Heike Baumeler, Nadine Beusch, Sarah Blanc, Susann Drerup, Janine Garibay, Franziska Hochreutener, Monika Imbach, Friedgard Julmy, Eléna Lemmel, Rodolfo Lo Piccolo, Heike Markiewicz, Veneranda Mattielo, Annette Reinberg, Renate Siegenthaler, Astrid Schiltknecht, Beate Schwenke, and Verena Stahel) and the data managers and administrative staff of the SCCR (Meltem Altun, Erika Brantschen, Katharina Flandera, Elisabeth Kiraly, Nadine Lötscher, Verena Pfeiffer, Shelagh Redmond, Julia Ruppel, and Ursina Roder). This study is supported by Swiss Cancer League (KLS-3886-02-2016), Swiss Cancer Research (KFS-4157-02-2017 and KFS-4722-02-2019), and Lung League Bern.

The Swiss Pediatric Oncology Group (SPOG) M. Ansari^{6,7}, M. Beck Popovic¹³, J. P. Bourquin¹⁴, P. Brazzola¹⁵, J. Greiner¹⁶, J. Rössler¹², F. Schilling¹⁷, K. Scheinemann^{2,8,9}, N. von der Weid⁴

¹³Pediatric Hematology-Oncology Unit, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; ¹⁴Division of Oncology, University Children's Hospital Zurich-Eleonore Foundation, Zurich, Switzerland; ¹⁵Pediatria Bellinzona, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland; ¹⁶Division of Hematology and Oncology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland; ¹⁷Division of Oncology/ Hematology, Department of Pediatrics, Kantonsspital Luzern, Lucerne, Switzerland

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if

SPRINGER NATURE

changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

- 1. Merli P, Algeri M, Del Bufalo F, Locatelli F. Hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Curr Hematologic Malignancy Rep. 2019;14:94–105.
- Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2015: Cd006301.
- Guerra JA, Dhall G, Marachelian A, Castillo E, Malvar J, Wong K, et al. Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors. Bone Marrow Transplant. 2017;52: 1543–8.
- 4. Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma–results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165: 534–44.
- Niethammer D, Bader P, Handgretinger R, Klingebiel T. Stem cell transplantation. Klinische Padiatrie. 2013;225(Suppl 1):S94–8.
- Dopfer R, Henze G, Bender-Gotze C, Ebell W, Ehninger G, Friedrich W, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood. 1991;78:2780–4.
- Diab M, ZazaDitYafawi J, Soubani AO. Major pulmonary complications after hematopoietic stem cell transplant. Exp Clin Transplant: Off J Middle East Soc Organ Transplant. 2016;14: 259–70.
- Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematol/Oncol Stem Cell Ther. 2010;3:143–57.
- Collaco JM, Gower WA, Mogayzel PJ Jr. Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: overview, diagnostic considerations, and infectious complications. Pediatr Blood Cancer. 2007;49:117–26.
- Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140:881–901.
- 11. Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy. Semin Oncol. 2013;40:757–73.
- Versluys AB, Bresters D. Pulmonary complications of childhood cancer treatment. Paediatr Respiratory Rev. 2016;17:63–70.
- COG COG. Children's Oncology Group [COG] Long Term Follow-Up guidelines Version 5.0 2018. 2019. http://www. survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_ v5.pdf.
- 14. Sano H, Kobayashi R, Iguchi A, Suzuki D, Kishimoto K, Yasuda K, et al. Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2014;49:38–41.
- 15. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic

Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors...

GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant. 2011;46:1283.

- Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:749–59.
- Fidler MM, Reulen RC, Bright CJ, Henson KE, Kelly JS, Jenney M, et al. Respiratory mortality of childhood, adolescent and young adult cancer survivors. Thorax. 2018;73:959–68.
- Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-term cause-specific mortality among survivors of childhood cancer. Jama. 2010;304:172–9.
- Kirchhoff AC, Fluchel MN, Wright J, Ying J, Sweeney C, Bodson J, et al. Risk of hospitalization for survivors of childhood and adolescent cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology. 2014;23:1280–9.
- Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, et al. Long-term pulmonary disease among Swiss childhood cancer survivors. Pediatric Blood Cancer. 2018;65.
- Dietz AC, Chen Y, Yasui Y, Ness KK, Hagood JS, Chow EJ, et al. Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2016;122:3687–96.
- Fanfulla F, Locatelli F, Zoia MC, Giorgiani G, Bonetti F, Spagnolatti L, et al. Pulmonary complications and respiratory function changes after bone marrow transplantation in children. Eur Respiratory J. 1997;10:2301–6.
- Wieringa J, van Kralingen KW, Sont JK, Bresters D. Pulmonary function impairment in children following hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2005;45:318–23.
- Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, et al. Cohort profile: the Swiss childhood cancer survivor study. Int J Epidemiol. 2012;41:1553–64.
- Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss childhood cancer registry: rationale, organisation and results for the years 2001-2005. Swiss Med Wkly. 2007;137:502–9.
- Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002;95:2431–41.
- 27. Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014;61:53–67.
- Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:523–36.
- Fleischhauer K. Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching. Hematol Am Soc Hematol Educ Program. 2019;2019:532–8.
- Eyrich M, Schulze H. HLA Matching in Pediatric Stem Cell Transplantation. Transfus Med hemotherapy: offizielles Organ der Dtsch Ges fur Transfusionsmedizin und Immunhamatologie. 2019;46:348–55.
- Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005; 103:1457–67.
- Software S STATA manual: nptrend [22.04.2020]. https://www. stata.com/manuals13/rnptrend.pdf.
- Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitra-Roussou V, Yesilipek A, et al. Myeloablative conditioning for allo-HSCT in

pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020;55:1540–51.

- 34. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringden O, et al. Higher mortality after allogeneic peripheralblood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22:4872–80.
- 35. Simonin M, Dalissier A, Labopin M, Willasch A, Zecca M, Mouhab A, et al. More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party. Bone Marrow Transplant. 2017;52: 1071–3.
- 36. Pulsipher MA, Levine JE, Hayashi RJ, Chan KW, Anderson P, Duerst R, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant. 2005;35:361–7.
- Nysom K, Holm K, Olsen JH, Hertz H, Hesse B. Pulmonary function after treatment for acute lymphoblastic leukaemia in childhood. Br J Cancer. 1998;78:21–7.
- Venkatramani R, Kamath S, Wong K, Olch AJ, Malvar J, Sposto R, et al. Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. Pediatr Blood Cancer. 2014; 61:1277–81.
- Inaba H, Yang J, Pan J, Stokes DC, Krasin MJ, Srinivasan A, et al. Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer. 2010;116:2020–30.
- Ginsberg JP, Aplenc R, McDonough J, Bethel J, Doyle J, Weiner DJ. Pre-transplant lung function is predictive of survival following pediatric bone marrow transplantation. Pediatr Blood Cancer. 2010;54:454–60.
- Leung W, Ahn H, Rose SR, Phipps S, Smith T, Gan K, et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine. 2007;86:215–24.
- 42. Madanat-Harjuoja LM, Valjento S, Vettenranta K, Kajosaari M, Dyba T, Taskinen M. Pulmonary function following allogeneic stem cell transplantation in childhood: a retrospective cohort study of 51 patients. Pediatr Transplant. 2014;18:617–24.
- 43. Uderzo C, Pillon M, Corti P, Tridello G, Tana F, Zintl F, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant. 2007;39:667–75.
- Hoffmeister PA, Madtes DK, Storer BE, Sanders JE. Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation. Pediatr Blood Cancer. 2006;47:594–606.
- Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone Marrow Transplant. 2000;25:1191–6.
- Kaya Z, Weiner DJ, Yilmaz D, Rowan J, Goyal RK. Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children. Biol Blood Marrow Transplant. 2009;15:817–26.
- 47. Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GMT, Huang JT, et al. Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children's Oncology Group Report. Biol Blood Marrow Transplant 2016;22:782–95.
- 48. Dietz AC, Duncan CN, Alter BP, Bresters D, Cowan MJ, Notarangelo L, et al. The second pediatric blood and marrow

M. Otth et al.

transplant consortium international consensus conference on late effects after pediatric hematopoietic cell transplantation: defining the unique late effects of children undergoing hematopoietic cell transplantation for immune deficiencies, inherited marrow failure disorders, and hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23:24–9.

49. Shenoy S, Gaziev J, Angelucci E, King A, Bhatia M, Smith A, et al. Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2018;24:1313–21.

SPRINGER NATURE

Online Supplement

Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study

Maria Otth, MD, Christina Schindera, MD, Tayfun Güngör, MD, Marc Ansari, MD, Katrin Scheinemann, MD, Fabiën N. Belle, PhD, Philipp Latzin, MD PhD, Nicolas von der Weid MD, Claudia E. Kuehni, MD, for the Swiss Pediatric Oncology Group (SPOG)

SUPPLEMENTAL EXPLANATON E1

This supplemental document describes how we categorized smoking status in childhood cancer survivors participating in the Swiss Childhood Cancer Survivor Study

Lifestyle variables

We combined the answers on active and passive smoking into one variable with four categories: "active smoking", "passive smoking", "former active smoking", and "never active smoking". The category "passive smoking" includes adolescent and adult CCS who state that they are exposed to passive smoking and minor CCS, whose parents currently smoke or are former smokers. The category "never smoking" includes adolescents and adults, who never smoked and were not exposed to passive smoking, and children, whose parents never smoked.

Smoking questions asked in the adult and adolescent version

Do you currently smoke cigarettes?

No, I never smoked

No, I stopped smoking since ____ month

Yes, I smoke irregularly: number _____ of cigarettes per week

Yes, I smoke regularly: number _____ of cigarettes per day

If you count up all the situations, how many hours per day are you normally exposed to tobacco smoke of other people?

hours

Smoking questions asked in parents' version (separate for mother and father)

Have you ever smoked?

No, never

Yes, stopped since _____

Yes, still smoke today

SUPPLEMENTAL TABLE S1:

This supplemental table describes the characteristics of transplanted childhood cancer survivors eligible for the questionnaire stratified into responder and non-responder to the questionnaire, N=200. The patient tree is described in Supplemental Figure F2.

	Responder (n=132)	Non-responder (n=68)	p value ¹
	n (%)	n (%)	
Sociodemographic characteristics			
Sex, male	69 (52)	43 (63)	0.139
Age at survey, median years (IQR)	18.4 (13.8 – 22.9)	18.6 (14.3 – 22.6) ²	0.933
Language region			0.975
German	89 (67)	46 (68)	
French or Italian	43 (33)	22 (32)	
Clinical characteristics			
Age at diagnosis, median years (IQR)	6.5 (2.9 - 11.7)	6.7 (2.8, 11.8)	0.876
Age at first HSCT, median years (IQR)	8.8 (4.8 - 13.6)	11.1 (4.7 – 14.1)	0.221
Follow-up time ² , median years (IQR)	9.8 (7.2 - 15.9)	10.8 (7.6 – 14.9)	0.978
Era of diagnosis			0.712
1976-1995	40 (30)	22 (32)	
1996-2005	60 (46)	33 (49)	
2006-2010	32 (24)	13 (19)	
Cancer diagnosis according to ICCC-3			0.561
I: Leukemia	72 (55)	32 (46)	
la: lymphoid leukemia	43 (33)	21 (31)	
lb: acute myeloid leukemia	18 (14)	8 (11)	
Ic-e: CML, MDS, unspecified other leukemias	11 (8)	3 (4)	
II: Lymphoma	20 (15)	14 (21)	
IIa: Hodgkin lymphoma	7 (5)	1 (2)	
IIb: Non-Hodgkin lymphoma	8 (6)	7 (10)	
IIc: Burkitt lymphoma	4 (3)	6 (9)	
IId: miscellaneous	1 (1)	-	
IV: Neuroblastoma	19 (14)	8 (12)	
Other⁵	21 (16)	14 (21)	
History of any relapse			0.047
Yes	62 (47)	42 (62)	
No	70 (53)	26 (38)	

HSCT, hematopoietic stem cell transplantation; ICCC-3, International Classification of Childhood Cancer, 3rd edition; IQR, interquartile range; N, number

¹ chi-squared for categorical variables; t-test for continuous variables

 ² Time from first diagnosis until answering the survey (responder) or sending the survey (nonresponder)
 ³ Other diagnosis in nonresponder include: tumors of the central nervous system (n=6), retinoblastoma (n=1), renal tumors (n=1), hepatic tumors (n=1), malignant bone tumors (n=3), soft tissue sarcoma (n=1), malignant germ cell tumors (n=1)

Other diagnosis in responder include: tumors of the central nervous system (n=8), retinoblastoma (n=1), malignant bone tumors (n=7), soft tissue sarcomas (n=4), malignant germ cell tumors (n=1)

SUPPLEMENTAL TABLE S2: This supplemental table describes clinical, treatment and transp era of transplantation	transplant characteristics of childhood cancer survivors transplanted allogeneic (N=71) stratified by	thood cancer survivors tr	ansplanted allogeneic (N	l=71) stratified by
	1976-1995 (n=16)	1996-2005 (n=26)	2006-2015 (n=29)	Total (n=71)
Clinical characteristics	(%) u	(%) u	u (%)	u (%)
Cancer diagnosis according to ICCC-3 I: Leukemia II: Lymphoma IV: Neurohlastoma	16 (100) 0 0	23 (88) 3 (12) 0	29 (100) 0 0	68 (96) 3 (4) 0
Other ¹	00	00	00	00
Treatment characteristics Conditioning containing TBI	15 (94)	17 (65)	18 (62)	50 (70)
Conditioning regimens TBI + cyclophosphamide ± others TBI + others	13 (81) 2 (13)	12 (46) 5 (10)	6 (21) 12 (42)	31 (44) 19 (27)
Busulfan + cyclophosphamide ± other Busulfan + others	1 (6) -	9 (35) -	9 (31) 1 (3)	19 (27) 1 (1)
Melphalan ± Carboplatin ± others	ı	I	1 (3)	1 (1)
Alkylating agents combined ² Busulfan	16 (100) 2 (13)	25 (96) 9 (35)	29 (100) 9 (31)	70 (99) 20 (28)
Carmustine Cyclophosphamide Ifosfamide	- 16 (100) 4 (25)	- 25 (96) 8 (31)	- 28 (97) 14 (48)	- 69 (97) 26 (37)
Lomustin Melphalan	. 1 1	- 4 (15)	3 (10)	7 (10)
Thiotepa Bleomycin	1 (6) 1 (6)	1 (4) -	1 (4) -	3 (4) 1 (1)
Chemotherapeutic agents, mg/m² Alkylating agents combined ² Busulfan	7881 (4034 – 9588) 520 (454 – 587)	5892 (4000 – 10631) 320 (297 – 345)	5881 (3791 – 8006) 431 (324 – 449)	6100 (3871 – 9579) 360 (320 – 445)
Carmustine Cyclophosphamide Ifosfamide Lomustine	- 5540 (3767 – 7881) 7600 (4600 – 16948) -	3738 (2983 – 5372) 4003 (3052 – 6016) -		- 3990 (2983 – 6242) 4011 (3879 – 6126) -

Chapter 4 - Results

Melphalan Thiotepa Bloomvoin	- 168 80	140 (139 – 140) 304	140 (138 – 140) 307	140 (139 – 140) 304 (168 – 307) 80
Redition Thoracic surgery ⁴	15 (94) 0 (0)	18 (69) 1 (4)	18 (62) 0 (0)	51 (72) 1 (1)
Transplant characteristics				
First remission	8 (50)	17 (65)	13 (45)	38 (54)
Relapsed disease	8 (50)	9 (35)	16 (55)	33 (46)
HLA identical sibling / HLA matched other relative	13 (81)	15 (58)	11 (38)	39 (55)
HLA matched unrelated	3 (19)	4 (15)	10 (34)	17 (24)
HLA mismatch related / haploidentical		5 (19)	2 (7)	7 (10)
HLA mismatch unrelated Source of transplant	ı	2 (8)	6 (21)	8 (11)
Cord blood		1 (4)	5 (17)	6 (8)
Peripheral blood	1 (6)	10 (38)	15 (52)	26 (37)
Bone marrow	13 (81)	14 (54)	7 (24)	34 (48)
Unknown CMV status	2 (13)	1 (4)	2 (7)	5 (7)
Donor and recipient log negative	7 (44)	12 (46)	14 (48)	33 (46)
Donor and recipient IgG positive	2 (12)	7 (27)	5 (17)	14 (19)
Donor and recipient lgG mismatch	4 (25)	5 (19)	10 (35)	19 (26)
Donor or recipient missing	3 (19)	2 (8)		5 (9)
Match	10 (62)	15 (58)	16 (55)	41 (58)
Mismatch	4 (25)	11 (42)	13 (45)	28 (39)
Missing	2 (13)			2 (3)
Blood group				
Match	9 (56)	13 (50)	10 (34)	32 (45)
Major mismatch	1 (6)	7 (27)	10 (34)	18 (25)
Wilhor mismatch Bidiractional mismatch	(CZ) 4	(CI) 4	9 (31)	11 (24)
Missing	2 (13)	1 (4)		3 (4)
,				

Graft versus host disease Development of GvHD	12(75)	19 (73)	25 (86)	56 (79)
Type of GvHD (n=56) Acute Grade I & II Grade III & IV	11 (92) 7 (64) 3 (27)	15 (79) 13 (87) 2 (13)	19 (76) 15 (79) 4 (21)	45 (80) 35 (78) 9 (20)
Unknown Chronic Unknown	1 (9) 1 (8) -	- 4 (21) -	- 3 (12) 3 (12)	1 (2) 8 (14) 3 (5)
Location or acute GVHD (n=45) Skin only Skin and other Skin and intestine	7 (64) 2 (18) 1 (9)	10 (67) 2 (13) 3 (20)	15 (79) 4 (21) -	32 (71) 8 (18) 4 (9)
Skin, intestine and other Location of chronic GvHD (n=8)	1 (9)		· - 7	1 (2) E (62)
Skin and other		t ,	- 0	3 (37)
GVHD oraft versus host disease: HLA, human leukocorte antigen: ICCC-3. International Classification of Childhood Cancer. 3 rd edition: IOR, interquartile range: TBL total body	emational Classification	of Childhood Cancer. 3 rd e	adition: IOR, interduartile ran	de: TBL total body

GvHD, graft versus host disease; HLA, human leukocyte antigen; ICCC-3, International Classification of Childhood Cancer, 3rd edition; IQR, interquartile range; TBI, total body irradiation

¹ Other tumors: tumor of the central nervous system (n=1) ² Combination according to Cyclophosphamide Equivalent Dose (CED) (Green et al; Pediatr Blood Cancer. 2014 January; 61(1): 53–67. doi:10.1002/pbc.24679) ³ Thoracic radiation fields according to COG guidelines, Version 4.0, Oct 2018, including radiation to the chest, whole lung, mediastinum, (mini-)mantle field, TBI and additionally upper abdomen and thoracic spine, including craniospinal irradiation ⁴ Thoracic surgery according to COG guidelines, Version 4.0, Oct 2018, including thoracotomy, chest wall surgery, rib resection, lobectomy, pulmonary metastasectomy and wedge resection

SUPPLEMENTAL TABLE S3: This supplemental table describes clinical, treatment and era of transplantation		transplant characteristics of childhood cancer survivors transplanted autologous (N=61) stratified by	ivors transplanted autologou	s (N=61) stratified by
	1976-1995 (n=17)	1996-2005 (n=25)	2006-2015 (n=19)	Total (n=61)
	u (%)	u (%)	u (%)	u (%)
Clinical characteristics Cancer diagnosis according to ICCC-3				
I: Leukemia	2 (12)	3 (12)	0	5 (8)
II: Lymphoma IV: Neuroblastoma	8 (47) 5 (20)	4 (16) 8 (32)	5 (26) 6 (32)	17 (28) 19 (31)
Other	2 (12)	10 (42)	8 (42)	20 (33)
Treatment characteristics				
Conditioning containing TBI Conditioning regimens	5 (29)	3 (12)	1 (5)	9 (15)
TBI + cvclophosphamide ± others	3 (18)	I	ı	3 (5)
TBI + others	2 (12)	3 (12)	1 (5)	6 (9)
Busulfan + cyclophosphamide ± other	6 (35)	2 (8)	1 (5)	9 (15)
Busulfan ± others	1 (6)	4 (16)	2 (10)	
Contractions to the second sec	3 (18)	3 (12)	3 (16)	9 (15) 0 (15)
Oyciopriospriaring ± ourers Melphalan + Carboplatin + others	1 (0)	0 (24) 7 (28)	2 (11) 10 (53)	9 (13) 18 (30)
Chemotherapeutic agents				
Alkylating agents combined ²	17 (100)	25 (100)	19 (100)	
Busultan Carmistina	7 (41) A (24)	7 (28) 3 (12)	3 (16) 2 (11)	17 (28) 0 /15)
Carinasana Cvclonhosnhamide	4 (24) 17 (100)	21 (84)	2 (11) 16 (84)	9 (13) 54 (89)
Ifosfamide	5 (29)	15 (60)	16 (84)	36 (59)
Lomustine	1 (6)		1 (5)	2 (3)
Melphalan		13 (52)	15 (79)	37 (61)
Thiotepa	2 (12)	7 (28)	2 (11)	11 (18) 2 (11)
bleomycin Chemotherapeutic agents, ma/m²		3 (12)	7 (11)	(1.1)
Alkylating agents combined ²	17164 (15921 – 18380)	17286 (12650 – 35807)	16522 (11894 - 31601)	17154 (12650 – 31601)
Busultan Carmustine	480 (470 - 600) 300 (298 - 351)	480 (480 – 480) 300 (298 – 300)	443 (3/4 – 4/0) 300 (291 – 306)	480 (456 – 481) 300 (298 – 300)
Cyclophosphamide	7454 (6970 – 9352)	7491 (4000 – 9600)	3385 (1704 – 4938)	5980 (<u>3</u> 357 – 8845)

Ifosfamide	14000 (11500 – 16032)	22500 (10000 – 44782)	22500 (10000 – 44782) 18903 (11628 – 55978)	18
Lomustine	, 190 ,	-	, 600 ,	
Melphalan	140 (140 – 142)	140 (140 – 179)	140 (139 – 180)	140 (140 – 179)
Thiotepa	825 (750 – 900)	894 (594 – 900)	755 (610 – 900)	894 (604 – 900)
Bleomycin	41 (40 - 42)	40 (40 - 50)	30 (20 – 40)	40 (40 – 42)
Radiotherapy involving the thorax 3	10 (59)	14 (56)	11 (58)	35 (57)
Thoracic surgery ⁴	1 (6)	4 (16)	6 (32)	11 (18)
Transplant characteristics				
Remission status at transplantation				
First remission	8 (47)	18 (72)	11 (58)	37 (61)
Relapsed disease	9 (53)	7 (28)	8 (42)	24 (39)
Stem cell donor				
Autologous marrow	8 (47)	3 (12)	0	11 (18)
Autologous apheresis	9 (53)	22 (88)	19 (100)	50 (82)
Source of transplant				
Peripheral blood	8 (47)	22 (88)	19 (100)	49 (80)
Bone marrow	9 (53)	3 (12)	ı	12 (20)

ICCC-3, International Classification of Childhood Cancer, 3rd edition; IQR, interquartile range; TBI, total body irradiation

³ Thoracic radiation fields according to COG guidelines, Version 4.0, Oct 2018, including radiation to the chest, whole lung, mediastinum, (mini-)mantle field, TBÍ and additionally upper abdomen and thoracic spine, including craniospinal irradiation ⁴ Thoracic surgery according to COG guidelines, Version 4.0, Oct 2018, including thoracotomy, chest wall surgery, rib resection, lobectomy, pulmonary metastasectomy and ¹ Other tumors: tumor of the central nervous system (n=5), retinoblastoma (n=1), malignant bone tumor (n=7), soft tissue sarcoma (n=4), germ cell tumors (n=3) ² Combination according to Cyclophosphamide Equivalent Dose (CED) (Green et al; Pediatr Blood Cancer. 2014 January; 61(1): 53–67. doi:10.1002/pbc.24679)

wedge resection

SUPPLEMENTAL TABLE S4:

This supplemental table compares clinical, treatment and transplant characteristics of childhood cancer survivors after allogeneic and autologous hematopoietic stem cell transplantation, N=132, 52%male

	Allogeneic HSCT N=71	Autologous HSCT N=61	p value ^{1,2}
	n (%)	n (%)	
Sociodemographic characteristics	11 (70)	11 (70)	
Sex, male	38 (54)	31 (51)	0.757
Age at survey, median years (IQR)	18.5 (13.8 – 23.5)	18.3 (13.8 – 22.6)	0.688
Smoking status	10.0(10.0-20.0)	10.5 (15.6 – 22.6)	0.863
Active smoking	4 (6)	3 (5)	0.000
Passive smoking	30 (42)	26 (43)	
Former active smoking	6 (8)	3 (5)	
Never active smoking	31 (44)	29 (47)	
Never delive smoking	51 (++)	20 (47)	
Clinical characteristics	_		
Age at diagnosis, median years (IQR)	7.1 (3.2 - 11.1)	5.6 (2.6 – 12.9)	0.731
Age at diagnosis, years			0.083
0-4	26 (37)	27 (44)	
5-9	27 (38)	12 (20)	
10-14	15 (21)	15 (25)	
15-21	3 (4)	7 (11)	
Age at first HSCT, median years (IQR)	8.7 (5.7 - 13.0)	9.6 (3.1 – 14.3)	0.953
Follow-up time, median years (IQR)	10.2 (7.4 - 16.1)	9.5 (7.2 – 15.8)	0.420
Time to HSCT, median years (IQR)	0.9 (0.4 – 2.8)	0.7 (0.5 – 1.9)	0.511
Era of HSCT	4.0 (0.0)		0.501
1976 - 1995	16 (22)	17 (28)	
1996 - 2005	26 (37)	25 (41)	
2006 - 2015	29 (41)	19 (31)	
Cancer diagnosis according to ICCC-3	07 (0.4)	5 (0)	<0.005
I: Leukemia	67 (94)	5 (8)	
II: Lymphoma	3 (4)	17 (28)	
IV: Neuroblastoma	0	19 (31)	
Other ³	1 (2)	20 (33)	
Treatment characteristics			
Conditioning regimens			<0.001
TBI + cyclophosphamide ± others	31 (44)	3 (5)	
TBI + others	19 (27)	6 (10)	
Busulfan + cyclophosphamide ± others	19 (27)	9 (15)	
Busulfan ± others	1 (1)	7 (11)	
BCNU ± others	-	9 (15)	
CYC ± others	-	9 (15)	
Melphalan ± Carboplatin ± others	1 (1)	18 (29)	
Chemotherapeutic agents			
Alkylating agents combined ⁷	70	61	
Busulfan	21	16	
Carmustin	0	10	
Cyclophosphamide	69	54	
Ifosfamide	26	36	
Lomustin	0	2	
Melphalan	7	37	
Thiotepa	3	11	
Bleomycin	1 (1)	7 (12)	
Chemotherapeutic agents, mg/m ^{2 3}			
Alkylating agents combined ⁷	6,100 (3871 - 9579)	17,154 (12,650 – 31,601)	<0.001

Busulfan Carmustin Cyclophosphamide Ifosfamide Lomustin Melphalan Thiotepa Bleomycin Radiotherapy involving the thorax ⁸ Yes No Thoracic surgery ⁹ Yes	360 (320 - 445) - 3990 (2983 - 6242) 4011 (3879 - 6126) - 140 (139-140) 304 (168 - 307) 80 51 (72) 20 (28) 1 (1) 70 (99)	480 (456 - 481) 300 (298-300) 5980 (3357 - 8845) 18,038 (10,113-49,792) 395 (190-600) 140 (140-179) 894 (604 - 900) 40 (40-42) 34 (54) 27 (44) 11 (18) 50 (82)	0.0038 na 0.01 0.0001 na 0.093 <0.001 na 0.054
No	70 (99)	50 (82)	
Transplant characteristics	_		
Remission status at transplantation			0.409
First remission	38 (54)	37 (61)	
Relapsed disease	33 (46)	24 (39)	

HSCT, hematopoietic stem cell transplantation; IQR, interguartile range

¹ p-value calculate by Pearson chi-square to compare categorical variables between allogeneic and autologous transplant cohort

² p-value calculate by t-test to compare categorical variables between allogeneic and autologous transplant cohort

⁴ body mass index (BMI) defined as normal if z-score ≥-2 and ≤1 (responder ≤19) or kg/m² ≥18.5 and ≤24.9 (responder >19 years) ⁶ Relation sex of donor to recipient: match= both male or female; mismatch= donor male and recipient female or


vice versa ⁷ Combination according to Cyclophosphamide Equivalent Dose (CED) (Green et al; Pediatr Blood Cancer. 2014 January; 61(1): 53–67. doi:10.1002/pbc.24679) ⁸ Thoracic radiation fields defined according to COG guidelines, Version 4.0, Oct 2018

⁹ Relevant thoracic surgery defined according to COG guidelines, Version 4.0, Oct 2018

thor	thoracic surgery, N=12					
	Diagnosis	Year of diagnosis	Age at first thoracic surgery [vears]	Relapse	Description of thoracic surgery/ surgeries	Lung toxic exposure
~	Hodgkin lymphomas	1986	10	Yes	Thoracotomy: tumor resection mediastinal	BCNU, Bleomycin, CCNU, CYC, Mel Radiotherapv: mediastinal, lung
2	Ewing sarcoma	1997	26	Yes	Thoracoscopy: metastasectomy	CYC, IFO, Mel
З	Non-Hodgkin lymphomas	1996	21	Yes	Thoracotomy: lobectomy upper lobe and lingual left side	Busulfan, CYC Radiotherapy: mediastinal
4	Acute myeloid leukemias	1999	2	Yes	Thoracoscopy: lobectomy left lower lobe due to infection	Radiotherapy: TBI, mediastinal
5	Ewing sarcoma	2002	71	No	1x Thoracoscopy: metastasectomy 3x Thoracotomy: 2x Metastasectomy and resection left lower lobe	Busulfan, CYC, IFO, Mel Radiotherapy: lung
9	Ewing sarcoma	2004	13	Yes	Thoracotomy: lobectomy left lower lobe and parietal pleura Thoracotomy: extended extrapleural residual pneumonectomy Thoracic wall: partial scapula resection	Busulfan, IFO, Mel Radiotherapy: lung
2	Ewing sarcoma	2004	2	Yes	Thoracotomy: subtotal tumor resection Thoracotomy: marginal tumor resection, resection of two ribs Thoracotomy: metastasectomy, partial resection right upper lobe	CYC, IFO, Mel Radiotherapy: lung, chest wall
ø	Ewing sarcoma	2006	4	Yes	Thoracoscopy (VATS): two lung biopsies	Busulfan, CYC, IFO, Mel
თ	Non-Hodgkin lymphomas	2006	13	No	Sternotomy and mediastinotomy: tumor biopsy Sternotomy: partial tumor resection	Busulfan, CYC, IFO Radiotherapy: mediastinal
10	Hodgkin lymphomas	2007	21	Yes	Thoracotomy: tumor resection	BCNU, Bleo, CYC, IFO, Mel Radiotherapy: mediastinal
1	Ewing sarcoma	2008	10	Yes	Thoracotomy and resection of two ribs	CYC, IFO, Mel Radiotherapy: thoracic spine


SUPPLEMENTAL TABLE S5: This supplemental table describes the characteristics of childhood cancer survivors who have been treated with hematopoietic stem cell transplantation and

C, IFO, Mel	Radiotherapy: lung
	Bilateral VAIS: metastasectomy
	Yes bilateral
C	19
	2008
	Ewing sarcoma
ç	71



SUPPLEMENTAL FIGURE F1: Population tree of transplanted and non-transplanted childhood cancer survivors eligible for this study – approach 1 with division into transplanted and non-transplanted survivors at the end.

CCS, childhood cancer survivor; SPOG, Swiss Pediatric Oncology Group



SUPPLEMENTAL FIGURE F2: Population tree of transplanted childhood cancer survivors eligible for this study – approach 2 with division into transplanted and non-transplanted survivors at the beginning.

CCS, childhood cancer survivor; HSCT, Hematopoietic Stem Cell Transplantation

4.2. Publication II

Pulmonary function in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a retrospective study

Original article

Maria Otth, Sophie Yammine, Jakob Usemann, Philipp Latzin, Tayfun Güngör, Katrin Scheinemann, Claudia E Kuehni

(Manuscript in preparation, to be submitted to Journal of Clinical Oncology)

Own contribution to the project when submitting the thesis: Concept and design of the study, organization and conduct of data collection, data analysis, preliminary interpretation of the results, start writing manuscript

Lung function in Swiss childhood cancer survivors after Hematopoietic Stem Cell
Transplantation – a retrospective study
Otth M ^{1,2,3} , Yammine S ⁴ , Usemann J ⁵ , Latzin P ⁴ , Mader L ¹ , Spycher B ¹ , Güngör T ⁶ ,
Scheinemann K ^{2,7,8} , Kuehni CE ^{1,4} , for the Swiss Pediatric Oncology Group (SPOG)
¹ Childhood Cancer Research Group, Institute of Social and Preventive Medicine (ISPM), University
of Bern, Switzerland
² Division of Hematology and Oncology, Department of Pediatrics, Kantonsspital Aarau, Switzerland
³ Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland
⁴ Division of Respiratory Medicine, Department of Pediatrics, Inselspital, University Hospital,
University of Bern, Bern, Switzerland
⁵ Division of Respiratory Medicine, Department of Pediatrics, University Children's Hospital Zurich-
Eleonore Foundation, Switzerland
⁶ Division of Hematology and Oncology, University Children's Hospital Zurich-Eleonore Foundation,
Switzerland
⁷ University of Basel, Switzerland
⁸ Department of Pediatrics, McMaster University Hamilton, Canada
Corresponding author
Claudia E. Kuehni; Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43,
3012 Bern, Switzerland; E-mail: claudia.kuehni@ispm.unibe.ch; Telephone: +41 31 631 35 07
Funding: Lung League Bern

28 Abstract

Background: Several treatment modalities used in the setting of hematopoietic stem cell transplantation
(HSCT) in children and adolescents put the young patients at risk for pulmonary dysfunction.
Information on longitudinal trajectories of pulmonary function and factors influencing changes over
time was lacking.

Research Question: The purpose of this study was to evaluate longitudinal pulmonary function
trajectories and treatment-related factors associated with changes over time in a cohort of 5-year
childhood cancer survivors (CCSs) treated with allogeneic or autologous HSCT in Switzerland.

Study Design and Methods: This retrospective cohort study included 5-year CCSs registered in the 36 Swiss Childhood Cancer Registry, diagnosed below 21 years of age, between 1980 and 2010, treated 37 with allogeneic or autologous HSCT, and having at least two pulmonary function tests performed 38 39 following the diagnosis. We described pulmonary function parameters as age-, sex-, and height-adjusted z-scores in terms of lung volumes (FVC, RV, TLC), air flow (FEV1), and diffusion capacity for carbon 40 monoxide (DLCO). We assessed the influence of treatment factors and elapsed time since diagnosis on 41 pulmonary function parameters using multivariable regression analysis with random intercept and 42 43 slope.

Results: Seventy-four 5-year CCSs were included in this study. Median age at diagnosis was 7 years,
with 9 years of follow-up. Most CCSs received allogeneic HSCT (68%) and radiotherapy involving the
chest (70%). The median z-score of all analysed pulmonary function parameters were below the
expected over the observed 15 years, but the individual trajectories differed largely between CCSs. The
z-scores for FEV1 (-0.06, 95%CI -0.09 - -0.03) and FVC (-0.06, 95%CI -0.09 - -0.02) showed a
significant annual decrease in multivariable regression analysis, which was not the case for TLC, RV,
and DLCO. Relapsed disease had a significantly impact on the annual change of TLC and RV.

51 Interpretation: Our results show that pulmonary function in 5-year CCSs treated with HSCT was 52 constantly below the expected but did not show a prominent deterioration over the observed first 15 53 years from diagnosis. In a sub-analysis of CCSs with a first test preformed before HSCT, FEV1 and

- 54 FVC z-scores have not significantly deteriorated in the first five years after HSCT, but subsequently.
- 55 Our results illustrate that this population of 5-year CCSs needs long-term follow-up care. We also
- 56 emphasize that longitudinal, prospective studies are needed to better understand the long-term course
- 57 of pulmonary function in these CCSs.
- 58
- 59 Key words:
- 60 Childhood cancer, survivor, late effects, pulmonary function, hematopoietic stem cell transplantation
- 61

62 Abbreviations:

63 64 65 66 67 68 69 70 71 72 73 74	BCNU CCNU CCS CMV DLCO FEV1 FVC GLI GvHD HLA HSCT IQR	Carmustine Lomustine Childhood Cancer Survivors Cytomegalovirus Diffusion capacity for carbon monoxide Forced expiratory volume in first second Forced vital capacity Global Lung Initiative Graft versus host disease Human leucocyte antigen Hematopoietic stem cell transplantation Interquartile range
69	FVC	1 2
70	GLI	Global Lung Initiative
71	GvHD	Graft versus host disease
72	HLA	Human leucocyte antigen
73	HSCT	Hematopoietic stem cell transplantation
74	IQR	Interquartile range
75	PFT	Pulmonary function test
76	RV	Residual volume
77	SCCR	Swiss Childhood Cancer Registry
78	SCCSS	Swiss Childhood Cancer Survivor Study
79	SPOG	Swiss Pediatric oncology Group
80	TLC	Total lung capacity
81		

82 Introduction

83 Childhood cancer survivors (CCSs) treated with allogeneic or autologous hematopoietic stem cell transplantation (HSCT) are at increased risk to develop pulmonary dysfunction (1-4). Pulmonary 84 dysfunction reflects different underlying structural damages to the lung tissue. In CCSs treated with 85 86 HSCT, these damages can result from oxidative stress induced by specific chemotherapeutic agents, from free radical formation due to radiotherapy, or from transplant-specific pulmonary complications. 87 Lung-toxic chemotherapeutic agents include busulfan, bleomycin, carmustine and lomustine (5, 6). 88 Transplant-specific complications include the idiopathic pulmonary syndrome and complications from 89 the spectrum of pulmonary graft versus host disease (GvHD), such as bronchiolitis obliterans or 90 bronchiolitis obliterans organizing pneumonia (7, 8). Because the lung has a large functional reserve, it 91 can take years to decades until pulmonary dysfunction becomes clinically manifest. Pulmonary function 92 93 testing (PFT) allows to detect pulmonary dysfunction in this asymptomatic period and different test modalities are available. Spirometry and body plethysmography, measuring lung volumes and flow, are 94 widely available but seem to detect less survivors with pulmonary dysfunction than measuring the 95 96 diffusion capacity for carbon monoxide (DLCO) (9, 10).

97 Most studies which assessed pulmonary function in CCSs treated with allogeneic or autologous 98 HSCT longitudinally have rather short follow-up periods (3, 4, 11, 12). In addition, not all CCSs in 99 these studies were long-term survivors and might have died within the first five years following the 100 diagnosis. In this population-based, retrospective cohort study of Swiss CCSs treated with HSCT and 101 surviving \geq 5 years from diagnosis, we aimed to close this knowledge gap. We described pulmonary 102 function trajectories over time, starting at diagnosis, and addressed risk factors associated with a decline 103 in pulmonary function in the literature.

104

105 Methods

106 *Study population*

Eligible for this study was a subgroup of CCSs who participated in the Swiss Childhood Cancer
Survivor Study (SCCSS), a long-term national cohort study of all children and adolescents who have

109 survived ≥ 5 years after initial cancer diagnosis and who have been registered in the Swiss Childhood 110 Cancer Registry (SCCR) (13). The SCCR registers since 1976 all children and adolescents diagnosed 111 with leukemia, lymphoma, central nervous system tumors, malignant solid tumors, or Langerhans cell 112 histiocytosis below the age of 21 years (14). We finally included CCSs who had participated in the 113 SCCSS, had answered the questions on pulmonary health, had been treated in a clinic affiliated to the 114 Swiss Pediatric Oncology Group (SPOG) between 1976 and 2010, had undergone autologous or allogeneic HSCT, and had at least two pulmonary function tests (PFTs) performed at any time following 115 116 the cancer diagnosis. We have decided to sample the cohort for this study from the SCCSS cohort 117 because all CCSs eligible for the SCCSS have met the inclusion criterion of being a 5-year survivor. Furthermore, we know from a previous study, that the response rate of transplanted CCSs in the SCCSS 118 119 is very good with 71% (15). The Ethics Committee of the Canton of Bern approved the SCCR and 120 SCCSS (KEK-BE: 166/2014), and the SCCSS is registered at ClinicalTrials.gov (identifier: 121 NCT03297034).

122

123 Pulmonary function test results and data cleaning

124 We searched pulmonary function test (PFT) results in the archives of the initially treating clinic 125 and the transplant clinic. We collected all results performed by spirometry, body plethysmography, and 126 measurement of diffusion capacity for carbon monoxide (DLCO). The following PFT parameters were 127 considered for this study: forced expiratory volume in first second (FEV1 [liter]), forced vital capacity 128 (FVC [liter]), residual volume (RV [liter]), total lung capacity (TLC [liter]), resistance ([kPa*s/liter]), 129 and DLCO. If available we recorded DLCO corrected for hemoglobin (DLCO_{corr} [mmol/min/kPa] or 130 [cmH₂O/L/sec]) otherwise we recorded the uncorrected DLCO. We divided DLCO expressed as [cmH₂O/L/sec] by 2.98 to convert it into [mmol/min/kPa] (16). We used EpiData to enter the PFT 131 132 results (17). To avoid data entry errors, the entry of every second PFT result in EpiData was doublechecked for correctness. 133

Using the Global Lung function Initiative equations (GLI 2012), we converted FEV1, FVC, and DLCO into age-, height- and sex-standardized z-scores and percentage of predicted (18). To calculate the z-scores for TLC and RV we used the reference equations by Zapletal et al for children 137 aged 4-17 years and the European Community of Coal and Steel (ECCS) equations for adults aged ≥ 18 years (19, 20). We defined z-scores <-1.645 as abnormal (21). For resistance we used the cutoff value 138 for sReff (sRtot) $\geq 1,2$ kPa*s for adults and $\geq 1,0$ kPa*s for children to define abnormal results (22). We 139 140 performed quality checks by plotting the z-scores of each patient over time and checked for outliers. 141 For all outliers we consulted the raw data and corrected data entry errors. We excluded PFT results if poor cooperation, cough or cold was noted on the test result. Two authors assessed the quality of the 142 PFTs by evaluating the flow-volume curve and the respiratory loop independently and according to 143 criteria from the American Thoracic Society and European Respiratory Society and the German Lung 144 League (23, 24) (Supplemental Explanation E1). We excluded PTFs with bad quality. As this study 145 focused on the longitudinal course of pulmonary function we excluded 12 CCSs who had one test of 146 good quality performed only (Supplemental S1). We additionally excluded 23 tests of good quality 147 148 (5% of all tests) of 8 CCSs which have been performed \geq 15 years from cancer diagnosis (mean 23 149 years; range 15 - 34 years).

150

151 Treatment characteristics

152 We collected treatment information from medical records at the respective SPOG clinic where 153 the patient was initially treated and received HSCT. If the initially treating clinic and the transplant 154 clinic were not the same, we searched the records in both clinics. We recorded exposure to lung-toxic chemotherapeutic agents listed in the Children's Oncology Group (COG) long-term follow-up (LTFU) 155 156 guidelines version 5.0, including bleomycin, busulfan, carmustin (BCNU), and lomustin (CCNU) as 157 yes/no variable and additionally calculated the cumulative doses (25). We converted busulfan administered orally to intravenously by multiplying it by factor 0.8 (26). We categorized radiation to 158 the chest and thoracic surgery as yes/no variables according to the COG-LTFU guidelines (25). For 159 HSCT we collected information on remission status, source of transplant, stem cell donor, 160 cytomegalovirus (CMV) status and sex of donor and recipient, and information on graft versus host 161 disease (GvHD). For remission status, we assigned patients with initially refractory disease into the 162 category "first remission". For patients transplanted allogeneic we recorded the Human Leucocyte 163

164 Antigen- (HLA-) match and differentiated between HLA-matched and HLA-mismatched donors (27).

165 We categorized GvHD into acute and chronic according to information from medical records.

166

167 *Statistical analyses*

168 We used descriptive statistics, such as median and interquartile range (IOR), number and 169 proportion to characterize the study population and to describe the PFT results. We used a cross-170 sectional approach to describe the pulmonary function parameters performed during the first and last 171 available test of each CCS and compared them by using t-test for continuous variables. The parameters 172 for resistance and DLCO were missing in >50% of first or last tests. Therefore we did not consider them in the cross-sectional description. To model the longitudinal course of pulmonary function parameters 173 174 over time, we used multivariable logistic regression analysis with random intercept and random slope. 175 The model with random intercept and random slope takes clustering by patient and the previous 176 measurement at patient level into account. We used the command "mixed" in Stata. We modelled a 177 random slope, by performing an interaction term between the respective risk factor and time since diagnosis, for each risk factor separately. To account for autocorrelation of the residuals of repeated 178 measurements we introduced a respective exponential term in the analyses. We included time since 179 180 diagnosis as continuous variable. We only kept the risk factors in the final model for the random slope 181 with a significance level of p<0.05 at individual level. We visualized pulmonary function graphically 182 by plotting the overlaid trajectories for all CCSs over time. We additionally analyzed two subgroup of CCSs. We compared changes from baseline (before HSCT) to <2 years from HSCT, to 3-5 years, and 183 to \geq 5 years from HSCT in CCSs with baseline measurement available. The second subgroup consisted 184 of CCSs with at least one test performed in each of three defined categories: 1st and 2nd year from HSCT, 185 3rd to 5th year from HSCT, and 6th to 10th year from HSCT. If CCSs had more than one test performed 186 187 within a category, we included the respective mean over all performed tests per CCS and per category. 188 We used the statistical software Stata (StataCorp LLC) for analysis.

189

190 Results

191 *Patient characteristics*

Two hundred CCSs who received autologous or allogeneic HSCT could be contacted for the 192 SCCSS. Of those, 142 responded to the survey (71%) and 74 CCSs (37%) could be included in our 193 194 analysis as they received at least two pulmonary function tests of good quality after cancer diagnosis 195 (Supplemental Figure 1). The median age at diagnosis was 7.4 years (interquartile range, IQR 3.5 – 12.2) and 9.4 years (IQR 5.6 - 14.5) at transplantation. The time between diagnosis and last available 196 pulmonary function test (PFT) was 9.3 years (IQR 1.2 - 12.3). The most frequent diagnosis was 197 198 leukemia (69%), followed by lymphoma (15%), and other tumors (15%). Half of the CCSs (55%) had suffered from relapsed disease and had been diagnosed between 2001 and 2010 (57%) (Table 1). Of 199 200 the four assessed lung toxic chemotherapeutic agents, busulfan was the most frequently used (34%) with a median cumulative dose of 422 mg/m^2 (IOR $324 - 470 \text{ mg/m}^2$). Seventy percent (n=52) of CCSs 201 received radiotherapy to the thorax, and 14% (n=10) thoracic surgery. For HSCT, two thirds were 202 203 transplanted allogeneic (68%) and in half of the CCSs (55%) peripheral blood was the source of 204 transplant (Table 1). Additional information on cancer diagnosis and transplant characteristics is 205 available in Supplemental Table S2.

206

207 Pulmonary function

The 74 CCSs performed 411 PFTs of good quality with 5 tests per survivor on average (range 208 209 2-12). FEV1, as proxi for the performance of a spirometry, was carried out in 99% of PFTs (n=407 210 tests), in 95% of the tests (n=390) TLC was preformed, indicative for body plethysmography, and in 45% of the tests (n=185) DLCO measurement was performed. The median time from diagnosis to first 211 212 PFT was 3.0 years (IQR 1.2 - 5.4) and 9.3 years (IQR 6.1 - 12.3) to the last test (Supplemental Table 213 **S3**). The number of PFT results included in the comparison of first and last test differed slightly for each pulmonary function parameters. This difference is because the last available test did not always 214 215 include all parameters or some CCSs only received spirometry for example. We excluded DLCO from 216 this analysis, as it was missing in up to 80% of first or last tests. None of the five analysed pulmonary

function parameters (FEV1, FVC, FEV1/FVC, TLC, RV) showed a significant deterioration between first and last test (**Table 2**). FEV1 and FVC showed a tendency to worse median z-scores in the last compared to the first test. The TLC z-score showed a tendency to higher z-scores, but still below the predicted. The z-score for RV was even slightly higher than predicted at both time points. Stratification into CCSs with normal or reduced (z-score <-1.645) parameters only showed a significant decline in FEV1 z-score and FEV1/FVC ratio in the category of normal parameters.

We could graphically show that the median z-score of each pulmonary function parameter is constantly below the expected value for FEV1, FVC, and TLC, and most of the time for DLCO and RV (Figure 1, Figure 2, Figure 3, Figure S2, and Figure S3). Each longitudinal course is rather stagnant with no clear worsening in the observed 15 years. The variability in the longitudinal course between CCSs is large. Some CCSs show a deterioration with each PFT performed, others a steady improvement, and others an undulating course.

229 We included 25 CCSs in the subgroup analysis with available baseline testing before HSCT. In 230 24 CCSs FEV1 was available and FVC in 23 CCS. A total of 147 tests were performed in this subgroup. We excluded DLCO from these analyses because it was missing in a high proportion of baseline tests. 231 The median FEV1 z-score was -0.96 at baseline (IQR -1.89 - 0.01) and did not significantly change in 232 233 the following five years, but decreases to -1.66 (IQR -3.16 - -0.41; p=0.063) in the median of the test performed \geq 5 years from HSCT (Figure 4a). The course for FVC z-score was very similar but on a 234 235 lower z-score level (Figure 4b). The median FVC z-score was -1.1 (IQR -2.28 - -0.10) at baseline with no significant changes in the following five years but a significant decrease to -2.12 (IQR -3.28 - -1.14) 236 237 in the median of tests performed \geq 5 years from HSCT.

238

239 Risk factors for decrease in pulmonary function

In the risk factor analysis we examined the impact of the risk factors on the starting value of the longitudinal trajectory of each pulmonary function parameter (intercept) and on its annual change (slope). The reference in this analysis is a male patients treated with autologous HSCT, diagnosed 243 between 1980 and 1990 with no exposure to any of the risk factors. For FEV1 z-score, being female 244 (Coefficient, Coeff. -0.664; 95% Confidence interval, 95%CI -1.187 - -0.140) and treated with radiotherapy to the lung (Coeff. -1.3; 95%CI -2.022 - -0.558) led to a significant reduction in the 245 intercept. The annual decrease (slope) of FEV1 z-score was -0.06 (95%CI -0.094 - -0.027) in the 246 reference person and was not significantly changed by any of the risk factors. For FVC z-score, 247 radiotherapy (Coeff. -1.473; 95%CI -2.207- -0.739) led to a significant reduction in the intercept. The 248 annual decrease of FVC z-score was -0.058 (95%CI -0.097 - -0.019) and was not significantly 249 influenced by any of the risk factors. For TLC z-score, we adjusted the model by taking the interaction 250 of time with type of transplantation into account. In the final model, no risk factor had a significant 251 impact on the intercept of TLC z-score. TLC z-score decreased annually by -0.092 (95%CI -0.220 -252 0.035). Treatment with allogeneic HSCT led to an annual improvement of 0.216 (95%CI 0.059 - 0.373) 253 254 compared to autologous HSCT. For RV z-score, we adjusted the model and took the interaction of time with relapse into account. Afterwards, none of the risk factors was significantly associated with a change 255 in the intercept. The annual increase in RV z-score was 0.108 (95%CI -0.019 - 0.234), but having 256 257 suffered from relapse led to an annual decrease of -0.231 (95%CI -0.405 - 0.055). For DLCO, being 258 diagnosed 1991-2000 (Coeff. -2.465; 95%CI -4.151- -0.780) and 2001-2010 (Coeff. -2.447; 95%CI -4.111- -0.784) led to a significant reduction in the intercept of DLCO z-score. None of the risk factors 259 significantly influenced the annual increase of 0.015 (95%CI -0.079 - 0.111) z-scores. Finally, the 260 261 results of this analysis allow to calculate the longitudinal course of each pulmonary function parameter 262 for CCSs exposed to different combinations of risk factors. The term "intercept" in Table 3 corresponds 263 to the starting value of the male reference patients. A female CCSs treated with radiotherapy to the lung 264 would start at a FEV1 z-score of -1.471 (-0.664 for being female, -1.306 for radiotherapy). The annual decrease is -0.061 z-scores. As no factor was significantly associated at single levels, no time interaction 265 was included in the final model (Supplemental Table S4). The detailed risk factor analysis for each 266 267 pulmonary function parameter is shown in Supplemental Table S4 to S8).

268 Discussion

269 A median of 9 years from diagnosis on third of CCSs had a reduced z-score for FEV1 (34%), 270 FVC (38%), or TLC (32%) and RV was reduced in 11%. None of the analyzed pulmonary function 271 parameters showed a significant decrease between the first and last available test. However, the median 272 z-score for FEV1, FVC, and TLC was constantly below the expected and most of the time also for 273 DLCO and RV. In the sub-group analysis of CCSs with baseline testing, already the median z-score 274 before HSCT was below the expected for FEV1 and FVC and did not significantly change in the following five years after HSCT. In the risk factor analysis only relapsed disease and type of HSCT 275 276 were significantly associated with an annual deterioration of TLC and RV. Also only few factors were associated with a significant decrease in the intercept. All these findings highlight the complexity and 277 278 multifactorial cause of pulmonary dysfunction in CCSs after HSCT and that most probably already the 279 treatment preceding HSCT contributes to the long-term course.

280

Paragraph on contextualization with other literature and risk factors in progress

The findings from our sub-group analysis on CCSs with test results available before HSCT go 281 282 partly in line with the publication from Cerveri et al (12). All 75 CCSs in this cohort treated with 283 allogeneic (69%) and autologous HSCT had baseline testing available. As in our cohort, already the 284 mean baseline FVC z-score was reduced (-0.3 \pm 1.1). Different from our cohort, the subsequent tests 285 have been performed at defined time points (6 months, 12 months, and 24 months) and the mean FVC z-score was significantly lower compared to the baseline assessment (mean z-score -0.9, p<0.001). The 286 287 results from both studies underline, that some CCSs already go into transplantation with reduced 288 pulmonary function and that the lung may already be pre-damaged by the previous treatment or other 289 underlying conditions. The question on the impact of cancer treatment preceding HSCT and underlying 290 conditions can currently not be answered, as baseline testing before any cancer treatment is often 291 lacking.

The strengths of this study are the large sample size of 74 CCSs with at least two pulmonary function tests performed and the high quality of patient, diagnosis, and treatment information. For pulmonary function data, the strengths are the check of pulmonary function quality and data entry into EpiData by two persons, the control for outliers at z-score level and correction if needed, and mostimportantly, the exclusion of all PFT results with poor quality.

297 The results of this study have to be considered with some limitations. The retrospective design 298 influenced the data availability and the data quality. Even though we searched different archives and 299 tried to find all PFT results, we might have missed some results or the results got lost, which might 300 especially have happened in CCSs diagnosed in the 80s and 90s. In addition, we did not know why the 301 PFTs have been performed. We assume that some PFTs have been performed for surveillance purpose, 302 but other tests may have been performed due to symptoms or other diseases, such as asthma. 303 Retrospective data collection leads to specific limitations in the PFT quality. Tests have been performed 304 in different laboratories over a long period with changes in equipment, staff, and testing procedures. We also had to assume that the tests have been performed according to standard practice and that the 305 results we found in the medical records correspond to the best repetition out of three. Taking the SCCSS 306 307 cohort to define 5-year survivors could have introduced selection bias. Our results might therefore not 308 be representative for all 5-year CCSs treated with autologous or allogeneic HSCT. In addition, we cannot rule out, that the more symptomatic and sicker CCSs received PFT and are included in our 309 cohort, which would lead to an overestimation of the burden of pulmonary dysfunction. Even though 310 311 we included CCSs treated with HSCT only, the cohort is still very heterogeneous in terms of relapsed disease and exposure to different treatment modalities. This heterogeneity and the multimodal treatment 312 approach in all included survivors has made it impossible for us to define risk factors associated with 313 changes in pulmonary function parameters over time. 314

315

316 Interpretation

Pulmonary function z-scores in 5-year childhood cancer survivors treated with hematopoietic
stem cell transplantation are constantly below the predicted, from shortly after diagnosis until 15 years
later. These low parameters indicate that long-term follow-up care of these survivors is needed.

320

321	Take-Home Points
322	Study question: We aimed to evaluate pulmonary function longitudinally and treatment-related factors
323	associated with changes in pulmonary function over time in a cohort of 5-year childhood cancer
324	survivors (CCSs) treated with allogeneic or autologous hematopoietic stem cell transplantation (HSCT)
325	in Switzerland.
326	Results: Most pulmonary function parameters were constantly below the predicted z-score over the
327	observed period of 15 years in the 74 included CCSs with the risk factor analysis highlighting the
328	multifactorial influence of each single risk factor, resulting in a complex interplay.
329	Interpretation: Our data underline the necessity that CCSs treated with HSCT are at risk for pulmonary
330	dysfunction and that long-term pulmonary follow-up care may be indicated.
331	
332	Acknowledgements
552	
333	Guarantor: Dr. Maria Otth takes responsibility for the content of this manuscript.
334	Author contributions: M.O. performed funding acquisition, developed the study, performed data
335	collection, analyzed and interpreted the data, and wrote the manuscript. S.Y., J.U., and P.L. provided
336	important pediatric pulmonology input, helped in data interpretation, and revised the manuscript for
337	important intellectual content. G.T. and K.S. provided important input on pediatric oncology and
338	pediatric transplantation, helped in data interpretation, and revised the manuscript for important
339	intellectual content. L.M. helped in data analysis and revised the manuscript for important intellectual
340	content. B.S. helped in statistical design, data analysis, and revised the manuscript for important

341 intellectual content. C.E.K. performed funding acquisition, developed the study, interpreted the data,

342 and revised the manuscript for important intellectual content.

343 Names of collaborators: Swiss Paediatric Oncology Group (SPOG): Ansari M; Beck Popovic M;
344 Bourquin JP; Brazzola P; Greiner J; Rössler J; Schilling F; Scheinemann K; von der Weid N

Financial/nonfinancial disclosures: This study was supported financially by the Lung league Bern

346 Role of the sponsors: The content of this study is the responsibility of the authors and the sponsor had 347 no influence on design, implementation and output of the study [input or contributions provided by the 348 funding sources in the development of the research and manuscript]

Other contributions: The authors thank the study team of the Childhood Cancer Research Group at 349 350 the ISPM, Morena Elber for her support in the data extraction, the data managers of the SPOG centers 351 (Claudia Althaus, Nadine Assbichler, Pamela Balestra, Heike Baumeler, Nadine Beusch, Sarah Blanc, Susann Drerup, Janine Garibay, Franziska Hochreutener, Monika Imbach, Friedgard Julmy, Eléna 352 Lemmel, Rodolfo Lo Piccolo, Heike Markiewicz, Veneranda Mattielo, Annette Reinberg, Renate 353 354 Siegenthaler, Astrid Schiltknecht, Beate Schwenke, and Verena Stahel) and the data managers and administrative staff of the SCCR (Meltem Altun, Erika Brantschen, Katharina Flandera, Elisabeth 355 Kiraly, Nadine Lötscher, Verena Pfeiffer, Shelagh Redmond, Julia Ruppel, and Ursina Roder). 356

357

358 References

359

Hoffmeister PA, Madtes DK, Storer BE, Sanders JE. Pulmonary function in long-term
 survivors of pediatric hematopoietic cell transplantation. Pediatric blood & cancer. 2006;47(5):594 606.

Inaba H, Yang J, Pan J, Stokes DC, Krasin MJ, Srinivasan A, et al. Pulmonary dysfunction in
 survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell
 transplantation. Cancer. 2010;116(8):2020-30.

 Madanat-Harjuoja LM, Valjento S, Vettenranta K, Kajosaari M, Dyba T, Taskinen M.
 Pulmonary function following allogeneic stem cell transplantation in childhood: a retrospective cohort study of 51 patients. Pediatric transplantation. 2014;18(6):617-24.

4. Uhlving HH, Bang CL, Christensen IJ, Buchvald F, Nielsen KG, Heilmann CJ, et al. Lung
function after allogeneic hematopoietic stem cell transplantation in children: a longitudinal study in a
population-based cohort. Biology of blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation. 2013;19(9):1348-54.

5. Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy.
Seminars in oncology. 2013;40(6):757-73.

Liles A, Blatt J, Morris D, Wardrop R, 3rd, Sharma A, Sznewajs A, et al. Monitoring
pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care
physician. Cleveland Clinic journal of medicine. 2008;75(7):531-9.

378 7. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and
379 treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in
380 chronic GVHD. Bone marrow transplantation. 2011;46:1283.

 Saglio F, Zecca M, Pagliara D, Giorgiani G, Balduzzi A, Calore E, et al. Occurrence of longterm effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone marrow transplantation. 2020;55(10):1918-27.

386 9. Armenian SH, Landier W, Francisco L, Herrera C, Mills G, Siyahian A, et al. Long-term
387 pulmonary function in survivors of childhood cancer. Journal of clinical oncology : official journal of
388 the American Society of Clinical Oncology. 2015;33(14):1592-600.

Mulder RL, Thonissen NM, van der Pal HJ, Bresser P, Hanselaar W, Koning CC, et al.
Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax. 2011;66(12):1065-71.

392 11. Griese M, Rampf U, Hofmann D, Fuhrer M, Reinhardt D, Bender-Gotze C. Pulmonary
393 complications after bone marrow transplantation in children: twenty-four years of experience in a
394 single pediatric center. Pediatric pulmonology. 2000;30(5):393-401.

12. Cerveri I, Fulgoni P, Giorgiani G, Zoia MC, Beccaria M, Tinelli C, et al. Lung function
abnormalities after bone marrow transplantation in children: has the trend recently changed? Chest.
2001;120(6):1900-6.

398 13. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, et al. Cohort
399 profile: the Swiss childhood cancer survivor study. International journal of epidemiology.
400 2012;41(6):1553-64.

401 14. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss
402 Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. Swiss
403 medical weekly. 2007;137(35-36):502-9.

404 15. Otth M, Schindera C, Güngör T, Ansari M, Scheinemann K, Belle FN, et al. Transplant
405 characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after
406 hematopoietic stem cell transplantation-a cohort study. Bone marrow transplantation. 2020.

16. Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW, et al. Official
 ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide

transfer factor for Caucasians. The European respiratory journal. 2017;50(3).

410 17. Christiansen TBL, J.M. EpiData - Comprehensive Data Management and Basic Statistical Analysis System: Odense Denmark, EpiData Association; [cited 2020 11.11.2020]. Available from: 411 412 http://www.epidata.dk. 18. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference 413 values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. The 414 415 European respiratory journal. 2012;40(6):1324-43. 416 Zapletal AS, M; Paul, T Lung Function in Children and Adolescents. Methods, Reference 19. 417 Values. Basel: S Karger AG. 1987. 418 20. Quanjer PHD, A; Van Zomeren, B.H. Summary equations of reference values. 1983;Bull 419 Europ Physiopathol Respir (19(Suppl. 5):45–51). 420 Baur X. [Recommendation of new reference values for spirometry and body 21. 421 plethysmography]. Pneumologie (Stuttgart, Germany). 2013;67(7):401-5. Criée CPB, D; Heise, D; Jörres, R.A; Kardos, P; Köhler, D; Leupold, W; Magnussen, H; 422 22. 423 Marek, W; Merget, R; Mitfessel, H; Rasche, K; Rolke, M; Smith, H. J.; Sorichter St.; Worth, H 424 Empfehlung der Deutschen Atemwegsliga: Empfehlungen zur Ganzkörperplethysmographie: Dustri-425 Verlag; 2009. Criée CP, Baur X, Berdel D, Bösch D, Gappa M, Haidl P, et al. [Standardization of 426 23. 427 spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and 428 German Society of Occupational and Environmental Medicine]. Pneumologie (Stuttgart, Germany). 429 2015;69(3):147-64. 430 Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. 24. 431 Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European 432 Respiratory Society Technical Statement. American journal of respiratory and critical care medicine. 433 2019;200(8):e70-e88. 434 COG COG. Children's Oncology Group [COG] Long Term Follow-Up guidelines Version 25. 5.0 2018 [cited 2019 05.04.2019]. Available from: 435 436 http://www.survivorshipguidelines.org/pdf/2018/COG LTFU Guidelines v5.pdf. 437 26. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biology of 438 blood and marrow transplantation : journal of the American Society for Blood and Marrow

439 Transplantation. 2009;15(5):523-36.

- Eyrich M, Schulze H. HLA Matching in Pediatric Stem Cell Transplantation. Transfusion
 medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft für Transfusionsmedizin
- 442 und Immunhamatologie. 2019;46(5):348-55.

443

TABLE 1: Characteristics of the study population (N=74)

Sociodemographic and lifestyle characteristics	
Sociodemographic and mestyle characteristics	43 (58)
Ethnicity, white	72 (97)
Age at first lung function test, median years (IQR)	9.9 (7.9 – 14.0)
Age at last lung function test, median years (IQR)	16.2 (14.2 – 20.0)
Smoking status ¹	
Active smoking	4 (5)
Former active smoking	5 (7)
Passive smoking	32 (43)
Never active smoking	33 (45)
Clinical characteristics	
Age at diagnosis, median years (IQR)	7.4 (3.5 – 12.2)
Age at transplantation, median years (IQR)	9.4 (5.6 – 13.5)
Era of diagnosis	• (())
1980-1990	8 (11)
1991-2000	24 (32)
2001-2010	42 (57)
Cancer diagnosis according to ICCC-3	54 (00)
I: Leukemia	51 (69)
II: Lymphoma	12 (16)
Other ²	11 (15)
Relapse	41 (55)
Treatment characteristics	
Lung toxic chemotherapeutic agents, type	/
Busulfan	25 (34)
Carmustine	5 (7)
Lomustine	1 (1)
Bleomycin	4 (5)
Lung toxic chemotherapeutic agents, dose, mg/m ² (IQR)	400 (204 470)
Busulfan	422 (324 – 470)
Carmustine	300 (300 – 300)
Lomustine	190
Bleomycin Radiotherapy involving the thorax ³	41 (30 - 46)
Conditioning containing TBI	52 (70) 39 (53)
Thoracic surgery ⁴	10 (14)
Transplant characteristics	
Stem cell donor	
Autologous	24 (32)
Allogeneic	50 (68)
HLA identical sibling / HLA matched (un-)related donor	29 (58)
HLA mismatch (un-)related / haploidentical	11 (22)
Source of transplant	
Cord blood	5 (7)
Peripheral blood	41 (55)
Bone marrow	26 (35)
Unknown	2 (3)

¹ For categorization of smoking status see supplemental material

¹ For categorization of smoking status see supplemental material
 ² Other tumors include: tumor of the central nervous system (n=1), retinoblastoma (n=1), malignant bone tumor (n=5), soft tissue sarcoma (n=3), malignant germ cell tumor (n=1), neuroblastoma (n=1)
 ³ Thoracic radiation fields according to COG guidelines, Version 4.0, Oct 2018, including radiation to the chest, whole lung, mediastinum, (mini-)mantle field, TBI and additionally upper abdomen and thoracic spine, including craniospinal irradiation
 ⁴ Thoracic surgery according to COG guidelines, Version 4.0, Oct 2018, including thoracotomy, chest wall

surgery, rib resection, lobectomy, pulmonary metastasectomy and wedge resection

	FIRST Test		LAST Test		
	Median (IQR)	n (%)	Median (IQR)	n (%)	p-value*
FEV1 z-score	<u> </u>		· ·	· ·	
Whole cohort normal reduced Missing	-0.77 (-2.16 – 0.08) -0.08 (-0.76 – 0.23) -2.52 (-3.16 – -2.16)	73 48 (65) 25 (34) 1 (1)	-0.96 (-2.040.54) -0.63 (-0.910.13) -2.62 (-3.542.04)	73 48 (65) 25 (34) 1 (1)	0.215 0.020 0.485
FVC z-score	_				
Whole cohort normal reduced Missing FEV1/FVC	-0.91 (-2.250.23) -0.51 (-0.880.10) -2.77 (-3.592.22)	68 45 (61) 23 (31) 6 (8)	-1.20 (-2.24 – -0.61) -0.68 (-1.11 – -0.15) -2.68 (-3.72 – -2.17)	71 43 (58) 28 (38) 3 (4)	0.246 0.217 0.762
Whole cohort (ratio) ratio ≥0.7 ratio <0.7 Missing TLC z-score	0.94 (0.89 – 0.97) 0.94 (0.89 – 0.97) 0.66	69 68 (92) 1 (1) 5 (7)	0.91 (0.87 – 0.94) 0.91 (0.87 – 0.94) 0.65	71 70 (95) 1 (1) 3 (4)	0.077 0.042 NA
Whole cohort normal reduced Missing RV z-score	-1.38 (-2.560.21) -0.25 (-1.16 - 1.13) -2.59 (-3.262.46)	64 35 (47) 29 (39) 10 (14)	-0.83 (-2.35 – 0.23) -0.17 (-0.80 – 0.38) -3.68 (-4.39 – -2.26)	66 43 (58) 23 (32) 7 (10)	0.887 0.517 0.343
Whole cohort normal reduced Missing Follow-up	0.36 (-1.34 – 2.05) 0.87 (-0.95 – 2.19) -2.24 (-2.96 – -1.96)	62 53 (72) 9 (12) 12 (16)	0.28 (-0.60 – 1.25) 0.52 (-0.32 – 1.51) -3.49 (-4.09 – -2.27)	66 58 (78) 8 (11) 8 (11)	0.345 0.298 0.241
Time since diagnosis, years	3.0 (1.2 – 5.4)	74	9.3 (6.1 – 12.3)	74	

TABLE 2: Proportion of normal and reduced pulmonary function parameters for the first and last available test in childhood cancer survivors and its median z-score; N=74

Normal: measured value ≥ -1.645 z-score

Reduced: measured value <-1.645

Resistance: normal if <1.2kPa*s in adults and <1.0kPa*s in children

*ttest for continuous variables comparing median z-score between first and last test

TABLE 3: Results of the final linear mixed-effect multilevel regression models. All coefficients are put in relation to a male reference patient treated with autologous HSCT between 1980-1990, with no radiotherapy to the chest, no lung toxic chemotherapy, and no relapse (N=74 CCSs)

	Coefficient	P> z	95% Car	Intonial
FEV1 z-score (n=407 PFT)	Coentcient	r ~ Z	95% Con	. merval
Final model: no time interaction	-			
	0.499	0.69	-0.921	1.919
Intercept (_cons) Gender (ref. male)	-0.664	0.69	-0.921	-0.140
Type of HSCT (ref. autologous)	0.481	0.013	-0.113	1.076
Radiotherapy to lung (ref. no)	-1.306	0.001	-2.055	-0.558
Lung toxic chemotherapy (ref. no)	-0.559	0.123	-1.270	0.152
Relapse (ref. = no)	0.395	0.123	-0.148	0.937
Decade of diagnosis (ref. 1980-1990)	0.535	0.134	-0.140	0.337
1991 – 2000	-0.667	0.183	-1.647	0.314
2001 - 2010	-0.197	0.678	-1.131	0.736
Time since diagnosis [decrease per year]	-0.061	0.000	-0.094	-0.027
	0.001	0.000	0.004	0.021
FVC z-score (n=395 PTF)				
Final model: no time interaction]			
Intercept (_cons)	0.147	0.837	-1.252	1.546
Gender (ref. male)	-0.387	0.152	-0.916	0.143
Type of HSCT (ref. autologous)	0.533	0.077	-0.058	1.123
Radiotherapy to lung (ref. no)	-1.473	<0.001	-2.207	-0.739
Lung toxic chemotherapy (ref. no)	-0.647	0.069	-1.347	0.051
Relapse (ref. = no)	0.237	0.395	-0.309	0.783
Decade of diagnosis (ref. 1980-1990)				
1991 – 2000	-0.312	0.531	-1.287	0.663
2001 - 2010	-0.083	0.861	-1.008	0.843
Time since diagnosis [decrease per year]	-0.058	0.003	-0.097	-0.019
TLC z-score (n=390 PFT)	-			
Final model: time interaction for type of HSCT and relapse				
	4 504	0.054	4 000	4 404
Intercept (_cons)	-1.584	0.251	-4.293	1.124
Gender (ref. male)	0.729	0.134	-0.224	1.682
Type of HSCT (ref. autologous)	-0.510	0.479	-1.923	0.903
Radiotherapy to lung (ref. no)	-0.717	0.292	-2.051	0.616
Lung toxic chemotherapy (ref. no)	-0.587	0.364	-1.855	0.681
Relapse (ref. no)	1.704	0.015	0.333	3.075
Decade of diagnosis (ref. 1980-1990)	1.050	0.044	2 04 4	0 744
1991 – 2000	-1.052	0.241	-2.814	0.711
2001 - 2010	-0.204	0.811	-1.874	1.465
Change in TLC z-score per year				
Time since diagnosis (continuous per year)	0.103	0.236	-0.067	0.272
Interaction Type of HSCT (ref. autologous)	0.123	0.136	-0.038	0.284
Interaction relapse (ref. no)	-0.258	0.001	-0.414	0.103
RV z-score (n=382 PFT)				
Final model: time interaction for relapse				
Intercept (_cons)	-0.309	0.764	-2.326	1.707
Gender (ref. male)	0.036	0.918	-0.650	0.722
Type of HSCT (ref. autologous)	-0.155	0.692	-0.923	0.612
Radiotherapy to lung (ref. no)	0.663	0.181	-0.307	1.634
Lung toxic chemotherapy (ref. no)	-0.298	0.518	-1.202	0.606
Relapse (ref. = no)	1.085	0.100	-0.208	2.378
Decade of diagnosis (ref. 1980-1990)	-0.785	0.226	-2.055	0.485
1991 – 2000	-0.127	0.838	-1.346	1.902
2001 - 2010				

Time since diagnosis (continuous per year) Time interaction with relapse (ref. no)	0.108 -0.231	0.095 0.010	-0.019 -0.405	0.234 -0.055
DLCO z-score (n=185 PFT)				
Final model: no time interaction				
Intercept (_cons)	1.948	0.192	-0.977	4.872
Gender (ref. male)	-0.514	0.341	-1.575	0.546
Type of HSCT (ref. autologous)	0.498	0.381	-0.616	1.613
Radiotherapy to lung (ref. no)	-1.279	0.093	-2.773	0.213
Lung toxic chemotherapy (ref. no)	-0.707	0.296	-2.033	0.619
Relapse (ref. = no)	0.138	0.809	-0.986	1.263
Decade of diagnosis (ref. 1980-1990)				
1991 – 2000	-2.465	0.004	-4.151	-0.780
2001 - 2010	-2.447	0.004	-4.111	-0.784
Time since diagnosis [decrease per year]	0.015	0.748	-0.079	0.111

Abbreviations: HSCT, hematopoietic stem cell transplantation; lufutime, time variable from diagnosis to pulmonary function test; PFT, pulmonary function test result

Time interaction was only included in the model when risk factors were significant (p < 0.05) at separate levels. Additional information (results from separate analyses and random effects parameters) in the supplement




FIGURE 1: Longitudinal trajectory of FEV1 z-score over time, upper part with results of each patient connected, lower part showing the median of all observations over time (n=74; 411 tests)




FIGURE 2: Longitudinal trajectory of FVC z-score over time (n=73; 395 tests)






FIGURE 3: Longitudinal trajectory of DLCO z-score over time (n=46; 185 tests)






В

FIGURE 4: Median FEV1 and FVC z-score 24 childhood cancer survivors with testing before HSCT compared to their results <2 years from HSCT, 2-<5 years and ≥5 years from HSCT. A) Course of FEV1, B) Course of FVC

SUPPLEMENTAL EXPLANATION E1: Factors considered in the quality assessment of pulmonary function test results

Table and included figures adapted from Salem et al



SUPPLEMENTAL TABLE S1: Characteristics of childhood cancer survivors with one pulmonary function test (N=12)

	Total one test (n=12)	Total ≥2 tests² (n=74)	
	n (%)		
Sociodemographic and lifestyle characteristics			
Sex, male	8 (67)	43 (58)	
Ethnicity, white	12 (100)	72 (97)	
Clinical characteristics			
Age at diagnosis, median years (IQR)	8.3 (3.5 – 15.1)	7.4 (3.5 – 12.2)	
Age at transplantation, median years (IQR)	10.5 (3.9 – 15.6)	9.4 (5.6 – 13.5)	
Era of diagnosis			
1980-1990	1 (8)	8 (11)	
1991-2000	6 (50)	24 (32)	
2001-2010	5 (42)	42 (57)	
Cancer diagnosis according to ICCC-3			
I: Leukemia	4 (33)	51 (69)	
II: Lymphoma	1 (9)	11 (15)	
IV: Neuroblastoma	4 (33)	1 (1)	
Other ²	3 (25)	11 (15)	
Relapse	2 (17)	41 (55)	
Pulmonary function characteristics			
Follow-up ¹ (years, IQR, range)	2.1 (0.6 – 10.6,	9.3 (1.2 – 12.3,	
	0.3 – 15.4)	1.2 – 14.9)	
FEV1 z-score (median, IQR)	-0.8 (-1.80.4)	-0.8(-2.2-0.08)	
FVC z-score (median, IQR)	-1.2 (-2.40.4)	-0.9 (2.20.2)	
TLC z-score (median, IQR)	-1.2 (-2.5 – 0.04)		
RV z-score(median, IQR)	0.7 (-0.7 – 2.6)		
DLCO z-score (median, IQR)	-0.5 (-1.1 – 0.2)	-1.3 (-2.9 – -0.2)	

¹ Follow-up: time from diagnosis to last PFT
 ² CCSs with at least two tests and follow-up time censored at 15 years

SUPPLEMENTAL TABLE S2: Additional characteristics of the included childhood cancer survivors (n=74)

	Total
	(n=74)
	n(%)
Diagnosis according to ICCC3	54 (000)
Leukemia	51 (69%)
(Ia) Acute lymphoblastic leukemia (Ib) Acute myeloid leukemia	30 (59) 12 (23)
(Ic) Chronic myeloproliferative syndrome	4 (8)
(Id) Myelodysplastic syndrome	5 (10)
Lymphoma	11 (14%)
(IIa) Hodgkin lymophoma	4 (36)
(IIb) Non-Hodgkin lymphoma	5 (45)
(IIc) Burkitt lymphoma Neuroblastoma	2 (18) 1 (1%)
Other Tumors	11 (15%)
(IIIc) Embryonal brain tumor	1 (9)
(V) Retinoblastoma	1 (9)
(VIIIc) Ewing tumor	5 (45)
(IXd) Other specified soft tissue sarcoma	3 (27)
(Xc) Malignant gonadal germ cell tumor	1 (9)
Specific transplant characteristics in allog	eneic population (n=50)
CMV status	
Donor and recipient negative	25 (50)
Donor and recipient positive	12 (24)
Donor positive, recipient negative	6 (12)
Donor negative, recipient positive	5 (10)
Unknown	2 (4)
Blood group	00 (40)
Match	23 (46)
Major mismatch	12 (24)
Minor mismatch	12 (24)
Bidirectional mismatch	1 (2)
Missing GvHD	2 (4)
No	8 (16)
Yes	42 (84)
Unknown	42 (04) 1 (2)
Acute	33 (79)
Chronic	6 (14)
Skin	5 (83)
Skin and other location	1 (17)
	• \ • • /

Abbreviations: CMV, cytomegalovirus; GvHD, graft versus host disease; HLA, human leukocyte antigen; ICCC-3, International Classification of Childhood Cancer, 3rd edition; TBI, total body irradiation

SUPPLEMENTAL TABLE S3: Characteristics of 411 pulmonary function test results in the study population (N=74)

	Total (n=411 PFTs)
	n (%)
Number of FEV1 measurements (indicative for spirometry) Number of TLC measurements (indicative for body plethysmography)	407 (99) 390 (95)
Number of DLCO measurements	185 (45)
Pulmonary function test per survivor (n=74 survivors)	Mean 5 (range 2 – 12)
Median time between diagnosis and first PFT, years Median time between diagnosis and last PFT, years	Median 3.0 (IQR 1.2 –5.4) Median 9.3 (IQR 6.1 – 12.3)

SUPPLEMENTAL TABLE S4: Linear mixed-effect multilevel regression model for FEV1 z-scores testing interaction with time since diagnosis for each risk factor separately

	Coefficient	Standard error	P> z	95% Conf. Interval	
Model without time interaction (Final model)					
Intercept (_cons)	0.499	0.724	0.69	-0.921	1.919
Gender (ref. male)	-0.664	0.267	0.013	-1.187	-0.140
Type of HSCT (ref. autologous)	0.481	0.304	0.113	-0.113	1.076
Radiotherapy to lung (ref. no)	-1.306	0.382	0.001	-2.055	-0.558
Lung toxic chemotherapy (ref. no)	-0.559	0.363	0.123	-1.270	0.152
Relapse (ref. = no)	0.395	0.277	0.154	-0.148	0.937
Decade of diagnosis (ref. 1980-1990)					
1991 – 2000	-0.667	0.500	0.183	-1.647	0.314
2001 - 2010	-0.197	0.476	0.678	-1.131	0.736
Time since diagnosis [decrease per year]	-0.061	0.017	0.000	-0.094	-0.027
Random effects Parameters	Estimate	Standard error		95% conf. Interval	
Variance "random effect slope" ¹ (lufutime)	0.009	0.003		0.005	0.019
Variance "random effect intercept" ²	1.657	0.359		1.084	2.534
Covariance ³	-0.076	0.029		-0.135	-0.018
Results from testing interaction with time	Coefficient	Standard orror	D> 7	95% Conf Interval	
			1		
Gender # Iufutime	0.018	0.036	0.602	-0.051	0.089
Type of HSCT # lufutime	0.015	0.037	0.677	-0.057	0.088
Radiotherapy # lufutime	0.007	0.039	0.849	-0.070	0.085
Lung toxic chemotherapy # lufutime	-0.009	0.035	0.793	-0.077	0.059
Relapse # lufutime	0.008	0.034	0.820	-0.059	0.075
Decade of diagnosis # lufutime					
1991 – 2000	-0.015	0.060	0.808	-0.132	0.104
2001 - 2010	0.0004	0.772	0.994	-1.044	1.984
•		:			
¹ Variance "random effect slope" = variance of av	verage change in	erage change in FEV1 per year of follow-up between patients (cluster)	ow-up between	patients (cluster)	

² Variance "random effect intercept" = variance of the slope and variance of the intercept; negative covariance ≈ the higher the intercept the lower the slope and variance of the slope and variance of the intercept.

Abbreviations: HSCT, hematopoietic stem cell transplantation; lufutime, time variable from diagnosis to pulmonary function test

or each risk	
ce diagnosis fo	
n with time sin	
sting interactio	
ffect multilevel regression model for FVC z-scores testing interaction with time since diagnosis for each risk	
n model for FV	
evel regression	
d-effect multile	
: Linear mixed	
NL TABLE S5	
SUPPLEMENTAL TABLE S5: Line	ctor separately
S	fac

"" 0.147 0.714 0.837 0.387 0.387 0.374 0.837 -0.387 0.372 0.0077 0.077 -0.387 0.327 0.0077 0.077 -0.387 0.327 0.302 0.077 -0.387 0.374 0.077 0.077 -0.647 0.357 0.007 0.077 -0.647 0.357 0.007 0.077 -0.312 0.279 0.355 0.007 0.237 0.237 0.237 0.035 -1.473 0.279 0.035 0.325 -0.083 0.040 0.004 0.003 -0.077 0.035 0.003 0.327 -1.471 0.035 0.003 0.003 -1.471 0.019 0.004 0.003 -0.077 0.041 0.023 0.003 -1.471 0.024 0.024 0.023		Coefficient	Standard error	P>Iz	95% Conf. Interval	
$ \begin{array}{c ccccc} 0.147 & 0.714 & 0.837 & -1.252 \\ -0.387 & 0.302 & 0.077 & -0.916 \\ 0.533 & 0.302 & 0.077 & -0.058 \\ 0.533 & 0.302 & 0.001 & -2.207 \\ -0.647 & 0.357 & 0.036 & -1.347 \\ 0.237 & 0.357 & 0.003 & -1.347 \\ 0.237 & 0.357 & 0.036 & -1.347 \\ 0.237 & 0.357 & 0.039 & -1.347 \\ 0.038 & 0.019 & 0.039 & -0.039 \\ 0.038 & 0.019 & 0.003 & 0.007 \\ 0.003 & 0.003 & 0.007 & -2.207 \\ 0.003 & 0.003 & 0.007 & -2.207 \\ 0.003 & 0.035 & 0.001 & -2.207 \\ 0.003 & 0.035 & 0.001 & -2.207 \\ 0.003 & 0.019 & 0.003 & 0.007 \\ 0.004 & 0.004 & 0.003 & 0.007 \\ 0.041 & 0.035 & 0.004 & 0.004 \\ 0.041 & 0.035 & 0.004 & 0.004 \\ 0.041 & 0.035 & 0.004 & 0.004 \\ 0.041 & 0.035 & 0.004 & 0.008 \\ 0.041 & 0.032 & 0.004 & 0.004 \\ 0.041 & 0.032 & 0.004 & 0.004 \\ 0.041 & 0.032 & 0.004 & 0.004 \\ 0.004 & 0.041 & 0.327 & 0.006 \\ 0.041 & 0.032 & 0.004 & 0.004 \\ 0.004 & 0.041 & 0.327 & 0.006 \\ 0.041 & 0.032 & 0.004 & 0.004 \\ 0.004 & 0.004 & 0.004 & 0.004 \\ 0$	Model without time-interaction (Final model)					
(1, 1, 1, 1, 2, 1) (0.387) (0.270) (0.152) (0.916) $(1, 1, 1, 1, 2, 2, 2, 2, 1)$ $(1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2,$	Intercept (_cons)	0.147	0.714	0.837	-1.252	1.546
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Gender (ref. male)	-0.387	0.270	0.152	-0.916	0.143
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Fype of HSCT (ref. autologous)	0.533	0.302	0.077	-0.058	1.123
-0.647 0.357 0.069 -1.347 0.237 0.279 0.395 -0.309 0.237 0.279 0.395 -0.309 0.237 0.279 0.531 -1.347 0.083 0.497 0.531 -1.287 -0.083 0.472 0.861 -1.008 -0.058 0.019 0.647 -0.097 -0.058 0.015 0.003 0.003 0.015 0.016 0.004 0.008 0.015 0.004 0.008 0.008 0.015 0.0325 -0.146 0.086 0.040 0.041 0.327 -0.040 0.040 0.041 0.327 -0.040 0.015 0.044 0.326 -0.040 0.015 0.024 0.038 -0.063 0.015 0.021 0.094 -0.063 0.015 0.039 0.770 -0.063 0.016 0.092 -0.098 -0.063 0.01	Radiotherapy to lung (ref. no)	-1.473	0.374	<0.001	-2.207	-0.739
0.237 0.279 0.395 -0.309 -0.312 0.497 0.531 -1.287 -0.083 0.472 0.861 -1.008 -0.058 0.019 0.003 95% conf. Interval e) 0.015 0.004 95% conf. Interval e) 0.015 0.004 0.008 e) 0.015 0.004 95% conf. Interval e) 0.015 0.004 0.008 0.0040 0.325 0.040 0.954 0.077 0.035 0.040 0.954 0.077 0.035 0.040 0.969 0.077 0.032 0.040 0.963 0.015 0.041 0.327 -0.040 0.040 0.041 0.327 -0.040 0.015 0.039 0.062 -0.040 0.016 0.039 0.062 -0.063 0.015 0.039 0.062 -0.063 0.016 0.039 0.0062 -0.063 <	-ung toxic chemotherapy (ref. no)	-0.647	0.357	0.069	-1.347	0.051
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Relapse (ref. = no)	0.237	0.279	0.395	-0.309	0.783
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Decade of diagnosis (ref. 1980-1990)					
-0.083 0.472 0.861 -1.008 -0.058 0.019 0.003 0.097 -0.058 0.015 0.003 0.003 e) 0.015 0.004 0.003 e) 0.015 0.004 0.008 e) 0.015 0.004 0.008 0.015 0.004 0.035 -0.146 0.040 0.035 -0.146 0.954 0.040 0.035 -0.040 0.954 0.040 0.035 -0.040 0.969 0.040 0.041 0.327 -0.040 0.040 0.041 0.327 -0.040 0.040 0.042 0.888 -0.040 0.015 0.039 0.709 -0.063 0.015 0.039 0.602 -0.063 0.015 0.058 -0.063 -0.063 0.015 0.058 -0.063 -0.063 0.015 0.098 -0.063 -0.063 0.015	1991 – 2000	-0.312	0.497	0.531	-1.287	0.663
-0.058 0.019 -0.097 Estimate Standard error 0.003 -0.097 e) 0.015 0.004 0.008 0.008 0.015 0.004 0.008 0.008 0.008 e) 0.015 0.035 -0.044 0.068 0.040 e) 0.040 0.035 -0.040 0.041 0.054 0.040 e) 0.040 0.035 -0.040 0.041 0.327 -0.040 0.040 0.041 0.327 -0.040 0.040 0.040 0.041 0.327 0.039 0.036 -0.040 0.040 0.007 0.041 0.327 -0.040 -0.040 -0.076 0.015 0.039 0.039 0.0602 -0.063 -0.063 -0.063 -0.015 0.039 0.0602 0.094 -0.063 -0.063 -0.063 -0.063 0.015 0.039 0.0709 0.094 -0.063 -0.098 -0.063 <t< th=""><th>2001 - 2010</th><th>-0.083</th><th>0.472</th><th>0.861</th><th>-1.008</th><th>0.843</th></t<>	2001 - 2010	-0.083	0.472	0.861	-1.008	0.843
arameters Estimate Standard error 95% conf. Interval effect slope"1 (lufutime) 0.015 0.004 95% conf. Interval effect slope"1 (lufutime) 0.015 0.035 0.008 effect intercept"2 1.471 0.035 0.068 ng interaction with time Coefficient Standard error P> z 95% Conf. Interval ng interaction with time 0.040 0.041 0.327 -0.040 nutime 0.041 0.327 -0.040 -0.040 futime 0.042 0.388 -0.040 interaction with time 0.041 0.327 -0.040 interme 0.042 0.042 0.388 -0.040 intime 0.015 0.039 0.007 -0.063 -0.063 is # lufutime 0.017 0.039 0.7709 -0.063 -0.063 is # lufutime -0.017 0.559 0.770 -0.155 -0.155	Time since diagnosis [decrease per year]	-0.058	0.019	0.003	-0.097	-0.019
arameters Estimate Standard error 95% conf. Interval effect slope"1 (lufutime) 0.015 0.004 95% conf. Interval effect slope"1 (lufutime) 0.015 0.004 0.008 neffect intercept"2 1.471 0.325 0.068 ng interaction with time 0.015 0.035 0.014 ng interaction with time Coefficient Standard error 0.040 futime 0.007 0.041 0.327 -0.040 futime 0.006 0.041 0.327 -0.040 futime 0.007 0.042 0.388 -0.040 interaction with time 0.004 0.044 0.327 -0.040 futime 0.0015 0.044 0.388 -0.063 interaction with time 0.015 0.039 0.003 -0.063 interme 0.015 0.039 0.709 -0.063 interme 0.017 0.559 0.155 -0.155						
effect slope" ¹¹ (luftutime) 0.015 0.004 0.008 effect intercept" ² 1.471 0.325 0.954 ng interaction with time 0.035 0.035 0.046 ng interaction with time Coefficient Standard error 0.146 futime 0.040 0.041 0.327 -0.040 futime 0.007 0.042 0.327 -0.040 futime 0.007 0.042 0.388 -0.040 futime 0.015 0.044 0.388 -0.040 intime 0.015 0.039 0.709 -0.063 intime 0.019 0.039 0.709 -0.063 is # lufutime -0.017 0.598 0.155 -0.155		Estimate	Standard error		95% conf. Interval	
effect intercept"2 1.471 0.325 0.954 ng interaction with time 0.035 0.035 0.0146 ng interaction with time Coefficient Standard error P> z 95% Conf. Interval futime 0.040 0.041 0.327 -0.040 -0.040 futime 0.040 0.041 0.327 -0.040 -0.040 futime 0.007 0.042 0.327 -0.040 -0.040 futime 0.007 0.044 0.327 -0.040 -0.040 interapy # lufutime 0.015 0.044 0.888 -0.063 -0.063 is # lufutime 0.019 0.559 0.602 -0.058 -0.155 -0.155		0.015	0.004			0.027
ng interaction with time -0.077 0.035 -0.146 ng interaction with time Coefficient Standard error P> z 95% Conf. Interval futime 0.040 0.041 0.327 -0.040 futime 0.007 0.042 0.327 -0.040 futime 0.007 0.044 0.327 -0.040 futime 0.007 0.044 0.327 -0.040 futime 0.007 0.044 0.388 -0.040 interval 0.006 0.044 0.388 -0.076 interval 0.007 0.044 0.888 -0.076 interval 0.0039 0.039 0.709 -0.063 is # lufutime -0.017 0.039 0.602 -0.098 is # lufutime -0.017 0.558 0.770 -0.155		1.471	0.325			2.269
ng interaction with time Coefficient Standard error P> z 95% Conf. Interval futime 0.040 0.041 0.327 -0.040 futime 0.007 0.041 0.327 -0.040 futime 0.007 0.042 0.327 -0.040 futime 0.007 0.042 0.869 -0.040 futime 0.015 0.044 0.888 -0.064 or 0.015 0.039 0.709 -0.063 or 0.039 0.602 0.003 -0.063 sis # lufutime -0.017 0.598 0.602 -0.058 or 0.039 0.602 0.0063 -0.058 or 0.039 0.602 0.0063 -0.058 or 0.039 0.602 0.0063 -0.058 or 0.019 0.559 0.770 -0.155		-0.077	0.035			-0.008
ng interaction with time Coefficient Standard error P> z 95% Conf. Interval futime 0.040 0.041 0.327 -0.040 futime 0.007 0.041 0.327 -0.040 futime 0.007 0.042 0.869 -0.040 futime 0.006 0.044 0.888 -0.094 futime 0.015 0.039 0.0602 -0.063 e 0.015 0.039 0.602 -0.063 e 0.019 0.559 0.709 -0.155						
futime 0.040 0.041 0.327 -0.040 futime 0.007 0.042 0.869 -0.076 futime 0.007 0.044 0.869 -0.076 therapy # lufutime 0.015 0.039 0.034 -0.063 e 0.015 0.039 0.0602 -0.063 e 0.015 0.039 0.0602 -0.063 e 0.015 0.039 0.0602 -0.063 e 0.015 0.039 0.1602 -0.063 e 0.016 0.039 0.602 -0.063 e 0.039 0.039 0.602 -0.063 e 0.039 0.0602 -0.063 -0.063 e 0.019 0.559 0.770 -0.155	Results from testing interaction with time	Coefficient	Standard error	P> z	95% Conf. Interval	
0.007 0.042 0.869 -0.076 -0.006 0.044 0.888 -0.094 -0.015 0.039 0.709 -0.063 -0.021 0.039 0.602 -0.063 -0.017 0.598 0.602 -0.098 -0.017 0.559 0.808 -0.155 -0.019 0.559 0.770 -0.112	Gender # lufutime	0.040	0.041	0.327	-0.040	0.121
-0.006 0.044 0.888 -0.094 0.015 0.039 0.709 -0.063 -0.021 0.039 0.602 -0.063 -0.017 0.598 0.602 -0.098 -0.017 0.559 0.808 -0.155 -0.019 0.559 0.770 -0.112	Type of HSCT # Iufutime	0.007	0.042	0.869	-0.076	0.089
0.015 0.039 0.709 -0.063 -0.021 0.039 0.602 -0.098 -0.017 0.598 0.808 -0.155 -0.019 0.559 0.770 -0.112	Radiotherapy # lufutime	-0.006	0.044	0.888	-0.094	0.081
-0.021 0.039 0.602 -0.098 -0.017 0.598 0.808 -0.155 0.019 0.559 0.770 -0.112	-ung toxic chemotherapy # lufutime	0.015	0.039	0.709	-0.063	0.093
-0.017 0.598 0.808 -0.155 0.019 0.559 0.770 -0.112	Relapse # Iufutime	-0.021	0.039	0.602	-0.098	0.057
-0.017 0.598 0.808 -0.155 0.019 0.559 0.770 -0.112	Decade of diagnosis # lufutime					
0.019 0.559 0.770 0.112	1991 – 2000	-0.017	0.598	0.808	-0.155	0.121
	2001 - 2010	0.019	0.559	0.770	-0.112	0.151

¹ Variance "random effect slope" = variance of average change in FVC per year of follow-up between patients (cluster) ² Variance "random effect intercept" = variance between patients in their average FVC z-scores at diagnosis ³ Covariance = correlation between the variance of the slope and variance of the intercept; negative covariance ≈ the higher the intercept the lower the slope

Abbreviations: HSCT, hematopoietic stem cell transplantation; lufutime, time variable from diagnosis to pulmonary function test

SUPPLEMENTAL TABLE S6: Linear mixed-effect multilevel regression model for TLC z-scores testing interaction with time since diagnosis for each risk factor separately (n=390 tests)

iacioi sepaiaieiy (ii-330 iesis)					
	Coefficient	Standard error	P> z	95% Conf. Interval	
Model without time-interaction					
Intercept (_cons)	-1.245	1.312	0.342	-3.816	1.326
Gender (ref. male)	0.628	0.484	0.194	-0.320	1.576
Type of HSCT (ref. autologous)	0.325	0.543	0.550	-0.738	1.388
Radiotherapy to lung (ref. no)	-0.788	0.679	0.246	-2.120	0.543
Lung toxic chemotherapy (ref. no)	-0.375	0.641	0.558	-1.632	0.881
Relapse (ref. = no)	0.135	0.500	0.787	-0.845	1.116
Decade of diagnosis (ref. 1980-1990)					
1991 – 2000	-1.104	0.900	0.220	-2.869	0.660
2001 - 2010	-0.280	0.854	0.743	-1.955	1.394
Time since diagnosis [decrease per year]	0.047	0.043	0.274	-0.037	0.130
Random effects Parameters	Estimate	Standard error		95% conf. Interval	
Voriance "readom officet alone"1 /Infinition					0 626
	0.012	0.024		0.0002	0.020
Variance "random effect intercept" ²	2.795 0.052	2.026		0.675	11.577
COVALIANTCE	CCD.D-	0.134		-0.404	170.0
Results from testing interaction with time	Coefficient	Standard error	P> z	95% Conf. Interval	
Gender # Iufutime	0.016	0.089	0.857	-0.159	0.192
Type of HSCT # lufutime	0.216	0.079	0.007	0.059	0.372
Radiotherapy # lufutime	-0.034	0.098	0.733	-0.227	0.159
Lung toxic chemotherapy # lufutime	-0.060	0.084	0.472	-0.225	0.104
Relapse # lufutime*	-0.308	0.076	<0.01	-0.457	-0.157
Decade of diagnosis # lufutime			0200		
	0.003	0.123 0.118	0.9/9	-0.430	0.243
0107 - 1007	00	00	0.1.0	000.0-	0.000
Final Model	Coefficient	Standard error	P> z	95% Conf. Interval	
Intercept (_cons)	-1.584	1.382	0.251	-4.293	1.124
Gender (ref. male)	0.729	0.486	0.134	-0.224	1.682
Type of HSCT (ref. autologous)	-0.510	0.721	0.479	-1.923	0.903
Radiotherapy to lung (ref. no)	-0.717	0.680	0.292	-2.051	0.616
Lung toxic chemotherapy (ref. no)	-0.587	0.646	0.364	-1.855	0.681
Relapse (ref. no)	1.704	0.699	0.015	0.333	3.075

Decade of diagnosis (ref. 1980-1990) 1991 – 2000 2001 - 2010	-1.052 -0.204	0.852 0.852	0.241 0.811	-2.814 -1.874	0.711 1.465	
Change in TLC z-score per year Time since diagnosis (continuous per year) Interaction Type of HSCT (ref. autologous) Interaction relapse (ref. no)	0.103 0.123 -0.258	0.087 0.082 0.079	0.236 0.136 0.001	-0.067 -0.038 -0.414	0.272 0.284 0.103	
¹ Variance "random effect slope" = variance of average change in TI G per vear of follow-up between patients (cluster	werade chande in	TI C per vear of follo	w-un hetween p;	atients (cluster)		

¹ Variance "random effect slope" = variance of average change in LC per year of follow-up between patients (cluster) ² Variance "random effect intercept" = variance between patients in their average TLC z-scores at diagnosis

³ Covariance = correlation between the variance of the slope and variance of the intercept; negative covariance ≈ the higher the intercept the lower the slope * autocorrelation of residuals omitted because convergence not achievable

Abbreviations: HSCT, hematopoietic stem cell transplantation; lufutime, time variable from diagnosis to pulmonary function test

SUPPLEMENTAL TABLE S7: Linear mixed-effect multilevel regression model for RV z-scores testing interaction with time since diagnosis for each risk factor separately (n=382 tests)

iacioi separateiy (ii-302 tesis)					
	Coefficient	Standard error	P> z	95% Conf. Interval	
Model without time-interaction			-		
Intercept (_cons)	0.481	0.999	0.48	-1.478	2.439
Gender (ref. male)	-0.072	0.347	0.836	-0.752	0.609
Type of HSCT (ref. autologous)	-0.084	0.391	0.831	-0.849	0.682
Radiotherapy to lung (ref. no)	0.562	0.497	0.259	-0.413	1.537
Lung toxic chemotherapy (ref. no)	-0.192	0.457	0.676	-1.088	0.705
Relapse (ref. = no)	-0.330	0.352	0.348	-1.019	0.359
Decade of diagnosis (ref. 1980-1990)					
1991 – 2000	-0.790	0.649	0.224	-2.063	0.483
2001 – 2010	-0.160	0.626	0.798	-1.387	1.067
Time since diagnosis [decrease per year]	-0.016	0.049	0.750	-0.112	0.081
Boudow offorto Boundation	Cotimoto	Ctondord order		0E0/ conf lutomicl	
Ranuonii enecus Parameters	Esumate	Stanuaru error		33 % COIII. IIILEI VAI	
Variance "random effect slope" ¹ (lufutime)	0.061	0.037		0.018	0.201
Variance "random effect intercept" ²	3.084	1.708		1.042	9.131
Covariance ³	-0.381	0.253		-0.878	0.115
Results from testing interaction with time	Coefficient	Standard error	P> z	95% Conf. Interval	
Gender # lufutime	0.054	0.101	0.591	-0.144	0.252
Type of HSCT # lufutime	0.166	0.094	0.077	-0.018	0.349
Radiotherapy # lufutime	-0.071	0.111	0.522	-0.289	0.147
Lung toxic chemotherapy # lufutime	-0.036	0.099	0.718	-0.229	0.158
Relapse # Iufutime	-0.231	0.089	0.010	-0.405	-0.056
Decade of diagnosis # lufutime					
1991 - 2000	0.217	1.110	0.845	-1.958	2.393
2001 - 2010	-0.469	1.032	0.649	-2.493	1.553
Final Model	Coefficient	Standard error	P> z	95% Conf. Interval	
			192.0	1 20G	107 1
Intercept (_cons)	-0.309	1.029	0.764	-2.320	1./0/
Gender (ret. male)	0.036	0.350	0.918	-0.650	0.722
Type of HSCT (ref. autologous)	-0.155	0.392	0.692	-0.923	0.612
Radiotherapy to lung (ref. no)	0.663	0.495	0.181	-0.307	1.634
Lung toxic chemotherapy (ref. no)	-0.298	0.461	0.518	-1.202	0.606
Kelapse (rer. = no)	1.085	0.009	0.100	-0.208	2.3/8

Decade of diagnosis (ref. 1980-1990) 1991 – 2000 2001 - 2010	-0.785 -0.127	0.648 0.622	0.226 0.838	-2.055 -1.346	0.485 1.902	
Change in TLC z-score per year Time since diagnosis (continuous per year) Interaction with relapse (ref. no)	0.108 -0.231	0.065 0.089	0.095 0.010	-0.019 -0.405	0.234 -0.055	
¹ Variance "random effect slope" = variance of average change in RV per year of follow-up between patients (cluster)	average change in	RV per year of follov	v-up between pa	ttients (cluster)		


² Variance "random effect intercept" = variance between patients in their average RV z-scores at diagnosis ³ Covariance = correlation between the variance of the slope and variance of the intercept; negative covariance ≈ the higher the intercept the lower the slope

Abbreviations: HSCT, hematopoietic stem cell transplantation; lufutime, time variable from diagnosis to pulmonary function test

SUPPLEMENTAL TABLE S8: Linear mixed-effect multilevel regression model for DLCO z-scores testing interaction with time since diagnosis for each risk factor separately (n=185)


	Coefficient	Standard error	D>I7I	95% Conf Interval	_	
Model without time-interaction (Final model)						
Intercept (cons)	1.948	1.492	0.192	-0.977	4.872	
Gender (ref. male)	-0.514	0.541	0.341	-1.575	0.546	
Type of HSCT (ref. autologous)	0.498	0.568	0.381	-0.616	1.613	
Radiotherapy to lung (ref. no)	-1.279	0.762	0.093	-2.773	0.213	
Lung toxic chemotherapy (ref. no)	-0.707	0.677	0.296	-2.033	0.619	
Relapse (ref. = no)	0.138	0.574	0.809	-0.986	1.263	
Decade of diagnosis (ref. 1980-1990)						
1991 – 2000	-2.465	0.859	0.004	-4.151	-0.780	
2001 - 2010	-2.447	0.849	0.004	-4.111	-0.784	
Time since diagnosis [decrease per year]	0.015	0.048	0.748	-0.079	0.111	
Random effects Parameters	Estimate	Standard error		95% conf. Interval		
Variance "random effect slope" ¹ (lufutime)	0.015	0.017		0.002	0.138	
	3.311	1.872		1.094	10.026	
Covariance ³	-0.144	0.169		-0.475	0.188	
			-			
Results from testing interaction with time	Coefficient	Standard error	P> z	95% Conf. Interval		
Gender # Iufutime	0.183	0.098	0.063	-0.010	0.376	
Type of HSCT # lufutime	0.059	0.100	0.558	-0.138	0.256	
Radiotherapy # lufutime	-0.025	0.153	0.871	-0.325	0.275	
Lung toxic chemotherapy # lufutime	-0.050	0.102	0.622	-0.251	0.149	
Relapse # lufutime	0.051	0.106	0.627	-0.156	0.259	
Decade of diagnosis # lufutime						
1991 – 2000	-0.128	0.124	0.302	-0.371	0.115	
2001 - 2010	0.012	0.137	0.885	-0.249	0.289	
¹ Variance "random effect slope" = variance of average change in DLCO per year of follow-up between patients (cluster)	verage change in	DLCO per year of fo	llow-up between	patients (cluster)		
² Variance "random effect intercept" = variance between patients in their average DLCO z-scores at diagnosis	between patients i	n their average DLC	O z-scores at dia	agnosis		
³ Covariance = correlation between the variance of t	e of the slope and	variance of the interc	ept; negative co	variance ≈ the higher th	the slope and variance of the intercept; negative covariance \approx the higher the intercept the lower the slope	e slope

Abbreviations: HSCT, hematopoietic stem cell transplantation; lufutime, time variable from diagnosis to pulmonary function test




SUPPLEMENTAL FIGURE S1: Population tree of transplanted childhood cancer survivors eligible for this study.


CCS, childhood cancer survivor; HSCT, hematopoietic stem cell transplantation; SCCSS, Swiss Childhood Cancer Survivor Study; PFT, pulmonary function test




SUPPLEMENTAL FIGURE S2: Longitudinal trajectory of TLC z-score over time (390 tests)



SUPPLEMENTAL FIGURE S3: Longitudinal trajectory of RV z-score over time (390 tests)



SUPPLEMENTAL FIGURE S4: Longitudinal trajectory of MMEF z-score over time (270 tests)



ADDITIONAL SUPPLEMENTAL MATERIAL

FIGURE xx: Longitudinal trajectory of FEV1 z-score in CCSs transplanted autologous (upper figure) and allogeneic (bottom figure)

4.3. Publication III

Lung function in Swiss childhood cancer survivors- a retrospective study

Original article

Rahel Kasteler*, **Maria Otth***, Florian Halbeisen, Florian Singer, Jochen Rössler, Nicolas X von der Weid, Marc Ansari, Claudia E Kuehni

*shared first authors

(Manuscript in preparation, to be submitted to European Respiratory Journal)

Own contribution to the project when submitting the thesis: Data analysis, interpretation of the results, writing manuscript, integration of co-authors comments

1 Lung function in Swiss childhood cancer survivors – a

2 retrospective cohort study

4	Running title: Lung function in childhood cancer survivors
5	
6	Maria Otth MD ^{1,2,3*} , Rahel Kasteler MD PhD ^{1,4*} , Florian Halbeisen PhD ^{5,6} , Luzius
7	Mader ¹ , Florian Singer MD PhD ⁷ , Jochen Rössler MD ⁸ , Nicolas X von der Weid MD ⁹ ,
8	Marc Ansari MD ¹⁰ , Claudia E Kuehni MD ^{1,7**} , for the Swiss Pediatric Oncology Group
9	(SPOG)***.
10	
11	¹ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
12	³ Division of Oncology - Hematology, Department of Pediatrics, Kantonsspital Aarau,
13	Switzerland
14	⁴ Graduate School for Cellular and Biomedical Sciences, University of Bern,
15	Switzerland
16	⁴ Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern,
17	Bern
18	⁵ Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel,
19	Basel
20	⁶ University of Basel, Basel
21	⁷ Division of Respiratory Medicine, Department of Pediatrics, Inselspital, University
22	Hospital, University of Bern, Bern, Switzerland
23	⁸ Division of Pediatric Oncology - Hematology, Department of Pediatrics, Inselspital,
24	Bern University Hospital, University of Bern, Bern

- ⁹ Department of Pediatric Oncology Hematology, University Children's Hospital
- 26 Basel, University of Basel, Basel, Switzerland.

¹⁰ Department of Pediatrics, Oncology and Hematology Unit, Geneva University

- 28 Hospital, Geneva, Switzerland.
- 29
- 30 *Authors contributed equally to this work
- 31
- 32 **Corresponding author Claudia E. Kuehni, Institute of Social and Preventive
- 33 Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland. E-mail:
- 34 claudia.kuehni@ispm.unibe.ch; Telephone: +41 31 631 35 07
- 35
- 36 ***Swiss Paediatric Oncology Group (SPOG): Ansari M; Beck Popovic M; Bourquin
- 37 JP; Brazzola P; Greiner J; Rössler J; Schilling F; Scheinemann K; von der Weid N
- 38

39 FUNDING STATEMENT

40 This study was supported by Swiss Cancer Research (grant no: KFS-4157-02-2017).

41 The funders had no role in study design, data collection and analysis, decision to

42 publish, or preparation of the manuscript.

43

44 CONFLICT OF INTEREST STATEMENT

Dr. Singer reports personal fees from Vertex, personal fees from Novartis, grants
from the Swiss Society of Cystic Fibrosis (CFCH), Lungenliga Bern, outside the
submitted work.

- 48
- 49

50	AUTHOR CONTRIBUTIONS
51	Maria Otth: Data analysis and interpretation, manuscript writing
52	Rahel Kasteler: Conceptualization, data collection, data analysis and interpretation,
53	manuscript writing
54	Florian Halbeisen: Data analysis and interpretation
55	Florian Singer: Data interpretation
56	Marc Ansari: Manuscript review
57	Rössler J: Manuscript review
58	Nicolas X von der Weid: Manuscript review
59	Claudia E Kuehni: Conceptualization, funding acquisition, data analysis and
60	interpretation, manuscript writing
61	
62	All authors have revised earlier drafts and approved the final article.
63	

64 ACKNOWLEDGMENTS

We thank all childhood cancer survivors and families for participating in the 65 SCCR. We thank the data managers of the SPOG (Claudia Althaus, Brigitte 66 Andratschke, Nadine Assbichler, Pamela Balestra, Heike Baumeler, Nadine 67 Beusch, Sarah Blanc, Susann Drerup, Yves Franzosi, Janine Garibay, Franziska 68 Hochreutener, Sabine Holzapfel, Monika Imbach, Friedgard Julmy, Eléna 69 70 Lemmel, Rodolfo Lo Piccolo, Heike Markiewicz, Veneranda Mattielo, Annette 71 Reinberg, Marion Rizo, Renate Siegenthaler, Astrid Schiltknecht, Sophie Steiner, Beate Schwenke, and Verena Stahel) and the data managers and 72 73 administrative staff of the SCCR (Meltem Altun, Erika Brantschen, Katharina

- 74 Flandera, Elisabeth Kiraly, Nadine Lötscher, Verena Pfeiffer, Shelagh Redmond,
- 75 Julia Ruppel, and Ursina Roder).
- 76
- 77

78 Abbreviations:

CCS	Childhood cancer survivors
CNS	Central nervous system
CSI	Craniospinal irradiation
CI	Confidence interval
DLCO	Diffusion capacity of the lung for carbon monoxide
FEV1	first second of forced expiration
FVC	forced vital capacity
HSCT	Hematopoietic stem cell transplantation
ICCC-3	International Classification of Childhood Cancer, Third edition
IQR	Interquartile range
PFT	Pulmonary function tests
SCCR	Swiss Childhood Cancer Registry
TLC	Total lung capacity

80 Abstract

81 Background

Many cancer treatments are lung toxic and contribute to increased pulmonary
mortality and morbidity in childhood cancer survivors (CCSs). Pulmonary function
tests allow to detect pulmonary dysfunction in early stages among asymptomatic
patients. This study investigated pulmonary function in Swiss CCSs after exposure to
lung toxic treatments, longitudinal pulmonary function trajectories, and associations
with lung toxic treatments.

88

89 Methods

We retrospectively searched pulmonary function tests in hospital charts of CCSs
who had been diagnosed with cancer between 1990 and 2013 and exposed to lung
toxic chemotherapeutics or thoracic radiotherapy. We described pulmonary function
(FEV1, FVC, FEV1/FVC, TLC and DLCO) as z-scores and percentage predicted,
plotted lung function trajectories over time by fitting a loess curve, and determined
risk factors for changes in FEV1 and FVC using multivariable linear regression
models.

97

98 **Results**

We found 835 pulmonary function tests in 190 CCS, with a median of four spirometry
and body plethysmography results per CCS and three DLCO measurements. 57% of

101 190 exposed CCSs showed at least one abnormal lung function parameter at

median 6 years from diagnosis, with restrictive impairment being the most frequent

103 (34%). The FVC and FEV1 trajectories started at z-scores around -1.5 at time of

104 diagnosis and stayed lower than the general population mean (z-score of 0). CCSs

105	treated with	thoracic surgerv	started at l	ower FEV1	compared to	non-exposed CCSs

- 106 (z-score: -1.19, 95%CI -2.03 -0.36). None of the risk factors contributed
- 107 significantly to an annual decrease in FVC or FEV1 z-scores, but exposure to lung
- 108 toxic chemotherapeutics led to an annual increase in FEV1 (0.11, 95%CI 0.03 -
- 109 0.18).
- 110

111 Conclusion

- 112 A relevant proportion of CCSs showed reduced pulmonary function. The young age
- of the study population and rather short follow-up period indicate that long-term
- 114 follow-up care is needed.
- 115
- 116 Keywords: childhood cancer survivors, lung toxic, lung function, longitudinal,
- 117 Switzerland
- 118

Chapter 4 - Results

119 Introduction

120 Childhood Cancer Survivors (CCSs) have an increased pulmonary mortality and 121 morbidity compared to siblings or the general population (1-4). Lung toxic 122 treatments, inevitable to treat cancer, can cause reversible and irreversible damage. 123 Known for lung toxicity are chemotherapy with bleomycin, busulfan and nitrosureas 124 (lomustine and carmustine), radiotherapy to the chest, and thoracic surgery. CCSs 125 report more pulmonary symptoms, such as dyspnea at exertion or chronic cough, 126 and suffer more often from recurrent pneumonia, fibrosis or emphysema than 127 siblings (3-5). CCSs are more often hospitalized and die more frequently due to 128 pulmonary diseases (6-8). All these outcomes are relatively late signs of pulmonary 129 dysfunction, because the lung has a large functional reserve and pulmonary disease 130 can be masked for a long time (9). Thus, data on self-reported diseases, 131 hospitalization, and mortality are not representative of all CCSs with pulmonary 132 dysfunction after lung toxic treatment. Pulmonary function tests (PFTs) may allow to detect pulmonary dysfunction at an earlier and often asymptomatic stage. Therefore, 133 134 PFTs are recommended in several long-term follow-up guidelines for CCSs (10-12). Most studies described pulmonary function in CCSs based on percent predicted 135 values calculated from different reference populations, with different reference 136 values used for adults and children (13, 14). This makes it difficult to compare results 137 across age groups and between studies. The Global Lung Initiative (GLI) published 138 139 in 2012 spirometric prediction equations for patients aged 3-95 years and for all 140 ethnic groups (15). In 2017 prediction equations for diffusion capacity of carbon 141 monoxide (DLCO) have been published, which cover the age spectrum of 5-85 years 142 (16).

143

In this study, we aim to describe pulmonary function in Swiss CCSs who had been
exposed to lung toxic treatments, by comparing them to normal values from GLI and
by describing the longitudinal trajectories. We also investigated associations with
treatment exposure.

148

149 Methods

150 Study population

151 This study is nested in the Swiss Childhood Cancer Registry (SCCR). The 152 SCCR is national, population-based registry of all children and adolescents 153 diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, 154 malignant solid tumors, or Langerhans cell histiocytosis prior to the age of 21 years 155 who were living in Switzerland at diagnosis (17). The registered data include 156 information on cancer diagnosis, classified according to the International 157 Classification of Childhood Cancer, third edition (ICCC-3) (18), cancer treatments, 158 and personal information such as date of birth or sex. Ethics approval was granted 159 by the Ethics Committee of the Canton of Bern to the SCCR (KEK-BE: 166/2014). 160 For the purpose of this study, we extracted information on date of birth, sex, 161 diagnosis, date of diagnosis, and treatment protocol from the SCCR. 162 163 Inclusion criteria

We included all CCSs registered in the SCCR who have been diagnosed in one of the nine Swiss pediatric oncology centers before age of 16 years, between 1990 and 2013, have been exposed to at least one lung toxic chemotherapeutic agent or thoracic radiotherapy, and who have consented to further use of their medical data. We excluded CCSs with no medical records available in the clinics,

where we could not find a PFT, and those aged ≤6 years at time of the study due tofeasibility of PFT.

We defined exposure to lung toxic chemotherapeutic agents as treatment with busulfan, bleomycin, and/or nitrosoureas (lomustine, carmustine) according to international long-term follow-up care guidelines (11, 12, 19). Radiotherapy was considered as lung toxic when administered as total body irradiation (TBI) or involving the mantle-field, chest, lungs, mediastinum or thoracic spine, which also includes craniospinal irradiation (11, 12, 19).

177

178 Medical records review and lung function measurements

179 We collected results of spirometry, body plethysmography, and diffusion 180 capacity for carbon monoxide (DLCO), and information on treatment exposure during 181 the year 2016. All medical records until 31th December 2015 were considered. We searched the electronic and paper-based medical records of all included CCSs in the 182 183 Swiss pediatric oncology centers where the children had been diagnosed and 184 treated, and the corresponding pediatric respiratory clinics. Swiss pediatric oncology 185 centers refer CCSs to PFT laboratories on cite, which are all part of pediatric 186 pulmonology departments in tertiary health centers. They generally perform PFTs according to ERS guidelines (20-22). 187

From the PFT results we extracted the test date, height and weight, and following outcome measures: forced vital capacity (FVC [I]) and forced expiratory volume in the first second (FEV₁ [I]) from spirometry, total lung capacity (TLC [I]) from body plethysmography, and diffusion capacity for carbon monoxide (DLCO [mmol/min/kPa]). As we assumed that the tests have been performed according to the ERS guidelines we did not check the test quality and did not assess the flow-

Chapter 4 - Results

194 volume curve. We did check for consistency of the pulmonary function test results 195 within patients. In case of outliers we consulted the original data again. We 196 converted all outcomes into sex-, height-, and age-adjusted z-scores and percentage 197 predicted using the Global Lung Initiative (GLI) 2012 reference values for FEV1, FVC, and DLCO (15, 23). For TLC z-score we used the reference equations by 198 199 Stocks/Quanier (24). We plotted the raw data of each outcome and for each patient 200 longitudinally over time since cancer diagnosis and evaluated them for outliers. If we 201 detected outliers, we checked the entered raw data, corrected them if needed or kept 202 them if the data had been entered correctly.

203 We calculated percentage predicted of FEV1, FVC, and DLCO to allow 204 comparison of our results with existing literature. We categorized all outcome 205 parameters calculated as z-scores as abnormal if they were <±1.645, which 206 corresponds to the 5th and 95th percentile respectively of normally distributed lung 207 function parameters (25). According to the Global Initiative for Chronic Obstructive 208 Lung Disease (GOLD) criteria (26), we considered FEV1 <80% of predicted value 209 and a FEV1/FVC ratio <0.70 as abnormal. Reduced FVC and diffusion capacity impairment were defined as <75% of predicted value, according to the Common 210 211 Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) (27). We took 212 CTCAE version 3.0 as the following versions no longer contain cutoff values for 213 DLCO, and this version was also used by other authors assessing pulmonary 214 function in CCSs (Supplemental Table S4). We grouped pulmonary dysfunction in three binary outcomes: restrictive impairment (TLC z-score <-1. 645), obstructive 215 impairment (FEV1/FVC <0.70 and FEV1 <80% of predicted or FEV1/FVC <0.70 and 216 FEV1<-1. 645), and diffusion capacity impairment (DLCO <75% predicted or z-score 217

218 <-1. 645). For this grouping we used the result of the last PFT in those with more</p>

than one test and the single available result in those with one test only.

220 For treatment exposure we collected detailed information on

221 chemotherapeutics and radiation fields. We recorded information on thoracic surgery

222 performed by thoracotomy or thoracoscopy for tumor/metastasis resection (wedge,

lobe, whole lung), rib resection, laminectomy, bone biopsy, en bloc resection of rib,

lung tissue, and/or diaphragm. We recorded autologous or allogeneic hematopoietic

stem cell transplantation (HSCT) and we also collected information on relapse and

survival. We classified CCS into three groups depending on the exposure to lung

toxic treatment: chest radiotherapy, lung toxic chemotherapy, or both.

228

229 Statistical analysis

230 We used descriptive statistics, such as medians and interguartile ranges 231 (IQR) to describe the study population and the presence of restrictive, obstructive 232 and diffusion capacity impairment. In CCSs with at least two PFTs, we compared z-233 scores for FVC, FEV1, TLC, and DLCO between the first and last PFT by students t-234 test. We plotted trajectories of lung function z-scores for FEV1 and FVC by fitting a 235 loess curve (locally weighted smoothing) and the respective 95% confidence interval. 236 We evaluated the association of potential risk factors with FEV1 and FVC 237 trajectories, including time since first exposure to a lung toxic treatment, sex, cancer 238 diagnosis, radiotherapy to the chest including CSI (yes/no), lung toxic chemotherapy 239 (yes/no), HSCT (yes/no), and thoracic surgery (yes/no) by using multivariable linear 240 mixed effects regression models with random intercept and random slope. This 241 analysis allows to use repeated measurements per patient and takes clustering 242 within each patient into account. We included time since first exposure to a lung toxic 243 treatment modality as a linear term. To evaluate whether changes over time in FEV1 244 or FVC were modified by the effect of a potential risk factor we included interaction 245 terms between all a potential risk factor and time since first exposure to a lung toxic 246 treatment. We performed likelihood ratio tests to assess whether each of the potential risk factors was associated with changes in FEV1 and FVC. 247 248 All analyses were performed using Stata (Version 16, Stata Corporation, 249 Austin, Texas) or R 3.1.2 (www.r-project.org), linear mixed models were performed 250 using the R-package Imer. 251

252 **Results**

253 Characteristics of study population

254 2989 CCSs had been diagnosed in a Swiss pediatric oncology center below 255 the age of 16 years, between 1990 and 2013 and survived more than two years from 256 cancer diagnosis. Of those, 14% (n=419) CCSs received lung toxic treatment according to the information on treatment protocols from the SCCR and were at least 257 six years old at start of data collection. Medical records were not available for 47 258 259 CCSs (11%). In half (51%, n=190) of the remaining 372 CCSs we could find a PFT 260 result (Supplementary Figure S1). Half of the CCSs were male (57%, n=109), 261 diagnosed with lymphoma (53%, n=100), and had a median follow-up time from 262 diagnosis of 14 years (IQR 9 - 19). The most frequent lung toxic exposure was radiotherapy involving the chest (87%, n=165), followed by lung toxic chemotherapy 263 264 (39%, n=49), HSCT (23%, n=44), and thoracic surgery (11%, n=21). One guarter of CCSs (26%, n=49) was exposed to a combination of radiotherapy involving the chest 265 266 and lung toxic chemotherapy (Table 1).

268 Findings on pulmonary function test results

269 Most of the 190 eligible CCSs had at least one spirometry (n=188; 99%) or body plethysmography (n=179; 94%) performed during the follow-up period. DLCO 270 271 had been performed in 137 CCS (72%). We collected 835 PFT results in total. The median number of spirometry tests per CCS was 4 (IQR 2-6, range 1-16), 4 (IQR 2-272 273 6, range 1-14) for body plethysmography, and 3 (IQR 2–5, range 1-13) for DLCO. In 274 one fifth (n=36, 19%) of CCSs we found one PFT result only (data not displayed in 275 table). As the last test of some CCSs did not include all measurements, only 187 276 CCS had data on FEV1, 186 on FVC, 178 on TLC, and 131 on DLCO. The median 277 follow-up time from diagnosis to the last PFT was 6 years (IQR 3-9 years) (Table 2). 278 In their last available test, one third (34%, n=64) of CCSs had a FEV1 z-score 279 below -1.645 and slightly more (39%, n=72) had a FVC z-score below -1.645. Only 280 two patients had a Tiffenau (FEV1/FVC ratio) below 0.7 plus FEV1 z-score below -1.645, meeting the GOLD-criteria for obstructive disease. TLC z-scores were lower 281 than 1.645 in the last test of one third of CCSs (34%, n=64), indicating restrictive 282 283 disease. Diffusion capacity impairment was present in 21% (n=28) (Table 2, 284 Supplementary table S1). Half of all CCSs (52%, n=99) had at least one outcome 285 (z-score for FEV1, FVC, TLC or DLCO) below -1.645 in the last test. When looking at 286 percentage predicted instead of z-scores to assess abnormal test results for FEV1, FVC, and DLCO, the proportion of CCSs with pathological values were similar for 287 288 FEV1 (33% vs. 34%), FVC (30% vs. 39%), and DLCO (16% vs. 21%), eventhough z-289 score cutoffs detected more pathological tests (Table 2, Supplementary Table S1). 290

291 Pulmonary function trajectories

The median time from diagnosis to first PFT was one year (IQR 0.3-2) and 6 292 293 years (IQR 4-9) to the last PFT with an average of 5 years evolved between first and 294 last test. The median percent predicted or z-scores of the spirometric values (FEV1, 295 FVC, FEV1/FVC) did not differ between the first and last test in CCSs with at least 296 two tests performed (Supplemental Table S2). The trajectories of FEV1 and FVC 297 are displayed in Figure 1 and Figure 2. For both outcomes, the curves started at z-298 scores around the value of -1.5 and did not show improvement or deterioration over 299 the observed period. The course of the curves eight years and more from diagnosis 300 has to be interpreted with caution as the number of tests diminishes rapidly and the 301 95% confidence is therefore becoming increasingly large but does not include the 302 norm of the reference population (z-score of 0).

303

304 Risk factor analysis

305 Our multivariable linear mixed regression model showed that the intercept, 306 corresponding to the starting point of the z-score at first exposure to a lung toxic 307 treatment, starts at a z-score of -0.6 (95%CI -0.16 - 0.42) for FEV1 and -1.37 308 (95%Cl -2.41 – -0.33) for FVC. For further explanation of the model see 309 Supplementary Explanation E1. For FEV1, none of the analyzed risk factor led to 310 an additional significant reduction in FEV1 z-score. For FVC, thoracic surgery led to 311 an additional reduction in FVC z-score at time of first exposure (z-score estimate -312 1.19, 95%CI -2.03 – -0.36) (**Table 4**). Taking the intercept of the reference patient into account, CCSs treated with thoracic surgery started at a FVC z-score of -2.56 313 314 compared to CCSs not treated with thoracic surgery. Exposure to lung toxic 315 chemotherapy was associated with an increase of FEV1 z-score over time of 0.11

316 (95%Cl 0.03 – 0.18) per year, compared to CCSs without lung toxic chemotherapy.

317 Taking the annual decrease of -0.07 for a reference patient without lung toxic

318 chemotherapy into account, this results in an annual improvement of 0.04 (-0.07 +

0.11). None of the analyzed risk factors was significantly associated with a significant
annual change in FVC z-score.

321

322 **Discussion**

323 PFT results of more than half of the CCSs in our cohort showed at least one 324 abnormal parameter a median of 6 years after cancer diagnosis with no major 325 changes in the longitudinal trajectories of FEV1 and FVC. CCSs treated with thoracic 326 surgery started at a significantly lower FVC z-score compared to those not treated 327 with thoracic surgery.

328

329 Prevalence of abnormal PFT measurements

330 The overall prevalence of any abnormal PFT measurement was 52% in our 331 cohort. This proportion is slightly lower than in the SJLIFE cohort, where 65% 332 showed at least one abnormal pulmonary function test (28). Applying the criteria of 333 obstructive disease, restrictive disease and diffusion capacity impairment, 38% of 334 CCSs from our cohort had at least one of these conditions. Again, this proportion 335 was slightly lower than what had been found in two other publications, with 44% (29) and 45.5% (9) of CCSs who had obstructive disease, restrictive disease or diffusion 336 337 capacity impairment. The proportion of CCSs having obstructive disease, defined as FEV1/FVC<0.7 and FEV1<80% of predicted value, was <5% in all three studies (our 338 cohort: 1%, Mulder at al: 2%, Armenian et al: 4%) (9, 29). One third (34%) of CCSs 339 340 in our cohort had restrictive disease, defined as TLC z-score <-1.645 and one fourth

341 (24%) to one fifth (18%) in the other two studies, which used the definition of TLC 342 <75% of predicted value. For diffusion capacity impairment, a lower proportion of 343 CCSs did suffer from diffusion capacity impairment, defined as <75% of predicted 344 value, in our cohort (16%) compared to the other cohorts (40% and 35%). The difference in the prevalence of diffusion capacity impairment might be explained by 345 346 the source of the PFT results. For this study we collected all available tests, 347 independent of the reason why they were carried out. It might be that some tests had 348 not been performed for surveillance purposes but for further evaluation of symptoms 349 of lung disease, including asthma. For such questions DLCO is often not measured, 350 but only spirometry and/or body plethysmography are done. The tests analyzed by 351 Mulder and Armenian, in contrast, came from late effects outpatient clinics and had 352 been performed for surveillance purpose only.

353

354 Comparing the proportion of CCSs with obstructive disease from our cohort with data 355 from Record et al. underlines that different definitions of obstructive disease largely 356 impact the primary outcome (Supplemental Table S4) (13). The broader definition used by Records et al resulted in a larger proportion of CCSs with obstructive 357 358 disease (26%). This comparison highlights that results on pulmonary dysfunction can 359 only be interpreted after taking the reference values used and cutoff values into 360 account. The use of different cutoff values makes the interpretation and practical 361 implementation of the results in clinics difficult. Also the use of z-scores instead of percentage predicted results in different proportions of pathological results 362 363 (Supplementary Table S1). The research community should agree on standard 364 cutoffs to make research on pulmonary disease in childhood cancer survivors more 365 homogenous and comparable.

Chapter 4 - Results

366

367 Longitudinal trajectory

368 The slightly undulating curve of FEV1 and FVC trajectories in our cohort is 369 similar to the results of other studies, which assessed pulmonary function in CCSs 370 after HSCT (30, 31) or CCSs exposed to whole lung irradiation (32). The initial 371 improvement might be explained by a recovery of partially reversible processes, 372 such as pneumonitis. This subsequent decrease could be due to progressive 373 irreversible changes, such as pulmonary fibrosis, or by physiological aging, which 374 has been shown to begin earlier in CCSs compared to the general population (33). 375 Despite this undulating shape, the best fitted line for the whole cohort is constantly 376 below -1 z-score for FEV1 and FVC. Considering that the population included in this 377 study is rather young and included mainly the first 10 years after diagnosis, it might 378 be that the deterioration would increase with longer observation. Research is needed 379 to determine how lung function develops in aging and adult survivors of childhood 380 cancer. Until then long term surveillance seems to be indicated in the CCSs.

381

382 Risk factors

383 We found that only thoracic surgery as a risk factor, was significantly 384 associated with lower PFT results, which was FVC z-score. This finding is most 385 probably due to the fact that the whole cohort was exposed to at least one lung toxic 386 treatment modality and therefore, the effects of single lung toxic treatment modalities might be underestimated. The high exposure of the entire cohort is also supported 387 388 by the low z-scores of the evaluated PFT results (-1.5) compared to the general 389 population mean of z-scores of zero. As treatment with thoracic surgery alone was 390 not an inclusion criterion for this study, all CCSs exposed to thoracic surgery have

391 been exposed to at least one other lung toxic treatment modality, e.g. chemotherapy 392 or radiotherapy. As a result, the negative effect of thoracic surgery on FEV1 and 393 FVC in our population might result from an overrepresentation of heavily treated 394 CCSs who received thoracic surgery as part of their multimodal treatment strategies. 395 Of the 21 CCSs treated with thoracic surgery in our cohort, 19 have also been 396 exposed to radiotherapy involving the chest, seven to autologous HSCT, and four to 397 a known lung toxic chemotherapeutic agent (**Supplemental Table S3**). Nine (43%) 398 have been exposed to at least two other lung toxic treatments in addition to surgery. 399 When looking at thoracic surgeries in more detail, 85% of surgeries included 400 thoracotomy, 42% a partial resection of the lung. Only two CCSs had a minor 401 surgical intervention with thoracoscopic biopsies. This illustrates the intensive 402 treatments these CCSs have been exposed to and point to multiple causes for the 403 reduced FVC z-score, rather than surgery alone. None of the other risk factors was 404 independently associated with a decrease in the intercept or slope of FEV1 and FVC 405 z-scores.

Exposure to lung toxic chemotherapy was associated with an increase in the slope of FEV1 z-score. Only 39% of all CCSs have been exposed to lung toxic chemotherapy. As most of them additionally received radiotherapy to the chest, only a small proportion was exposed to lung toxic chemotherapy alone. The annual increase in FEV1 z-score might indicate a partly reversible effect, which might also explain the observed initial decrease in the longitudinal trajectories.

412

413 Strengths and limitations

This study describes a large national cohort of CCSs exposed to at least one lung toxic treatment. Treatments have been verified in the medical records. We used

internationally recognized reference equations to calculate percent predicted valuesand z-scores of pulmonary function values.

The results of this study have to be considered with some limitations. 418 419 Although we tried to be as comprehensive as possible when collecting PFTs from 420 hospital records, we could have missed some PFTs or the tests have been 421 performed, but the results got lost. This might especially be the case for survivors 422 diagnosed in earlier years. In addition, some tests might not have been performed 423 for surveillance purpose due to the cancer treatment but due to other diseases. As 424 the cohort is heterogeneous with regards to underlying diagnoses, treatments, and 425 relapse status, it is difficult to draw conclusions for single cancer diagnoses. This 426 heterogeneity resulted in small groups exposed to chemotherapy, HSCT or surgery. 427 PFTs have been performed in different laboratories over a long period with changes 428 in equipment, staff, and testing procedures and it was therefore not possible to 429 uniformly assess quality of the test procedure. Our results might be limited by 430 selection bias, as we could find medical records and at least one PFT result of only 45% of the original cohort. We cannot rule out, that the more symptomatic and sicker 431 CCSs are included in our cohort and therefore rather overestimates the burden of 432 433 pulmonary dysfunction. In contrast, the studies by Armenian, Mulder and Green 434 recruited their cohorts from regular follow-up clinics with a response rate between 435 61-88%, where selection bias seems to be less likely.

436

437 Conclusion

Every second CCS exposed to lung toxic treatments in Switzerland showed at least one abnormal PFT parameter a median of 6 years after cancer diagnosis with reduced FVC being the most frequent. CCSs after multimodal treatment approaches

- 441 with more than one lung toxic treatment are particularly at risk. Our findings
- 442 underline the importance of surveillance screening for pulmonary dysfunction in long-
- term CCSs beyond 10 years after cancer diagnosis to show and monitor changes
- 444 over time.

445 **References**

446 Fidler MM, Reulen RC, Bright CJ, Henson KE, Kelly JS, Jenney M, et al. Respiratory 1. 447 mortality of childhood, adolescent and young adult cancer survivors. Thorax. 2018. 448 2. Smith L, Glaser AW, Peckham D, Greenwood DC, Feltbower RG. Respiratory 449 morbidity in young people surviving cancer: Population-based study of hospital admissions, 450 treatment-related risk factors and subsequent mortality. International journal of cancer. 451 2018. 452 3. Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, et al. Long-453 term pulmonary disease among Swiss childhood cancer survivors. Pediatric blood & cancer. 454 2018;65(1). 455 4. Dietz AC, Chen Y, Yasui Y, Ness KK, Hagood JS, Chow EJ, et al. Risk and impact of 456 pulmonary complications in survivors of childhood cancer: A report from the Childhood 457 Cancer Survivor Study. Cancer. 2016;122(23):3687-96. 458 5. Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood 459 460 Cancer Survivor Study. Cancer. 2002;95(11):2431-41. 461 Kirchhoff AC, Fluchel MN, Wright J, Ying J, Sweeney C, Bodson J, et al. Risk of 6. 462 hospitalization for survivors of childhood and adolescent cancer. Cancer epidemiology, 463 biomarkers & prevention : a publication of the American Association for Cancer Research, 464 cosponsored by the American Society of Preventive Oncology. 2014;23(7):1280-9. 465 7. Schindler M, Spycher BD, Ammann RA, Ansari M, Michel G, Kuehni CE, et al. Cause-466 specific long-term mortality in survivors of childhood cancer in Switzerland: A population-467 based study. International journal of cancer. 2016;139(2):322-33. 468 8. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-469 term cause-specific mortality among survivors of childhood cancer. Jama. 2010;304(2):172-470 9. 471 9. Armenian SH, Landier W, Francisco L, Herrera C, Mills G, Siyahian A, et al. Long-term 472 pulmonary function in survivors of childhood cancer. Journal of clinical oncology : official 473 journal of the American Society of Clinical Oncology. 2015;33(14):1592-600. 474 10. COG COG. Children's Oncology Group [COG] Long Term Follow-Up guidelines Version 475 5.0 2018 [cited 2019 05.04.2019]. Available from: 476 http://www.survivorshipguidelines.org/pdf/2018/COG LTFU Guidelines v5.pdf. 477 11. SKION DCOGD. Guidelines for follow-up in survivors of childhood cancer 5 years after 478 diagnosis. 2010 [cited 2018 08.05.2018]. Available from: https://www.skion.nl/voor-479 patienten-en-ouders/late-effecten/533/richtlijn-follow-up-na-kinderkanker/. 480 12. Group UKCsCS. Therapy based long term follow-up - Practice Statement 2005. 481 13. Record E, Williamson R, Wasilewski-Masker K, Mertens AC, Meacham LR, Popler J. 482 Analysis of risk factors for abnormal pulmonary function in pediatric cancer survivors. 483 Pediatric blood & cancer. 2016;63(7):1264-71. 484 Hoffmeister PA, Madtes DK, Storer BE, Sanders JE. Pulmonary function in long-term 14. 485 survivors of pediatric hematopoietic cell transplantation. Pediatric blood & cancer. 486 2006;47(5):594-606. 487 Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic 15. 488 reference values for spirometry for the 3-95-yr age range: the global lung function 2012 489 equations. The European respiratory journal. 2012;40(6):1324-43.

490 16. Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW, et al.
491 Official ERS technical standards: Global Lung Function Initiative reference values for the
492 carbon monoxide transfer factor for Caucasians. The European respiratory journal.
493 2017;50(3).

494 17. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss
495 Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005.
496 Swiss medical weekly. 2007;137(35-36):502-9.

497 18. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of
498 Childhood Cancer, third edition. Cancer. 2005;103(7):1457-67.

19. [COG] COG. Children's Oncology Group [COG] Long Term Follow-Up guidelines 2013
[cited 2018 08.05.2018]. Available from: <u>http://www.survivorshipguidelines.org</u>.

Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General
considerations for lung function testing. The European respiratory journal. 2005;26(1):15361.

504 21. Hsia CC, Hyde DM, Ochs M, Weibel ER. An official research policy statement of the
505 American Thoracic Society/European Respiratory Society: standards for quantitative
506 assessment of lung structure. American journal of respiratory and critical care medicine.
507 2010;181(4):394-418.

Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, et al. An official
American Thoracic Society/European Respiratory Society statement: pulmonary function
testing in preschool children. American journal of respiratory and critical care medicine.
2007;175(12):1304-45.

512 23. (GLI) GLI. Desktop Sheet Calculator [Available from: <u>https://www.ers-</u>

513 <u>education.org/guidelines/global-lung-function-initiative/spirometry-tools/desktop-sheet-</u>
 514 <u>calculator/</u>.

515 24. Stocks J, Quanjer PH. Reference values for residual volume, functional residual
516 capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official
517 Statement of The European Respiratory Society. The European respiratory journal.
518 1995;8(3):492-506.

519 25. Criée CP, Baur X, Berdel D, Bösch D, Gappa M, Haidl P, et al. [Standardization of
520 spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society
521 and German Society of Occupational and Environmental Medicine]. Pneumologie (Stuttgart,
522 Germany). 2015;69(3):147-64.

523 26. From the Pocket Guide to COPD diagnosis, management, and prevention. Global
524 Strategy Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Available from:
525 <u>https://goldcopd.org/</u>.

526 27. Institute NC. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE527 v3.0). 2003.

528 28. Green DM, Zhu L, Wang M, Ness KK, Krasin MJ, Bhakta NH, et al. Pulmonary function
529 after treatment for childhood cancer. A report from the St. Jude Lifetime Cohort Study
530 (SJLIFE). Annals of the American Thoracic Society. 2016;13(9):1575-85.

531 29. Mulder RL, Thonissen NM, van der Pal HJ, Bresser P, Hanselaar W, Koning CC, et al.
532 Pulmonary function impairment measured by pulmonary function tests in long-term
533 survivors of childhood cancer. Thorax. 2011;66(12):1065-71.

534 30. Inaba H, Yang J, Pan J, Stokes DC, Krasin MJ, Srinivasan A, et al. Pulmonary

535 dysfunction in survivors of childhood hematologic malignancies after allogeneic

hematopoietic stem cell transplantation. Cancer. 2010;116(8):2020-30.

537 31. Madanat-Harjuoja LM, Valjento S, Vettenranta K, Kajosaari M, Dyba T, Taskinen M. 538 Pulmonary function following allogeneic stem cell transplantation in childhood: a 539 retrospective cohort study of 51 patients. Pediatric transplantation. 2014;18(6):617-24. 540 32. Motosue MS, Zhu L, Srivastava K, Stokes DC, Hudson MM, McPherson V, et al. 541 Pulmonary function after whole lung irradiation in pediatric patients with solid 542 malignancies. Cancer. 2012;118(5):1450-6. 543 33. Ness KK, Kirkland JL, Gramatges MM, Wang Z, Kundu M, McCastlain K, et al.

544 Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse

545 Health Across the Lifespan of Survivors of Childhood Cancer. Journal of clinical oncology :

official journal of the American Society of Clinical Oncology. 2018;36(21):2206-15.

547

549 Legends

550 **Table 1** Characteristics of childhood cancer survivors, N=190

Table 2 Observed lung function parameters in last available lung function test.

552 Results shown as median z-score for all test results and separate for those meeting

the definition for abnormal (z-score <-1.645). Parameters compared to GLI 2012

reference. N=190

555 **Table 3** FEV1 z-scores in childhood cancer survivors compared to GLI 2012

556 reference values; multivariable linear mixed regression analysis adjusted for all

557 covariates in the model. N=190 survivors and 821 test results

558 **Table 4** FVC z-scores in childhood cancer survivors compared to GLI 2012

559 reference values; multivariable linear mixed regression analysis adjusted for all

560 covariates in the model. N=190 survivors and 821 test results

561 **Figure 1** Longitudinal changes in FEV1 z-score of childhood cancer survivors

562 compared to Global Lung Function Initiative 2012 reference. Time zero corresponds

to time point of diagnosis. The loess curve (blue line) shows the best fitted line by

taking each single data point into account at each time point on the x-line. The

shaded band corresponds to the 95% confidence interval. Dots represent single test

results, which are combined with a line and show the individual trajectories of each

567 patient included in the study. The dashed red line represents the mean z-score of the 568 normal population.

569 **Figure 2** Longitudinal changes in FVC z-score, of childhood cancer survivors

570 compared to Global Lung Function Initiative 2012 reference. Time zero corresponds

to time point of diagnosis. The loess curve (blue line) shows the best fitted line by

572 taking each data point into account at each time point on the x-line. The shaded

573 band corresponds to the 95% confidence interval. Dots represent single test results,

574	which are combined with a line and show the individual trajectories of each patient
575	included in the study. The dashed red line represents the mean z-score of the
576	normal population.
577	
578	Supplementary Material
579	Supplementary Explanation E1 Explanation of multivariable linear mixed
580	regression analysis with random intercept and random slope
581	Supplementary Table S1 Comparison of abnormal lung function parameters
582	assessed by percentage predicted and z-scores of last available lung function test,

- 583 N=190
- 584 Supplementary Table S2 Observed spirometric lung function parameters assessed
- as percentage predicted (% predicted) and z-scores in first and last available lung
- 586 function test in survivors with at least two tests, N=154
- 587 **Supplementary Table S3** Description of childhood cancer survivors treated with
- 588 thoracic surgery, N=21
- 589 **Supplementary Table S4** Characteristics of other studies assessing pulmonary
- 590 function in childhood cancer survivors
- 591 **Supplementary Figure S1** Flow chart of study population

	Curreline -	-
	Survivor: N = 190	5
	n - 150	(%) ^a
Sex		(70)
Male	109	(57)
Age at diagnosis, median (IQR) [years]	12.1 (6.5	. ,
0-4	30 [`]	, (16)
5–9	49	(26)
10–15	111	(58)
Follow-up from diagnosis to data collection, median [IQR) [years]	14.2 (8.9	– 19.3)
0–9	56	(29)
10-19	96	(51)
≥ 20	38	(20)
Period of cancer diagnosis		
1990–1997	65	(34)
1998–2005	82	(43)
2006–2013	43	(23)
Diagnosis (ICCC-3)		
I Leukemia	21	(11)
II Lymphoma	100	(53)
III CNS tumor	23	(12)
IV–XII all other tumors ^b	46	(24)
Relapse		
Yes, one relapse	32	(17)
Yes, two or more relapses	17	(9)
Death during follow-up ^c	20	(11)
_ung-toxic chemotherapy	74	(39)
Busulfan	14	(7)
Nitrosoureas (CCNU/BCNU)	15	(8)
Bleomycin	48	(25)
Chest radiotherapy incl. CSI	165	(87)
ung-toxic chemotherapy and chest radiotherapy	49	(26)
Thoracic surgery	21	(11)
Hematopoietic stem cell transplantation	44	(23)
Autologous	24	(13)
Allogeneic	20	(10)
Pulmonary function tests (n=835)		
Spirometry (median, IQR, range) per CCS	4 (IQR 2 -	– 6, range 1 – 16)
Body plethysmography (median, IQR, range) per CCS	4 (IQR 2 -	– 6, range 1 – 14)
DLCO (median, IQR, range) per CCS	3 (IQR 2 -	– 5, range 1 – 13)

TABLE 1 Characteristics of childhood cancer survivors, N=190

Abbreviations: CNS, central nervous system; CSI, craniospinal irradiation; Gy, Gray; ICCC3, International Classification of Childhood Cancer, version 3; IQR, interquartile range

^a Column percentages are given

^b Other tumors: n=13 Ewing tumor and related sarcoma, n=11 malignant extracranial germ cell tumors, n=10 nephroblastoma, n=5 neuroblastoma, n=5 other specified soft tissue sarcoma, n=2 rhabdomyosarcoma

^c Death during the whole time observed.

Table 2 Observed lung function parameters in last available lung function test ^a. Results shown as median z-score for all test results and separate for those meeting the definition for abnormal (z-score <-1.645). Parameters compared to GLI 2012 reference. N=190

	Survivors	
	n (%)	median (IQR)
Time from diagnosis to last test [years](median, IQR)	190 ^b	5.7 (3.2 – 9.4)
FEV1		
z-score	187	-1.1 (-1.90.3)
z-score <-1.645	64 (34%)	-2.4 (-3.11.9)
FVC		
z-score	186	-1.3 (-2.20.4)
z-score <-1.645	72 (39%)	-2.5 (-3.32.1)
FEV1/FVC		
z-score	184	0.3 (-0.5 – 1.1)
z-score FEV1/FVC <-1.645	4 (2%)	-2.1 (-2.41.8)
TLC		
z-score	178	-1.11 (-2.20.03)
z-score TLC <-1.645	61 (34%)	-2.2 (-3.22.2)
DLCO		
z-score	131	-0.5 (-1.50.5)
z-score DLCO <-1.645	28 (21%)	-2.7 (-3.91.8)
FEV1, FVC, TLC and/or DLCO z-score < -1.645	99 (52%)	n.a.
Obstructive ^c , restrictive ^d , or diffusion capacity impairment ^e	72 (38%)	

Abbreviations: IQR, interquartile range; n.a., not applicable

^a Last lung function test: one results in those with one test only, last result in those with more than one test

^b As not every last test included spirometry, body plethysmography and DLCO, the total number of CCSs per test parameter does not sum up to 190

^cObstructive = FEV17FVC<0.7 and FVC z-score <-1.645

^dRestrictive = TLC z-score <-1.645

^e Diffusion capacity impairment = DLCO z-score <-1.645

Table 3. FEV1 z-scores in childhood cancer survivors compared to GLI 2012 reference values; multivariable linear mixed regression analysis adjusted for all covariates in the model. N=190 survivors and 821 test results

	Estimate	95% CI	p-value
Intercept (FEV1 z-score at first exposure to lung toxic			
treatment for "reference patient" ²)	-0.60	-0.16 0.42	
Sex			0.527
Male	0.14	-0.30 0.58	
Cancer diagnosis (ref. Lymphoma)			0.172
CNS tumor	-0.13	-0.81 0.55	
Bone tumors	-1.27	-2.43 -0.12	
Germ cell tumors	0.86	-0.39 2.10	
Leukemia	0.19	-1.27 0.88	
Neuroblastoma	-0.52	-2.12 1.08	
Renal tumors	0.32	-0.72 1.37	
Soft tissue sarcoma	-0.95	-2.11 0.20	
Radiotherapy (ref. no)	-0.28	-1.19 0.63	0.542
Chemotherapy (ref. no)	-0.41	-0.93 0.09	0.113
HSCT (ref. no)	-0.08	-0.85 0.68	0.829
Thoracic surgery (ref. no)	-0.80	-1.69 0.09	0.077
Change of FEV1 z-score per year			
Time since first exposure to lung toxic treatment			
(continuous, per year)	-0.07	-0.21 0.08	
Interaction Sex			0.115
Male	-0.05	-0.11 0.01	
Interaction Cancer diagnosis (ref. Lymphoma)			0.357
CNS tumor	-0.09	-0.19 0.01	
Bone tumors	0.08	-0.07 0.24	
Germ cell tumor	-0.07	-0.24 0.08	
Leukemia	0.01	-0.13 0.16	
Neuroblastoma	0.04	-0.14 0.22	
Renal tumors	-0.08	-0.20 0.04	
Soft tissue sarcoma	0.01	-0.15 0.18	
Interaction Radiotherapy (ref. no)	0.09	-0.04 0.22	0.169
Interaction Chemotherapy (ref. no)	0.11	0.03 0.18	0.006
Interaction HSCT (ref. no)	-0.02	-0.12 0.08	0.670
Thoracic surgery (ref. no)	-0.06	-0.17 0.05	0.274

¹ Likelihood ratio test p-value indicating whether the characteristic explains differences in FEV₁ within the study


population. ² Reference patient corresponds to a female person, at first exposure to lung toxic agent, diagnosed with lymphoma, and not exposed to radiotherapy, chemotherapy, HSCT, and thoracic surgery.


	Estimate	95	% CI	p-value ^{1¶}
a)				
Intercept (FVC z-score at first exposure to lung toxic	4.07	-2.41	0.00	
treatment for "reference patient" ²)	-1.37	-2.41	-0.33	0 500
Sex	0.11	0.24	0 52	0.599
Male Concer diangoogie (ref. Lymphome)	0.11	-0.31	0.53	0.259
Cancer diangosis (ref. Lymphoma) CNS tumor	0.01	0 02	0.42	0.259
	-0.21 -0.44	-0.83 -1.53	0.42	
Bone tumors				
Germ cell tumors	1.18	-0.03	2.39	
Leukemia	0.11	-0.90	1.13	
Neuroblastoma	-0.59	-2.07	0.88	
Renal tumors	0.26	-0.71	1.24	
Soft tissue sarcoma	-0.79	-1.89	0.29	
Radiotherapy (ref. no)	0.24	-0.69	1.18	0.605
Chemotherapy (ref. no)	0.03	-0.46	0.51	0.909
HSCT (ref. no)	-0.42	-1.13	0.30	0.254
Thoracic surgery (ref. no)	-1.19	-2.03	-0.36	0.005
b)				
Change of FVC z-score per year				
Time since first exposure to lung toxic treatment				
(continuous, per year)	0.06	-0.07	0.21	
Interaction Sex				0.152
Male	-0.04	-0.09	0.02	
Interaction Cancer diagnosis (ref. Lymphoma)				0.168
CNS tumor	-0.11	-0.19	-0.02	
Bone tumors	-0.08	-0.22	0.05	
Germ cell tumor	-0.09	-0.24	0.05	
Leukemia	-0.06	-0.18	0.07	
Neuroblastoma	-0.002	-0.16	0.15	
Renal tumors	-0.10	-0.21	0.001	
Soft tissue sarcoma	0.001	-0.14	0.14	
Interaction Radiotherapy (ref. no)	-0.02	-0.15	0.09	0.704
Interaction Chemotherapy (ref. no)	0.02	-0.05	0.08	0.651
Interaction HSCT (ref. no)	0.02	-0.06	0.11	0.589
Thoracic surgery (ref. no)	0.02	-0.08	0.12	0.694

 Table 4 FVC z-scores in childhood cancer survivors compared to GLI 2012
 reference values; multivariable linear mixed regression analysis adjusted for all covariates in the model. N=190 survivors and 821 test results

¹ Likelihood ratio test p-value indicating whether the characteristic explains differences in FVC within the study

population. ² Reference patient corresponds to a female person, at first exposure to lung toxic agent, diagnosed with lymphoma, and not exposed to radiotherapy, chemotherapy, HSCT, and thoracic surgery.








Figure 2: Longitudinal changes in FVC z-score, of childhood cancer survivors compared to Global Lung Function Initiative 2012 reference. Time zero corresponds to time point of diagnosis. The loess curve (blue line) shows the best fitted line by taking each data point into account at each time point on the x-line. The shaded band corresponds to the 95% confidence interval. Dots represent single test results, which are combined with a line and show the individual trajectories of each patient included in the study. The dashed red line represents the mean z-score of the normal population.

Lung function in Swiss childhood cancer survivors - a retrospective cohort study

Supporting information

Journal:

Lung function in Swiss childhood cancer survivors – a retrospective cohort study

Rahel Kasteler*, Maria Otth*, Florian Halbeisen, Florian Singer, Nicolas X von der

Weid, Marc Ansari, Jochen Rössler, Claudia E Kuehni

Corresponding author:

Prof. Claudia E. Kuehni, MD MSc

Swiss Childhood Cancer Registry Institute of Social and Preventive Medicine University of Bern Mittelstrasse 43 3012 Bern Switzerland

E-mail: claudia.kuehni@ispm.unibe.ch

Lung function in Swiss childhood cancer survivors - a retrospective cohort study

Supplementary Explanation E1 Explanation of multivariable linear mixed regression analysis with random intercept and random slope

The multivariable linear mixed regression analysis with random intercept and random slope allows to take clustering and longitudinal trajectories of pulmonary outcomes by each patient into account.

Here we explain the data output with the example of FEV1:

The upper part of the table describes the FEV1 z-scores at time "zero", which refers to the time of first exposure to a lung toxic treatment modality. It can be considered as the extrapolated baseline FEV1 z-score, where each patient starts at first exposure. Depending on the subsequent exposure to risk factors, this starting point might be higher or lower. The reference patient (female, with Lymphoma, no radiotherapy, no chemotherapy, no HSCT and no thoracic surgery) starts at a z-score of -0.60. If a person of interest is male (z-score estimate 0.14) and additionally received radiotherapy to the chest (z-score estimate -0.28), he starts at a modelled FEV1 z-score of -0.74 (-0.60 (baseline) + 0.14 (difference female to male) -0.28 (difference from no radiotherapy to radiotherapy)).

The lower part of the table describes the change of FEV1 z-score per year. The reference patient (female, with Lymphoma, no radiotherapy, no chemotherapy, no HSCT and no thoracic surgery) has an annual decrease in FEV1 z-score of -0.07. For the male person (z-score estimate -0.05) exposed to radiotherapy to the chest (zscore estimate 0.09) the annual change in FEV1 z-score would be +0.03.

Lung function in Swiss childhood cancer survivors – a retrospective cohort study

With this approach the starting point (intercept) and annual decrease (slope) can be calculated for patients with different diagnoses and exposure to different lung toxic treatment modalities.

Lung function in Swiss childhood cancer survivors - a retrospective cohort study

Supplementary Table S1 Comparison of abnormal lung function parameters assessed by percentage predicted and z-scores of last available lung function testa, N=190

			Survivors
	n	%	median (IQR)
FEV1			
FEV1% predicted	187		87.4 (77.0 – 96.5)
FEV1 <80%predicted ^b	61	33	70.6 (63.4 – 76.8)
FEV1 z-score	187		-1.1 (-1.90.3)
FEV1 z-score <-1.645	64	34	-2.4 (-3.11.9)
FVC			
FVC% predicted	186		84.6 (73.9 – 95.1)
FVC <75% predicted ^c	52	30	66.5 (58.2 - 71.6)
FVC z-score	186		-1.3 (-2.20.4)
FVC z-score <-1.645	72	39	-2.5 (-3.32.1)
FEV1/FVC			
FEV1/FVC% predicted	184		102 (96.7 – 107.3)
FEV1/FVC <0.7	2	1	0.67 and 0.68
FEV1/FVC <0.7 and FEV1<80%predicted	2		
z-score	184		0.3 (-0.5 – 1.1)
z-score FEV1/FVC <-1.645	4	2	-2.1 (-2.41.8)
DLCO			
DLCO% predicted	131		92.9 (79.8 – 107.4)
DLCO <75% predicted ^c	21	16	60.1 (48.5 – 67.9)
z-score	131		-0.5 (-1.50.5)
z-score DLCO <-1.645	28	21	-2.7 (-3.91.8)

Abbreviations: IQR, interquartile range

^a Last lung function test: one results in those with one test only, last result in those with more than one test ^b Cutoff value according to GOLD criteria (Global Initiative for Chronic Obstructive Lung Disease)

° Cutoff value according to CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0)

Supplementary Table S2 Observed spirometric lung function parameters assessed as per scores in first and last available lung function test in survivors with at least two tests, N=154	Observed spi able lung fun	rometric lung functio ction test in survivors	n parameter s with at leas	s assessed as percen it two tests, N=154	Supplementary Table S2 Observed spirometric lung function parameters assessed as percentage predicted (% predicted) and z- scores in first and last available lung function test in survivors with at least two tests, N=154	ı
	Survivors First Test		Last Test		p-value ^a	
	c	median (IQR)	L	median (IQR)		
Time between lung toxic exposure and test [years] (median, IQR)	154	0.8 (0.3 – 1.7)	154	5.7 (3.6 – 8.7)	<0.005	
Age, median (IQR) [years] e_0	50 (76%)	13.8 (9.7 – 15.8)	10 (5%)	16.9 (13.7 – 19.5)		
0-3 10-13	49 (26%)		40 (21%)			
14-17 ≥18	84 (44%) 7 (4%)		65 (34%) 75 (40%)			
FEV1 FEV1% predicted	150	88.7 (74.3 – 97.7)	153	87.5 (77.1 – 97.5)	0.748	
FEV1 z-score	150	-0.9 (-2.10.2)	153	-1.1 (-1.90.2)	0.866	
FVC FVC% predicted	151	84.6 (74.6 – 98.3)	153	85.3 (74.1 – 96.8)	0.810	
FVC z-score	151	-1.3 (-2.20.1)	153	-1.2 (-2.10.3)	0.853	
FEV1/FVC FEV1/FVC% nredicted	147	103.6 (96.2 – 108.8)	152	102.4 (96.7 – 106.7)	0.834	
FEV1/FVC z-score	147	0.6 (-0.5 – 1.4)	152	0.3 (-0.4 – 1.0)	0.515	

a t-test

Lung function in Swiss childhood cancer survivors – a retrospective cohort study

Lung function in Swiss childhood cancer survivors – a retrospective cohort study

Whole lung irradiation, autologous HSCT Whole lung irradiation, autologous HSCT Radiotherapy other, autologous HSCT Mediastinal radiotherapy, autologous HSCT Mediastinal radiotherapy, bleomycin Mediastinal radiotherapy, busulfan, Chest irradiation, autologous HSCT Additional lung toxic exposure Mantle irradiation, bleomycin No radiotherapy, bleomycin Mediastinal radiotherapy Craniospinal irradiation Whole lung irradiation Whole lung irradiation Whole lung irradiation Whole lung irradiation Radiotherapy chest Radiotherapy other autologous HSCT Thoracotomy, resection lower lobe right side, resection of pleura and part of the Rib resection (rib 3-9), partial resection Thoracotomy, resection upper lobe left Thoracotomy, resection upper lobe left Thoracotomy, resection lower lobe left Thoracotomy, resection lower lobe left Thoracotomy, en bloc resection upper side, resection lower lobe right side Rib resection 7-9, Thoracotomy for Description of thoracic surgery Rib resection, resection of lingula Thoracotomy, wedge resection Thoracotomy, tumor resection Rib resection en bloc (5-7 resection of metastasis Laminectomy Th2-Th5 Rib resection (rib 9-10) side, metastasectomy Thoracoscopy, biopsy Thoracoscopy, biopsy Rib resection (6th rib) of the diaphragm obe left side diaphragm surgeries side side Relapse Yes Yes Yes Yes Yes Yes Yes Yes ŕes ۶ å ۶ ۶ å å å ۶ thoracic surgery [years] 10.0 13.9 16.8 15.3 14.3 13.5 13.7 16.4 4.8 6.6 5.6 9.6 8.3 4.9 6.3 5.1 3 3 Age at first diagnosis 1995 1995 1996 1998 1999 1999 2000 2002 2003 2003 2004 2006 1990 1992 2001 2004 Year of 2001 (IXd) Other specified soft (IIa) Hodgkin lymphoma (IIa) Hodgkin lymphoma (Xc) Malignant gonadal (VIa) Nephroblastoma (Vla) Nephroblastoma (VIa) Nephroblastoma (VIIIc) Ewing tumor extragonadal GCT (IIb) Non-Hodgkin (IIb) Non-Hodgkin aerm cell tumors extracranial and tissue sarcoma (Xb) Malignant Diagnosis ymphoma ymphoma 10 <u>5</u> 10 17 2 4 4 ശ <u>ო</u> 2 ო S ω ~ σ

Supplementary Table S3 Description of childhood cancer survivors treated with thoracic surgery, N=21

18	18 (VIIIc) Ewing tumor	2007	12.9	Yes	Thoracotomy, tumor resection, rib resection (9 th rib)	
19	19 (VIIIc) Ewing tumor	2009	14.6	Yes	Thoracotomy, wedge resection, rib resection (rib 8-9)	Whole lung irradiation, autologous HSCT
20	20 (IXd) Other specified soft tissue sarcoma	2009	8.1	No	Thoracotomy, metastasectomy	Whole lung irradiation
21	21 (IXa) Rhabdomyosarcoma	2012	14.6	Yes	Thoracotomy, tumor resection, partial rib resection (rib 3-5)	Radiotherapy other

Lung function in Swiss childhood cancer survivors – a retrospective cohort study

144

Supplementary 1	Fable S4 Characteristi	cs of other studies	Supplementary Table S4 Characteristics of other studies assessing pulmonary function in childhood cancer survivors	ood cancer survivors
Author, journal, year	Number (response rate)	Outcome variables	References and cutoff values	Results
Armeinan S et al,	155 with baseline PFT	FEV1	Reference values used to calculate	Obstructive: 4.1%
JCO, 2015	at entry in COH	FEV ₁ /FVC ratio	percentage of predicted not stated.	Restrictive: 24.0%
	Survivorship Clinic	DLCO adj		Diffusion capacity abnormality: 34.7%
		A dn DLCI/VA	<u>Obstructive:</u> GOLD criteria; FEV ₁ /FVC <0.70	
	Final cohort: 121 with	TLC	and FEV ₁ <80% predicted	→ obstructive, restrictive, and/or
	follow-up (78%)	FVC	Restrictive: CTCAE v3.0; TLC <75% predicted	diffusion defect: 45.5%
			and FEV₁ ≥80% predicted	
			Diffusion capacity abnormality: CTCAE v3.0;	
			DLCO _{corr} <75% predicted	
Green DM et al,	989 eligible for SJLIFE	FEV1	Equation for FEV1 and FVC: Hankinson at al	FEV1 <80%: 50.7%
Ann Am Thorac	and received	FVC	and GLI reference values (Quanjer PH et al)	FVC <80%: 47.2%
Soc, 2016	pulmonary toxic	DLCOcorr	Equation for TLC: Goldman HI et al, Boren	FEV ₁ /FVC ratio <0.7: 0.8%
	therapy	TLC	HG et al	DLCO _{corr} <75%: 44.6%
			Equation for DLCO: Miller A et al	TLC <75%: 31.2%
	606 completed PFT			
	(61%)		CTCAE v4.03: FEV1, FVC <80% predicted	Obstructive: 0.8%
			CTCAE v3.0: DLCO _{corr} <75% predicted	Restrictive: 31.2%
			TLC <75% predicted	
				→ At least one PFT abnormal: 65%
			<u>Obstructive</u> : FEV ₁ /FVC <0.7 or	
			FEV ₁ /FVC <lln< td=""><td></td></lln<>	
			<u>Restrictive</u> : TLC<75% or FEV ₁ /FVC ≥LLN and	
			FVC <lln< td=""><td></td></lln<>	

Cancer 7 childh 2 2 2. studio of other tarietioe È -

Lung function in Swiss childhood cancer survivors – a retrospective cohort study

∞


~
≥
Ĕ
S
E
P
5
ive coho
Φ
ž
Ŧ
ĕ
ă
S
5
et
Ľ
a
1
۰.
vors – a retrospi
Š
÷
2
ŭ
childhood cancer survivors – a
5
õ
2
- CO
-
ŏ
ŏ
Ē
פ
Ē
Ċ
٥.
Ŭ.
<u>Swi</u>
ú
Ē
in
Ę
<u>e</u> .
t d
Ĕ
2
ing function
g
Б
Lu

146

														.5%									
FEV ₁ <80%: 20.7%	FEV ₁ /VC _{max} <0.70: 3.1%	→ obstructive: 2.1%	TLC <75%: 18.7%	FVC<75%: 11.4%	→ restrictive: 17.6%	DLCO <75%: 39.9%	KCO <75%: 4.3%		→ overall pulmonary function	impairment: 44.0%	Obstructive: 25.9%	Restrictive: 13.3%	Hyperinflation: 41.3%	Pulmonary vascular disease: 5.5%	Any abnormal PFT: 65.0%								
Reference values used to calculate	percentage of predicted not stated.		Obstructive: GOLD criteria; FEV ₁ /VC _{max} <0.70	and FEV ₁ <80% predicted	Restrictive: CTCAE v3.0; TLC <75%	predicted; if no TLC available: FVC<75%	predicted with normal FEV1/VCmax ratio	Diffusion capacity impairment: CTCAE v3.0	DLCO or KCO <75% predicted		Reference equations used: Wang X et al,	Hankinson JL et al		Obstructive: FVC <80% predicted or FEV ₁	<80% predicted or FEF25-75% <68%	predicted or FEV ₁ /FVC <0.8	Restrictive: TLC <80% predicted	<u>Hyperinflation:</u> RV >120% predicted and	RV/TLC ratio >28% predicted	Pulmonary vascular disease: DLco/VAadj <4	ml/mm Hg/min/l	Any PFT abnormality: presence of one or	more abnormalities
FEV ₁	FEV ₁ /VC _{max} ratio	TLC	FVC	DLCO	KCO						FEV1	FEV ₁ /FVC ratio	FEF25-75%	TLC	RV	DLco adj							
248 qualified for Late	Effects Outpatient	Clinic in EKZ/AMC and	qualified for pulmo-	toxic screening		220 participated	193 with PFT	(88%)			226 original cohort	143 PFT available	(63%)										
Mulder RL et al,	Thorax, 2011										Record E, PBC,	2016											

CTCAE v3.0, Common Terminology Criteria for Adverse Events version 3.0; GOLD, Global Initiative for Chronic Obstructive Lung Disease; DLco adj, DLco adjusted for hemoglobin; LLN, lower limit of normal

Lung function in Swiss childhood cancer survivors - a retrospective cohort study



Supplementary Figure 1 Flow chart of study population

^a Including the following centers with pediatric oncology units: Kinderklinik Kantonsspital Aarau AG, Universitäts-Kinderspital Basel, Universitäts-Kinderklinik Inselspital Bern, Hospital des Enfants Geneve, CHUV Lausanne, Kinderklinik Kantonsspital Luzern, Ostschweizer Kinderspital St. Gallen, Universitäts-Kinderspital Zürich

^b Pulmotoxic treatment defined as chemotherapy with busulfan, bleomycin, lomustine or carmustine and/or chest radiotherapy

4.4. Publication IV

The Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) – Protocol of a prospective, national, multicenter cohort study

Study protocol

Maria Otth, Marc Ansari, Maja Beck Popovic, Fabiën N Belle, Jean-Pierre Bourquin, Piere Brazzola, Jeanette Greiner, Luzius Mader, Jochen Rössler, Katrin Scheinemann, Freimut Schilling, Christina Schindera, Tomas Slama, Sven Strebel, Nicolas Waespe, Nicolas von der Weid, Claudia E Kuehni

(Manuscript in preparation, to be submitted to BMC Cancer)

Own contribution to the project when submitting the thesis: Concept and design of the SCCSS-FollowUp study and the study protocol, writing manuscript, integration of co-authors comments

1	The Swiss Childhood Cancer Survivor Study – Follow-up: Study protocol of a
2	prospective multicenter cohort study for standardized collection and analysis of medical
3	conditions in Swiss childhood cancer survivors
4	
5	Authors: Otth M ^{1,2,3} , Ansari M ^{4,5} , Beck Popovic M ⁶ , Belle FN ^{1,7} , Bourquin JP ⁸ , Brazzola P ⁹ ,
6	Greiner J ¹⁰ , Luzi F ¹ , Mader L ¹ , Rössler J ¹¹ , Scheinemann K ^{3,12,13} , Schilling F ¹⁴ , Schindera
7	C ^{1,15} , Sláma T ^{1,2} , Strebel S ¹ , Waespe N ^{1,2,4} , von der Weid N ¹⁵ , Kuehni CE ^{1,11}
8	
9	Author Affiliation:
10	¹ Institute of Social and Preventive Medicine, University of Bern, Switzerland;
11	maria.otth@ispm.unibe.ch, nicolas.waespe@ispm.unibe.ch, luzius.mader@ispm.unibe.ch,
12	christina.schindera@ispm.unibe.ch, sven.strebel@ispm.unibe.ch,
13	tomas.slama@ispm.unibe.ch, fabielnne.luzi@ispm.unibe.ch, claudia.kuehni@ispm.unibe.ch
14	² Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland
15	³ Division of Pediatric Oncology- Hematology, Department of Pediatrics, Kantonsspital
16	Aarau, Switzerland; maria.otth@ksa.ch, katrin.scheinemann@ksa.ch
17	⁴ CANSEARCH Research Laboratory, Department of Pediatrics, Faculty of Medicine,
18	University of Geneva, Geneva, Switzerland
19	⁵ Division of Hematology and Oncology, Department of Pediatrics, University Hospital
20	Geneva, Switzerland; marc.ansari@hcuge.ch
21	⁶ Division of Pediatric Hematology and Oncology, Department of Pediatrics, Lausanne
22	University Hospital CHUV, Switzerland; maja-beck-popovic@chuv.ch
23	⁷ Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne,
24	Switzerland

- ⁸ Division of Hematology and Oncology, University Children's Hospital Zurich-Eleonore
- 26 Foundation, Switzerland; Jean-Pierre.Bourquin@kispi.uzh.ch
- ⁹ Division of Pediatric Hematology and Oncology, Children's Hospital Lugano, Switzerland;
- 28 Pierluigi.Brazzola@eoc.ch
- ¹⁰ Division of Pediatric Hematology and Oncology, Children's Hospital St. Gallen,
- 30 Switzerland; jeanette.greiner-lang@kispisg.ch
- ¹¹ Division of Pediatric Hematology and Oncology, University Children's Hospital Bern,
- 32 Switzerland; Jochen.roessler@insel.ch
- 33 ¹² University of Children Basel, Switzerland
- ¹³ Department of Pediatrics, McMaster University Hamilton, Canada
- ¹⁴ Division of Pediatric Hematology and Oncology, Children's Hospital Lucern, Switzerland;
- 36 <u>freimut.schilling@luks.ch</u>
- ¹⁵ Division of Hematology and Oncology, University Children's Hospital Basel;
- 38 <u>Nicolas.VonderWeid@ukbb.ch</u>
- 39
- 40

41 Corresponding author:

- 42 Claudia E Kuehni, Childhood Cancer Research Group, Institute of Social and Preventive
- 43 Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland;
- 44 <u>claudia.kuehni@ispm.unibe.ch</u>
- 45
- 46
- 47

Chapter 4 - Results

49 Abstract (275/350 words)

50 Background

The overall survival of childhood cancer reaches >80% in developed countries, but a majority 51 52 of childhood cancer survivors (CCSs) develop late effects. Medical data of high quality are essential to perform research and to subsequently provide information relevant to clinicians 53 54 and CCSs. Few national, prospective, and longitudinal CCS cohorts exist to date. Most of them include CCSs who survived more than 5 years from diagnosis. The main goal of the 55 Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) is to describe the 56 57 health status and development of late effects in CCSs prospectively and in a longitudinal way and starting directly after completion of treatment. 58

59

60 *Methods*

The SCCSS-FollowUp is a prospective longitudinal study, based on the recruitment of CCSs qualifying for follow-up care in Switzerland and is integrated in their regular follow-up care visits. With its umbrella-like design, the SCCSS-FollowUp study incorporates multiple projects evaluating late effects and its risk factors in different organ systems, starting directly after completion of treatment. All CCSs diagnosed and treated in Switzerland since 1976 qualifying for follow-up care are eligible for this study. Recruitment is done by a projectdriven approach.

68

69 Discussion

The few national CCS cohorts existing to date, including CCSs who survived more than 5 years from diagnosis only, might miss conditions developing early in the post-treatment phase. These early conditions can contribute to the development of subsequent late effects or can even be fatal in the first five years. With the SCCSS-FollowUp study, we aim to close

74	this gap and to provide data and knowledge on the development and longitudinal course of
75	late effects in CCSs.
76	
77	
78	Trial registration
79	ClinicalTrial.gov identifier SCCSS-FollowUp:
80	
81	
82	Keywords: childhood cancer, survivors, follow-up care, aftercare, longitudinal, clinical

83 assessment, Switzerland

84 Background

Survival after childhood cancer has improved dramatically in recent decades and leads 85 to increasing numbers of childhood cancer survivors (CCSs) (1). This increase is achieved 86 87 through improvements in cancer treatment and supportive care. For chemotherapeutic agents, improvements include for example dose reduced of certain drugs (e.g. doxorubicin), the 88 attempt to avoid others (e.g. bleomycin) or the more targeted administration according to 89 disease stage. In addition, the introduction of new drugs increased survival, especially in 90 relapsed diseases. Substantial improvement was also observed for radiotherapy. Radiation 91 92 techniques changed to smaller radiation fields, lower doses and indications are made more stringent. Furthermore, improvement in supportive care such as antibiotic or antiviral 93 94 treatments, antiemetics, immunosuppressive treatment in children after hematopoietic stem 95 cell transplantation or specific antimetabolites, such as folinic acid for high-dose methotrexate, contributed to the improvement in overall survival. Despite all this progress, a 96 large proportion of survivors suffer from chronic medical conditions, so called late effects (2-97 98 4). Late effects can be caused by the cancer itself, such as neurocognitive impairment after long-standing hydrocephalus or by the different treatment modalities. Regarding treatment 99 modalities, chemotherapy, radiotherapy, surgery, and hematopoietic stem cell transplantation 100 (HSCT) can cause late effects. Severe infections (e.g. shunt infection; colitis) can additionally 101 102 contribute to late effects. Late effects can potentially affect every organ system and lead to increased morbidity and mortality in CCSs (2, 3, 5). Knowledge on late effects led to the 103 development of different national and international long-term follow-up (LTFU) guidelines 104 (6-8). These guidelines provide recommendations for follow-up care based on previous 105 treatment exposure. 106

107 The increase in long-term survival and the growing knowledge on late effects led to108 the establishment of six prospective national cohort studies, including the French COHOPER,

109	FSSCC and LEA cohort, the Scandinavian ALiCCS, the St. Jude Lifetime Cohort (SJLIFE)		
110	in the US, and the Dutch DCOG LATER. The French COHOPER (9) and Scandinavian		
111	ALiCCS cohort (10) collect clinical data thorough linkage from the national health insurance		
112	database and health registries, respectively. The French LEA cohort includes children and		
113	adolescents diagnosed with leukemia and collects data from prospective follow-up		
114	examinations (11). The French FCCSS is the "solid" counterpart of the LEA cohort, includes		
115	all solid tumors, and collects prospective clinical data in a subset of CCSs only (12). The		
116	SJLIFE cohort in the US (13) and the Dutch DCOG LATER (14) collect follow-up		
117	information during the clinical visits. Both cohorts include CCSs with all types of childhood		
118	cancer. The SJLIFE cohort starts recruitment ten years after diagnosis and includes adult		
119	CCSs only. The DCOG LATER starts recruitment five years after cancer diagnosis.		
120			
121	In Switzerland, approximately 300 children and adolescents <21 years of age are		
122	diagnosed with cancer every year (15). Since 1976, these children and adolescents are		
123	registered in the Childhood Cancer Registry (ChCR;		
124	https://www.childhoodcancerregistry.ch). The ChCR is a nationwide, population-based		
125	cancer registry including all Swiss children and adolescents who were diagnosed below age		
126	<20 years with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid		
127	tumors, or Langerhans cell histiocytosis (LCH) (16). The registry receives data from persons		
128	with a reporting obligation, such as doctors, hospitals, institutes of pathology and medical		
129	laboratories that diagnose and/or treat cancer. For childhood cancer the nine specialized		
130	pediatric oncology centers, united in the Swiss Pediatric Oncology Group (SPOG), which		

- 131 diagnose and treat childhood cancer in Switzerland, are the main source. Besides data on
- newly diagnosed children or adolescents, the ChCR also receives annual updates on treatment
- and clinical course of the patients. Today there are around 7,000 CCSs living in Switzerland

and most of them need long-term follow-up care. According to a position paper, published in 134 2019, the situation for follow-up care for CCSs in Switzerland is very heterogeneous (17, 18). 135 This heterogeneity is present in the use of follow-up care guidelines, treatment summaries, 136 137 and transition into adulthood. Besides describing the current follow-up care practices, the authors identified possible approaches for harmonization between the centers. 138 139 The SCCSS-FollowUp aims to assess late effects early in survivors through standardized 140 risk-adapted medical examinations starting directly after completion of treatment, and to 141 142 study risk factors for late effects including information on treatment exposure, sociodemographic and socioeconomic characteristics, lifestyle factors, and comorbidities, 143 144 such as arterial hypertension or obesity. 145

146 Methods/Design

147 Design of the SCCSS-FollowUp

The Swiss Childhood Cancer Survivor Study – Follow-up (SCCSS-FollowUp) is a 148 national, observational, prospective, multicenter cohort study, which is is not limited to one 149 specific late effect or cohort of CCSs. The study has an umbrella-like design and incorporates 150 multiple projects evaluating late effects and its risk factors in different organ systems. 151 Signing the informed consent corresponds to the "umbrella". An example of a project 152 153 incorporated in the SCCSS-FOllowUp study could be the assessment of bone mineral density in CCSs treated with high-dose steroids. If a CCS consents to participate in SCCSS-154 FollowUp, all already available data and all data newly generated during regular follow-up 155 care visits can be collected and analyzed at a later stage. With the previously mentioned 156 example this includes the collection of information on initial cancer diagnosis and its 157 treatment, results of already performed and future bone mineral density tests. Importantly, the 158

159	data collection cannot be carried out freely but is always bound to a project and to a specific
160	research question. The incorporation of such projects within the SCCSS-FollowUp study is
161	illustrated in Figure 1.
162	Ethical approval of the SCCSS-FollowUp was granted by the Ethics Committee of the
163	Canton of Bern as lead ethics committee (KEK-BE:).
164	
165	Study population
166	Eligible for the SCCSS-FollowUp study are all childhood cancer patients registered in
167	the ChCR since 1976, diagnosed with cancer before the age of 20 years, alive and residing in

168 Switzerland at recruitment for SCCSS-FollowUp, and ≥ 1 year since diagnosis or at the end of

active treatment, whichever comes first. Only CCSs who sign the SCCSS-FollowUp

170 informed consent are included. We exclude CCSs in palliative situations or with relapsed

disease in the 12 months prior to defining eligibility for project-specific research questions.

172 We continuously include all children and adolescents entering follow-up care.

173

174 General considerations

Data collection and eligibility criteria within SCCSS-FollowUp are always linked to a 175 specific project and research question. Therefore, depending on the exposure to certain 176 177 treatment modalities or risk to develop specific late effects, eligible survivors differ between 178 projects. In addition, SCCSS-FollowUp does not specify the time point and type of test performed in participating CCSs. All data are generated during regular follow-up care visits 179 and are subsequently collected for the purpose of the SCCSS-FollowUp study. The approach 180 of integrating SCCSS-FollowUp in regular clinical visits leads to the involvement of different 181 teams and specialties which we describe here. The SCCSS-FollowUp team is located at the 182 Institute for Social and Preventive Medicine (ISPM) in Bern and leads the study and its 183

projects. The local team corresponds to members of the participating clinics involved in the 184 SCCSS-FollowUp study, such as the heads of (pediatric) oncology departments, local 185 physicians, office of oncology departments, or clinical research assistants. Lastly, close 186 187 collaborations with specialists, such as cardiologist, pulmonologist, audiologists, endocrinologists, and their teams will be established depending on the project. The 188 collaboration with clinics involved in follow-up care of CCSs is the key element of the 189 SCCSS-FollowUp study. This collaboration will initially be established mainly with the 190 SPOG clinics. 191

192

193 *Eligibility, first recruitment and informed consent procedure*

The SCCSS-FollowUp team identifies potentially eligible CCSs through information 194 from the ChCR by applying general and project-specific inclusion criteria. Project-specific 195 criteria correspond to exposure to specific treatment modalities or risk to develop specific late 196 effects. The SCCSS-FollwoUp team generates a patient list for each center participating in 197 the SCCSS-FollowUp study. (Figure 2). The local physician in charge of follow-up care at 198 each center receives this list and verifies eligibility (e.g. remove CCSs who recently relapsed 199 or are in a palliative situation). All finally eligible CCSs or his/her legal representatives 200 receive the study documents shortly before the next planned regular follow-up visit via post 201 202 mail. The study documents consist of an invitation letter, study information, informed consent form, and a reply form, where the CCS can decline participation (Figure 2). Sending 203 the study documents is done either by the SCCSS-FollowUp team or the local team. In 204 205 addition to the study documents, the letter may include a questionnaire, if the first recruitment is linked to a project including the collection of questionnaire data. The CCSs are asked to 206 bring the study documents to the next follow-up care visit at the respective centre. 207

208	During the follow-up care visit, the CCSs or their legal representatives are orally			
209	informed about the study by the local physician and the informed consent must be signed by			
210	both parties to be included (Figure 2). The subsequent follow-up care visit does not change			
211	for the CCSs.			
212	Following the CCSs' clinical visit, the SCCSS-FollowUp team starts with the			
213	extraction of medical data, including information on cancer diagnosis, treatment exposure,			
214	and clinical data generated during the follow-up visit. These clinical data are obtained by the			
215	local physicians (e.g. patient history, physical examination) and by the specialists (e.g. bone			
216	mineral density) (Figure 2). This information is entered in the study database by the SCCSS-			
217	FollowUp team.			
218				
219	Subsequent follow-up visits and recruitment for new project			
220	Most CCS qualify for repeated standardized examinations of several organ systems at			
221	risk at repeated time points. If a CCS has consented to the SCCSS-FollowUp study and is			
222	included in a project, the data from all follow-up visits on this organ system can be collected.			
223	If a CCS has consented to the SCCSS-FollowUp study and is now eligible for a new project			
224	evaluating another organ system or risk factor, all data to answer the new research question			
225	can be collected. The CCS will not be informed with the exception if the new project is			
226	linked to a questionnaire (Figure 3). The approach to identify CCSs who already consented			
227	to the SCCSS-FollowUp study for new projects is identical to the first recruitment (Figure 2,			
228	"Eligibility"). Newly eligible CCSs will go through the consenting process as described for			
229	the first recruitment (Figure 2).			
230				

232 Data collection

The three main pillars of the SCCSS-FollowUp are retro- and prospectively collected 233 medical data, results from regular follow-up visits, and information collected in project-234 235 specific questionnaires. Medical data collected retrospectively include information on cancer diagnosis, relapse, secondary malignancy, chemotherapy, including cumulative doses, 236 radiotherapy, surgery and hematopoietic stem cell transplantation. Data collected 237 prospectively result from regular follow-up care visits and include information from physical 238 examinations and functional tests. Wherever possible, organ-specific case report forms 239 240 (CRFs) are developed in cooperation with local physicians and specialists to enable standardization of the physical examination. If a questionnaire is considered helpful to assess 241 subjective symptoms, risk factors, or quality of life, it can be added for individual projects 242 243 and specific organ systems.

All data collected are entered in the study-specific database by the SCCSS-FollowUp team, built in RedCap® *(Reference)*. The database consists of five different modules: 1) Patient Data and Eligibility, 2) Medical Data Extraction, 3) Clinical Visit, 4) Physical Examination, 5) Functional Tests. The first three modules build a common part and can be used for all CCSs included in the SCCSS-FollowUp study. The fourth and fifth module are project- and organ-specific. The modules four and five have a longitudinal design and each visit can be added separately.

251

252 Data analysis

The exact approaches used for data analysis will differ between projects and specific research questions. This also applies to the selection and use of comparators to standardize test results, if appropriate. Whenever age-standardized reference values exist, they will be used.

257 For all projects, we will apply descriptive statistics (such as mean and standard 258 deviation, median and range, summary tables and graphics) to describe organ function and 259 the prevalence of late effects in CCSs. To examine differences in characteristics between 260 groups we will use the appropriate tests depending on the type of variable in question (t test or Mann-Whitney test, chi-squared or Fisher's exact test). In addition, and if needed to 261 262 answer the study question, the SCCSS-FollowUp dataset will allow longitudinal analysis of 263 organ function. Time-to-event data can be analyzed non-parametrically using the Kaplan-Meier method for example. Associations with covariates can be modelled using Cox 264 265 regression. For repeated data we will apply the respective statistical methods for longitudinal data (e.g., mixed-models). The collection of treatment data or socioeconomic data from the 266 267 medical records and questionnaires, will additionally allow us to perform risk factor analysis. 268 For this we will use uni- or multivariable regression models adjusted for possible 269 confounders (e.g., age, gender, height, ethnicity, type of cancer).

270


271 Discussion

The national multicenter cohort study SCCSS-FollowUp enables the prospective 272 273 collection and analysis of medical data generated during regular follow-up care visits of CCSs in Switzerland. Compared to the SJLIFE and DCOG LATER study, which also collect 274 275 and analyze clinical data of CCSs prospectively, the SCCSS-FollowUp study starts 276 recruitment earlier after completion of treatment. Information on medical conditions in the first years after completion of treatment are important to be able to evaluate pathological 277 findings that occur later. This early recruitment into SCCSS-FollowUp is a key strength of 278 279 the study. Additionally, survivors of all age categories, from infants to adults, can be included. The umbrella-like design enables the collection of longitudinal data and research on 280 281 all organ systems potentially affected by late effects without the need of repeatedly asking the 282 CCSs for informed consent. By integrating the study into regular follow-up care, loss to follow-up can be reduced. The development of CRFs for the purpose of the SCCSS-283 FollowUp study might allow the harmonization of tests performed by participating centers 284 285 and on a national level. The assessment of self-reported symptoms by questionnaires on the same day or close to the objective assessment of organ function enables to study the 286 correlation between subjective symptoms and objective findings. In the longer term, the 287 SCCSS-FollowUp study enables the generation of a rich database with prospectively 288 collected data. Integrating SCCSS-FollowUp into regular follow-up care has one 289 290 disadvantage. Examinations and tests performed during regular visits adhere to long-term follow-up guidelines and recommendations. Therefore only survivors exposed to known risk 291 292 factors or symptomatic survivors receive certain tests. The assessment of potential risk 293 factors for late effects, which are not required according long-term follow-up guidelines and without good evidence, is not possible or at least limited when it comes to time- and cost-294 consuming examinations. Looking in the future, the design and setup of the SCCSS-295 296 FollowUp study allows expansion of the study in different areas, including the recruiting centers, data entry in the study database, and initiators of projects. Regarding participating 297 centers, the SCCSS-FollowUp study recruits CCSs in a stepwise approach, starting with those 298 still in follow-up care in a SPOG center. At a later stage, also CCSs who left follow-up care 299 in a SPOG center or are lost to follow-up will be recruited. The recruitment of these CCSs 300 will be coupled with the possibility of continuing follow-up care. By providing different 301 access rights to each participating center, only patients from the respective center can be seen. 302 This can additionally divided in different specialties per center. This will allow data entry by 303 members of the local teams in the future. And lastly, the design also allows the initiation of 304 projects within the SCCSS-FollowUp study by clinicians from participating centers. 305

306	In conclusion	n, the SCCSS-FollowUp study enables the collection of medical data,		
307	including diagnosis	and its course, treatment exposure, results from clinical examinations,		
308	organ-specific tests,	and self-reported symptoms of Swiss childhood cancer survivors.		
309	Through this approach, all relevant information to analyze late effects in CCSs are located at			
310	one place, in the constantly growing SCCSS-FollowUp database. With results from the			
311	SCCSS-FollowUp study, we aim to contribute to the growing knowledge on clinical courses			
312	of late effects and to influence long-term follow-up care in CCSs within Switzerland and on			
313	an international level.			
314				
315				
316	List of abbreviations			
317	CCS(s)	Childhood cancer survivor(s)		
517				
318	ChCR	Childhood cancer registry		
319	GLI	Global Lung Initiative		
320	SCCSS-FollowUp	Swiss Childhood Cancer Survivor Study – Follow-up		
321	SPOG	Swiss Pediatric Oncology Group		
322				

323 **References**


324 Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer 1. 325 survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. The Lancet 326 Oncology. 2014;15(1):35-47. 327 Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic 2. 328 health conditions in adult survivors of childhood cancer. The New England journal of medicine. 329 2006;355(15):1572-82. 330 3. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving 331 childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017. 332 4. Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, et al. Health status of adult 333 long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Jama. 334 2003;290(12):1583-92. 335 5. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical 336 ascertainment of health outcomes among adults treated for childhood cancer. Jama. 337 2013;309(22):2371-81. 338 COG COG. Children's Oncology Group [COG] Long Term Follow-Up guidelines Version 5.0 6. 339 2018 [cited 2019 05.04.2019]. Available from: 340 http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf. 341 7. Group UKCsCS. Therapy based long term follow-up - Practice Statement 2005. 342 8. SKION DCOGD. Guidelines for follow-up in survivors of childhood cancer 5 years after 343 diagnosis. 2010 [cited 2018 08.05.2018]. Available from: <u>https://www.skion.nl/voor-patienten-en-</u> ouders/late-effecten/533/richtlijn-follow-up-na-kinderkanker/. 344 345 9. COHOPER – National COHOrt of the PaEdiatric cancer Registries [Available from: 346 https://rnce.inserm.fr/index.php/en/plateform/national-cohort-of-the-paediatric-cancer-registries. 347 10. Asdahl PH, Winther JF, Bonnesen TG, De Fine Licht S, Gudmundsdottir T, Anderson H, et al. 348 The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study: Design and Characteristics. 349 Pediatric blood & cancer. 2015;62(12):2204-10. 350 11. Berbis J, Michel G, Baruchel A, Bertrand Y, Chastagner P, Demeocq F, et al. Cohort Profile: 351 the French childhood cancer survivor study for leukaemia (LEA Cohort). International journal of 352 epidemiology. 2015;44(1):49-57. 353 12. French Childhood Cancer Survivor Study [Available from: https://fccss.fr/. 354 13. Hudson MM, Ness KK, Nolan VG, Armstrong GT, Green DM, Morris EB, et al. Prospective 355 medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and 356 feasibility of the St. Jude Lifetime Cohort study. Pediatric blood & cancer. 2011;56(5):825-36. 357 14. DCOG LATER Study [Available from: <u>https://www.skionlaterstudie.nl/english/43:skion-later-</u> study/. 358 359 15. Kinderkrebsregister S. Swiss Childhood Cancer Registry. Annual report 2017-2018 2019 [cited 2020 04.02.2020]. Available from: https://www.kinderkrebsregister.ch/wp-360 361 content/uploads/sites/2/2019/09/FINAL-Annual-Report 2017 2018 with-CC-license.pdf. 362 Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss 16. 363 Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. Swiss 364 medical weekly. 2007;137(35-36):502-9. 365 17. Meier JH, Ansari M, Beck Popovic M, Bergstraesser E, Brazzola P, Eisenreich B, et al. 366 Aftercare in Pediatric Oncology in Switzerland – Current State, Challenges and Future Directions. 367 Schweizer Krebsbulletin. 2018;3:273-9. Tinner EM G-PF, Diezi M, Bergsträsser E, Hengartner H, Eisenreich B, Brazzola P, von der 368 18. 369 Weid N, Tomášiková Z, Scheinemann K. Long-term follow-up after childhood cancer in Switzerland: a 370 position statement from the pediatric Swiss LTFU working group. Schweizer Krebsbulletin. 371 2019;3:213-5.



373

Figure 1 Pictogram of SCCSS-FollowUp illustrating the umbrella-like design which allows to

375 perform research on several different late effects.






visit of eligible survivors 28

76

*General inclusion criteria: registered in the ChCR since 1976, cancer diagnosis before age 21 years, alive and resident in Switzerland at 79

recruitment, ≥ 1 year since diagnosis or at the end of active treatment, whichever comes first õ 17





33 bone health and later for project on pulmonary late effects

21

Chapter 5 - Discussion and outlook

5.1. Summary of findings

One out of five Swiss long-term childhood cancer survivors reported at least one pulmonary disease (lung fibrosis, emphysema or pneumonia) or symptom (chronic cough or other pulmonary problem) at a median of 10 years from diagnosis. This proportion was nearly identical between survivors treated with hematopoietic stem cell transplantation (HSCT) (20%, 95%CI 13-27%) compared to nontransplanted survivors (18%, 95%CI 13-21%). I could not identify factors significantly associated with more frequent reporting of pulmonary outcomes, but the results point to older age at diagnosis and thoracic surgery as possible risk factors in the multivariable analysis (Publication I). Self-reported outcome data on medical conditions have their limitations. This is especially true in diseases which can be asymptomatic for long period such as pulmonary fibrosis. These limitations are also true for diseases, which can be perceived differently by the general population than by doctors or researchers, such as pneumonia. Evaluating pulmonary function test results is therefore an objective approach to describe pulmonary function. In the last test of 75 CCSs treated with HSCT and a median of 9 years after cancer diagnosis, around one third had reduced z-score for FEV1 (34%, total n=73), FVC (39%, total n=71), and TLC (35%, total n=66), defined as z-score <-1.645. RV was reduced in 12% (total n=66) and DLCO in 43% (total n=35) (**Publication II**). With the exception of RV, the average z-score for each of the parameters was constantly below the expected z-score over time. In the preliminary results from the regression model FEV1, FVC, and TLC decreased continuously with every additional year from cancer diagnosis in the male reference patient and RV and DLCO showed a trend to increasing z-scores with every additional year. Taking the risk factors into account, allogeneic HSCT led to a significant annual increase in TLC z-score compared to autologous HSCT and relapsed disease led to a significant annual reduction in RV z-score. No risk factor had a significant effect on the annual change of FEV1, FVC, and DLCO z-score. The starting point of the regression line, corresponding to the time of diagnosis, was significantly lower for FEV1 z-score in case of female gender and radiotherapy and for FVC zscore in case of radiotherapy. The starting point for TLC, RV, and DLCO z-scores were not significantly influenced by any risk factor. One could assume that CCSs treated with HSCT represent a heavily treated population of survivors. However, the proportion of CCSs with z-scores for FEV1 (34%, total n=187), FVC (39%, total n=186), TLC (34%, total n=178) and DLCO (21%, total n=131) <-1.645 is very similar in CCSs treated either with lung toxic chemotherapy or radiotherapy (Publication III). The median follow-up in this cohort was 6 years and only 23% were treated with HSCT. The longitudinal course for FEV1 and FVC, plotted as median z-score over time, was constantly below the expected. Different to publication II, not radiotherapy to the chest had a significant association with lower intercept for FEV1 and FVC, but thoracic surgery. The risk factor analysis in both cohorts (publication II: HSCT only; publication III: pulmonary toxic chemotherapy or radiotherapy) highlighted the complexity and multifactorial etiology of pulmonary dysfunction. One factor might have a negative impact on the longitudinal course of a selected pulmonary function parameter, but might have a positive impact on another parameter. Additional factors, such as host factors, possible genetic susceptibility or pulmonary infections were not included in all these analysis. Importantly, the findings from publication II and III highlight, that pulmonary function testing is more sensitive than questionnaire data to assess pulmonary dysfunction in childhood cancer survivors. On the other hand, abnormal pulmonary function test results do not necessarily reflect the survivors' health status in terms of symptoms, wellbeing or quality of life. With the SCCSS-FollowUp we aim to close this gap (**Publication IV**). In SCCSS-FollowUp information on subjective symptoms and wellbeing are collected at the same time as objective tests are performed, including pulmonary function tests.

5.2. Strength and limitations

The data sources used for this thesis go along with some overall strength and limitation, which I would like to discuss in this section. The strength and limitation specific for each publication can be found in Chapter 4.

Swiss Childhood Cancer Registry (SCCR)

Data from the SCCR served as a basis to identify childhood cancer patients and survivors for all my publications. The SCCR is described in chapter 3.1.1. Completeness of registration for children and adolescents <16 years of age is \geq 95% (56). The diagnoses are coded according to the International Classification of Childhood Cancer, third edition (ICCC-3). Additional coding exists amongst other variables for tumor location according to the International Classification of Diseases for Oncology (ICD-O-3) and for the site of metastasis. For treatment exposure, the SCCR records the name of the treatment protocols. The treatment arm is often missing. This is especially the case for patients registered in the beginning of the SCCR and those with changes in treatment arms due to poor response to treatment. In addition, chemotherapeutic agents are recorded as free-text fields and not in a systematic way, such as tick boxes or drop-down lists. This results in very variable completeness of exact medical data in the SCCR, depending on the underlying disease and complexity of the patient history. As treatment exposure and its associated risk to develop pulmonary late effects was a key factor in all publications, I only used date and type of cancer diagnosis according to ICCC3 directly from the SCCR. I searched and collected all information on treatment exposure, relapse date, and transplant information in the medical records.

The big advantage of the SCCR is its high completeness in terms of registered patients. Also date and type of first cancer diagnosis are very accurate. With regards to treatment exposure, the SCCR has its limitations. This is also understandable, as a lot has changed in pediatric oncology since its establishment in 1976. The following four examples illustrate the complexity: 1) patient receive more

often second and third-line treatment, 2) patients change protocol arms or treatment protocols in case of refractory disease, 3) reading the treatment protocols with different arms, risk stratification, and individual modifications is not always straightforward for people not primary trained in pediatric oncology, and 4) the relevant information from medical letters is not always directly evident. This limitation regarding clinical data must be kept in mind and is especially important, when it comes to invite patients into clinics to perform specific screening tests based on treatment exposure. Here, review of the exposure in the medical records and verification of final eligibility by the treating pediatric oncologists is needed. This approach is also chosen to recruit patients and survivors for the SCCSS-FollowUp.

Swiss Childhood Cancer Survivor Study (SCCSS)

The SCCSS is a questionnaire-based study nested within the SCCR, including all \geq 5-year childhood cancer survivors. It is described in more detail in Chapter 3.1.2. I used data from the SCCSS for publication I.

The strength of the SCCSS is its national and population-based nature. The high response rate (wave 1: 70 %; wave 2: 58 %) makes the study population representative for \geq 5-year Swiss childhood cancer survivors. As shown in a publication by Rueegg et al., nonresponse bias seems to play only a minor role in the SCCSS (57). However, it is unclear if nonresponse bias is a relevant problem in sub-groups of survivors, for example in survivors treated with hematopoietic stem cell transplantation (HSCT). In addition, all outcomes are only representative for long-term survivors (\geq 5-year survivors) and may therefore lead to an underestimation of the true prevalence in all survivors, including those with a shorter follow-up. Survival bias caused by death within the first five years after completion of treatment might be especially relevant in children and adolescents treated with HSCT, as treatment with HSCT often implies an underlying diagnosis with a rather poor prognosis, such as refractory or relapsed acute lymphoblastic leukemia, relapsed Hodgkin's disease or Ewing sarcoma, or high-risk neuroblastoma. No study assessed pulmonary conditions as cause of death within the first five years after HSCT in children separately. Over all age categories, relapse, infections, and graft versus host disease are the most relevant contributors to cause of death in patients after HSCT. Stycznski et al evaluated causes of death in 114'491 pediatric and adult leukemia patients registered in the EBMT database. Slightly more than half of all death occurred within the first five years after HSCT with 58% in those transplanted allogeneic and 53% in those transplanted autologous, but only 15% of all death were linked to "other causes", including pulmonary conditions (58). This let us assume that only few patients, who die within the first five years, die due to a pulmonary disease, but probably a larger proportion might die with a pulmonary condition in the following years. In addition, the development of pulmonary conditions and becoming symptomatic can take up to several decades (e.g. pulmonary fibrosis). Therefore asking for

pulmonary diseases and symptoms at a too early stage may also lead to an underestimation of the true prevalence. This bias is similar to immortal time bias, which refers to a period of follow-up time during which the outcome cannot occur.

The questions on pulmonary health included in the SCCSS derive from other childhood cancer survivor studies from the US and UK (7, 8, 59). This allowed me to compare the results from Publication I in a global context. In addition, a previous PhD student evaluated the same questions in the whole cohort of Swiss CCSs and I could compare the prevalence in transplanted CCSs to the whole cohort of Swiss CCSs (60).

Despite the widespread use of the questions on pulmonary health, they bear some limitations. Key questions like absence or presence of shortness of breath and situations, where these symptoms occur, were missing. Additionally, some questions left room for interpretation by the participant. It was for example not defined, what the term "pneumonia" exactly means; for lay persons "pneumonia" may also include viral infections of the lower airways or a flue associated with cough and tightness in the chest. Retrospectively it would have been good to specify "pneumonia" by adding a short explanation. I assume that these limitations are related to the very comprehensive design of the SCCSS, where the addition of detailed questions would make the questionnaire even longer.

In summary, the SCCSS is a rich source for self-reported medical conditions, general health, and health behavior in long-term childhood cancer survivors in Switzerland. Due to the high response rate, the findings are representative for the whole cohort of Swiss long-term childhood cancer survivors. Still, the comprehensive approach goes to a certain extent at the expense of organ-specific questions, which would be important to make clinically meaningful conclusion.

Medical records

I used data collected from the medical records for publication I - III. The method of collecting information form medical records is described in Chapter 3.3.2.

I performed a retrospective medical records review for all patients, who participated in the SCCSS and have been treated with autologous or allogeneic HSCT. The collected data allowed me to describe the transplant characteristics in Switzerland over a period of 30 years (Publication I, Chapter 4.1), to perform risk factor analysis for self-reported pulmonary outcomes or changes in pulmonary function parameters over time (Publication I, Chapter 4.1 and Publication II, Chapter 4.2), and to describe pulmonary function trajectories in CCSs treated with HSCT (Publication II, Chapter 4.2).

During the data collection I found medical records of 132 (93%) of 142 transplanted CCSs, who participated in the SCCS. Until January 1st 2020, all medical records in Switzerland had to be archived

for a minimum of 10 years in any case and for a minimum of 20 years, if the patient received blood products. Since January 1st 2020 all medical records have to be archived for at least 20 years (61). Despite these requirements I found many files of CCSs diagnosed > 20 years prior to the data collection (30% diagnosed prior to 1995). This may be related to the fact, that these survivors are still in long-term follow-up care and that therefore all medical records are kept. I did not expect, that the 10 CCSs, I had to exclude due to missing medical records, would have changed the results of Publication I.

For publication III (Chapter 4.3), the medical records review has been performed by a previous PhD student and medical students supporting her. Of initially 419 eligible CCSs treated with lung toxic chemotherapy or radiotherapy to the chest, the medical records of 372 (89%) CCSs could be found.

I used information from the medical records to confirm or reject final eligibility of CCSs for a first phase of the SCCSS-FollowUp study (Chapter 5.4.1). CCSs from the SPOG centers in Aarau, Basel, Bern, and Geneva, were included. Preliminary eligibility to quality for screen for pulmonary dysfunction was based on information from the SCCR and included information on exposure to beomycin, busulfan, nitrosures, radiotherapy, and thoracic surgery. I additionally included all patients diagnosed with a cancer with a high possibility of having received one of the pulmonary toxic agents (e.g. germ cell tumors due to belomycin; Hodgkin lymphoma due to radiotherapy to the chest or BNCU in relapsed disease) in this preliminary group. I searched the medical records of all these preliminary eligible CCSs to verify or reject the expoures. The revised list of CCSs was subsequently checked by the division head.

Pulmonary function test results

To assess pulmonary function longitudinally in publication II (Chapter 4.2), I required at least two pulmonary function tests of good quality. The quality criteria are described in Chapter 3.3.3. This led to a reduction in the sample size from 132 to 74 (56%) CCSs.

For publication III, at least one pulmonary function test result could be found for 190 survivors (51%). For 44% of CCSs no pulmonary function test result could be found, 5% had pulmonary function tested before exposure to lung toxic treatment and 3 patients were <6 years of age at pulmonary function testing.

The retrospective collection of pulmonary function data goes in line with two main limitations:

1. We could not check the quality on how the tests have been performed. We had to assume that the archived tests have been performed according to established guidelines, such as the guidelines from the American Thoracic Society, and that the best result out of three has been archived.

2. The equipment used to perform pulmonary function tests differed between clinics and probably also differed within one clinic over the years. This can lead to minimal differences between the centers and within a center and over time.

To overcome these limitations I worked in close collaboration with pediatric pulmonologists. We defined some assumptions: we assumed that the test have been performed according to guidelines, that the tests have been performed three times, and that the best result was stored in the archive. To overcome the limitation of different machines, we only used the raw data and converted them into z-scores, using the same equations over the tested years.

In summary, searching medical records in different archives and with a national approach is very time consuming. This effort is worthwile, since the medical information is of the highes possible quality and it describes the cohort best. A reduction in the final cohort due to missing medical data is at a certain degree at the expense of generalizability. This can be neglected for Publication I, as I found the medical records of 93% of survivors. The results are therefore generalizable to all CCSs treated with HSCT who survived \geq 5-years following the cancer diagnosis. For Publication II and III, we could find pulmonary function test results in half of eligible CCSs only. The results might therefore not be generalizable to all CCSs treated with HSCT and not to all CCSs exposed to at least lung toxic treatment modality respectively. A prospective study design including harmonization on how the tests should be performed and how the results should be reported would overcome these limitations. Until we have this prospective study and enough data collected, we have to clearly communicate this as limitations in each manuscript. Despite the limitations, these results are still very valuable for physicians and researchers.

5.3. Interpretation and implications for childhood cancer survivors and health care professionals

Despite the rather short follow-up period and young age of childhood cancer survivors assessed in publications I-III, a large proportion reported pulmonary symptoms or diseases or suffered from pulmonary dysfunction. Based on our results and by comparing the proportions of CCSs with abnormal pulmonary function test results, CCSs treated with HSCT (publication II) did not clearly perform worse than those treated with pulmonary toxic chemotherapy or radiotherapy (publication III). Even though we know from literature that certain treatment modalities put CCSs ar risk to develop pulmonary dysfunction, we could not clearly shown this in the publications included in this thesis. In the following paragraph I elaborate reasons and insurmountable limitations, which contributed to this "missing effect". I am convinced, that most of the limitations can be solved through (inter-)national collaboration and prospective data collection.

The publication on self-reported pulmonary outcomes (publication I) and both studies on pulmonary dysfunction (publication II and publication III) included rather heterogeneous groups of Swiss childhood cancer survivors. Even though I restricted to survivors treated with hematopoietic stem cell transplantation for publications I and II, the cohorts still contain many different underlying diagnoses, combinations of treatment modalities, disease courses, and indications for transplantation. This heterogeneity makes it difficult to draw conclusions on sub-groups of survivors, such as leukemia or neuroblastoma patients, but this information would be important for health care professionals. Also the graphical illustration of the median z-score for separate pulmonary function parameters since cancer diagnosis was influenced by the heterogeneity. Even though the median value of the whole cohort was below the expected, the individual trajectories varied widely; some CCSs showed a steady decrease, others increase, and a third group showed an undulating course. Due to the heterogeneity, the number of CCSs exposed to separate risk factors, such as belomycin or total body irradiation were too small to perform separate analysis. The same applies for separate diagnostic categories. Therefore we could not answer the clinically relevant question on which groups of survivors are at risk for a steady decrease in pulmonary function. Larger datasets and homogeneous cohort would be needed.

Other publications analyzing pulmonary function in relation to treatment exposure are often limited by low quality on how pulmonary function and its quality were assessed or reported (62, 63). We could show this within the International Guideline Harmonization Group (IGHG) on pulmonary dysfunction (see Chapter 5.4.2). National and international collaboration would help to overcome the limitations of heterogeneous study populations by increasing the number of CCSs per disease or treatment modality (e.g. busulfan in neuroblastoma survivors treated with autologous HSCT). Such collaboration could also be used as a starting point to generate and collect clinical data prospectively and on a larger scale. The prospective collection of medical data on a national level is the aim of the SCCSS-FollowUp study. On European level, PanCare (the Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer) launched the PanCareFollowUp project. Within PanCareFollowUp, the consortium aims to develop and evaluate care interventions (e.g. survivorship care plan), needs of survivors, and lifestyle intervention to improve long-term follow-up care. On an international level, the International Guideline Harmonization Group (IGHG) aims to achieve harmonized recommendations for long-term follow-up care (46). Different to SCCSS-FollwoUp and PanCareFollowUp, the harmonization within IGHG is not based on the generation and collection of medical data but on currently available evidence. To date, harmonized guidelines are available for surveillance for breast cancer, cardiomyopathy, premature ovarian insufficiency, male gonadotoxicity, thyroid cancer, ototoxicity, and cancer-related fatigue (64).

Performing research on late effects in childhood cancer survivors and providing information on prevalence, incidence, risk factors, and recommendations for screening is essential to improve care and

quality of life. In my opinion, the task of transferring these results in a meaningful way to health care professionals and survivors is as important as performing the research itself, but might be more demanding. Only when this transfer of knowledge from researcher to the health care professionals and survivors works, research is successful.

5.4. Outlook

In the following two chapters I summarize two projects I have worked on during my PhD and where I will continue working on until they are handed over to a next PhD student (Pilot Project SCCS-FollowUp, Chapter 5.4.1) or finalized (IGHG Pulmonary Dysfunction, Chapter 5.4.2).

5.4.1 Pilot Project SCCSS-FollowUp

In the initial assumption that the protocol and additional documents for SCCSS-FollowUp would go faster through all instances and the ethics committees, I have started working on a pilot project. Under the umbrella-structure of the SCCSS-FollowUp study, I have planned and initiated the first project on pulmonary health (**Figure 18**).




Figure 18: Pictogram of the umbrella-structure of SCCSS-FollowUp study under which several projects can be carried out

For the purpose of the project on pulmonary health, I developed a questionnaire focusing on pulmonary health. Compared to the SCCSS questionnaire, the new questions are more specific for pulmonary health, such as presence or absence of exercise induced dyspnea or dyspnea at rest, its trigger and intensity. Further questions cover the topics of wheezing, cough, pneumonia, otitis, sinusitis, hay fever, doctor visits for pulmonary problems, smoking habits, and sports. Appendix C contains the adult version of the questionnaire in German. Additional versions are available for parents, adolescents and legal representatives in German and in French. In addition, I developed a separate documentation sheet

for oncologists and pulmonologists to collect important medical data from the clinical visits and the pulmonary function test results in a standardized way (Appendix C). All this information can be entered in the study-specific RedCap® database, which I developed and coded for SCCSS-FollowUp. This database consists of two main parts: 1) a common part with information on diagnosis and treatment exposure, and 2) an organ-specific part, including individual variables for each project. The variables included in the common part and the part on pulmonary health of this database are summarized in Appendix C.

To summarize, I developed the following documents and database for the umbrella-structure of SCCSS-FollowUp and the project on pulmonary health:

- 1. Study protocol with a multicenter design
- 2. Data transfer and user agreement (DTUA) to be completed by the Institute od Social- and Preventive Medicine (ISPM) and each participating center, starting with the pediatric oncology centers
- 3. Information letter and informed consent document for three age categories (children, adolescents, adults) in two languages (German, French)
- 4. Questionnaire on pulmonary health for three age categories (children, adolescents, adults) in two languages (German, French)
- 5. Documentation sheet for oncologists and pulmonologists to be filled out during clinical visit
- 6. RedCap® database

To estimate the number of patient eligible for a first phase of SCCSS-FollowUp, I searched the medical records of patients from the SPOG clinics in Aarau, Basel, Bern, and Geneva, who fulfilled the following in inclusion criteria:

- 1. Initial treatment in one of the three clinics, registered in SCCR, signed SCCR consent
- 2. Age at first diagnosis 0 18 years
- 3. Current age ≥ 6 years (to perform pulmonary function tests)
- 4. Oncological treatment is finished (theoretically eligible from first day of follow-up care)
- 5. Treatment with at least one of the following modalities:
 - a. Chemotherapy with busulfan, bleomycin or nitrosureas
 - b. Radiotherapy to the chest wall, lung, mediastinum, craniospinal axis, thoracal or lumbal spine if performed with photons
 - c. Surgery including muscular or sceletal chest wall, lung, mediastinum, open heart surgery. Not considered as thoracic surgery are insertion of central venous device, needle aspiration or biopsies.

- d. Allogeneic hematopoietic stem cell transplantation
- e. Autologous hematopoietic stem cell transplantation if conditioning included at least one lung toxic treatment modality
- 6. Still in follow-up care in the respective SPOG clinic

I used a rather inclusive approach to search for eligible patients and initially included all those treated for Hodgkin's disease, knowing that not all received radiotherapy, but that it might be missing in the treatment data from the SCCR. **Table 7** summarizes this approach for the four clinics. Initial eligibility was based on the information form the SCCR. CCSs eligible for PFT were assigned after checking medical records at the clinics.

Clinic	Eligibility criteria	Initially eligible	Eligible for PFT	In regular follow-up care
Aarau	Diagnosed 1988 – 2018; age max. 30 years at follow-up	55	23	23
Basel	Diagnosed 1998 – 2018; age max. 20 years at follow-up	29	12	10
Bern	Diagnosed 1993 – 2018; age max. 25 years at follow-up	69	44	12
Geneva	Diagnosed 1993 – 2018; age max. 25 years at follow-up	36	20	20
Total		189	99	65

Table 7: Eligible childhood cancer survivors for first phase of SCCSS-FollowUp

I searched the medical records of all 189 patients and proposed a summary Excel-sheet containing name, date of birth, diagnosis, date of diagnosis and exposure to all previously mentioned potential risk factors to the respective head of the pediatric oncology division. The head himself or a deputy checked the data and completed them in case a patent died or relapsed recently. Finally 65 patients would have been eligible to be recruited in the project on pulmonary dysfunction. Due to the delay in ethics approval, we could not start the recruitment yet. The population and the structure is now in place for the next PhD student.

5.4.2 International Guideline Harmonization Group - Pulmonary Dysfunction

This chapter summarized the current status of the project to harmonize long-term follow-up care for pulmonary surveillance worldwide, as part of the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) (46). The IGHG aims to provide comprehensive long-term

follow-up guidelines tailored to separate late effects. Besides screening available guidelines, the final recommendations will be based on available evidence, after a thorough systematic literature search, or based on expert opinion.

In autumn 2015 it was decided to start working on these recommendations and I have been involved in autumn 2018 after the PhD student previously working on the project (Rahel Kasteler) has successfully finished her PhD. Rahel Kasteler is still involved in the project. In the following paragraphs I mainly focus on the steps I have been involved and explain the initial steps only briefly.

The general approach of the IGHG, used for all recommendations, consists of three phases:

- 1. Preparation phase
- 2. Development phase
 - a. Step 1: Evaluate concordances and discordances of current recommendations
 - b. Step 2: Formulate clinical questions
 - c. Step 3: Identify and select the evidence
 - d. Step 4: Summarize and appraise quality of evidence
 - e. Step 5: Formulate recommendations
- 3. Finalization phase

Independent of the late effect assessed, the IGHG recommendations aims to answer the following four questions in four working groups (WG):

WG 1: Who needs surveillance?

- WG 2: What surveillance modality should be used? At what frequency should surveillance be performed?
- WG 3: With what frequency should be screened? / When should follow up be initiated?
- WG 4: What should be done when abnormalities are found?

Preparation phase

The guideline panel

The working group on pulmonary dysfunction consists of two chairs, two coordinators, five advisors, two members of the advisory board, and 21 additional working group members, being pediatric oncologists, pediatric or adult pulmonologists, radiotherapists and epidemiologists.

Scope of the guideline

The initial definition of pulmonary outcomes included 1) pulmonary function impairment assessed by pulmonary function tests and considered single parameters (e.g. FEV1, FVC, DLCO) and combined parameters (e.g. obstructive or restrictive disease), 2) self-reported pulmonary outcomes (e.g. chronic cough, pneumonia), and 3) doctors reported diseases (e.g. radiation induced pneumonia). In summer 2020 we decided in the whole guideline panel to restrict the outcome to pulmonary function test results only.

We included only studies if $\geq 50\%$ of the study population were survivors of childhood, adolescent and young adult cancer diagnosed prior to age 30 years and if pulmonary function was assessed ≥ 2 years after completion of cancer treatment. We excluded reviews, case reports or studies with a sample size of < 20 survivors. We additionally excluded studies who reported only the prevalence of pulmonary outcomes but did not perform risk factor analysis.

Development phase

Step 1: Evaluate concordances and discordances of current recommendations

This step was performed by Rahel Kasteler. She compared the guidelines from the North American Children's Oncology Group, the Dutch Childhood Oncology Group, the UK Children's Cancer and Leukaemia Group, and from the Scottish Intercollegiate Guidelines Network for concordances and discordances (Appendix D).

Step 2: Formulate clinical questions

Based on the findings from step 1, twelve clinical PICO questions and sub-questions were formulated to answer the question of <u>working group 1</u> (for simplicity I did not write down the sub-PICO on different doses and age at treatment for each PICO, but only for cyclophosphamide and abbreviated it with [plus a. and b.] for the following substances):

- 1. What is the risk of pulmonary dysfunction in childhood and young adult cancer survivors (CAYA) treated with **allogeneic hematopoietic stem cell transplantation** compared to CAYA not treated with allogeneic hematopoietic stem cell transplantation?
 - a. What is the risk in younger compared to older age at treatment?
 - b. What is the risk in patients with cGvHD compared to patients without cGvHD?
 - c. What is the risk in patients who had a pulmonary infection during HSCT compared to patients without pulmonary infection during HSCT?

- 2. What is the risk of pulmonary dysfunction in CAYA treated with **cyclophosphamide** compared to CAYA not treated with cyclophosphamide?
 - a. What is the risk associated with different doses?
 - b. What is the risk in younger compared to older age at treatment?
- What is the risk of pulmonary dysfunction in CAYA treated with methotrexate compared to CAYA not treated with methotrexate? [plus a. and b.]
- 4. What is the risk of pulmonary dysfunction in CAYA treated with gemcitabine compared to CAYA not treated with gemcitabine? [plus a. and b.]
- 5. What is the risk of pulmonary dysfunction in CAYA treated with **bleomycin** compared to CAYA not treated with bleomycin? [plus a. and b.]
 - c. What is the risk in patients with renal dysfunction versus patients without renal dysfunction?
- 6. What is the risk of pulmonary dysfunction in CAYA treated with **busulfan** compared to CAYA not treated with busulfan? [plus a. and b.]
- What is the risk of pulmonary dysfunction in CAYA treated with lomustine (CCNU) compared to CAYA not treated with lomustine (CCNU)? [plus a. and b.]
- 8. What is the risk of pulmonary dysfunction in CAYA treated with **carmustine** (BCNU) compared to CAYA not treated with carmustine (BCNU)? [plus a. and b.]
- 9. What is the risk of pulmonary dysfunction in CAYA treated with **radiotherapy exposing lung tissue** compared to CAYA not treated with radiotherapy exposing lung tissue?
 - a. What is the risk associated with different doses and volumes?
 - b. What is the risk in different radio therapeutic fields?
 - c. What is the risk associated with patient age at the time of radiation?
 - d. What is the risk of pulmonary dysfunction in CAYA treated with radiosensitizer combined with radiotherapy involving lung tissue compared to CAYA not treated with radiosesnitizer but with radiotherapy involving lung tissue?
 - e. What is the risk for patients treated with total body irradiation in the setting of stem cell transplantation?

- 10. What is the risk of pulmonary dysfunction in CAYA treated with **surgery** (resection of lung tissue or resection of thoracic cage or respiratory muscles) compared to CAYA not treated with surgery?
 - a. What is the risk associated with different resection volumes?
 - b. What is the risk in younger compared to older age at treatment?
- 11. What is the risk of pulmonary dysfunction in CAYA treated with **combinations** of the therapies above?
 - a. What is the risk of thoracic surgery combined with pulmotoxic chemotherapy?
 - b. What is the risk of thoracic surgery combined with radiotherapy to the chest?
 - c. What is the risk of pulmotoxic chemotherapy combined with radiotherapy to the chest?
- 12. What is the risk of pulmonary dysfunction in CAYA who have a history of **tobacco exposure** compared to CAYA with no history of tobacco exposure?
 - a. What is the risk in smokers/ex-smokers compared to non-smokers?
 - b. What is the risk associated with different doses (pack-years)?
 - c. What is the risk in patients exposed to environmental tobacco smoke compared to not exposed?
 - d. What is the risk in marijuana smokers compared to non-smokers?

For working group 2 to 4 it was decided at the very beginning by all members, that there will be no evidence in the available literature to answer these questions with a comprehensive literature search. We therefore searched existing guidelines of diseases with similar pathomechanisms or manifestations as expected in childhood cancer survivors. This task was coordinated by myself. For the extraction of information from the guidelines I was supported by four members of the group (Neel Bhatt, Christina Schindera, Nicolas Waespe, and Rahel Kasteler). The guidelines searched and the extracted information are summarized in Appendix D.

Step 3: Identify and select the evidence

A comprehensive PubMed and Embase literature search for studies published after January 1st 1990 has been performed by the Rahel Kasteler in January 2017. I updated the search in June 2019. For both searches we used the same strategy to answer the question from working group 1 (Who needs surveillance?) (Appendix D).

The screening of abstracts from the first search and the first extraction of evidence has already been performed when I entered the group. I entered as a second reviewer for the full text paper in the project.

For the search update I performed the literature search and the abstract and full text screening. Rahel Kasteler acted as second reviewer for the search update. After comparing the in- and excluded studies we discussed few studies with discrepancies and I subsequently performed the extraction of evidence.

After applying all in- and exclusion criteria to the initial literature search and the re-search, we came up with 22 eligible papers to answer the question on "Who needs surveillance" (Figure 19).

Step 4: Summarize and appraise quality of evidence

As we decided in the core group at a rather late stage to include only studies with pulmonary function test results and to exclude those with prevalence only, self-reported outcomes, and doctors' diagnoses, the evidence has initially been extracted for 94 studies. This task has been distributed by all members of working group 1 and was then checked by me and Rahel Kasteler (Appendix D). Later, the evidence of the 22 studies were combined in "summary of findings" tables. I generated separate tables for each PICO question and sub-PICO question, and additionally for each pulmonary outcome. For pulmonary outcomes, we decided to distinguish between obstructive and restrictive disease, hyperinflation, and diffusion capacity impairment. At this stage, I assessed the risk of bias for each study and assessed the overall quality of evidence for each PICO question. This was subsequently checked by Rahel Kasteler, and we received great support from Renée Mulder from the IGHG core group. **Figure 20** shows the criteria we used to assess the risk of bias for each study separately. **Table 9** summarizes how we assessed the overall quality per PICO based on adapted GRADE criteria, given by the IGHG group.

After grading all PICO questions we summarized the findings in an overall conclusion (**Table 9**). This summary shows, that there were several questions and outcomes where no study could be found (e.g. pulmonary infections in the setting of allogeneic HSCT or studies on gemcitabine). We could also show that the overall quality of evidence was low to very low for most PICO questions. This was mostly due to limitations in the way pulmonary function test results were reported in each study (e.g. reference equations not stated, ATS guidelines or similar not stated etc.), but also on how the risk factor analysis was performed. Most studies performed univariable analysis only, some showed p-values only or reported odds rations without confidence intervals. In addition, if only one study was available per PICO, the points in the GRADE assessment decreased.




Figure 19: PRISMA flow diagram describing the selection of finally eligible publications for IGHG on pulmonary dysfunction

	Internal validity	
Study group	Selection bias - Low risk/high risk/unclear	
	Is the study group representative?	
	Low risk if:	
	 the study group consisted of more than 75% of the original cohort 	
	of childhood cancer survivors	
	 or it was a random sample with respect to the cancer treatment 	
Follow-up	Attrition bias - Low risk/high risk/unclear	
	Is the follow-up adequate?	
	Low risk if:	
	 the outcome was assessed for more than 75% of the study group 	
Outcome	Detection bias - Low risk/high risk/unclear	
	Are the outcome assessors blinded for important determinants	
	related to the outcome?	
	Low risk if:	
	 the outcome assessors were blinded for important determinants 	
	related to the outcome	
Risk	Confounding - Low risk/high risk/unclear	Figure 20: Risk of bias assessmen
estimation	Are the analyses adjusted for important confounding factors?	
	Low risk if:	of observational studies, according
	 important prognostic factors (i.e. age, gender, co-treatment, 	
	follow-up) were taken adequately into account	IGHG

Table 8: GRADE quality assessment according to IGHG

Initial score based on type of evidence

- +4: RCTs/ SR of RCTs
- +2: CCTs or observational evidence (e.g., cohort, case-control) for intervention questions
- +4: Observational evidence for etiologic, prognostic and diagnostic questions

Factors that might decrease the quality of the body of evidence

- <u>1.</u> <u>Study limitations</u>: risk of bias based on selection bias, attrition bias, detection bias and confounding as defined in the risk of bias table.
 - 0: No problems
 - -1: Problem with 1 element
 - -2: Problem with 2 elements
 - -3: Problem with 3 or more elements
- 2. Consistency: degree of consistency of effect between or within studies
 - 0: All/most studies show similar results
 - -1: Lack of agreement between studies (statistical heterogeneity / conflicting result, e.g. effect sizes in different directions)
- <u>3.</u> <u>Directness</u>: the generalizability of population and outcomes from each study to the population of interest
 - 0: Population and outcomes broadly generalizable
 - -1: Problem with 1 element (population different from the defined inclusion criteria OR outcomes different from the defined inclusion)
 - -2: Problem with 2 elements (population and outcomes)
- <u>4.</u> <u>Precision</u>: the precision of the results
 - 0: No important imprecision when studies include many patients and many events and thus have narrow confidence intervals; Determine with the chairs and advisors what is seen as many patients, many events and narrow confidence intervals
 - -1: Important imprecision when studies include relatively few patients and few events and thus have wide confidence intervals (especially when the confidence interval cross the 0). Another criteria to consider is the clinical decision threshold. This is the threshold of the effect size that would change the decision whether or not to adopt a clinical action. Downgrade if the effect estimate and confidence intervals cross the clinical decision threshold. Determine with the chairs and advisors the clinical decision threshold.
 - OR if only one study has been identified
 - -2: If there is important imprecision (see -1) AND if only one study has been identified
- 5. <u>Publication bias</u>: if investigators fail to report studies and outcomes (typically those that show no effect)
 - 0: Publication bias unlikely
 - -1: Risk of publication bias when for example published evidence is limited to industry funded trials

Factors that might increase the quality of the body of evidence

- 1. Magnitude of effect:
 - +1: Large magnitude of effect; all studies show significant effect sizes (point estimate) >2 or <0.5
 - +2: Very large magnitude of effect; all studies show significant effect sizes (point estimate) >5 or
 <0.2
- 2. <u>Dose response gradient:</u>
 - +1: Evidence of clear relation with increases in the outcome with higher exposure levels across or within studies
- 3. <u>Plausible confounding:</u>
 - +1: If adjustment for confounders would have increased the effect size; for example the estimate of effect is not controlled for the following possible confounders: smoking, degree of education,

but the distribution of these factors in the studies is likely to lead to an underestimate of the true effect

Total score

 $\begin{array}{c} \bigoplus \bigoplus \bigoplus & \text{High quality evidence} \\ \bigoplus \bigoplus \bigoplus \bigoplus & \text{Moderate quality evidence} \\ \bigoplus \bigoplus \bigoplus \bigoplus & \text{Low quality evidence} \\ \bigoplus \bigoplus \bigoplus \bigoplus & \text{Very low quality evidence} \end{array}$

Step 5: Formulate recommendations

When writing this thesis, we were in the middle to formulate recommendations and finding consensus. For working group 1, we will most probably only be able to formulate recommendations on exposure yes versus no (e.g. exposure to radiotherapy to the chest is a risk factor compared to no radiotherapy). The formulation of additional recommendations, taking age at exposure or cumulative dose into account, will most probably not be possible. For working group 2-4, the recommendations will most probably be based on expert opinion only. For surveillance modality, we will recommend tests, which are widely used internationally, such as spirometry and DLCO measurement and body plethysmography if available. For screening frequency, no consensus is found at this stage. The last question on "what should be done when abnormalities are found?" will be held most probably very general and recommend referral to pulmonologist or discussion in interdisciplinary teams. A separate section will focus on guidance for pulmonologists. This section will cover topics on how PFTs should be perforemed, which reference should be used and how results should be reported.

Finalization phase

We have not started this phase when writing this thesis, but we aim to have a first manuscript written in summer 2021.

				1 Increased risk
				L Decreased risk
Tabla 0. Original roundination of	Tabla 0. Overall conclusion of evidence on "Who needs curreillance" by DICO meetion and hy milmonery outcome	lonne" his DICO attaction and	ky milmonany autoama	 No significant effect
Table 7. Overall colletusion of		iance by FICO question and	оу риппонагу оиссоне	① Conflicting evidence
Who is at risk?				
Risk and risk factors for pulmona	Risk and risk factors for pulmonary dysfunction in survivors of childhood, adolescent and young adult cancer (>50% of population diagnosed prior to age 30 years)	lood, adolescent and young ad	ult cancer (≥50% of population diag	nosed prior to age 30 years)
	Obstructive dysfunction	Restrictive dysfunction	Hyperinflation	Diffusion capacity impairment
	Included studies used differe	nt cutoff-values to define pulmo the outcome was dichtor	off-values to define pulmonary function as normal or pathological the outcome was dichtomous (normal/ abnormal) or continuous	ed different cutoff-values to define pulmonary function as normal or pathological. Depending on PICO question, the outcome was dichtomous (normal/ abnormal) or continuous
Treatment factors				
Allogeneic HSCT (y/n)	$= \oplus \Theta \Theta \Theta$ Very Low (1)	$= \oplus \Theta \Theta \Theta$ VERY LOW (1)	1 0000 VERY LOW (1)	No study
Older vs younger	1 000 LOW (2)	1 ⊕⊖⊖⊖ very low (2)	No study	1 @ \000000000000000000000000000000000000
Chronic GvHD (y/n)	↑ ⊕⊖⊖⊖ VERY LOW (2)	1 ⊕⊖⊖⊖ very low (1)	No study	
Pulmonary infection (y/n)	No study	No study	No study	No study
TBI (y/n)	↑ ⊕⊖⊖⊖ VERY LOW (2)	1 0000 VERY LOW (2)	No study	1 ⊕⊕⊕⊖ MODERATE (1)
Cyclophosphamide (y/n)		1 0000 VERY LOW (2)	No study	$= \oplus \oplus \ominus \ominus \text{LOW} (1)$
Higher dose	$= \oplus \Theta \Theta \Theta$ VERY LOW (1)	1 ⊕⊖⊖⊖ very low (1)	No study	No study
Older vs younger	No study	No study	No study	No study
Methotrexate (y/n))	No study	No study	No study	No study
Higher dose	No study	$= \oplus \Theta \Theta \Theta$ VERY LOW (1)	No study	No study
Younger vs older	No study	No study	No study	No study
Gemcitabine (y/n)	No study	No study	No study	No study
Different dose	No study	No study	No study	No study
Younger vs older	No study	No study	No study	No study
Bleomycin (y/n)	↓ ⊕⊖⊖⊖ VERY LOW (3)	$= \oplus \ominus \ominus \ominus$ very low (5)	↓ ⊕⊖⊖⊖ VERY LOW (2)	↓ ⊕⊖⊖⊖ VERY LOW (4)
Higher dose	$= \oplus \Theta \Theta \Theta$ very low (1)	$= \oplus \Theta \Theta \Theta$ VERY LOW (1)	$= \bigoplus \ominus \ominus \ominus$ VERY LOW (1)	$= \bigoplus \ominus \ominus \ominus$ very low (2)
Older vs younger	No study	No study	No study	No study
Renal dysfunction (y/n)	No study	No study	No study	No study

Busulfan (y/n)	No study	$= \oplus \Theta \Theta \Theta$ very low (1)	No study	$= \oplus \Theta \Theta \Theta$ Very Low (1)
Higher dose	No study	No study	No study	No study
Younger vs older	No study	No study	No study	No study
Nitrosureas ^a (y/n)	No study	$= \bigoplus \ominus \ominus \ominus \ominus$ VERY LOW (1)	No study	$= \oplus \ominus \ominus \ominus$ very low (1)
Different dose	No study	No study	No study	No study
Younger vs older	No study	No study	No study	No study
Radiotherapy to lung tissue (y/n)	1 (13) T (13) (13)	↑ ⊕⊖⊖⊖ VERY LOW (4)	↑ ⊕⊖⊖⊖ VERY LOW (2)	1 ⊕⊖⊖⊖ VERY LOW (4)
Higher doses & volumes	1 ⊕⊖⊖⊖ very low (3)	↑ ⊕⊖⊖⊖ VERY LOW (5)	↑ ⊕⊖⊖⊖ VERY LOW (1)	1 ⊕⊖⊖⊖ very low (5)
Different fields	No study	No study	No study	No study
Older vs younger	$= \oplus \Theta \Theta \Theta$ VERY LOW (2)	$= \bigoplus \ominus \ominus \ominus \ominus$ VERY LOW (2)	$= \oplus \Theta \Theta \Theta$ Very Low (1)	$= \oplus \Theta \Theta \Theta$ Very Low (2)
Radiosensitizer (y/n)	No study	No study	No study	No study
Surgery (y/n)	1 ⊕⊖⊖⊖ very low (3)	↑ ⊕⊖⊖⊖ VERY LOW (4)	↑ ⊕⊖⊖⊖ VERY LOW (2)	$= \oplus \ominus \ominus \ominus$ Very Low (3)
Different resection volumes	No study	No study	No study	No study
Younger vs. older	No study	No study	No study	No study
Combinations				
Surgery PLUS chemo	No study	$= \oplus \Theta \Theta \Theta$ Very Low (1)	No study	$= \oplus \Theta \Theta \Theta$ very low (1)
Surgery PLUS radio vs bleomycin	No study	↓ ⊕ ⊖ ⊖ ⊖ ⊖ ∨ ERY LOW (1)	No study	↑ ⊕⊖⊖⊖ VERY LOW (1)
Chemo PLUS radio vs chemo	↓ ⊕⊖⊖⊖ very low (1)	↓ ⊕⊖⊖⊖ very low (2)	No study	↑ ⊕⊖⊖⊖ VERY LOW (2)
Health behaviors				
Tobacco exposure (y/n)	No study	No study	No study	No study
(ex)smoker vs non-smoker	↑ ⊕⊖⊖⊖ very low (1)	$= \bigoplus \ominus \ominus \ominus$ very low (3)	No study	$= \oplus \Theta \Theta \Theta$ Very Low (4)
Different doses (pack years)	No study	No study	No study	No study
Environmental tobacco	No study	No study	No study	No study
Marijuana vs. non-smoker	No study	No study	No study	No study

Page | 74

5.5. Conclusion

With the results from this PhD thesis I can answer the open questions on pulmonary health in Swiss childhood cancer survivors treated with hematopoietic stem cell transplantation (HSCT). I can additionally answer the question on how pulmonary function changes over time in childhood cancer survivors exposed to hematopoietic stem cell transplantation, lung toxic chemotherapy or radiotherapy to the chest- at least in a first general approach for those exposed to HSCT. I showed that one out of five survivors treated with HSCT reported at least one pulmonary outcome and that most pulmonary function parameters slightly declined over time. The same is true for survivors exposed to lung toxic chemotherapy or radiotherapy to the chest. These findings highlight that screening for pulmonary dysfunction, using pulmonary function tests, is needed in survivors at risk. But the questions on who is at risk exactly, cannot be answered straight forward with the current results from publications I-III. As shown in the systematic literature search performed within by the IGHG project, only a few studies really assessed different risk factors in relation to pulmonary function test results and many did not have a longitudinal design. In addition, the quality of evidence was low to very low in most studies. This highlights the need for prospective studies, which assess pulmonary function in childhood cancer survivors longitudinally. For that reason I have developed SCCSS-FollowUp. But even when SCCSS-FollowUp is running, the number of Swiss survivors is small. We need international collaboration to reach numbers of survivors high enough to assess the possible effect of different risk factors and in different sub-groups of survivors. But even if we, as researchers or clinicians involved in research, think we have a good study design and plan to invite survivors, we always have to consider the benefit and potential burden for the survivors. From this perspective, SCCSS-FollowUp is ideal, as it is integrated into regular follow-up care and it does not require any additional tests or examinations.

Chapter 6 - References

- Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. The Lancet Oncology. 2017;18(6):719-31.
- 2. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(2):83-103.
- Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. The Lancet Oncology. 2014;15(1):35-47.
- Kinderkrebsregister S. Swiss Childhood Cancer Registry. Annual report 2017-2018 2019 [cited 2020 04.02.2020]. Available from: https://www.kinderkrebsregister.ch/wpcontent/uploads/sites/2/2019/09/FINAL-Annual-Report_2017_2018_with-CC-license.pdf.
- Farber S. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood. 1949;4(2):160-167. Blood. 2016;127(3):271.
- 6. Mukherjee S. Der Köng aller Krankheiten: Dumont; 2015.
- Hawkins MM, Lancashire ER, Winter DL, Frobisher C, Reulen RC, Taylor AJ, et al. The British Childhood Cancer Survivor Study: Objectives, methods, population structure, response rates and initial descriptive information. Pediatric blood & cancer. 2008;50(5):1018-25.
- Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multiinstitutional collaborative project. Medical and pediatric oncology. 2002;38(4):229-39.
- Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, et al. Cohort profile: the Swiss childhood cancer survivor study. International journal of epidemiology. 2012;41(6):1553-64.
- Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. The New England journal of medicine. 2006;355(15):1572-82.
- Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. Jama. 2013;309(22):2371-81.
- 12. Lucas JT, Jr., Fernandez-Pineda I, Tinkle CL, Bishop MW, Kaste SC, Heda R, et al. Late toxicity and outcomes following radiation therapy for chest wall sarcomas in pediatric patients. Practical radiation oncology. 2017;7(6):411-7.
- 13. Interiano RB, Kaste SC, Li C, Srivastava DK, Rao BN, Warner WC, Jr., et al. Associations between treatment, scoliosis, pulmonary function, and physical performance in long-term

survivors of sarcoma. Journal of cancer survivorship : research and practice. 2017;11(5):553-61.

- 14. Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140(4):881-901.
- 15. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Current opinion in oncology. 2001;13(4):242-8.
- 16. Jenney ME. Malignant disease and the lung. Paediatric respiratory reviews. 2000;1(3):279-86.
- Liles A, Blatt J, Morris D, Wardrop R, 3rd, Sharma A, Sznewajs A, et al. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. Cleveland Clinic journal of medicine. 2008;75(7):531-9.
- Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy. Seminars in oncology. 2013;40(6):757-73.
- 19. Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest. 2004;126(3):1007.
- O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA.
 Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
 The New England journal of medicine. 1990;323(6):378-82.
- Children's Oncology Group [COG] Long Term Follow-Up guidelines 2013
 [cited 2018 08.05.2018]. Available from: http://www.survivorshipguidelines.org.
- Witkowska M, Majchrzak A, Smolewski P. The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years? BioMed research international. 2015;2015:485071.
- Mohan R, Grosshans D. Proton therapy Present and future. Advanced drug delivery reviews. 2017;109:26-44.
- 24. Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. Technology in cancer research & treatment. 2012;11(3):267-78.
- 25. Denbo JW, Zhu L, Srivastava D, Stokes DC, Srinivasan S, Hudson MM, et al. Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. Journal of the American College of Surgeons. 2014;219(2):265-71.
- Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematology/oncology and stem cell therapy. 2010;3(3):143-57.
- 27. Diab M, ZazaDitYafawi J, Soubani AO. Major Pulmonary Complications After Hematopoietic Stem Cell Transplant. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2016;14(3):259-70.
- 28. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30-7.

- 29. Bresters D, van Gils ICM, Kollen WJW, Ball LM, Oostdijk W, van der Bom JG, et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone marrow transplantation. 2009;45:79.
- Leung W, Ahn H, Rose SR, Phipps S, Smith T, Gan K, et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine. 2007;86(4):215-24.
- 31. Uderzo C, Pillon M, Corti P, Tridello G, Tana F, Zintl F, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone marrow transplantation. 2007;39(11):667-75.
- 32. Wilhelmsson M, Vatanen A, Borgström B, Gustafsson B, Taskinen M, Saarinen-Pihkala UM, et al. Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT—two decades of longitudinal follow-up. Bone marrow transplantation. 2015;50:850.
- 33. Armenian SH, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011;118(5):1413-20.
- 34. Hoo AF, Stocks J, Lum S, Wade AM, Castle RA, Costeloe KL, et al. Development of lung function in early life: influence of birth weight in infants of nonsmokers. American journal of respiratory and critical care medicine. 2004;170(5):527-33.
- 35. Kotecha SJ, Watkins WJ, Heron J, Henderson J, Dunstan FD, Kotecha S. Spirometric lung function in school-age children: effect of intrauterine growth retardation and catch-up growth. American journal of respiratory and critical care medicine. 2010;181(9):969-74.
- Visscher H, Otth M, Feijen E, Nathan PC, Kuehni CE. Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer. Pediatric clinics of North America. 2020;67(6):1155-70.
- Gnädinger M CM, Natterer N, Thurnheer R. Praxis-Spirometrie. Swiss Medical Forum. 2014;14(37):683-688.
- Criée CP, Baur X, Berdel D, Bösch D, Gappa M, Haidl P, et al. [Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine]. Pneumologie (Stuttgart, Germany). 2015;69(3):147-64.
- 39. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. The European respiratory journal. 2005;26(5):948-68.
- 40. Criée CP, Sorichter S, Smith HJ, Kardos P, Merget R, Heise D, et al. Body plethysmography--its principles and clinical use. Respiratory medicine. 2011;105(7):959-71.

- 41. Modi PC, M. Diffusing Capacity Of The Lungs For Carbon Monoxide (DLCO): StatPearls Publishing LLC; 2020 Available from: https://www.ncbi.nlm.nih.gov/books/NBK556149/.
- 42. D'Angio GJ. Pediatric cancer in perspective: cure is not enough. Cancer. 1975;35(3 suppl):866-70.
- 43. Children's Oncology Group [COG] Long Term Follow-Up guidelines Version 5.0 2018 [cited 05.04.2019]. Available from: http://www.survivorshipguidelines.org
- 44. SKION DCOGD. Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis. 2010 [cited 08.05.2018]. Available from: https://www.skion.nl/voor-patienten-en-ouders/late-effecten/533/richtlijn-follow-up-na-kinderkanker/.
- 45. United Kingdom Children's Cancer Study Group. Therapy based long term follow-up -Practice Statement 2005. Avalable from: http://www.uhb.nhs.uk/Downloads/pdf/ CancerPbTherapyBasedLongTermFollowUp.pdf
- 46. Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatric blood & cancer. 2013;60(4):543-9.
- Meier JH, Ansari M, Beck Popovic M, Bergstraesser E, Brazzola P, Eisenreich B, et al. Aftercare in Pediatric Oncology in Switzerland – Current State, Challenges and Future Directions. Schweizer Krebsbulletin. 2018;3:273-9.
- 48. Tinner EM G-PF, Diezi M, Bergsträsser E, Hengartner H, Eisenreich B, Brazzola P, von der Weid N, Tomášiková Z, Scheinemann K. Long-term follow-up after childhood cancer in Switzerland: a position statement from the pediatric Swiss LTFU working group. Schweizer Krebsbulletin. 2019;3:213-5.
- Otth M, Denzler S, Koenig C, Koehler H, Scheinemann K. Transition from pediatric to adult follow-up care in childhood cancer survivors-a systematic review. J Cancer Surviv. 2020. Online ahead of print.
- Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. Swiss medical weekly. 2007;137(35-36):502-9.
- Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. American journal of respiratory and critical care medicine. 1999;159(1):179-87.
- 52. Zapletal AS, M; Paul, T Lung Function in Children and Adolescents. Methods, Reference Values. Basel: S Karger AG. 1987.
- 53. Quanjer PHD, A; Van Zomeren, B.H. Summary equations of reference values. 1983;Bull Europ Physiopathol Respir (19(Suppl. 5):45–51).
- 54. National Cancer Institute. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0). [cited: 06.08.2018] Available from https://ctep.cancer.gov/
 protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf

- 55. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. The European respiratory journal. 2012;40(6):1324-43.
- 56. Schindler M, Mitter V, Bergstraesser E, Gumy-Pause F, Michel G, Kuehni CE. Death certificate notifications in the Swiss Childhood Cancer Registry: assessing completeness and registration procedures. Swiss medical weekly. 2015;145:w14225.
- 57. Rueegg CS, Gianinazzi ME, Michel G, Zwahlen M, von der Weid NX, Kuehni CE. No evidence of response bias in a population-based childhood cancer survivor questionnaire survey - Results from the Swiss Childhood Cancer Survivor Study. PloS one. 2017;12(5):e0176442.
- 58. Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone marrow transplantation. 2020;55(1):126-36.
- 59. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(14):2308-18.
- Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, et al. Long-term pulmonary disease among Swiss childhood cancer survivors. Pediatric blood & cancer. 2018;65(1).
- BAG BfG. Obligationenrecht (Revision des Verjährungsrechts) 2018 [cited 19.10.2020].
 Available from: https://www.admin.ch/opc/de/federal-gazette/2018/3537.pdf.
- Record E, Williamson R, Wasilewski-Masker K, Mertens AC, Meacham LR, Popler J. Analysis of risk factors for abnormal pulmonary function in pediatric cancer survivors. Pediatric blood & cancer. 2016;63(7):1264-71.
- Mulder RL, Thonissen NM, van der Pal HJ, Bresser P, Hanselaar W, Koning CC, et al.
 Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax. 2011;66(12):1065-71.
- 64. International Guideline Harmonization Group. [cited 04.11.2020] Available from: https://www.ighg.org/.

Chapter 7 – Co-Author publications

7.1. Co-Author publication I

Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer

Original article

Henk Visscher, Maria Otth, E.A.M. (Lieke) Feijen, Paul C. Nathan, Claudia E. Kuehni

(Published, Pediatr Clin N Am, 2020)

Own contribution to the project: Writing section on pulmonary challenges and integration of co-authors comments in this section

Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer

Henk Visscher, мD, PhD^{a,b,*}, Maria Otth, мD^{c,d}, E.A.M. (Lieke) Feijen, PhD^b, Paul C. Nathan, мD, мsc^e, Claudia E. Kuehni, мD^{c,f}

KEYWORDS

• Late effects • Childhood cancer survivor • Cardiovascular • Pulmonary

KEY POINTS

- Cardiovascular disease and pulmonary disease are the second leading nonrecurrence causes of death in childhood cancer survivors.
- Anthracyclines and radiotherapy to heart, head, and neck cause substantial cardiovascular disease, in particular, congestive heart failure, ischemic and valvular heart disease, and stroke.
- Bleomycin, busulfan, nitrosoureas, chest radiation, and lung surgery are the main contributors to pulmonary disease.
- Prevention and regular screening according to established are crucial because treatment options are limited once disease becomes clinically manifest.
- Childhood cancer survivors should be encouraged to adopt healthy lifestyles (exercise, healthy diet, and no smoking) and modifiable risk factors should be addressed.

INTRODUCTION

Both cardiovascular disease and pulmonary disease occur with increased frequency in childhood cancer survivors (CCSs), although both might not become apparent until many years after treatment.¹ These late effects of cancer therapy can vary from subclinical to life threatening and can substantially increase mortality and morbidity. After

E-mail address: h.visscher-6@prinsesmaximacentrum.nl

Pediatr Clin N Am 67 (2020) 1155–1170 https://doi.org/10.1016/j.pcl.2020.07.007 0031-3955/20/© 2020 Elsevier Inc. All rights reserved.

pediatric.theclinics.com

^a Division of Haematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; ^b Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, The Netherlands; ^c Childhood Cancer Research Platform, Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, Bern 3012, Switzerland; ^d Division of Hematology-Oncology, Department of Pediatrics, Kantonsspital Aarau, Switzerland; ^e AfterCare Program, Division of Haematology/Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada; ^f Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Mittelstrasse 43, Bern 3012, Switzerland

^{*} Corresponding author. Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, The Netherlands.

subsequent malignancies, cardiovascular disease and pulmonary disease are the leading nonrecurrence causes of death in CCSs.²⁻⁴

In particular, there is a 5-fold to 10-fold increase in mortality due to cardiovascular disease (CVD),^{2–4} which is in large part due to the 5-fold to 15-fold increased risk of congestive heart failure (CHF)⁵ and more than 10-fold increased risk of ischemic heart disease and stroke.⁶ Similarly, the risk of death from a pulmonary event is 7-times to 14-times higher in CCSs compared with the general population,^{2,7,8} and hospitalization due to respiratory conditions is 2-times to 5-times higher in survivors.^{9–11}

The purpose of this review is to describe the current knowledge of cardiac and pulmonary late effects, including risk factors, early detection, possible treatments, and opportunities for prevention.

CARDIOVASCULAR DISEASE

CVD after childhood cancer usually manifests as left ventricular (LV) systolic dysfunction/heart failure, ischemic (coronary artery) heart disease, or stroke.^{1,12–15} Patients, however, also can develop pericardial disease, arrhythmias, or valvular and peripheral vascular dysfunction.^{13,16} Both chemotherapy and radiotherapy can contribute to these conditions either alone or in combination. For example, in a study of 5845 CCSs, those who received both cardiotoxic chemotherapy and radiotherapy involving the heart (7%) had a cumulative incidence of heart failure 40 years after diagnosis of 28%, whereas patients who received only cardiotoxic chemotherapy or only radiotherapy involving the heart had cumulative incidence of 11% and 3%, respectively.¹⁷

Risk Factors and Pathophysiology

The increased risk of CVD in CCSs is due mainly to exposure to anthracyclines and radiotherapy involving the heart.^{4–6,13,18} Other conventional chemotherapeutic drugs, radiotherapy to head and neck, and a growing list of newer targeted agents that increasingly are used in children, however, all can affect this risk (**Table 1**).^{4,6,13,15,16,18–21} In addition, standard risk factors for CVD, such as hypertension, dyslipidemia, diabetes mellitus, and obesity, many of which are more prevalent in CCSs, contribute to the increased CVD risk.^{22–24}

Conventional chemotherapy

Anthracyclines (eg, doxorubicin, daunorubicin, idarubicin, and epirubicin), including the anthraquinone, mitoxantrone, commonly are used to treat a variety of childhood cancers and have been known for several decades to cause dose-dependent cardiotoxicity that can range from subclinical, with only mildly reduced shortening fraction,^{25,26} to severe overt clinical heart failure.^{13,17,27}

Anthracycline cardiotoxicity (ACT) historically has been described based on the time of onset, which can be acute, early (within the first year of treatment), or late (after the first year). Although early-onset ACT can resolve without intervention, some patients continue to have LV systolic dysfunction, which might be progressive, whereas others develop late-onset ACT after a latency period free of symptoms, suggesting this might be a continuum rather than clearly different entities and that additional myocardial injury or stress might contribute to developing later symptoms.^{28–30}

The effects of anthracyclines are dose dependent and increase over time with CCSs who received a cumulative doxorubicin-equivalent dose greater than or equal to 250 mg/m², having a 30-year follow-up cumulative incidence of CHF of 8% to 13%.^{17,27} Not all anthracyclines are equally cardiotoxic, with mitoxantrone carrying the highest risk for CHF and hence the conversion into doxorubicin equivalents.³¹

Cardiovascular and Pulmonary Challenges 1157

Freatment Modality	Late Effect/Disease	References
Chemotherapy		
Anthracyclines (eg, doxorubicin, daunorubicin, idarubicin, and mitoxantrone)	LV systolic dysfunction/heart failure, pericardial disease, and arrhythmia	5,13,17,25–28
Alkylators (eg, cyclophosphamide, carmustine, lomustine, and ifosfamide)	Stroke, LV systolic dysfunction/heart failure, pericardial disease, and arrhythmias	6,15–17,19,27,35–3
Antimetabolites (eg, cytarabine and 5-Fluorouracil)	Pericardial disease, arrhythmias, ischemic heart disease, and heart failure	16,35
Platinums (eg, cisplatin)	Stroke, arrhythmias, vascular disease, and ischemic heart disease	6,16,35
Vinca alkaloids (eg, vincristine and vinblastine)	Ischemic heart disease	4,38
Radiotherapy		
Chest (heart)	lschemic heart disease, valvular disease, pericardial disease, arrhythmia, and heart failure	5,6,13,17,27
Head/neck	Stroke	6,15,19,37
New targeted agents		
BCR-ABL TKIs (eg, imatinib, dasatinib, and ponatinib)	LV systolic dysfunction/heart failure, arrhythmias, ischemic heart disease, stroke, and vascular disease	39
Immune checkpoint inhibitors (eg, nivolumab, ipilimumab, and pembrolizumab)	Myocarditis and heart failure	21,40
Proteasome inhibitors (eg, bortezomib)	Heart failure, ischemic heart disease, and arrythmias	20
VEGF inhibitors or TKIs with anti-VEGF activity (eg, bevacizumab and sorafenib)	Vascular disease, ischemic heart disease, stroke, and cardiomyopathy/heart failure	20,41

Patients who were younger during the exposure and, although not consistently, female, also seem to be at higher risk. 5,17,27

Despite being studied extensively, the exact mechanism of anthracycline toxicity has not been fully unraveled. Many preclinical studies have focused on redox cycling of anthracyclines and generation of reactive oxygen species (ROS), with cardiomyocytes particularly susceptible to ROS,³² whereas others have found mitochondrial iron accumulation to be involved.³³ Another important mediator of ACT is topoisomerase IIb (Top2b): cardiomyocyte-specific deletion of this gene, which is one of the forms of topoisomerase 2, the presumed cellular target of doxorubicin, protects mice from doxorubicin cardiotoxicity.³⁴ Several of genetic risk factors for ACT that have been found (discussed later) are in genes related to ROS and iron metabolism or that interact with Top2b.

Alkylators are another large group of drugs commonly used in childhood cancer or hematopoietic stem cell transplantation (HSCT), some of which have been associated

with different types of CVD. Most of these toxicities initially were reported in adults but can occur in children.^{16,35} In particular, cyclophosphamide at higher doses, such as in myeloablative HSCT conditioning, can cause acute myocarditis with subsequent LV systolic dysfunction and acute CHF, although most patients recover.^{16,35} Similarly, ifosfamide can cause CHF as well as arrhythmias. More recently, cyclophosphamide, but not ifosfamide, was found to be associated with CHF in long-term CCSs.¹⁷ Another study linked cyclophosphamide to pericardial disease, but not CHF.²⁷ Alkylators also were associated with a higher risk of stroke,^{6,19,36} although this might be limited to certain subgroups, such as patients with brain tumors.^{15,19,37}

Case reports in adults have noted pericarditis, arrhythmias, and CHF after high doses of the antimetabolite cytarabine.³⁵ While cytarabine frequently is used in children, it is unclear how often, if at all, cardiotoxicities occur and what the long-term outcomes are. Similarly, the antimetabolite 5-fluorouracil, although used only occasionally in children, has been linked to ischemic heart disease, arrhythmias, and heart failure, including in some pediatric case reports.¹⁶

Platinums, specifically cisplatin, have been found to cause arrhythmias, possibly through electrolyte disturbances.³⁵ In addition, vascular dysfunction, either through vasospasm or endothelial damage and platelet aggregation, can lead to myocardial infarction and stroke.^{6,16,35}

Vinca alkaloids, such as vincristine and vinblastine, seem to increase risk for ischemic heart disease in adults.³⁸ Results in CCSs are more conflicting; one study found an increased risk of cardiovascular death after vinca alkaloid exposure,⁴ whereas others failed to find such an association^{13,17} or found even lower risk of myocardial infarction.²⁷ Possibly, the increased CVD death could be due to the often concomitant exposure to alkylators.⁴

Radiotherapy

Radiation involving the heart has been known for decades to cause ischemic heart disease and pericardial and valvular disease, and radiotherapy also can increase the risk of anthracycline-induced heart failure.^{5,6,13,17,27} Arrhythmias also are common but might occur only after longer follow-up. These effects also are dose dependent, with patients treated with higher doses, in particular those greater than or equal to 35 Gy, at highest risk.^{5,6,27}

Radiation to head and neck both has been consistently associated with stroke in CCSs, including transient ischemic attacks, cerebral infarction, and intracranial hemorrhage.^{6,15,19,37} Again, this effect is dose-dependent, with patients receiving greater than or equal to 30 Gy to the brain at highest risk, in particular patients treated for brain tumors.^{6,19} The risk of stroke increases over time and can be as high as 20% in high risk patients by age 50.^{6,15,19} The toxic effect of radiotherapy is presumed to be through the cerebral vasculature, with radiation causing an inflammatory response in the vessel wall, leading to luminal narrowing and weakening of the wall that can over time result in occlusion or hemorrhage.¹⁴

New targeted agents

Better understanding of the biology and molecular pathways involved in cancers has led to the discovery and use of many new targeted agents, which have revolutionized the treatment of some cancers. Although these agents were developed against cancer-specific molecules or aberrant pathways, many have specific toxicities both on-target/off-tumor (target also expressed elsewhere) as well as off-target (drug not specific for the target), including the cardiovascular system.²⁰ Because some of these agents increasingly are used in children, the long-term impact of these toxicities in

Cardiovascular and Pulmonary Challenges 1159

CCSs needs to be considered, especially because these agents are given in addition to conventional treatments.²¹

BCR-ABL-directed tyrosine kinase inhibitors (TKIs), such as imatinib, but also the newer dasatinib and ponatinib, commonly are used in pediatric Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) and block the BCR-ABL fusion gene kinase. Newer TKIs, especially, have been associated with a variety of CVD toxicities, including LV dysfunction/cardiomyopathy, ischemic heart disease, stroke, and vascular disease.³⁹ Although they were developed primarily for targeting BCR-ABL, they are multikinase inhibitors that also affect kinases in the cardiovascular system, in particular vascular endothelial growth factor (VEGF) (discussed later), which might explain this toxicity.³⁹ Because some patients require long-term treatment with TKIs (eg, CML and Ph + ALL), these toxicities are becoming more important.

Immune checkpoint inhibitors restore antitumor immunity by blocking inhibitory signals or receptors on tumors or immune cells, such as PD-1, PD-L1 or CTLA-4.⁴⁰ Commonly used drugs in adults, such as nivolumab, ipilimumab, and pembrolizumab, are studied and used in children.²¹ Blocking the inhibitory pathways, however, can shift the balance toward autoimmunity, including myocarditis with associated heart failure, which carries a high fatality rate.⁴⁰

Proteasome inhibitors have been found to cause heart failure, ischemic heart disease, and arrythmias, although this risk might be lower for bortezomib, which is used for pediatric relapsed or refractory ALL.²⁰

VEGF inhibitors or TKIs with anti-VEGF activity can have various cardiovascular toxic effects similar to BCR-ABL-directed TKIs. VEGF inhibitors, such as bevacizumab, used in certain central nervous system tumors (eg, gliomas), inhibit tumor angiogenesis by directly blocking VEGF, whereas the anti-VEGF effect of TKIs, including FLT3 inhibitors, such as sorafenib, used in certain high-risk acute myelogenous leukemia patients, is off-target.⁴¹ Cardiovascular toxicity include thromboembolic events leading to ischemic heart disease, stroke, and cardiomyopathy with heart failure, which is mediated partly through an increased risk of hypertension.^{20,41} These toxicities are important in CCSs, especially for acute myelogenous leukemia patients, who often receive anthracyclines and FLT3 inhibitors.

Genetic risk factors

In addition to exposure to specific therapies, certain germline genetic variations also have been found to modify CVD risk, in particular for ACT. Studies that focused specifically on ACT in CCSs have found variants in genes related to anthracycline transport and metabolism (*SLC28A3*,^{42,43} *UGT1A6*,^{42,43} *CBR3*,^{44,45} *SLC22A7*,⁴⁶ *SLC22A17*,⁴⁶ and *ABCC5*⁴⁷), iron metabolism (*HFE*⁴⁸), oxidative stress (*CAT*,⁴⁹ *GSTP1*,⁵⁰ *NOS3*,⁴⁷ and *HAS3*⁵¹), hypertension (*PLCE1*⁵² and *ATP2B1*⁵²), cardiac physiology or structure (*HAS3*,⁵¹ *CELF4*,⁵³ *GPR35*,⁵⁴ and *TTN*⁵⁵), and DNA damage (*RARG*⁵⁶). Some variants have been replicated in multiple cohorts, whereas others have not, and the functional consequences of these variants have been explored only partly.⁵⁷

Diagnosis, Surveillance, Treatment, and Prevention

Echocardiography remains the mainstay for screening and diagnosis of cardiac disease in CCSs, in particular for LV dysfunction after anthracyclines and chest radiotherapy, measuring shortening or ejection fraction.⁵⁸ Echocardiography also can diagnose valvular abnormalities, diastolic dysfunction, and pericardial disease. When more sensitive parameters, such as global longitudinal strain, are used,

echocardiography can detect more subclinical systolic dysfunction than by measuring ejection fraction alone.⁵⁹ Cardiac magnetic resonance imaging is even more sensitive but also more costly and not readily available in every center.⁵⁸ Imaging to detect vascular or cerebrovascular disease are not used routinely to screen asymptomatic CCSs.

Currently, international harmonized guidelines provide recommendations for screening for cardiomyopathy in CCSs using echocardiography.⁵⁸ Further refinement of risk for CVD using clinical risk factors^{5,6} or incorporating genetic variants⁶⁰ might aid to decide which CCSs to screen and how often, thereby likely improving screening cost effectiveness.^{58,61,62}

Electrocardiography at baseline is recommended by most CCS long-term follow-up guidelines, ^{61,62} but its role to detect conduction abnormalities in asymptomatic CCSs is unclear.⁶³

Cardiac biomarkers, such as troponins or the N-terminal prohormone of brain natriuretic peptide, have been studied extensively in CCSs, but although elevations of these markers during treatment might predict long-term LV dysfunction, their role for screening asymptomatic survivors is limited due to their low sensitivity.^{58,64} These markers may be used to monitor or screen symptomatic patients similar to the general population.⁵⁸

Prevention

To prevent cardiovascular toxicities from occurring, treatment protocols have evolved over time, reducing, omitting, or replacing certain chemotherapeutic agents and radiotherapy without affecting cancer treatment outcome. For example, maximum cumulative doses for anthracyclines are recommended in many protocols, and radiotherapy has been successfully reduced in the treatment of Hodgkin disease.¹⁶ Risk prediction models might identify patients who will benefit most from these preventative measures.^{5,6,57,60} Newer radiation techniques, including intensity-modulated radiation therapy or proton therapy, might further reduce the harmful effects to cardiovascular structures.¹⁶ Cardioprotective agents, specifically dexrazoxane, have been studied extensively, and dexrazoxane seems to reduce ACT without affecting antitumor efficacy or increasing secondary malignancies.⁶⁵

Secondary prevention, aimed at preventing CVD after treatment exposures, relies in part on screening and early detection of subclinical disease to initiate pharmacologic treatment, as discussed previously for heart failure. In adult cancer survivors, the combination of angiotensin-converting enzyme (ACE) inhibitors and β -blockers was shown to help recover cardiac function after early detection of LV dysfunction, even in asymptomatic survivors.³⁰ Although the role of pre-emptive heart failure treatment in asymptomatic CCSs is less clear, it still is employed often.^{16,66} Other strategies focus on targeting modifiable risk factors, such as hypertension, dyslipidemia, diabetes mellitus, obesity, and adopting a healthy lifestyle (ie, regular exercise, healthy diet, and no smoking),^{16,24} which have been incorporated in survivor quidelines.^{61,62}

Treatment

Treatment of CVD in CCSs depends on the type of disease and usually is managed similar to the general population.¹⁶ Childhood Cancer Survivors patients with heart failure commonly are treated with ACE inhibition often in combination with β -blockers, although the evidence in children is scarce.^{16,67,68} Once symptoms occur, heart function can rapidly decline and become refractory to treatment necessitating mechanical support or heart transplant.¹⁶

PULMONARY DISEASE

Pulmonary disease is another important long-term complication in CCSs with high morbidity and mortality. It is due to a range of pulmonary conditions, such as fibrosis, emphysema, recurrent pneumonia, or chronic cough, that affects survivors throughout their life and increases in frequency with longer time elapsed from cancer treatment.^{1,69,70}

Risk Factors and Pathophysiology

Several important treatment modalities, such as bleomycin, busulfan, lomustine (CCNU) or carmustine (BCNU), radiation of the thorax, and surgery to the lung or chest wall, impart a risk of pulmonary damage. Patients after HSCT are at particular risk because their treatment often incorporates more than one treatment-related risk factor. Unlike in CVD, no studies have systematically investigated genetic risk factors for pulmonary toxicity.

Chemotherapy

For most categories of chemotherapeutic agents and their combinations, reports of chemotherapy-induced lung injuries have been published, although often only as case reports or case series. Consistent and robust evidence for pulmonary toxicity is available for bleomycin, busulfan, and nitrosoureas (BCNU and CCNU).^{71–73}

Bleomycin is used to treat Hodgkin lymphoma and germ cell tumors. The lung is vulnerable to this agent because it lacks the bleomycin-inactivating enzyme bleomycin hydrolase. This leads to free radical formation and oxidative damage to lung tissues. Subsequent inflammatory processes eventually cause alveolar damage, hypersensitivity reaction, pneumonitis, and pulmonary fibrosis (Table 2). Reported prevalence of bleomycin-induced pneumonitis (BIP) ranges from 0% to 46%. BIP usually develops during treatment, resulting in cough, dyspnea, and fever.⁷⁴ Data on longterm prognosis after BIP are inconsistent. One review concluded that radiographic changes and lung function abnormalities usually resolve completely.⁷⁴ However, 2 studies that assessed lung function by spirometry, body plethysmography, and measurement of diffusion capacity for carbon monoxide (DLCO) in children, 2 years and 4 years after exposure to bleomycin, found that 41% and 52% of children, respectively, had pathologic test results at these time points.^{75,76} The toxicity is dose dependent and more common with doses greater than 400 U/m², which seldom are used in pediatrics. Simultaneous or subsequent radiotherapy to the lung, exposure to elevated oxygen concentrations, renal dysfunction, smoking, and higher age at treatment may exacerbate bleomycin toxicity.72,74,77

Busulfan is an alkylating agent used mainly to condition children before autologous or allogeneic HSCT. The exact mechanism of lung injury is unknown, and the dose-response relationship is unclear. It seems, however, that cumulative doses less than 500 mg do not cause pulmonary injury in adults.^{72,73,78} As with bleomycin, concomitant irradiation may magnify the toxic effect of busulfan.⁷²

Nitrosoureas, including CCNU and BCNU, mainly are used to treat brain tumors and to condition patients for autologous HSCT. Nitrosoureas are risk factors for pneumonitis and pulmonary fibrosis (see **Table 2**). Pulmonary fibrosis usually develops slowly over years or decades with asymptomatic periods of various length.⁷⁹ In nitrosoureainduced pulmonary fibrosis, inflammatory reactions followed by depletion of type I pneumocytes and hyperplasia of type II pneumocytes lead to increased collagen deposition.⁸⁰ Higher cumulative doses are associated with increasing risk of lung injury. Patients exposed to thoracic irradiation may develop lung injury at lower doses of nitrosoureas than those not exposed.^{72,73,81} A case series followed 17 long-term

Table 2 List of treatments for childhood	cancer associated with pulmonary disease	
Treatment Modality	Late Effect/Disease	References
Chemotherapy		
Bleomycin	Acute respiratory distress syndrome Interstitial or hypersensitivity pneumonitis Bronchiolitis obliterans organizing pneumonia Pulmonary veno-occlusive disease Pulmonary fibrosis	72–76
Busulfan	Acute respiratory distress syndrome Alveolar proteinosis Pulmonary fibrosis	72,73,78
Nitrosoureas (carmustine, and lomustine)	Hypersensitivity pneumonitis Alveolitis Pulmonary veno-occlusive disease Pulmonary fibrosis	72,73,79,81,82
Radiotherapy to the chest	Bronchiolitis obliterans organizing pneumonia Interstitial pneumonitis Impaired chest wall growth Pulmonary fibrosis	71–73,83,84
Surgery		
(eg, pulmonary lobectomy, pulmonary wedge resection, pulmonary metastasectomy, and chest wall resection)	Restrictive lung function impairment Scoliosis Chest wall deformity	72,85
Stem cell transplantation		
Lung toxic agents used for conditioning	See Busulfan and Nitrosoureas	_
Transplant-specific noninfectious pulmonary complications	IPS BOS Bronchiolitis obliterans organizing pneumonia DAH	72,86,87

brain tumor survivors treated with high-dose BCNU and spinal irradiation (n = 12) for up to 25 years. Half (53%) of the survivors died of pulmonary fibrosis, whereas all 7 patients who were still alive after 25 years of follow-up showed radiologic and physiologic (ie, lung function) evidence of pulmonary fibrosis.^{79,82}

Radiotherapy

Direct irradiation of the lung, but also scattered radiation after radiotherapy to the chest wall, abdomen, or spine, increases the risk for pulmonary damage. Radiation can lead to DNA strand breaks and trigger lung injury by starting a cascade of inflammatory reactions, with capillary leaks and alveolar and interstitial exudate, which later organizes into collagen. Acute radiation pneumonitis usually develops within 6 weeks to 3 months after radiotherapy (see **Table 2**). The most frequent symptoms are dyspnea and cough. Although early stages of radiation pneumonitis can be self-limited and resolve completely, most patients develop progressive fibrosis.⁸⁰ Toxicity due to radiation depends on the irradiated lung volume; total dose; method of irradiation, such as dose fraction; and application of radiosensitizer. At least 10% of the lung volume has to be irradiated to produce significant toxicity. Radiation pneumonitis rarely

Cardiovascular and Pulmonary Challenges 1163

develops in cases of fractionated radiotherapy with a total dose less than 20 Gy, but is common if the cumulative dose exceeds 40 Gy to 60 Gy.^{71,73,83,84}

Surgery

Extensive pulmonary and chest wall surgery can alter pulmonary function.⁸⁵ Lobectomy or resection of multiple metastases leads to reduced lung volumes. Removal of ribs or part of the chest wall can cause restrictive ventilation impairment due to a reduction in expansibility of the chest wall.

Hematopoietic stem cell transplantation

Children treated with HSCT face transplant-specific pulmonary complications and late effects, in addition to those discussed previously. Approximately 37% of patients after HSCT develop pulmonary complications.⁸⁶ Pulmonary complications are divided in infectious and noninfectious, depending on the underlying cause. The noninfectious complications generally are transplant-specific, such as bronchiolitis obliterans syndrome (BOS), diffuse alveolar hemorrhage (DAH), and idiopathic pneumonia syndrome (IPS) (see Table 2). DAH and IPS typically present with an acute onset of respiratory failure within the first 30 days and 120 days after HSCT, respectively.⁸⁶ Both diseases have a high mortality, but no data on long-term outcomes exist.⁸⁶ BOS typically is diagnosed greater than 100 days after transplantation.^{86,87} The main symptoms of BOS are dry cough and dyspnea. BOS has a variable clinical course, but most patients have slowly progressive airflow obstruction. Stabilization or improvement of lung function is rare.⁸⁷

Diagnosis, Surveillance, Treatment and Prevention

Lung function tests

Lung function impairment in CCSs is assessed by pulmonary function tests. Pulmonary symptoms, such as chronic cough or dyspnea at exertion, are late signs of pulmonary dysfunction. One study found that only 24% of those with restrictive disease diagnosed by lung function tests reported symptoms using the Medical Research Council dyspnea questionnaire.⁸⁸

Lung function usually is assessed by spirometry, body plethysmography, and measurement of the diffusing capacity for carbon monoxide (DLCO), with restrictive, obstructive, mixed restrictive-obstructive patterns, and decreased diffusion capacity having been reported. Decreased diffusion capacity is the most frequent abnormality (35%–45%), followed by restrictive (13%–32%) and obstructive disease (1%– 4%).^{75,76,88–91} Few studies have assessed lung function longitudinally, so that knowledge on long-term prognosis is scarce. Repeated lung function tests in survivors after HSCT found 3 phases in lung function trajectories: (1) an initial decrease in lung function after completion of treatment, lasting for 3 months to 6 months; (2) a subsequent recovery until 1 year to 2 years after completion, usually not reaching baseline values; and (3) stable values or slow deterioration in the long-term follow-up.^{92–94}

Multiple breath washout tests (MBWs) might be more sensitive to identify early changes. They measure ventilation inhomogeneity in the lung, which is increased in case of central and peripheral airway obstruction. One study assessed pulmonary function in adults (n = 225) with BOS after HSCT with MBW and found the test highly sensitive for detecting abnormal lung function in their cohort (95% abnormal MBW test compared with 56% abnormal forced expiratory volume in the first second of expiration/forced vital capacity [FEV1/FVC]).⁹⁵ Whether this test will be valuable in the early detection of lung function impairment in CCSs still must be evaluated. Additional examinations, such as imaging or lung biopsy, are used in case of suspected pulmonary disease but not in regular follow-up care.

Surveillance

National and international follow-up guidelines concerning pulmonary late effects specify that the use of the chemotherapeutic agents (discussed previously), radio-therapy to the chest, and thoracic surgery are indications for pulmonary follow-up using lung function tests.^{61,62,96} The available evidence is scarce, however, and the effect of other chemotherapies unclear, so more dedicated research is needed.

Treatment and prevention

Treatment options for pulmonary diseases and functional impairment in CCSs depend on the underlying disease. In general, treatment options are limited but the field is evolving quickly. This article focuses on treatment options for noninfectious pulmonary diseases beyond the acute-phase. BOS can be treated with systemic steroids. but these can increase the risk of pulmonary infection.^{97,98} Inhaled bronchodilators do not improve pulmonary function in these patients.⁹⁸ One case series reported that patients with BOS who received inhaled fluticasone, azithromycin, and montelukast (FAM) could reduce their doses of systemic steroids compared with those not treated with FAM, thereby sparing them from the serious toxicities associated with long-term steroid use.98 The subsequent phase II study confirmed that the FAMregimen with reduced doses of systemic steroids was well tolerated and resulted in a reduction in pulmonary function decline in most patients.⁹⁹ Systemic steroid therapy improves radiation pneumonitis, but most experts agree that corticosteroid therapy is ineffective for the treatment of pulmonary fibrosis.^{71,73} A few newer drugs, such as the TKI nintedanib, are available for adults with idiopathic pulmonary fibrosis. Data for the use in children are lacking. Nintedanib slows lung function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.^{100,101}

Because treatment options are limited, prevention of pulmonary damage has high priority. Bleomycin no longer is a first-line therapy for lymphoma, although it remains a core component of germ cell tumor therapy, and radiotherapy has been reduced in many protocols, but avoidance of pulmonary toxic chemotherapy or radiation not always is possible. Therefore, any additional damage to the lung should be avoided throughout a survivor's life. Survivors must be counseled to not smoke and to avoid secondhand smoke exposure. Pneumococcal and influenza vaccinations should be advised to inform anesthetists about previous bleomycin treatment in cases of general anesthesia, because high fraction of inspired oxygen (>30%) concentration may further affect preexisting pulmonary damage.¹⁰² Also survivors who desire to scuba dive should have a pulmonary consultation prior to undertaking the activity.^{61,62,96}

SUMMARY

Cardiovascular disease and pulmonary disease after childhood cancer treatment impose great challenges for survivors. The cardiovascular system and lungs can be severely affected by cancer treatment in many ways, resulting in increased morbidity and mortality. Treatment options once disease becomes clinically manifest are focused on decreasing symptoms but do not cure cardiovascular or pulmonary disease. Therefore, prevention and regular screening according to established follow-up guidelines are crucial, even in the absence of symptoms, which generally occur rather late. Survivors should be encouraged to adopt a healthy lifestyle, and modifiable risk factors should be addressed. Close collaboration and early referral to experienced specialists (eg, cardiologist and pulmonologist) are essential for optimal diagnosis and management.

ACKNOWLEDGMENTS

This study was supported by the Swiss Cancer Research (grant no: 04157-02-2017) to C.E. Kuehni.

DISCLOSURE

Authors have nothing to disclose.

REFERENCES

- 1. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014;32(12):1218–27.
- Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27(14):2328–38.
- Fidler MM, Reulen RC, Henson K, et al. Population-based long-term cardiacspecific mortality among 34 489 five-year survivors of childhood cancer in great Britain. Circulation 2017;135(10):951–63.
- Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28(8):1308–15.
- 5. Chow EJ, Chen Y, Kremer LC, et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 2015;33(5):394–402.
- 6. Chow EJ, Chen Y, Hudson MM, et al. Prediction of ischemic heart disease and stroke in survivors of childhood cancer. J Clin Oncol 2018;36(1):44–52.
- Schindler M, Belle FN, Grotzer MA, et al. Childhood cancer survival in Switzerland (1976-2013): Time-trends and predictors. Int J Cancer 2017; 140(1):62–74.
- 8. Fidler MM, Reulen RC, Bright CJ, et al. Respiratory mortality of childhood, adolescent and young adult cancer survivors. Thorax 2018;73(10):959–68.
- Smith L, Glaser AW, Peckham D, et al. Respiratory morbidity in young people surviving cancer: Population-based study of hospital admissions, treatmentrelated risk factors and subsequent mortality. Int J Cancer 2019;145(1):20–8.
- Kirchhoff AC, Fluchel MN, Wright J, et al. Risk of hospitalization for survivors of childhood and adolescent cancer. Cancer Epidemiol Biomarkers Prev 2014; 23(7):1280–9.
- Brewster DH, Clark D, Hopkins L, et al. Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland: a population based, retrospective cohort study. Br J Cancer 2014; 110(5):1342–50.
- Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012;30(10):1050–7.
- 13. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012;30(13):1429–37.
- 14. Morris B, Partap S, Yeom K, et al. Cerebrovascular disease in childhood cancer survivors: a children's oncology group report. Neurology 2009;73(22):1906–13.
- van Dijk IW, van der Pal HJ, van Os RM, et al. Risk of symptomatic stroke after radiation therapy for childhood cancer: a long-term follow-up cohort analysis. Int J Radiat Oncol Biol Phys 2016;96(3):597–605.

- 16. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013;128(17):1927–95.
- Feijen E, Font-Gonzalez A, Van der Pal HJH, et al. Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER study. J Am Heart Assoc 2019;8(1):e009122.
- **18.** Haddy N, Diallo S, El-Fayech C, et al. Cardiac diseases following childhood cancer treatment: cohort study. Circulation 2016;133(1):31–8.
- 19. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006;24(33):5277–82.
- Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016;375(15):1457–67.
- 21. Chow EJ, Antal Z, Constine LS, et al. New agents, emerging late effects, and the development of precision survivorship. J Clin Oncol 2018;36(21):2231–40.
- 22. van Waas M, Neggers SJ, Pieters R, et al. Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol 2010; 21(5):1121–6.
- Meacham LR, Sklar CA, Li S, et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med 2009;169(15):1381–8.
- 24. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013; 31(29):3673–80.
- Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23(12):2629–36.
- 26. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac Function in 5-Year Survivors of Childhood Cancer: A Long-term Follow-up Study. Arch Intern Med 2010;170(14):1247–55.
- 27. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
- 28. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266(12):1672–7.
- 29. Lipshultz SE, Cochran TR, Franco VI, et al. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol 2013;10(12):697–710.
- **30.** Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131(22):1981–8.
- Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol 2019;5(6):864–71.
- 32. Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61(1):154–71.
- Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 2014;124(2):617–30.

Cardiovascular and Pulmonary Challenges 1167

- 34. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18(11):1639–42.
- **35.** Fulbright JM. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract 2011;2011:942090.
- **36.** Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke 2012;43(11):3035–40.
- Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23(27):6508–15.
- Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23(30):7685–96.
- Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015;33(35):4210–8.
- Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16(9):563–80.
- Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 2018;12(6):409–25.
- Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30(13): 1422–8.
- Visscher H, Ross CJ, Rassekh SR, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013;60(8):1375–81.
- 44. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracyclinerelated congestive heart failure after childhood cancer. Cancer 2008;112(12): 2789–95.
- **45.** Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the Children's Oncology Group. J Clin Oncol 2012;30(13):1415–21.
- **46.** Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics 2015;16(10):1065–76.
- **47.** Krajinovic M, Elbared J, Drouin S, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2016;16(6):530–5.
- **48.** Lipshultz SE, Lipsitz SR, Kutok JL, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013;119(19):3555–62.
- **49.** Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009;50(10):1693–8.
- **50.** Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 2012;118(7):1856–67.
- Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracyclinerelated cardiomyopathy: a report from the children's oncology group. J Clin Oncol 2014;32(7):647–53.

- 52. Hildebrandt MAT, Reyes M, Wu X, et al. Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors. Sci Rep 2017;7(1):9698.
- **53.** Wang X, Sun CL, Quinones-Lombrana A, et al. CELF4 variant and anthracyclinerelated cardiomyopathy: a children's oncology group genome-wide association study. J Clin Oncol 2016;34(8):863–70.
- 54. Ruiz-Pinto S, Pita G, Patino-Garcia A, et al. Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer. Pharmacogenet Genomics 2017;27(12):445–53.
- 55. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019;140(1):31–41.
- **56.** Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015;47(9):1079–84.
- 57. Tripaydonis A, Conyers R, Elliott DA. Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling. Clin Pharmacol Ther 2019;105(3):614–24.
- 58. Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):e123–36.
- **59.** Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015;65(23):2511–22.
- Aminkeng F, Ross CJD, Rassekh SR, et al. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol 2017;83(5):1143–5.
- Children's Oncology Group. Long term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, version 5.0. 2018. Available at: http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5. pdf. Accessed November 13, 2019.
- 62. Dutch Childhood Oncology Group. Guidelines for follow-up in survivors of childhood cancer 5 years after diagnosis. Available at: https://www.skion.nl/voorpatienten-en-ouders/late-effecten/533/richtlijn-follow-up-na-kinderkanker/. Accessed November 13, 2019.
- Pourier MS, Mavinkurve-Groothuis AM, Loonen J, et al. Is screening for abnormal ECG patterns justified in long-term follow-up of childhood cancer survivors treated with anthracyclines? Pediatr Blood Cancer 2017;64(3). https://doi. org/10.1002/pbc.26243.
- 64. Leerink JM, Verkleij SJ, Feijen EAM, et al. Biomarkers to diagnose ventricular dysfunction in childhood cancer survivors: a systematic review. Heart 2019; 105(3):210–6.
- 65. Reichardt P, Tabone MD, Mora J, et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol 2018;14(25):2663–76.
- Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22(5):820–8.

Cardiovascular and Pulmonary Challenges 1169

- Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant 2014;33(9):888–909.
- **68.** Cheuk DK, Sieswerda E, van Dalen EC, et al. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev 2016;(8):CD008011.
- **69.** Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002;95(11):2431–41.
- Kasteler R, Weiss A, Schindler M, et al. Long-term pulmonary disease among Swiss childhood cancer survivors. Pediatr Blood Cancer 2018;65(1). https:// doi.org/10.1002/pbc.26749.
- 71. Skinner R, Kaplan R, Nathan PC. Renal and pulmonary late effects of cancer therapy. Semin Oncol 2013;40(6):757–73.
- 72. Huang TT, Hudson MM, Stokes DC, et al. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest 2011;140(4):881–901.
- **73.** Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001;13(4):242–8.
- 74. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120(2):617-24.
- **75.** De A, Guryev I, LaRiviere A, et al. Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin. Pediatr Blood Cancer 2014;61(9): 1679–84.
- **76.** Zorzi AP, Yang CL, Dell S, et al. Bleomycin-associated Lung Toxicity in Childhood Cancer Survivors. J Pediatr Hematol Oncol 2015;37(8):e447–52.
- 77. Liles A, Blatt J, Morris D, et al. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. Cleve Clin J Med 2008;75(7):531–9.
- **78.** Jenney ME. Malignant disease and the lung. Paediatr Respir Rev 2000;1(3): 279–86.
- **79.** Lohani S, O'Driscoll BR, Woodcock AA. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood. Chest 2004;126(3):1007.
- Hinkle AS, Proukou C, Chen Y. Pulmonary Effects of Antineoplastic Therapy. In: Schwartz CL, Hobbie WL, Constine LS, et al, editors. Survivors of Childhood and Adolescent Cancer. A Multidisciplinary Approach. 2nd Edition. Berlin Heidelberg: Springer-Verlag; 2005.
- Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med 1980;303(4):183–8.
- O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323(6):378–82.
- Bolling T, Konemann S, Ernst I, et al. Late effects of thoracic irradiation in children. Strahlenther Onkol 2008;184(6):289–95.
- Venkatramani R, Kamath S, Wong K, et al. Correlation of clinical and dosimetric factors with adverse pulmonary outcomes in children after lung irradiation. Int J Radiat Oncol Biol Phys 2013;86(5):942–8.
- Denbo JW, Zhu L, Srivastava D, et al. Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. J Am Coll Surg 2014;219(2):265–71.

- Diab M, ZazaDitYafawi J, Soubani AO. Major pulmonary complications after hematopoietic stem cell transplant. Exp Clin Transplant 2016;14(3):259–70.
- Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther 2010;3(3):143–57.
- 88. Armenian SH, Landier W, Francisco L, et al. Long-term pulmonary function in survivors of childhood cancer. J Clin Oncol 2015;33(14):1592–600.
- Green DM, Zhu L, Wang M, et al. Pulmonary function after treatment for childhood cancer. A report from the St. Jude Lifetime Cohort Study (SJLIFE). Ann Am Thorac Soc 2016;13(9):1575–85.
- **90.** Mulder RL, Thonissen NM, van der Pal HJ, et al. Pulmonary function impairment measured by pulmonary function tests in long-term survivors of childhood cancer. Thorax 2011;66(12):1065–71.
- Record E, Williamson R, Wasilewski-Masker K, et al. Analysis of risk factors for abnormal pulmonary function in pediatric cancer survivors. Pediatr Blood Cancer 2016;63(7):1264–71.
- 92. Green DM, Merchant TE, Billuyps CA, et al. Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation. Int J Radiat Oncol Biol Phys 2015;93(1):47–53.
- **93.** Wieringa J, van Kralingen KW, Sont JK, et al. Pulmonary function impairment in children following hematopoietic stem cell transplantation. Pediatr Blood Cancer 2005;45(3):318–23.
- Inaba H, Yang J, Pan J, et al. Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Cancer 2010;116(8):2020–30.
- 95. Nyilas S, Baumeler L, Tamm M, et al. Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation. Chest 2018;154(1):157–68.
- Skinner R, Wallace WHB, Levitt GA. Practice Statement: Therapy Based Long Term Follow-up. United Kingdom Children's Cancer Study Group Late Effects Group. 2nd Edition; 2005.
- Uhlving HH, Buchvald F, Heilmann CJ, et al. Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant 2012; 47(8):1020–9.
- **98.** Norman BC, Jacobsohn DA, Williams KM, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011;46(10):1369–73.
- **99.** Williams KM, Cheng GS, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016;22(4):710–6.
- Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071–82.
- 101. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192(2): e3–19.
- 102. Mathes DD. Bleomycin and hyperoxia exposure in the operating room. Anesth Analg 1995;81(3):624–9.

7.2. Co-Author publication II

Physical activity and screen time in children who survived cancer – A report from the Swiss Childhood Cancer Survivor Study

Original article


Christina Schindera, Annette Weiss, Niels Hagenbuch, **Maria Otth**, Tamara Diesch, Nicolas von der Weid, Claudia E. Kuehni, Swiss Pediatric Oncology Group

(Published, Pediatr Blood Cancer, 2020 Feb;67(2):e28046. doi: 10.1002/pbc.28046. Epub 2019 Nov 20)

Own contribution to the project: Involved interpretation of results and several reviews of the manuscript

Received: 22 June 2019 Revised: 20 September 2019 Accepted: 30 September 2019


DOI: 10.1002/pbc.28046



Cancer

aspho

Wiley



Physical activity and screen time in children who survived cancer: A report from the Swiss Childhood Cancer Survivor Study

Christina Schindera^{1,2} D | Annette Weiss³ Niels Hagenbuch¹ | Maria Otth¹ Tamara Diesch² | Nicolas von der Weid² | Claudia E. Kuehni^{1,4} D | for the Swiss Pediatric Oncology Group (SPOG)

¹Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland ²Division of Pediatric Hematology and Oncology, University Children's Hospital Basel, Basel, Switzerland ³Department for Epidemiology and Preventive Medicine, Medicine Sociology, University of Regensburg, Regensburg, Germany

⁴Division of Pediatric Hematology and Oncology, University Children's Hospital Bern, Switzerland

Correspondence

Claudia E, Kuehni, Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland. Email: claudia.kuehni@ispm.unibe.ch

Swiss Pediatric Oncology Group (SPOG) Scientific Committee: Prof Dr med R. Ammann, Bern; Prof Dr med M. Ansari, Geneva; Prof Dr med M. Beck Popovic, Lausanne; Dr med P. Brazzola, Bellinzona; Dr med J. Greiner, St. Gallen; Prof Dr med M. Grotzer, Zurich: Dr med H. Hengartner, St Gallen: Prof Dr med C. Kuehni Bern: Prof Dr med F. Niggli, Zurich; Prof Dr med J. Rössler, Bern; Dr med F. Schilling, Lucerne; Dr med K. Scheinemann, Aarau; Prof Dr med N. von der Weid Basel

This study has been previously reported as a meeting abstract. Name of presentation: "Physical activity and screen time in children after childhood cancer: A report from the Swiss childhood cancer survivors study," 2019 National Symposium on Late Complications after Childhood Cancer (NASLCCC), Atlanta, GA, USA, June 21, 2019, abstract number P48.

Abstract

Background: Physical activity (PA) can reduce the risk of chronic adverse health conditions in childhood cancer survivors. We examined PA and sedentary screen time behavior in a nationwide study in Switzerland.

Procedures: The Swiss Childhood Cancer Survivor Study sent questionnaires to parents of all Swiss resident ≥5-year survivors diagnosed between 1995 and 2010. We assessed PA including compulsory school sport, recreational sport, commuting to school, and time spent with screen media in those aged 5-15 years, and compared results with international recommendations.

Results: We included 766 survivors with a median age at diagnosis of 2.8 (interguartile range 1.4-5.0) years and a median age at study of 12.5 (10.0-14.3) years. Median PA time was 7.3 (4.8-10.0) h/week and median screen time was 82 (45-120) min/day. Compulsory school sport hours and walking or cycling to school contributed significantly to total PA. Note that 55% of survivors met PA and 68% screen time recommendations. PA was lower for children living in regions of Switzerland speaking French or Italian compared to German, and for those who had a relapse or musculoskeletal/neurological conditions. Screen time was higher in males, children with lower parental education, and a migration background.

Conclusions: PA and sedentary screen watching were associated with social factors, and PA also with clinical risk factors. Structural preventions that afford active commuting to school and sufficient school sport are essential, as is counseling vulnerable survivor groups such as those with musculoskeletal and neurological problems, and those who have had a relapse.

KEYWORDS

childhood cancer survivors, chronic health conditions, exercise, late effects, Swiss Childhood Cancer Registry

Abbreviations: AAP, American Academy of Pediatrics; BMI, body mass index; CCS, childhood cancer survivor; ICCC-3, International Classification of Childhood Cancer, third edition; MICE, multivariate imputation by chained equations; PA, physical activity; TBI, total body irradiation; WHO, World Health Organization,

Pediatr Blood Cancer. 2020;67:e28046. https://doi.org/10.1002/pbc.28046

wileyonlinelibrary.com/journal/pbc

wiley

1 | INTRODUCTION

Adult childhood cancer survivors (CCS) have an elevated risk of poor health^{1,2} and early death³: almost 75% suffer from a chronic adverse health condition² and their cumulative mortality reaches nearly 10% 30 years after cancer diagnosis.³ Physical activity (PA) can reduce the risk of cancer and inhibit chronic health conditions such as diabetes and hypertension in the general population,⁴ while among adult CCS, PA has been associated with reduced risk factors for cardiovascular disease⁵ and cardiovascular disease itself,⁶ and with lower overall mortality.⁷ Yet while PA can mitigate many health hazards,^{6,7} only half of adult CCS meet PA recommendations.^{8–10}

An active lifestyle might be even more important for young children and teenage survivors, but only a few studies, usually at single centers or with low participant numbers, have been performed in this age group.^{11–14} Their results vary, with 31–74% meeting recommendations for PA^{11–15} and 28–46% meeting those for screen time behavior.^{11,14} Research also has neither distinguished between different types of physical activities nor described how school sports or an active daily commute to school might contribute to overall PA. Better knowledge of screen time behavior and PA and the factors influencing both could inform recommendations for structured prevention and identify risk groups that could profit from counseling or focused interventions.

We aimed to investigate PA and screen time behavior in Swiss CCS aged 5-15 years to assess how PA and screen time are compared with international recommendations, and to examine demographic, socioeconomic, lifestyle, and clinical factors associated with PA and screen time.

2 | METHODS

2.1 | The Swiss Childhood Cancer Survivor Study

The Swiss Childhood Cancer Survivor Study is a population-based, long-term cohort study of all children registered in the Swiss Childhood Cancer Registry who have been diagnosed since 1976, survived ≥ 5 years after initial diagnosis, and were alive at the time of the study.¹⁶ The registry includes all patients in Switzerland who were diagnosed at age <21 years with leukemia, lymphoma, central nervous system tumors, malignant solid tumors, or Langerhans cell histiocytosis.¹⁷ Recent estimates indicate that the registry includes 95% of those diagnosed below age 16 since 1995 in Switzerland.¹⁸ We included survivors aged 5-15 years at survey who had been diagnosed between 1995 and 2010. From 2010 to 2016, we traced addresses and sent a questionnaire to parents. We mailed the questionnaire a second time to those who did not respond, and further lack of response included an attempt to reach parents by phone. Among 1068 survivors whose parents were contacted, we received responses from parents of 766 (72%) (Table S1, Figure S1).

Ethics approval was granted by the Ethics Committee of the Canton of Bern, Switzerland, to the Swiss Childhood Cancer Registry and SCHINDERA ET AL.

the Swiss Childhood Cancer Survivor Study (KeK-BE: 166/2014), and the Swiss Childhood Cancer Survivor Study is registered at ClinicalTrials.gov (identifier: NCT03297034).

2.2 | Outcomes: PA and screen time

We examined PA as compulsory school sport, recreational sport, and commuting to school. We derived the time for compulsory school sport, 2.3 h/week (3 \times 45 min), from the Swiss school curriculum, which is regulated by "The federal Council of Switzerland" both for regular and special needs schools.¹⁹ Children going to special needs schools might do different exercises in their sports lessons than children attending regular schools, but have the same weekly time. Information on recreational sport activities and the commute to school were obtained via questionnaire. Parents were asked about types of recreational sports and how many hours per week CCS devoted to each (Figure S2, question 1), and we categorized answers into 16 different types of sports. We also asked how the child usually went to school (on foot or by bike/kickboard, by bus/streetcar, or by car) and the time required (<10 min, 10-20 min, or >20 min; Figure S2, guestions 2-3); the durations observed in the analysis were 5, 15, and 30 min. We considered only transit by foot or bike/kickboard as active. To obtain weekly estimates, we multiplied the times reported for one way to school by 15 to account for 5 school days per week, and an average of three trips to school per day because there are two to four afternoon school sessions per week at Swiss schools, with most children going home for lunch. Questions on PA (Figure S2, questions 1-3) were taken from established studies of unselected Swiss school children from the general population, which were derived from validated questionnaires.^{20–23}

We used the World Health Organization (WHO) recommendations to characterize whether a child had sufficient PA (\geq 7 h/week or \geq 60 min/day of any PA for children aged 5-17 years).²⁴ We created the binary outcome of those who had "sufficient" PA and those who did not.

Screen time was assessed by asking parents how much time their child spent on average each day interacting with screen media including television, computer games, game boys, PlayStation, or Nintendo (Figure S2, question 4). We used the 2013 American Academy of Pediatrics (AAP) recommendations for screen-based media exposure to determine acceptable screen time, less than 120 min/day,²⁵ as the current 2016 AAP recommendations only give qualitative, but no quantitative screen time recommendations.²⁶ We created the binary outcome of those who had media exposure that was "acceptable" screen time and those who did not.

2.3 | Clinical characteristics

We extracted the following clinical characteristics from the cancer registry: age at cancer diagnosis, cancer diagnosis, year of cancer diagnosis, treatment protocol, chemotherapy, radiotherapy, surgery, and hematopoietic stem cell transplantation. We classified cancer diagnoses in terms of 12 main groups and Langerhans cell histiocytosis

SCHINDERA ET AL.

 $\begin{array}{ll} \textbf{TABLE 1} & \text{Demographic, socioeconomic, lifestyle, and clinical} \\ characteristics of childhood cancer survivors included in the study, \\ N=766 \end{array}$

	N = 766	
	N	% ^a
Demographic and socioeconomic chara	cteristics	
Male sex	428	56
Age at study, years		
5-7	65	8
8-10	196	26
11-13	282	37
14-15	223	29
Language region		
German	535	70
French	197	26
Italian	34	4
Migration background ^b	212	28
Parental education ^c		
Primary education	61	8
Secondary education	462	60
Tertiary education	219	29
Lifestyle characteristics		
Child's BMI (kg/m ²) z-scores		
Underweight	124	16
Normal	456	59
Overweight	89	12
Obese	23	3
Clinical characteristics		
Age at diagnosis, years		
<1	149	20
1-4	423	55
5-10	194	25
Time since diagnosis, years		
5-10	607	79
11-15	159	21
Cancer diagnoses ^d	107	
Leukemia	286	37
Lymphoma	52	7
Central nervous system tumor	125	16
Other tumors	303	40
History of relapse	100	13
Any chemotherapy	624	82
Anthracyclines	388	51
Any radiation	122	16
Stem cell transplantation	55	7
Chronic health conditions	55	1
Cardiopulmonary	72	9
Endocrine	82	
	02	11

(Continues)

WILEY 3 of 10

TABLE 1 (Continued)

	N = 766	
	N	% ^a
Hearing and vision	210	27
Musculoskeletal/neurological	275	36
Number of chronic health conditions		
None	354	46
1	239	31
≥2	173	23

Abbreviations: BMI, body mass index; N, number.

^aColumn percentages are given.

^bMigration background: survivors who were not Swiss citizens at birth, not born in Switzerland, or had at least one parent who was not a Swiss citizen were defined as having a migration background.

^cParental education categorized by three categories: Primary education (compulsory schooling only [\leq 9 years]), secondary education (vocational training [10–13 years]), and tertiary education (higher vocational training, college, or university degree). If parents achieved different levels of education, we selected the parent with the highest education.

^d More detailed cancer diagnoses according to ICCC-3, International Classification of Childhood Cancer, third edition, in Table S4.

according to the International Classification of Childhood Cancer, third edition (ICCC-3).²⁷ We assessed whether children had been treated with anthracyclines. Thoracic radiation included the mantle field, mediastinum, thoracic spine, and total body irradiation (TBI); abdominal radiation included the abdomen, the pelvis, testis, and TBI; and radiation to the head/neck included the head, the neck, and TBI. We went back to medical records when registry treatment information was incomplete. The questionnaire collected information on chronic health conditions involving the cardiopulmonary and endocrine systems, problems affecting ears and eyes, and musculoskeletal/neurological conditions (Table S2). Chronic health conditions were asked using questions from the North American²⁸ and British²⁹ Childhood Cancer Survivor Studies with some adaptions because of the younger age in our Swiss Childhood Cancer Survivor Study.¹⁶ The questions on chronic health conditions included multiple choice questions and additional free text options where parents of survivors could specify and add chronic health conditions not asked in the questions. Free text answers were classified by a pediatric oncologist (CS) and discussed with other experienced pediatricians (CEK, MO) when in doubt.

2.4 Demographic, socioeconomic, and lifestyle characteristics

The questionnaire included demographic (sex, age at study, Swiss language region), socioeconomic (migration background, parental education), and lifestyle characteristics (child's body mass index [BMI], mother's BMI). We used self-reported weight and height and calculated children's BMI and corresponding z-scores.³⁰ BMI z-scores lower than -2 were classified as underweight, -2 to 1 as normal weight, >1 to 2 as overweight, and >2 as obese.³¹ Self-reported mother's BMI was calculated and categorized according to the National Institutes of Health.³²

4 of 10 WILEY

2.5 | Statistical analyses

We compared characteristics of participating survivors and those in families from whom we received no response using chi-square tests. We used multivariate imputation by chained equations (MICE) to complete missing values in the outcome variables and demographic, socioeconomic, lifestyle, and clinical variables. Missing values for hours of recreational sport were predicted by corresponding description of recreational sport. All other variables with missing values were imputed by using all other variables with the exception of the outcome variables (Supporting Information Text). In an alternative approach, we determined PA and screen times using the original data before MICE (Table S3). Using multivariable logistic regression, we explored the association between the two binary outcomes, sufficient PA (meeting the WHO recommendations) and acceptable screen time (according to AAP recommendations), and demographic, socioeconomic, lifestyle, and clinical characteristics using an a priori selection of clinically important variables. We also investigated the correlation between PA and screen time using the pooled Spearman correlation coefficient. We used STATA software (Version 15.1, Stata Corporation, Austin, TX) and R (Version 3.5.2; R Foundation for Statistical Computing, Vienna, Austria).33

3 | RESULTS

3.1 | Study population

The median age at diagnosis of the study population of 766 children (428 were male) was 2.8 years (interquartile range, 1.4-5.1), median age at survey was 12.5 years (10.1-14.3), and median time since diagnosis was 9.0 years (7.5-10.8) (Table 1). The two most frequent diagnoses were leukemia (37%) and central nervous system tumor (16%), and 51% received anthracyclines and 16% any radiation. Overall, 54% of children reported one or more adverse chronic health condition. At survey, the median BMI z-score in children was 0.08 (-0.7 to 0.9), and 59% of survivors were of normal weight. Full demographic, socioeconomic, lifestyle, and clinical characteristics of CCS are given in Table 1 and Table S4. Participants were compared with surviving nonparticipants for the following characteristics obtained from the Swiss Childhood Cancer Registry: sex, age at study, language regions, migration backgound, age at diagnosis, time since diagnosis, cancer diagnosis, history of relapse, time era of treatment, and chemotherapy being part of cancer treatment (Table S1). Characteristics on lifestyle and chronic conditions were unavailable for nonparticipants as this information was collected from the questionnaire.

3.2 | Physical activity

Over one-half of CCS (55%) had sufficient PA according to the WHO recommendations and the median time devoted to PA was 7.3 h/week, with recreational sport contributing 3.0 h/week (Table 2, Figures S3 and S4). The most common recreational sports were soccer (13%),

SCHINDERA ET AL.

gymnastics (12%), swimming (11%), cycling/driving a scooter (10%), and free outdoor/indoor play (10%). For male survivors, soccer (21%), scooter (11%), and free indoor/outdoor play (10%) were most relevant, and for female survivors, gymnastics (17%), swimming (13%), and dancing (12%) were most relevant (Figure 1). We found no important difference using the alternative analysis approach that assessed PA time and meeting the WHO recommendations using the original data before MICE (Table S3).

3.3 | Screen time

Median screen time was 82 min/day, and 68% of children had acceptable screen time in accordance with AAP recommendations (Table 2, Figure S3). We found no important difference in the alternative analysis approach that assessed screen time and meeting AAP recommendations using the original data before MICE (Table S3).

3.4 | Predictors for PA and screen time

PA was lower for children who lived in the French and Italian language regions than it was in the German-speaking region of Switzerland. It was also lower for those who had a relapse or suffered from musculoskeletal/neurological conditions (Table 3, Figure 2). We observed no association between PA and sex, age at study, BMI of survivors and mothers, cancer diagnoses, cardiopulmonary conditions, and treatment exposures. Screen time was higher in male survivors, children with lower parental education, or migration background (Table 4, Figure 2), but not associated with sex, age at study, endocrine and musculoskeletal/neurological problems, and all other clinical characteristics.

3.5 | Correlation between low PA and high screen times

We found no correlation between PA and screen time in survivors (pooled Spearman correlation coefficient -0.05), and no correlation between time spent for recreational sports and an active way to school (pooled Spearman correlation coefficient 0.16) (Figure S5).

4 DISCUSSION

This comprehensive survey of PA and screen time in children and adolescents who have survived cancer found that half of young survivors met the recommendation for PA and two-thirds did not exceed the maximum recommended for screen time. Having an active way to get to school and compulsory school sport greatly contributed to overall hours of PA.

Our results for PA are superior compared to those of a cohort study that included 1300 Swiss children and adolescents between 6 and 16 years of age, among whom only 39% of children aged 12-13 years met or exceeded PA recommendations assessed by accelerometer.³⁴ Young survivors in our study preferred recreational sports including soccer

SCHINDERA ET AL.

WILEY 5 of 10

TABLE 2 Compulsory school sport, recreational sport, active way to school, total physical activity, screen time, and adherence to WHO/AAP recommendations in childhood cancer survivors, N = 766, 56% males, median age 12.5 years

	N = 766				
	Median ^a , IQR	Mean ^b , SD	10 th -90 th percentile	Range	Adherence ^c to WHO/AAP
Compulsory school sport (h/week) ^d	2.3, NA	2.3, NA	NA	NA	
Recreational sport (h/week) ^e	3.0, 1.0-5.0	3.7, 3.9	0-8.0	0-32	
Active way to school (h/week) ^f	1.3, 0-3.8	2.0, 1.9	0-3.8	0-7.5	
Total physical activity (h/week) ^g	7.3, 4.8-10.0	8.0, 4.5	3.3-13.5	2.3-35.5	55%
Screen time (min/day) ^h	82, 45-120	91,66	15-180	0-480	68%

Abbreviations: AAP, American Academy of Pediatrics, (recommending <120 min screen time per day); IQR, interquartile range; N, number; NA, not applicable; SD, standard deviation; WHO, World Health Organization (recommending \geq 7 h of physical activity per week).

^aPooled median over the complete imputed dataset.

^bPooled mean over the complete imputed dataset.

^cPercent of adherence refers to the pooled medians.

^dCompulsory school sport defined as 3×0.75 h/week = 2.3 h/week.

^eRecreational sport as asked in the questionnaire (question 1, Figure S2): Which types of sport does your child perform?

^fActive way to school by foot or bike/kickboard as asked in the questionnaire (questions 2 and 3, Figure S2): How does your child usually go to the kindergarten or to school? How long is your child's way to the kindergarten or school?

^gTotal physical activity consisting of compulsory school sport, recreational sport, and an active way to school. Please indicate, how often your child performs different types of sports (h/week).

^hScreen time as asked in the questionnaire (question 4, Figure S2): How much time does your child spend on average with the following activities per day? Watching television, computer games, game boy, PlayStation, Nintendo.




FIGURE 1 Frequencies of the 16 different recreational sports in childhood cancer survivors (N = 766, 56% males, median age 12.5 years), stratified by sex; there can be multiple (1-5) different recreational sports per child

for males, and gymnastics, swimming, and dancing for females, and these preferences are similar to those of other school children.³⁵ A study of screen time in healthy adolescent school children in Switzerland found higher median screen times of 122 min/day (compared to 82 min/day in our population), although screen time was assessed differently and focused on internet use.³⁶

Studies of PA and screen time in children after cancer are few and report variable results. A 2012 Australian study assessed 40 children in two centers after hematopoietic stem cell transplantation at a mean age of 12.5 years by questionnaire; 48% of the children met the PA recommendation and 28% that for screen time.¹¹ Another single-center Australian study that used a 3-day diary assessed 74 young survivors with a mean age of 15.0 years between 2012 and 2014 and reported that 74% adhered to PA and 46% to screen time recommendations.¹⁴ Gilliam and colleagues performed phone interviews between 2010 and 2011 in 105 North American survivors aged 11.1 years who reported

^{6 of 10} WILEY

TABLE 3 Factors associated with sufficient physical activity (WHO recommendation) in childhood cancer survivors, N = 766, 56% males, median age at study 12.5 years

	Sufficient physical activity			
	% ^a	Odds ratio ^b	95% CI	P- value ^c
Demographic characteristics				
Sex				
Female	50	1.0		
Male	60	1.3	0.9-1.8	.113
Age at study, years				
5-7	48	1.4	0.4-4.4	
8-10	55	1.5	0.7-3.3	
11-13	60	1.6	1.0-2.6	.306
14-15	51	1.0		
Language region				
German	59	1.0		
French/Italian	48	0.6	0.4-0.9	.005
Socioeconomic characteristics				
Migration background				
No	57	1.0		
Yes	51	0.9	0.6-1.3	.473
Parental education				
Tertiary education	60	1.0		
Secondary education	54	0.8	0.6-1.1	
Primary education	48	0.6	0.3-1.1	.218
Lifestyle characteristics				
Child's BMI (kg/m ²) z-scores				
Normal weight	43	1.0		
Underweight	50	0.8	0.5-1.2	
Overweight/obesity	45	1.0	0.7-1.7	.409
Mother's BMI (kg/m²) (continuous)	NA	1.0	0.9-1.0	.381
Clinical characteristics				
Cancer diagnoses				
Leukemia	59	1.0		
Lymphoma	60	1.1	0.6-2.1	
CNS tumor	46	0.7	0.4-1.3	
Other tumor	55	0.9	0.6-1.4	.588
Relapse				
No	58	1.0		
Yes	40	0.5	0.4-1.0	.030
Cardiopulmonary conditions				
No	55	1.0		
Yes	56	1.1	0.7-1.9	.642
Endocrine conditions				
No	57	1.0		
Yes	42	0.6	0.4-1.1	.112
				Continues

(Continues)

SCHINDERA ET AL.

TABLE 3 (Continued)

	Sufficient physical activity			
	% ^a	Odds ratio ^b	95% CI	P- value ^c
Hearing/vision conditions				
No	56	1.0		
Yes	54	1.3	0.9-1.9	.195
Musculoskeletal/neurological	conditions			
No	59	1.0		
Yes	49	0.7	0.5-0.9	.017
Anthracyclines				
No	53	1.0		
Yes	57	0.9	0.6-1.3	.506
Radiotherapy				
No	55	1.0		
Yes	59	1.2	0.8-1.9	.410
Stem cell transplantation				
No	55	1.0		
Yes	55	1.2	0.5-1.5	.543

Abbreviations: BMI, body mass index; CI, confidence interval; CNS, central nervous system; N, number; NA, not applicable; WHO, World Health Organization.

^aColumn percentages are given.

^bPooled odds ratios from multivariable logistic regression comparing those with high physical activity to those with low physical activity, adjusted for demographic, socioeconomic, lifestyle, and clinical characteristics. ^cP-value from likelihood ratio tests.

a mean PA time of 6.7 h/week, which is lower than the mean 8.0 h we observed,¹² but times since diagnosis differed between the two cohorts (9.0 years in our study versus 4.6 years in the North American study). Another study from two North American centers reported a mean PA time of 47 min/day for 319 survivors aged 14.6 years, which corresponds to 5.5 h/week and again is lower than in our cohort.¹⁵ But that study used questionnaires that focused on past-year leisure-time PA, whereas our questionnaire also included the way to school and school sport. This could explain the difference.

Important predictors for higher PA in our study were living in the German-speaking region compared to the French and Italian linguistic regions of Switzerland. This was also shown in studies in healthy Swiss school children.³⁴ Also, Swiss school children from the Frenchcompared to the German-speaking regions were less likely to play outside and to actively commute to school^{37,38} and PA behavior was not associated with sociodemographic and neighborhood factors.39 This indicates that the language spoken is a marker of underlying cultural factors that influence PA behavior. In adults, prevalence of physical inactivity, smoking, alcohol consumption, and unhealthy diet was higher in the French- compared to the German-speaking part of Switzerland, highlighting possible cultural differences within Switzerland.⁴⁰ Other important predictors for PA in young survivors in other studies are social support from family and peers.12 Additional predictors reported for adolescent and adult survivors include female sex, 8,9 low parental 8 or survivor education, 9,13,41

A) Sufficient physical activity

SCHINDERA ET AL.






FIGURE 2 Factors associated with (A) sufficient physical activity, and (B) acceptable screen time in childhood cancer survivors (N = 766, 56% males, median age 12.5 years). Pooled odds ratios from multivariable logistic regression adjusted for demographic, socioeconomic, lifestyle, and clinical characteristics. CI, confidence interval; Musculo/neuro, musculoskeletal/neurological

cranial radiation,^{8,9,41} overweight and obesity,^{9,41} physical limitations,^{8,41} and a diagnosis of central nervous system tumors and sarcomas.^{41,42} We also found that musculoskeletal/neurological problems are a predictor for PA and we also saw a trend for parental education, central nervous system tumors, and endocrine conditions.

Among our study's limitations is the reliance of the outcome variables PA and screen time on parental reporting. Parents might have overestimated PA and underestimated screen time because of both social desirability and recall biases. A second problem involves the questionnaire's having inquired about structured physical activities even though young children in particular are active mainly in an unstructured way with free inside and outside play.³⁴ This differential misclassification bias could have led to underestimation of activity in younger survivors. However, parents did mention free outdoor and indoor play in 10% of boys and 9% of girls (Figure 1). Accelerometers and pedometers may overcome this problem^{34,43}; although worn only for study purposes and short periods, their data might not be representative of daily life. A third limitation is that we assumed that all children participated in compulsory school sport according to the Swiss curriculum,19 which might have overestimated PA in this special population. However, we also asked parents whether and-if yeswhy their child is unable to perform sports. None of the survivor's parents affirmed this question. Some parents stated that their child goes to a special needs school. Also special needs schools in Switzerland are obliged to involve students to 3×45 min of compulsory school sport per week according to federal law.¹⁹ The exercises they do in these lessons may, however, differ somewhat from those done in regular schools. Forth, PA in Swiss school children differs between winter and summer.³⁴ but we did not account for the season when parents filled out the questionnaire. The questionnaire design did not allow to differentiate the different activity intensities light, moderate, and vigorous PA. Questions asked in the Swiss Childhood Cancer Survivor Study were based on the North American and British Childhood Cancer Survivors Studies^{28,29} to enable comparison, but the questionnaire has not formally been validated. Our screen time questions assessed traditional screen activities such as watching television and computer games, and did not account for the use of social media, mobile phones, iPads, and the use of multiple devices at the same time, such as mobile phone and television; the average screen time we observed might be an underestimate. Further, we did not differentiate between screen time for educational purposes and leisure screen time. Finally, our study had no control group because too few siblings met our inclusion criteria.

B) Acceptable screen time

This study is the first nationwide, population-based study of PA and screen time in children who survived cancer. Among its strengths is its relatively high response rate, 72%, which makes us confident that the results are representative for Swiss CCS. Also, being nested in the Swiss Childhood Cancer Registry provided us with important and comprehensive data on demographic, socioeconomic, lifestyle, and clinical characteristics.

Our results indicate that structural support via compulsory school sport and an active daily commute to school are important contributors to PA. Public health policy should at least preserve if not increase support for both compulsory and voluntary school sport. Further research should inquire into why PA is lower in the parts of Switzerland speaking French and Italian than in the German-speaking part, and how PA levels might be increased in all three. Also, it goes without saying that family and community support for actively commuting to school should be maintained or increased.

For individual prevention, clinicians should counsel young survivors and their families to pursue active lives. In a German study, only 25% of 83 young survivors with a median age of 14 years and 3.8 years after cancer diagnosis participated in school sport, and medical advisories against sports participation were frequent.⁴⁴ Parents also might overprotect their children during and after completion of cancer therapy. PA not only is safe both during and after cancer therapy, it may positively influence evolving chronic health conditions. Pediatric oncologists therefore can and should assure families that PA is of particular importance to CCS and encourage participation in compulsory and

8 of 10 WILEY

TABLE 4 Factors associated with acceptable screen time (AAP recommendation) in childhood cancer survivors, N = 766, 56% males, median age at study 12.5 years

	Acceptable screen time			
	% ^a	Odds ratio ^b	95% CI	P- value ^c
Demographic characteristics				
Sex				
Female	72	1.0		
Male	64	0.7	0.4-0.9	.007
Age at study, years				
5-7	88	4.5	1.1-18.0	
8-10	78	2.9	1.2-6.9	
11-13	68	2.0	1.1-3.4	.074
14-15	52	1.0		
Language region				
German	68	1.0		
French/Italian	65	0.8	0.6-1.2	.354
Socioeconomic characteristics				
Migration background				
No	71	1.0		
Yes	59	0.6	0.4-0.9	.018
Parental education				
Tertiary education	77	1.0		
Secondary education	65	0.5	0.3-0.8	
Primary education	50	0.3	0.2-0.6	.004
Lifestyle characteristics				
Child's BMI (kg/m ²) z-scores				
Normal weight	66	1.0		
Underweight	74	1.2	0.7-2.1	
Overweight/obesity	64	0.8	0.6-1.6	.803
Mother's BMI (kg/m ²) (continuous)	NA	1.0	0.9-1.0	.247
Clinical characteristics				
Cancer diagnoses				
Leukemia	61	1.0		
Lymphoma	73	1.8	0.8-3.8	
CNS tumor	71	2.2	1.1-4.7	
Other tumor	71	1.3	0.8-2.1	.111
Relapse	/ =	110	010 212	
No	67	1.0		
Yes	67	1.0	0.6-1.8	.975
Cardiopulmonary conditions	07	1.0	0.0 1.0	.775
No	67	1.0		
Yes	68	1.0	0.6-1.9	.805
res Endocrine conditions	00	1.1	0.0-1.9	.005
	40	10		
No	68	1.0	0444	2/2
Yes	59	0.8	0.4-1.4	.360 Continues

(Continues)

SCHINDERA ET AL.

TABLE 4 (Continued)

	Acceptable screen time			
	% ^a	Odds ratio ^b	95% CI	P- value ^c
Hearing/vision conditions				
No	66	1.0		
Yes	70	1.0	0.7-1.6	.887
Musculoskeletal/neurological	conditions			
No	67	1.0		
Yes	69	1.0	0.7-1.5	.936
Anthracyclines				
No	68	1.0		
Yes	67	1.2	0.7-1.9	.492
Radiotherapy				
No	68	1.0		
Yes	66	1.1	0.7-1.9	.654
Stem cell transplantation				
No	68	1.0		
Yes	59	0.7	0.3-1.4	.300

Abbreviations: AAP, American Academy of Pediatrics; BMI, body mass index; CI, confidence interval; CNS, central nervous system; N, number; NA, not applicable.

^aColumn percentages are given.

^bPooled odds ratios from multivariable logistic regression comparing those with low screen time to those with high screen time, adjusted for demographic, socioeconomic, lifestyle, and clinical characteristics. ^cP-value from likelihood ratio tests.

voluntary school sports, and keep medical restrictions on activity to a minimum. Further research should include interventions that include social support as an important contributor to children's PA.¹²

In summary, we found that half of young cancer survivors are not active enough and one-third devote too much time to sedentary screen viewing. Compulsory school sport and an active commute to school are important components of an active lifestyle. Therefore, we need both individual-based prevention, such as better counseling of survivors and families, and structural prevention addressing all children in Switzerland, such as promotion of active commuting to school and extended school sport lessons.

ACKNOWLEDGMENTS

We thank all childhood cancer survivors and families for participating in our survey. We thank the study team of the SCCSS (Dr Fabiën Belle, Carole Dupont, Dr Rahel Kasteler, Rahel Kuonen, Nadine Lötscher, Jana Remlinger, Dr Grit Sommer, and Dr Nicolas Waespe) the data managers of the SPOG (Dr Claudia Althaus, Nadine Assbichler, Pamela Balestra, Heike Baumeler, Nadine Beusch, Sarah Blanc, Dr Pierluigi Brazzola, Susann Drerup, Janine Garibay, Franziska Hochreutener, Monika Imbach, Friedgard Julmy, Eléna Lemmel, Rodolfo Lo Piccolo, Heike Markiewicz, Dr Veneranda Mattielo, Annette Reinberg, Dr Renate Siegenthaler, Astrid Schiltknecht, Beate Schwenke, and Verena Stahel), and the team of the SCCR (Meltem

SCHINDERA ET AL.

Altun, Erika Brantschen, Katharina Flandera, Elisabeth Kiraly, Dr Verena Pfeiffer, Dr Shelagh Redmond, Julia Ruppel, Ursina Roder). We thank Dr Christopher Ritter for editorial assistance.

This study was supported by the Swiss Cancer League (grant numbers: KLS-3886-02-2016, KFS-4157-02-2017). The work of the Swiss Childhood Cancer Registry is supported by the Swiss Pediatric Oncology Group (www.spog.ch), Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und –direktoren (www.gdk-cds.ch), Swiss Cancer Research (www.krebsforschung.ch), Kinderkrebshilfe Schweiz (www.kinderkrebshilfe.ch), the Federal Office of Public Health (FOPH), and the National Institute of Cancer Epidemiology and Registration (www.nicer.org).

CONFLICT OF INTEREST

The commercial funders of the Swiss Childhood Cancer Registry support the daily running of the registry and have not had and will not have any role in the design, conduct, interpretation, or publication of the Swiss Childhood Cancer Registry itself as well as the related research projects.

DATA AVAILABILITY STATEMENT

The Swiss Childhood Cancer Registry and Swiss Childhood Cancer Survivor Study are a collaborative project of the Swiss Pediatric Oncology Group (SPOG) and the Institute of Social and Preventive Medicine, University of Bern, Switzerland. Our homepage displays detailed information in methods, results, and publications (www.childhoodcancerregistry.ch). Researchers interested in collaborative work can contact the corresponding author (Claudia E. Kuehni; claudia.kuehni@ispm.unibe.ch) to discuss planned projects or analyses of existing data. The final decision will be made upon presentation of the project to the Scientific Council of the Swiss Pediatric Oncology Group.¹⁶

ORCID

Christina Schindera (b) https://orcid.org/0000-0002-4511-287X Annette Weiss (b) https://orcid.org/0000-0001-8295-3574 Maria Otth (b) https://orcid.org/0000-0002-2839-502X Claudia E. Kuehni (b) https://orcid.org/0000-0001-8957-2002

REFERENCES

- Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371-2381.
- Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572-1582.
- Schindler M, Spycher BD, Ammann RA, et al. Cause-specific long-term mortality in survivors of childhood cancer in Switzerland: a populationbased study. Int J Cancer. 2016;139(2):322-333.
- Kushi LH, Doyle C, McCullough M, et al. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62(1):30-67.

 Howell CR, Wilson CL, Ehrhardt MJ, et al. Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort study. *Cancer.* 2018;124(5):1036-1043.

WILEY

9 of 10

- Jones LW, Liu Q, Armstrong GT, et al. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. J Clin Oncol. 2014;32(32):3643-3650.
- Scott JM, Li N, Liu Q, et al. Association of exercise with mortality in adult survivors of childhood cancer. JAMA Oncol. 2018;4(10):1352-1358.
- Devine KA, Mertens AC, Whitton JA, et al. Factors associated with physical activity among adolescent and young adult survivors of early childhood cancer: a report from the childhood cancer survivor study (CCSS). *Psychooncology*. 2018;27(2):613-619.
- Florin TA, Fryer GE, Miyoshi T, et al. Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev.* 2007;16(7):1356-1363.
- Rueegg CS, von der Weid NX, Rebholz CE, et al. Daily physical activities and sports in adult survivors of childhood cancer and healthy controls: a population-based questionnaire survey. *PLoS One*. 2012;7(4):e34930.
- Bogg TF, Shaw PJ, Cohn RJ, et al. Physical activity and screen-time of childhood haematopoietic stem cell transplant survivors. *Acta Paediatr*. 2015;104(10):e455-e459.
- Gilliam MB, Madan-Swain A, Whelan K, Tucker DC, Demark-Wahnefried W, Schwebel DC. Social, demographic, and medical influences on physical activity in child and adolescent cancer survivors. J Pediatr Psychol. 2012;37(2):198-208.
- Mizrahi D, Wakefield CE, Simar D, et al. Do childhood cancer survivors achieve recommended physical activity levels? A report from the Anzchog Survivorship Study. Asia-Pacific J Clin Oncol. 2017.
- Murphy-Alford AJ, White M, Lockwood L, Hallahan A, Davies PSW. Body composition, dietary intake and physical activity of young survivors of childhood cancer. *Clin Nutr.* 2019;38(2):842-847.
- Slater ME, Ross JA, Kelly AS, et al. Physical activity and cardiovascular risk factors in childhood cancer survivors. *Pediatr Blood Cancer*. 2015;62(2):305-310.
- Kuehni CE, Rueegg CS, Michel G, et al. Cohort profile: the Swiss childhood cancer survivor study. Int J Epidemiol. 2012;41(6):1553-1564.
- Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001–2005. *Swiss Medical Weekly*. 2007;137(35-36):502-509.
- Schindler M, Mitter V, Bergstraesser E, Gumy-Pause F, Michel G, Kuehni CE. Death certificate notifications in the Swiss Childhood Cancer Registry: assessing completeness and registration procedures. Swiss Medical Weekly. 2015;145:w14225.
- The Federal Council of Switzerland. Federal Act on the Promotion of Sport and Exercise, Chapter 3 "Education and Research", Section 1 "Sport in Schools", Article 12.4. Status as of 1 January 2019; https://www.admin.ch/opc/en/classified-compilation/20091600/index. html. Accessed September 16, 2019.
- Niederer I, Kriemler S, Zahner L, et al. Influence of a lifestyle intervention in preschool children on physiological and psychological parameters (Ballabeina): study design of a cluster randomized controlled trial. BMC Public Health. 2009;9:94.
- Zahner L, Puder JJ, Roth R, et al. A school-based physical activity program to improve health and fitness in children aged 6–13 years ("Kinder-Sportstudie KISS"): study design of a randomized controlled trial [ISRCTN15360785]. BMC Public Health. 2006;6:147.
- Ainsworth BE, Jacobs DR, Jr, Leon AS. Validity and reliability of selfreported physical activity status: the Lipid Research Clinics questionnaire. *Med Sci Sports Exerc.* 1993;25(1):92-98.

10 of 10 WILEY

- Michaud PA, Narring F, Cauderay M, Cavadini C. Sports activity, physical activity and fitness of 9- to 19-year-old teenagers in the canton of Vaud (Switzerland). Schweiz Med Wochenschr. 1999;129(18):691-699.
- 24. World Health Organization. Global Recommendations on physical activity for health. 2011.
- Council on Communications and Media. Children, adolescents, and the media. *Pediatrics*. 2013;132(5):958-961.
- Council on Communications and Media. Media use in school-aged children and adolescents. *Pediatrics*. 2016;138(5). https://doi.org/ 10.1542/peds.2016-2592
- Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. *Cancer*. 2005;103(7):1457-1467.
- Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multiinstitutional collaborative project. *Med Pediatr Oncol.* 2002;38(4):229-239.
- Hawkins MM, Lancashire ER, Winter DL, et al. The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. *Pediatr Blood Cancer*. 2008;50(5):1018-1025.
- Braegger C, Jenni O, Konrad D, Molinari L. New growth curves for Switzerland. Paediatrica. 2011;22(1):9-11.
- de Onis M, Lobstein T. Defining obesity risk status in the general childhood population: which cut-offs should we use. *Int J Pediatr Obes*. 2010;5(6):458-460.
- National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report. Bethesda, MD: National Heart, Lung, and Blood Institute; 1998.
- R Core Team. R foundation for statistical computing, Version 3.5.2 [computer program]. Vienna, Austria. 2014.
- Bringolf-Isler B. Schlussbericht zur SOPHYA-Studie. Basel: Swiss Tropical and Public Health Institute; 2016.
- Lamprecht M, Sport Switzerland 2014. Report on children and adolescents. Basel: Swiss Federal Institute of Sports and Federal Statistical Office; 2015.
- Berchtold A, Akre C, Barrense-Dias Y, Zimmermann G, Suris JC. Daily internet time: towards an evidence-based recommendation. *Eur J Public Health*. 2018;28(4):647-651.
- 37. Bringolf-Isler B, Grize L, Mader U, Ruch N, Sennhauser FH, Braun-Fahrlander C. Personal and environmental factors associated with

SCHINDERA ET AL.

active commuting to school in Switzerland. Prev Med. 2008;46(1):67-73.

- Bringolf-Isler B, Grize L, Mader U, Ruch N, Sennhauser FH, Braun-Fahrlander C. Built environment, parents' perception, and children's vigorous outdoor play. *Prev Med*. 2010;50(5-6):251-256.
- Bringolf-Isler B, Mader U, Dossegger A, et al. Regional differences of physical activity and sedentary behaviour in Swiss children are not explained by socio-demographics or the built environment. *Int J Public Health*. 2015;60(3):291-300.
- Faeh D, Minder C, Gutzwiller F, Bopp M. Culture, risk factors and mortality: can Switzerland add missing pieces to the European puzzle. *J Epidemiol Community Health*. 2009;63(8):639-645.
- Ness KK, Leisenring WM, Huang S, et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Cancer*. 2009;115(9):1984-1994.
- Hoffman MC, Mulrooney DA, Steinberger J, Lee J, Baker KS, Ness KK. Deficits in physical function among young childhood cancer survivors. *J Clin Oncol.* 2013;31(22):2799-2805.
- Kühnis J, Bürgler A, Britschgi M, et al. Physical activity patterns of primary school children in everyday life. Schweizerische Zeitschrift für Sportmedizin und Sporttraumatologie. 2013;61(1):23-27.
- Kesting SV, Gotte M, Seidel CC, Rosenbaum D, Boos J. One in four questioned children faces problems regarding reintegration into physical education at school after treatment for pediatric cancer. *Pediatr Blood Cancer*. 2016;63(4):737-739.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Schindera C, Weiss A, Hagenbuch N, et al. Physical activity and screen time in children who survived cancer: A report from the Swiss Childhood Cancer Survivor Study. *Pediatr Blood Cancer*. 2020;67:e28046. <u>https://doi.org/10.1002/pbc.28046</u>

7.3. Co-Author publication III

Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study

Original article

Fabiën N Belle, Maja Beck Popovic, Marc Ansari, Maria Otth, Claudia E: Kuehni, Murielle Bochud

(Published. JMIR Res Protoc. 2019 Nov 18;8(11):e14427. doi: 10.2196/14427.)

Own contribution to the project: Involved in several reviews of the manuscript

JMIR RESEARCH PROTOCOLS

Original Paper

Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study

Fabiën Naomi Belle^{1,2}, PhD; Maja Beck Popovic³, MD, PD; Marc Ansari^{4,5}, MD, PD; Maria Otth¹, MD; Claudia Elisabeth Kuehni^{1,6}, MSc, MD; Murielle Bochud², MD, PhD

¹Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

²Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland

³Pediatric Hematology-Oncology Unit, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

⁴Pediatric Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland

⁵CANSEARCH Research Laboratory, Geneva Medical School, Geneva, Switzerland

⁶Children's University Hospital of Bern, University of Bern, Bern, Switzerland

Corresponding Author:

Fabiën Naomi Belle, PhD Institute of Social and Preventive Medicine University of Bern Mittelstrasse 43 Bern, 3012 Switzerland Phone: 41 31 631 33 47 Email: fabien.belle@ispm.unibe.ch

AAAAAAA

Background: Childhood cancer survivors are at high risk of developing adverse late health effects. Poor nutritional intake may contribute to this risk, but information about dietary intake is limited.

Objective: This study will assess childhood cancer survivors' dietary intake and compare two dietary assessment tools: a self-reported food frequency questionnaire, and dietary measurements from urine spot samples.

Methods: In a substudy of the Swiss Childhood Cancer Survivor Study (SCCSS), SCCSS-Nutrition, we assessed childhood cancer survivors' dietary intake via a validated food frequency questionnaire. We sent a urine spot collection kit to a subset of 212 childhood cancer survivors from the French-speaking region of Switzerland to analyze urinary sodium, potassium, urea, urate, creatinine, and phosphate content. We will compare the food frequency questionnaire results with the urine spot analyses to quantify childhood cancer survivors' intake of various nutrients. We collected data between March 2016 and March 2018.

Results: We contacted 1599 childhood cancer survivors, of whom 919 (57.47%) returned a food frequency questionnaire. We excluded 11 childhood cancer survivors who were pregnant or were breastfeeding, 35 with missing dietary data, and 71 who had unreliable food frequency questionnaire data, resulting in 802 childhood cancer survivors available for food frequency questionnaire analyses. To a subset of 212 childhood cancer survivors in French-speaking Switzerland we sent a urine spot collection kit, and 111 (52.4%) returned a urine sample. We expect to have the results from analyses of these samples in mid-2019.

Conclusions: The SCCSS-Nutrition study has collected in-depth dietary data that will allow us to assess dietary intake and quality and compare two dietary assessment tools. This study will contribute to the knowledge of nutrition among childhood cancer survivors and is a step toward surveillance guidelines and targeted nutritional recommendations for childhood cancer survivors in Switzerland.

Trial Registration: ClinicalTrials.gov NCT03297034; https://clinicaltrials.gov/ct2/show/NCT03297034 International Registered Report Identifier (IRRID): DERR1-10.2196/14427

(JMIR Res Protoc 2019;8(11):e14427) doi: 10.2196/14427

http://www.researchprotocols.org/2019/11/e14427/

JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 1 (page number not for citation purposes)



Belle et al

JMIR RESEARCH PROTOCOLS

KEYWORDS

child; cancer survivors; urine specimen collection; diet surveys; food frequency questionnaire; Swiss Childhood Cancer Registry; Switzerland

11 11 1 1 1 1 11 1

Background

Survival rates among childhood cancer patients have increased markedly and, due to new and improved treatments, now exceed 80% [1]. As patients live longer, strategies to promote long-term overall health of childhood cancer survivors (CCSs) become increasingly important. Complications and disabilities from treatment, such as chemotherapy and radiotherapy, cancer recurrence, or both, can affect morbidity and mortality many years after a cancer diagnosis [1,2]. The St. Jude Lifetime Cohort Study showed that a large proportion of CCSs experience late effects 25 years after diagnosis; 95% have had at least one chronic health condition and 80% have had a severe, life-threatening, or disabling condition [3]. Frequently reported late effects include cardiovascular diseases (CVDs), endocrine disorders, musculoskeletal problems, and secondary malignancies [2]. Such late effects may be increased by lifestyle habits and choices. Accumulating research in CCSs shows that late effects such as type 2 diabetes, metabolic syndrome, and CVD can be reduced through diet adaptations, weight management, and physical activity [4-7]. Nutrition is an important determinant of the health of CCSs.

However, little is known about the dietary habits of CCSs [8,9], and studies have shown that CCSs adhere poorly to dietary recommendations [10-13]. No evidence-based nutritional guidelines exist specifically for CCSs. Nutritional information can be obtained from, for example, self-reported food frequency questionnaires (FFQs) or 24-hour dietary recalls, whereas assays of biochemical indicators-nutrients or their metabolic products-in tissues or fluids, such as nails, feces, blood, and urine, can more directly quantify intake of nutrients [14]. Since self-reported dietary assessment tools are limited by misreporting and recall bias, which can lead to over- or underreporting, results need to be handled with caution [14]. This holds especially true for dietary assessment using FFQs; underestimation of dietary intake in 16 CCSs was greater when measured by the Block FFQ than by repeated 24-hour dietary recalls, validated by the doubly labelled water method [15]. A Canadian study among 80 CCSs showed that an FFQ could correctly rank CCSs according to their dietary intake when comparing it with 3-day food records [16].

The use of 24-hour urine samples to assess alkaline minerals, halide ions, and protein intake can complement self-reported dietary questionnaires, as well as producing nutritional indicators that potentially are more valid than data from questionnaires [14]. But collection of 24-hour urine samples can be a considerable burden for survivors, and it risks bias due to undetected incomplete sample collection and low response rates. Recent research has focused on the utility of estimating 24-hour urinary output from single spot urine samples [17]. These samples are less burdensome for participants and are more easily obtained by researchers, and potential under- or overcollection

http://www.researchprotocols.org/2019/11/e14427/



is irrelevant [14,17]. By adjusting for parameters such as age, sex, height, and weight, and by taking urinary creatinine into account, samples can yield interpretable results [18]. This makes spot urine samples a practical and cost-saving alternative to collection of 24-hour urine samples. To the best of our knowledge, neither spot urine nor 24-hour urine samples have been studied in CCSs to assess dietary intake.

This study will, to our knowledge, for the first time obtain insight into the dietary intake of CCSs from self-reported FFQs and urinary measurements. It will compare the 2 dietary assessment tools and determine whether spot urine collection from CCSs is feasible.

Objectives

This study will generate detailed data on the diets of Swiss long-term CCSs. The study's main objective is to compare the self-reported FFQ dietary assessment tool with assays of urine spot samples. This will give us more information about the reliability of the FFQ, the actual dietary intake of CCSs, and potential associations between dietary intake and the occurrence of somatic late effects. A secondary objective is to evaluate this study itself—that is, to determine the response rate, cost, and CCS reactions of the self-reported FFQ and the dietary markers in spot urine of CCSs.

| | || | | |

Study Design

This is a multicenter, observational study incorporated into the Swiss Childhood Cancer Survivor Study (SCCSS). The SCCSS is a population-based, long-term follow-up study of all childhood cancer patients registered in the Swiss Childhood Cancer Registry (SCCR [19]) with leukemia, lymphoma, central nervous system tumors, malignant solid tumors, or Langerhans cell histiocytosis diagnosed in Switzerland; who were under the age of 21 years at the time of diagnosis; who survived 5 years or more after the initial diagnosis of cancer; and who were alive at the time of the study [20-22]. This study is registered at clinicaltrials.gov (NCT03297034).

Eligibility

CCSs were eligible to participate in the SCCSS-Nutrition study if they had childhood cancer diagnosed between 1976 and 2005, completed a baseline SCCSS questionnaire between 2007 and 2013 [20], and were 18 years of age or older at the time of the follow-up survey in 2017. All CCSs who were enrolled in SCCSS-Nutrition received a follow-up questionnaire including an FFQ. CCSs living in the French-speaking part of Switzerland who returned the questionnaire were invited to provide a urine spot sample. Exclusion criteria were being pregnant or lactating at the time of the study, or having missing or implausible dietary intake information reported in the FFQ [23].

> JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 2 (page number not for citation purposes)


JMIR RESEARCH PROTOCOLS

Recruitment

We traced the addresses of all adult CCSs who had completed the baseline questionnaire (n=2527 CCSs) between 2007 and 2013 [20]. Among these, 1749 were 18 years old or older at the time of the survey and thus were eligible for the follow-up questionnaire. In February 2017, we traced 1599 CCSs and sent them a follow-up questionnaire (Figure 1). Nonresponders received a reminder after 8 weeks (Figure 2). If they again did not respond, we sent a second reminder. Finally, 919 (57.47%) CCSs completed the FFQ. We excluded 11 survivors who were pregnant or lactating, 35 who did not report their dietary intake, 71 who had implausible dietary intake data (<850 kcal or >4500 kcal per day) [24], and 581 who lived outside the French-speaking region in Switzerland. We thus sent an information letter signed by the project leader to 221 CCSs who lived in the French-speaking part of Switzerland and asked them for informed consent to provide a urine spot sample. Among these CCSs, 8 were no longer traceable, 1 was abroad, and 15 declined to participate. We sent urine collection kits to the CCSs who agreed to participate and asked them to collect a first morning sample within 2 weeks and post the sample by mail within 24 hours to the pediatric hematology-oncology unit of the University Hospital of Canton Vaud (Centre Hospitalier Universitaire Vaudois [CHUV]; Lausanne, Switzerland). Among these 212 CCS participants, 111 (52.4%) returned a sample. All 111 urine samples met the study protocol and will be available for dietary intake assessment comparison. Those enrolled received no compensation.

Belle et al

Figure 1. Response rates in the Swiss Childhood Cancer Survivor Study (SCCSS)-Nutrition study. The SCCSS-Nutrition study is subdivided into a food frequency questionnaire assessment (FFQ; gray) and a urine spot collection (black).



http://www.researchprotocols.org/2019/11/e14427/ XSL•FO RenderX JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 3 (page number not for citation purposes)

236

Belle et al

JMIR RESEARCH PROTOCOLS




Figure 2. Timelines and response rates of food frequency questionnaire (FFQ) assessment and urine spot collection.

Data Collection

Baseline and Follow-Up Questionnaire


From baseline or follow-up questionnaires, we collected CCSs' data on sex, age at survey, language region in Switzerland in which they lived, country of birth, educational level, living situation, physical activity, smoking status, and height and weight to calculate body mass index. The baseline questionnaire included core questions from the US and UK CCS studies [25,26], with further questions from the Swiss Health Survey and the Swiss census of health-related behaviors and sociodemographic measures [27,28]. The main domains covered by the questionnaire were quality of life, somatic health, fertility, current medication and health services use, psychological distress, health behaviors, and socioeconomic status. The follow-up questionnaire repeated baseline questions on quality of life, somatic health, health behaviors, and socioeconomic status, with the addition of an FFQ to assess dietary intake in detail [29,30].

Food Frequency Questionnaire

We assessed CCSs' dietary intake, including information on portion sizes, with a self-administered, semiquantitative FFQ [31,32] (Multimedia Appendix 1). The FFQ was originally developed and validated against 24-hour dietary recalls for the adult Swiss population who are French speaking [29,31,33,34]. It solicits information on consumption frequency and portion sizes during the 4 previous weeks for 97 fresh and prepared food items organized into 12 food groups (dietary supplements not included). Consumption frequencies range from "never during the last 4 weeks" to "2 or more times per day," and portion sizes are recorded as equal to, or smaller or larger than, a reference size. The reference portions were defined as common household measures representing the median portion size of a previous validation study performed with 24-hour dietary recalls [29]. The "smaller" and "larger" portions represented the first and fourth quartiles of this distribution. We used the French Information Center on Food Quality (Maisons-Alfort Cedex, France) food-composition table to convert the food portions into macro- and micronutrients [35].

Urine Collection

CCSs received a home specimen collection kit including an information sheet on how to perform first morning urine spot collection, a 50 mL plastic specimen tube with a screw-on lid, a sealed plastic bag, and a bubble-lined return envelope with labels addressed to postage-paid the pediatric hematology-oncology unit of CHUV. We asked CCSs to collect a first morning urine sample, filling the tube up to 40 mL, and to seal the tube and write the sample date and time on the lid. We asked CCSs not to mark personal information on the tube to preserve confidentiality, and to send their sample by post. The medical staff of the pediatric hematology-oncology unit cooled the urine spot samples as soon as they received them. They divided the samples into one 8-mL aliquot for direct urine chemistry and nine 3-mL aliquots for biobank storage; the 8-mL sample was sent within 1 hour to the CHUV laboratory for analyses. Levels of potassium, sodium, phosphate, urate, urea, and creatinine were measured using routine laboratory procedures (Table 1). The 3-mL urine samples were frozen at -80°C and stored in a biobank at CHUV for later analyses.



JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 4 (page number not for citation purposes)

Table 1. Primary and secondary end points and outcomes of interest.

End points and outcomes	Method	Quality promotion	(Expected) time point or window
Primary			
Detailed dietary intake, macro- and micronutrients	Dietary intake assessed by a validated FFQ ^a providing information on consumption fre- quency and portion sizes during the 4 previ- ous weeks for 97 fresh and prepared food items organized in 12 food groups.	Validated FFQ	CCSs ^b were expected to fill in and re- turn the FFQ within 8 weeks. In case of nonresponse, a first and second re- minder were sent.
Urinary measurements	Laboratory methods: Sodium: indirect potentiometry Potassium: indirect potentiometry Urea: urease Urate: uricase Creatinine: Jaffe reaction Phosphate: phosphomolybdate	Standard laboratory procedures	Analyses were performed together with routine analyses in the hospital labora- tory of Centre Hospitalier Universitaire Vaudois with Cobas 8000 (Roche Diag- nostics). Analyses were performed during the whole study period.
Secondary			
General response rate	The SCCSS ^c tracking system tracked the number of CCSs who did not respond or declined participation.	N/A ^d	Evaluation after finalizing the study.
Costs	Recording of costs, eg, laboratory, mailing, printing, urine collection sample kits.	N/A	Midterm evaluation and after finalizing the study.
Participants' reactions	Recording CCSs' reactions by telephone, emails, or letter.	N/A	Evaluation after finalizing the study.

^aFFQ: food frequency questionnaire.

^bCCS: childhood cancer survivor.

^cSCCSS: Swiss Childhood Cancer Survivor Study.

^dN/A: not applicable.

Data Management

Coding

We gave each participant an 8-digit identification (ID) code number to maintain anonymity. We used these ID codes in lieu of patient names for all data and urine spot samples. Data labelled with participant ID codes are stored on encrypted devices or secured servers. All participant data and biological samples are strictly confidential, and disclosure to third parties is prohibited. The coding key is stored at the Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland, and is only available to authorized personnel.

Storage

All biomedical material is archived for 10 years at CHUV. In case there is no intention for use or a participant withdraws consent, the respective biological material will be destroyed. FFQ answers and urine spot laboratory results will be archived on servers of the ISPM, Lausanne, Lausanne, Switzerland, and ISPM, Bern for at least 10 years. Timelines that record and archive outcomes are in line with Swiss regulation. All results will be archived at and analyzed by ISPM, Bern as a nested study of the SCCSS.

Statistical Analyses

We will include all CCSs who provided reliable dietary intake information and were neither pregnant nor lactating during the survey for FFQ analyses. Table 1 indicates the primary and

http://www.researchprotocols.org/2019/11/e14427/



secondary end points and outcomes of interest of the SCCSS-Nutrition study. We will evaluate whether CCSs meet dietary recommendations for Germany, Austria, and Switzerland [36]. We will compare mean intake with the recommended intake or, when not available, the adequate intake. We will calculate mean intake based on age and sex recommendations weighted by the age and sex distribution of the study population. Nutritional goals will be set at 100, where the mean intake meets the recommended or adequate intake. Total energy intake will be calculated including calories from alcohol consumption. We will calculate correlation coefficients to examine the strength and direction of the associations between the FFQ and urinary spot measurements. To validate the agreement between the 2 dietary assessment tools, we will perform cross-classification analyses to investigate whether the 2 dietary assessment tools rank CCSs' dietary intake similarly. We will calculate the proportion of CCSs correctly classified in the same or contiguous category or in the opposite category (misclassified). We will use Bland-Altman plots to assess the level of agreement between the FFQ and the urine spot samples at the CCS group level. We will plot the difference between the 2 measurements against the mean of the 2 measurements for each CCS. We will use Stata (version 14; StataCorp LLC) for all analyses.

Ethics

The cantonal ethics committee Commission cantonal d'éthique de la Recherche sur l'être humain, Lausanne approved the SCCSS-Nutrition study in March 2016. In July 2017, the cantonal ethics committee Geneva Commission Cantonal

> JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 5 (page number not for citation purposes)

Belle et al

d'éthique de la Recherche approved the study with an amendment (protocol of both approvals: 2016-00031). Ethical approval of the SCCR and the SCCSS questionnaires was granted by the Ethics Committee of the Canton of Bern (KEK-BE: 166/2014).

RRRR

Characteristics of Participants and Nonparticipants

Table 2 presents the sociodemographic and lifestyle characteristics of both CCSs who completed the FFQ and those who did not, and those who participated in the collection of

Belle et al

urine spot samples. The most common cancer diagnoses among CCSs completing the FFQ were leukemia, lymphoma, and central nervous system tumors (Table 3). Median age at diagnosis was 10 years (interquartile range 4-14 years) and median time from diagnosis to survey was 26 years (interquartile range 20-32 years). Of the 902 FFQ participants, 99 (12.34%) experienced a relapse.

Costs

The costs of this study have remained within budget (Table 4). Costs include material, shipment of FFQs and urine spot sample collection kits, reminders, data entry, data management, and laboratory urine analyses.

http://www.researchprotocols.org/2019/11/e14427/ XSL•FO RenderX JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 6 (page number not for citation purposes)

Belle et al

Table 2. Sociodemographic and lifestyle characteristics of participants and nonparticipants in the food frequency questionnaire (FFQ) and the urine spot sample collection.

Characteristics	FFQ		Urine spot sample		
	Participants (n=802)	Nonparticipants ^a (n=797)	Participants (n=111)	Nonparticipants ^b (n=110)	
Male sex, n (%)	401 (50.0)	443 (55.6)	49 (44.1)	53 (48.2)	
Age at survey (years), n (%	6)				
≤30	248 (30.9)	328 (41.2) ^c	26 (23.4)	44 (40.0)	
31-39	320 (39.9)	305 (38.3)	37 (33.3)	37 (33.6)	
≥40	234 (29.2)	164 (20.6)	48 (43.2)	29 (26.4)	
Country of birth, n (%)					
Switzerland	763 (95.1)	736 (92.3)	101 (91.0)	98 (89.1)	
Other	39 (4.9)	60 (7.5)	10 (9.0)	12 (10.9)	
Missing data	N/A ^d	1 (0.1)	N/A	N/A	
Education (highest degree), n (%)				
Lower than university	527 (65.7)	681 (85.4) ^e	69 (62.2)	71 (64.6)	
University	270 (33.7)	98 (12.3)	42 (37.8)	39 (35.5)	
Missing data	5 (0.6)	18 (2.3)	N/A	N/A	
Living situation, n (%)					
Alone	164 (20.4)	129 (16.2) ^e	19 (17.1)	24 (21.8)	
Other	634 (79.1)	655 (82.1)	91 (82.0)	86 (78.2)	
Missing data	4 (0.5)	13 (1.6)	1 (0.9)	N/A	
Physical activity ^f , n (%)					
Inactive	165 (20.6)	204 (25.6) ^e	32 (28.8)	32 (29.1)	
Active	628 (78.3)	572 (71.8)	76 (68.5)	77 (70.0)	
Missing data	9 (1.1)	21 (2.6)	3 (2.7)	1 (0.9)	
Smoking status, n (%)					
Never	532 (66.3)	511 (64.1) ^e	69 (62.2)	65 (59.1)	
Former	132 (16.5)	79 (9.9)	15 (13.5)	24 (21.8)	
Current	128 (16.0)	207 (26.0)	25 (22.5)	21 (19.1)	
Missing data	10 (1.3)	N/A	2 (1.8)	N/A	
Body mass index at survey	v (kg/m ²), n (%)				
Underweight (<18.5)	39 (4.9)	57 (7.2) ^e	7 (6.3)	3 (2.7)	
Normal (18.5-24.9)	490 (61.1)	500 (62.7)	76 (68.5)	67 (60.9)	
Overweight (25-29.9)	177 (22.1)	141 (17.7)	15 (13.5)	25 (22.7)	
Obese (≥30)	75 (9.4)	59 (7.4)	10 (9.0)	14 (12.7)	
Missing data	21 (2.6)	40 (5.0)	3 (2.7)	1 (0.9)	

^aIncludes 635 childhood cancer survivors (CCSs) who did not respond, 45 who declined, 11 who were pregnant or breastfeeding, 35 with missing dietary data, and 71 with unreliable dietary data.

^bIncludes 9 CCSs with no valid address available anymore or who were abroad, 15 who declined, and 86 who did not respond.

^cAge at survey is calculated for FFQ nonparticipants by taking the average participants' date of filling in the questionnaire.

^dN/A: not applicable.

^eBased on information from the Swiss Childhood Cancer Survivor Study baseline questionnaire filled in between 2007 and 2013 by FFQ nonparticipants. ^fActive: ≥150 minutes of moderately intense or 75 minutes of vigorously intense or a combination of moderately and vigorously intense physical activity per week.

http://www.researchprotocols.org/2019/11/e14427/

JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 7 (page number not for citation purposes)



Belle et al

Characteristics	FFQ		Urine spot sample	
	Participants (n=802)	Nonparticipants ^a (n=797)	Participants (n=111)	Nonparticipants ^b (n=110
ICCC-3 ^c diagnosis, n (%)	-			
I: Leukemia	246 (30.7)	264 (33.1)	30 (27.0)	27 (24.6)
II: Lymphoma	173 (21.6)	139 (17.4)	30 (27.0)	30 (27.3)
III: CNS ^d tumor	81 (10.1)	140 (17.6)	9 (8.1)	17 (15.5)
IV: Neuroblastoma	28 (3.5)	31 (3.9)	4 (3.6)	3 (2.7)
V: Retinoblastoma	12 (1.5)	22 (2.8)	2 (1.8)	3 (2.7)
VI: Renal tumor	52 (6.5)	41 (5.1)	4 (3.6)	3 (2.7)
VII: Hepatic tumor	6 (0.8)	3 (0.4)	1 (0.9)	1 (0.9)
VIII: Bone tumor	50 (6.2)	29 (3.6)	11 (9.9)	5 (4.6)
IX: Soft tissue sarcoma	66 (8.2)	32 (4.0)	7 (6.3)	10 (9.1)
X: Germ cell tumor	43 (5.4)	42 (5.3)	8 (7.2)	4 (3.6)
XI and XII: Other tu- mor	26 (3.2)	17 (2.1)	4 (3.6)	3 (2.7)
Langerhans cell histio- cytosis	19 (2.4)	37 (4.6)	1 (0.9)	4 (3.6)
Age at diagnosis (years), n	(%)			
<5	251 (31.3)	262 (32.9)	28 (25.2)	29 (26.4)
5-9	164 (20.4)	211 (26.5)	19 (17.1)	23 (20.9)
10-14	239 (29.8)	222 (27.9)	34 (30.6)	27 (24.6)
15-20	148 (18.5)	102 (12.8)	30 (27.0)	31 (28.2)
Time since diagnosis (years), median (interquar- tile range)	26.1 (20.2-31.7)	N/A ^e	28.3 (21.0-32.7)	22.8 (18.5-30.1)
History of relapse, n (%)	99 (12.3)	107 (13.4)	18 (16.2)	15 (13.6)

Table 3. Clinical characteristics of participants and nonparticipants in the food frequency questionnaire (FFQ) and the urine spot sample collection.

^aIncludes 635 childhood cancer survivors (CCSs) who did not respond, 45 who declined, 11 who were pregnant or breastfeeding, 35 with missing dietary data, and 71 with unreliable dietary data.

^bIncludes 9 CCSs with no valid address available anymore or who were abroad, 15 who declined, and 86 who did not respond.

^cICCC3: International Childhood Cancer Classification, Third Edition.

^dCNS: central nervous system.

^eN/A: not applicable.

Table 4. Costs to perform the Swiss Childhood Cancer Survivor Study-Nutrition study.

Expenses	Costs (US \$)
Material, eg, (return) envelopes, questionnaires, urine tubes	6514
Address update for childhood cancer survivors	20,232
Mailings	7125
Data entry for food frequency questionnaires	13,360
Laboratory analyses of urine spot samples	2908
Ethics committee approval	602
Total costs	50,741

http://www.researchprotocols.org/2019/11/e14427/



JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 8 (page number not for citation purposes)

Childhood Cancer Survivor Reactions

CCSs had varied reactions to the FFQ. The majority of CCSs wanted to participate and welcomed a follow-up questionnaire. Only a small number of the 1599 CCSs to whom FFQs were sent (n=45, 2.81%) declined to complete the FFQ. Of the 221 CCSs to whom information letters for urine collection were sent, 15 declined to collect a urine spot sample (Figure 1). All CCSs who declined participation expressed a willingness to participate in future studies. A total of 26 CCSs contacted us by telephone (n=13), email (n=5), or letter (n=8) with questions about the purpose of the study, its setup, eligibility, or another question, or to notify the study team about a delay in FFQ response or urine collection. Overall, the CCSs were supportive and open to participation in the study. We received no angry or aggressive reactions.

We anticipate that the results of the SCCSS-Nutrition study will be available mid-2019.

Principal Findings

SCCSS-Nutrition is, to our knowledge, the first study in Switzerland that has collected in-depth dietary data. It will allow researchers to assess dietary intake and quality in CCSs and to compare 2 dietary assessment tools: urine measurements and FFQs. Urine spot sample measurements can quantify nutrient intake objectively and can therefore complement self-reported dietary information from the FFQ.

Unhealthy dietary intake is an important element in the development of chronic morbidities such as type 2 diabetes, metabolic syndrome, and CVD in the general population. Populations with these morbidities are therefore widely recommended to consume a healthy and balanced diet. The extensively investigated Mediterranean diet, with high intakes of fish, fruit, vegetables, legumes, nuts, whole grains, and monounsaturated fats from olive oil, has been shown to reduce, or even prevent, CVD, diabetes, obesity, metabolic syndrome, and cancer in the general population [37-41] and in CCSs [5]. This makes nutrition one of the main determinants of health in the general population, and is particularly relevant for people with additional risk factors, including CCSs. Nevertheless, knowledge about CCSs' dietary intake and their nutritional status is lacking within Switzerland and is limited worldwide.

Strengths and Limitations

This study, nested within the SCCSS, assesses dietary intake information of CCSs and compares 2 dietary assessment tools: the FFQ and dietary measurements from urine spot samples. We found the SCCSS-Nutrition study to be well received and feasible. This is, to our knowledge, the first study to provide

Belle et al

detailed dietary information on Swiss CCSs and to demonstrate the feasibility of such a study. With the addition of dietary indicators from urine spot samples, SCCSS-Nutrition makes further comparison possible. Additionally, we had high response rates for completing the FFQ and collecting urine spot samples. Finally, we have access to detailed sociodemographic data from the SCCSS baseline and follow-up questionnaire, and high-quality clinical information extracted from medical records in the SCCR. This a very rich dataset available for analysis.

Limitations of this study were that some CCSs said the FFQ was too long. This might have influenced CCSs to either underor overreport dietary intake. Also, we asked CCSs for a single spot urine sample rather than multiple spot samples or a 24-hour urine collection to minimize participation burden. Comparison of the self-reported FFQ data, representing habitual dietary intake over 4 weeks, with urine spot analysis data, indicative of the dietary intake during the day before, should therefore be regarded with caution. Seasonal influences could play a role in the FFQ assessment, as we assessed dietary intake for the past 4 weeks rather than the past year. Finally, the interval between the FFQ assessment and urine spot collection could produce differences in dietary intake due to seasonal influences.

Lessons Learned

Setting up this study provided valuable insight into several methodological and logistic issues. We asked CCSs to return urine samples within 2 weeks and to post their urine samples between Monday and Thursday. This prevented the samples from arriving during the weekend. The time frame of 2 weeks was too short; several CCSs contacted us to ask for an extension. The urine collection tubes had a diameter of 3 cm and did not fit the opening slit of an official Swiss mailbox when the CCSs placed a sample in a sealed plastic bag and a bubble-lined postal return envelope. Given this, the response rate was higher than we expected, and we reached the recruitment target because of the up-to-date address list and personal information of SCCR, and the high motivation of CCSs to participate. Furthermore, including a study center took longer than expected, due to arranging appropriate urine storage within the hospital, and an extra briefing about the potential hazards of CCSs' urine contaminated with chemotherapeutic agents in case of cancer recurrence to safeguard the safety of laboratory staff.

Conclusions

The SCCSS-Nutrition study collected in-depth dietary data that will enable an assessment of dietary intake and dietary quality in CCSs and a comparison of dietary assessment tools. The study will help fill nutrition knowledge gaps and is a first step toward surveillance guidelines and targeted nutritional recommendations in Switzerland.

Acknowledgments

The authors express their gratitude to all childhood cancer survivors for supporting this study. Additionally, we thank Sarah Blanc, Eléna Lemmel, Rosa-Emma Garcia, Rodolfo Lo Piccolo, Sandrine Estoppey-Younes, and the medical staff of CHUV for their support in study setup, recruitment, and urine collection. We thank the study team of the Swiss Childhood Cancer Survivor Study (Carole Dupont, Rahel Kasteler, Rahel Kuonen, Nadine Lötscher, Jana Remlinger, Christina Schindera, Grit Sommer, Nicolas Waespe, and Annette Weiss), the data managers of the Swiss Paediatric Oncology Group (Dr Claudia Althaus, Nadine

http://www.researchprotocols.org/2019/11/e14427/



Belle et al

Assbichler, Pamela Balestra, Heike Baumeler, Nadine Beusch, Dr Pierluigi Brazzola, Susann Drerup, Janine Garibay, Franziska Hochreutener, Monika Imbach, Friedgard Julmy, Heike Markiewicz, Dr Veneranda Mattielo, Annette Reinberg, Dr Renate Siegenthaler, Astrid Schiltknecht, Beate Schwenke, and Verena Stahel), and the team of the Swiss Childhood Cancer Registry (Meltem Altun, Erika Brantschen, Katharina Flandera, Elisabeth Kiraly, Verena Pfeiffer, Shelagh Redmond, Julia Ruppel, and Ursina Roder). Finally, we would like to thank Christopher Ritter for editorial assistance.

This study is supported by Swiss Cancer Research (KLS-3644-02-2015 and KFS-4722-02-2019) and FORCE Fondation. The work of the Swiss Childhood Cancer Registry is supported by the Swiss Paediatric Oncology Group, Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -direktoren, Swiss Cancer Research, Kinderkrebshilfe Schweiz, the Swiss Federal Office of Public Health, and the National Institute for Cancer Epidemiology and Registration.

Authors' Contributions

FB wrote the manuscript, which was modified and adapted by all other authors. MBP and MA were the principal investigators. CEK and MB supported study setup.

Conflicts of Interest

None declared.

Multimedia Appendix 1

Food frequency questionnaire in French. [PDF File (Adobe PDF File), 1882 KB-Multimedia Appendix 1]

Multimedia Appendix 2

Peer-review report ethical committee. [PDF File (Adobe PDF File), 301 KB-Multimedia Appendix 2]

References

- Bhatia S, Armenian SH, Armstrong GT, van Dulmen-den Broeder E, Hawkins MM, Kremer LCM, et al. Collaborative research in childhood cancer survivorship: the current landscape. J Clin Oncol 2015 Sep 20;33(27):3055-3064 [FREE Full text] [doi: 10.1200/JCO.2014.59.8052] [Medline: 26304891]
- Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet 2017 Dec 09;390(10112):2569-2582 [FREE Full text] [doi: 10.1016/S0140-6736(17)31610-0] [Medline: 28890157]
- Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013 Jun 12;309(22):2371-2381 [FREE Full text] [doi: 10.1001/jama.2013.6296] [Medline: 23757085]
- 4. Zhang FF, Parsons SK. Obesity in childhood cancer survivors: call for early weight management. Adv Nutr 2015 Sep;6(5):611-619 [FREE Full text] [doi: 10.3945/an.115.008946] [Medline: 26374183]
- Tonorezos ES, Robien K, Eshelman-Kent D, Moskowitz CS, Church TS, Ross R, et al. Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia. Cancer Causes Control 2013 Feb;24(2):313-321 [FREE Full text] [doi: 10.1007/s10552-012-0116-6] [Medline: 23187859]
- Smith WA, Li C, Nottage KA, Mulrooney DA, Armstrong GT, Lanctot JQ, et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer 2014 Sep 01;120(17):2742-2750 [FREE Full text] [doi: 10.1002/cncr.28670] [Medline: 25070001]
- Barnea D, Raghunathan N, Friedman DN, Tonorezos ES. Obesity and metabolic disease after childhood cancer. Oncology (Williston Park) 2015 Nov;29(11):849-855 [FREE Full text] [Medline: 26568532]
- 8. Ladas E. Nutritional counseling in survivors of childhood cancer: an essential component of survivorship care. Children (Basel) 2014 Aug 14;1(2):107-118 [FREE Full text] [doi: 10.3390/children1020107] [Medline: 27417470]
- Zhang FF, Saltzman E, Must A, Parsons SK. Do childhood cancer survivors meet the diet and physical activity guidelines? A review of guidelines and literature. Int J Child Health Nutr 2012;1(1):44-58 [FREE Full text] [doi: 10.6000/1929-4247.2012.01.01.06] [Medline: 26973721]
- Belle F, Wengenroth L, Weiss A, Sommer G, Beck Popovic M, Ansari M, Swiss Paediatric Oncology Group (SPOG). Low adherence to dietary recommendations in adult childhood cancer survivors. Clin Nutr 2017 Oct;36(5):1266-1274. [doi: 10.1016/j.clnu.2016.08.012] [Medline: 28277304]
- Zhang FF, Ojha RP, Krull KR, Gibson TM, Lu L, Lanctot J, et al. Adult survivors of childhood cancer have poor adherence to dietary guidelines. J Nutr 2016 Dec;146(12):2497-2505 [FREE Full text] [doi: <u>10.3945/jn.116.238261</u>] [Medline: <u>27798341</u>]

http://www.researchprotocols.org/2019/11/e14427/

JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 10 (page number not for citation purposes)



- Berdan CA, Tangney CC, Scala C, Stolley M. Childhood cancer survivors and adherence to the American Cancer Society Guidelines on Nutrition and Physical Activity. J Cancer Surviv 2014 Dec;8(4):671-679. [doi: <u>10.1007/s11764-014-0376-0</u>] [Medline: <u>24996982</u>]
- 14. Willet W. Food Frequency Methods; Biochemical Indicators of Dietary Intake. In: Nutritional Epidemiology. Monographs in Epidemiology and Biostatistics. 2nd edition. New York, NY: Oxford University Press Oxford New York; 1998.
- Zhang FF, Roberts SB, Must A, Wong WW, Gilhooly CH, Kelly MJ, et al. Assessing dietary intake in childhood cancer survivors: food frequency questionnaire versus 24-hour diet recalls. J Pediatr Gastroenterol Nutr 2015 Oct;61(4):499-502 [FREE Full text] [doi: 10.1097/MPG.0000000000826] [Medline: 25883059]
- Morel S, Portolese O, Chertouk Y, Leahy J, Bertout L, Laverdière C, et al. Development and relative validation of a food frequency questionnaire for French-Canadian adolescent and young adult survivors of acute lymphoblastic leukemia. Nutr J 2018 Apr 21;17(1):45 [FREE Full text] [doi: 10.1186/s12937-018-0355-9] [Medline: 29679986]
- Huang L, Crino M, Wu JHY, Woodward M, Barzi F, Land M, et al. Mean population salt intake estimated from 24-h urine samples and spot urine samples: a systematic review and meta-analysis. Int J Epidemiol 2016 Feb;45(1):239-250. [doi: 10.1093/ije/dyv313] [Medline: 26796216]
- Mente A, O'Donnell MJ, Dagenais G, Wielgosz A, Lear SA, McQueen MJ, et al. Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens 2014 May;32(5):1005-14; discussion 1015. [doi: <u>10.1097/HJH.000000000000122</u>] [Medline: <u>24569420</u>]
- Swiss Childhood Cancer Registry. Bern, Switzerland: Institute of Social and Preventive Medicine, University of Bern; 2019. URL: <u>https://www.childhoodcancerregistry.ch</u> [accessed 2019-09-17]
- Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MF, Niggli FK, Swiss Paediatric Oncology Group (SPOG). Cohort profile: the Swiss childhood cancer survivor study. Int J Epidemiol 2012 Dec;41(6):1553-1564. [doi: 10.1093/ije/dyr142] [Medline: 22736394]
- Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE, Swiss Childhood Cancer Registry, Swiss Paediatric Oncology Group (SPOG) Scientific Committee. The Swiss Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. Swiss Med Wkly 2007 Sep 08;137(35-36):502-509. [doi: <u>10.7892/boris.22081</u>] [Medline: <u>17990137</u>]
- Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MF, Kuehni CE, Swiss Paediatric Oncology Group (SPOG). Incidence of childhood cancer in Switzerland: the Swiss Childhood Cancer Registry. Pediatr Blood Cancer 2008 Jan;50(1):46-51. [doi: <u>10.1002/pbc.21129</u>] [Medline: <u>17226849</u>]
- 23. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 1997 Apr;65(4 Suppl):1220S-1228S; discussion 1229S. [Medline: <u>9094926</u>]
- Marques-Vidal P, Vollenweider P, Grange M, Guessous I, Waeber G. Dietary intake of subjects with diabetes is inadequate in Switzerland: the CoLaus study. Eur J Nutr 2017 Apr;56(3):981-989. [doi: <u>10.1007/s00394-015-1146-0</u>] [Medline: <u>26744301</u>]
- Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol 2002 Apr;38(4):229-239. [doi: 10.1002/mpo.1316] [Medline: 11920786]
- Hawkins MM, Lancashire ER, Winter DL, Frobisher C, Reulen RC, Taylor AJ, et al. The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer 2008 May;50(5):1018-1025. [doi: <u>10.1002/pbc.21335</u>] [Medline: <u>17849473</u>]
- 27. Liebherr R, Marquis J, Storni M, Wiedenmayer G. Gesundheit und Gesundheitsverhalten in der Schweiz 2007 Schweizerische Gesundheitsbefragung. Neuchâtel, Switzerland: Neuchâtel Bundesamt für Statistik; 2010. URL: <u>https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/erhebungen/sgb.html</u> [accessed 2019-09-19]
- Germann U. Eidgenössische Volkszählung 2000: Abschlussbericht zur Volkszählung 2000. Neuchâtel, Switzerland: Swiss Federal Statistical Office; Oct 2005:1-114.
- Morabia A, Bernstein M, Kumanyika S, Sorenson A, Mabiala I, Prodolliet B, et al. [Development and validation of a semi-quantitative food questionnaire based on a population survey]. Soz Praventivmed 1994;39(6):345-369. [doi: 10.1007/bf01299666] [Medline: 7817624]
- Bochud M, Chatelan A, Blanco J, Beer-Borst S. Anthropometric characteristics and indicators of eating and physical activity behaviors in the Swiss adult population: results from menuCH 2014-2015. Report on behalf of the Federal Office of Public Health and the Food Safety and Veterinary Office. Contract Nr. OFSP 16.010537/204.0001/-1476 and contract Nr. FSVO 071400. Bern, Switzerland: Swiss Federal Food Safety and Veterinary Office; 2017. URL: https://www.blv.admin.ch/dam/ blv/de/dokumente/lebensmittel-und-ernaehrung/ernaehrung/menuch-bericht.pdf.download.pdf/menuch-bericht.pdf [accessed 2019-09-30]

http://www.researchprotocols.org/2019/11/e14427/

JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 11 (page number not for citation purposes)

XSL•FO RenderX

Belle et al

- 31. Bernstein L, Huot I, Morabia A. Amélioration des performances d'un questionnaire alimentaire semi-quantitatif comparé à un rappel des 24 heures [Improvement of the effectiveness of a food frequency questionnaire compared with a 24 hour recall survey]. Santé Publique 1995;7(4):403-413.
- 32. Bernstein M, Morabia A, Costanza MC, Landis JR, Ross A, Flandre P, et al. [Nutritional balance of the diet of the adult residents of Geneva]. Soz Praventivmed 1994;39(6):333-344. [doi: 10.1007/bf01299665] [Medline: 7817623]
- Beer-Borst S, Costanza MC, Pechère-Bertschi A, Morabia A. Twelve-year trends and correlates of dietary salt intakes for the general adult population of Geneva, Switzerland. Eur J Clin Nutr 2009 Feb;63(2):155-164. [doi: <u>10.1038/sj.ejcn.1602922</u>] [Medline: <u>17928805</u>]
- Morabia A, Bernstein M, Héritier S, Ylli A. Community-based surveillance of cardiovascular risk factors in Geneva: methods, resulting distributions, and comparisons with other populations. Prev Med 1997;26(3):311-319. [doi: <u>10.1006/pmed.1997.0146</u>] [Medline: <u>9144755</u>]
- 35. French Agency for Food, Environmental and Occupational Health & Safety. CIQUAL French food composition table version 2017. Maisons-Alfort Cedex, France: Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail; 2017. URL: https://ciqual.anses.fr/ [accessed 2019-07-08]
- Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. Am J Med 2015 Mar;128(3):229-238 [FREE Full text] [doi: 10.1016/j.amjmed.2014.10.014] [Medline: 25447615]
- Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Ruiz-Gutiérrez V, Covas MI, PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006 Jul 04;145(1):1-11. [doi: 10.7326/0003-4819-145-1-200607040-00004] [Medline: 16818923]
- Kastorini C, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011 Mar 15;57(11):1299-1313 [FREE Full text] [doi: 10.1016/j.jacc.2010.09.073] [Medline: 21392646]
- Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008 Sep 11;337:a1344 [FREE Full text] [doi: 10.1136/bmj.a1344] [Medline: 18786971]
- Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, et al. 'Mediterranean' dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013 Aug 12(8):CD009825. [doi: <u>10.1002/14651858.CD009825.pub2]</u> [Medline: <u>23939686</u>]

Abbreviations

CCS: childhood cancer survivor CHUV: Centre Hospitalier Universitaire Vaudois CVD: cardiovascular disease FFQ: food frequency questionnaire ID: identification ISPM: Institute of Social and Preventive Medicine SCCR: Swiss Childhood Cancer Registry SCCSS: Swiss Childhood Cancer Survivor Study SCCSS-Nutrition: Swiss Childhood Cancer Survivor Study-Nutrition study

Edited by G Eysenbach; submitted 17.04.19; peer-reviewed by C de Mestral, S Khalatbari, G Michel; comments to author 24.05.19; revised version received 17.07.19; accepted 14.08.19; published 18.11.19

Please cite as:

Belle FN, Beck Popovic M, Ansari M, Otth M, Kuehni CE, Bochud M Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study JMIR Res Protoc 2019;8(11):e14427 URL: <u>http://www.researchprotocols.org/2019/11/e14427/</u> doi: 10.2196/14427 PMID: <u>31738177</u>

©Fabiën Belle, Maja Beck Popovic, Marc Ansari, Maria Otth, Claudia Elisabeth Kuehni, Murielle Bochud. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 18.11.2019. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted

http://www.researchprotocols.org/2019/11/e14427/

JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 12 (page number not for citation purposes)

XSL•FO RenderX

Belle et al

use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.

http://www.researchprotocols.org/2019/11/e14427/ XSL•FO RenderX JMIR Res Protoc 2019 | vol. 8 | iss. 11 | e14427 | p. 13 (page number not for citation purposes) 7.4. Co-Author publication IV

Paediatric cohort studies on lower respiratory diseases and their reporting quality: systematic review of the year 2018

Review

Cristina Ardura-Garcia, Rebeca Mozun, Eva S.L. Pedersen, **Maria Otth**, Chritsina M. Mallet, Myrofora Goutaki, Claudia E. Kuehni

(Published. Eur Respir J. 2020 May 26;2000168. doi: 10.1183/13993003.00168-2020.)

Own contribution to the project: Involved in title and abstract screening, full text screening, data extraction, interpretation of results, and review of the manuscript



Early View

Original article

Paediatric cohort studies on lower respiratory diseases and their reporting quality: systematic review of the year 2018

Cristina Ardura-Garcia, Rebeca Mozun, Eva S.L. Pedersen, Maria Otth, Maria Christina Mallet, Myrofora Goutaki, Claudia E. Kuehni

Please cite this article as: Ardura-Garcia C, Mozun R, Pedersen ESL, *et al*. Paediatric cohort studies on lower respiratory diseases and their reporting quality: systematic review of the year 2018. *Eur Respir J* 2020; in press (https://doi.org/10.1183/13993003.00168-2020).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020

Paediatric cohort studies on lower respiratory diseases and their

reporting quality: systematic review of the year 2018

Authors: Cristina Ardura-Garcia¹, Rebeca Mozun¹, Eva SL Pedersen¹, Maria Otth^{1,2}, Maria Christina Mallet¹, Myrofora Goutaki^{1,3}, and Claudia E Kuehni^{1,3}.

Affiliation:

- 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
- Division of Haematology- Oncology; Department of Paediatrics, Kantonsspital Aarau, Switzerland.
- Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Bern, Switzerland.

Corresponding author: Claudia E Kuehni. Mittelstrasse 43, 3012, Bern, Switzerland, email: claudia.kuehni@ispm.unibe.ch

Take home message: We need a joined effort of editors, reviewers and authors to improve the reporting quality of paediatric cohort studies for respiratory problems.

Conflict of interest: None

Authors contributions: Claudia E Kuehni, Myrofora Goutaki, Cristina Ardura-Garcia, Eva Pedersen, and Rebeca Mozun conceptualised and designed the study. Cristina Ardura-Garcia, Rebeca Mozun, Eva SL Pedersen, Maria Otth, and Maria Christina Mallet performed the screening and data extraction. Cristina Ardura-Garcia analysed the data and drafted the manuscript. All authors critically revised the manuscript and approved the final manuscript as submitted.

Key words: systematic review, paediatric, cohort studies, respiratory symptoms

Abstract

The paediatric respiratory research community uses cohort studies extensively. However, the landscape of these studies and their quality of reporting has not been assessed.

We performed a systematic review of publications on cohort studies reporting on paediatric lower respiratory problems published in 2018. We searched Medline and EMBASE and extracted data on the studies' and journals' characteristics. We assessed the number of items of the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) checklist that a random sample (100 papers) reported. We analysed factors associated with the STROBE score and with the most poorly reported items, using Poisson and logistic regression

Of the 21 319 records identified, 369 full-text articles met our inclusion criteria. Most papers studied asthma aetiology through birth cohorts and were based in Europe or North America. The reporting quality was insufficient: 15% reported the 22 STROBE items; median score: 18 (IQR: 16-21). The most poorly reported items were: sources of bias, sample size, statistical methods, descriptive results and generalisability. None of the studies' or journals' factors were associated with the STROBE score.

We need a joined effort of editors, reviewers and authors to improve the reporting quality of paediatric cohort studies on respiratory problems.

Introduction

Cohort studies are extensively used in paediatric respiratory research to investigate risk factors, incidence and natural history of disease. The strengths of the longitudinal design include establishing temporality and reducing information bias. However, the study design has limitations, like high costs, selection bias, attrition bias, and residual confounding. There are solutions to overcome or mitigate these disadvantages like retrospective cohort design, nested case-control studies or linkage to nationwide available datasets. The use of these strategies, the type of questions investigated and the quality of reporting of cohort studies has not been assessed in paediatric respiratory research.

Adequate reporting is key for reproducibility of research and translation of results into clinical practice. STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) is an international, multidisciplinary and collaborative initiative started in 2004 to enhance the reporting quality and dissemination of observational studies [1]. The STROBE statement is being increasingly endorsed by journals, but mandatory submission of its checklist is not yet common practice for observational studies as it is for randomized controlled trials. Studies assessing the fulfilment of the STROBE criteria suggest that reporting quality is generally poor and that some items are frequently underreported [2-4]. Certain factors have been associated with reporting quality, such as journal's impact factor and STROBE endorsement policy, the authors' affiliation, and publication type (peer reviewed or not) [3,5-7]. Identifying which STROBE items are commonly misreported in paediatric respiratory cohort papers and which modifiable factors are associated with poor reporting may raise awareness and help improve the quality of publications in this area. We therefore conducted a systematic review of papers published in 2018 to present the landscape of cohort studies addressing paediatric lower respiratory problems, to describe the reporting quality of these papers according to STROBE guidelines and to examine characteristics associated with reporting quality.

Methods

The predefined review protocol that we followed for this systematic review has been registered in the Open Science Framework (OSF) repository (Registration DOI 10.17605/OSF.IO/F8X3B). We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, research checklist online) [8] to report our findings.

Eligibility criteria

We searched for papers reporting on lower respiratory problems from paediatric cohort studies worldwide, published in 2018 in peer-reviewed journals. For this we used all the following specific inclusion criteria: (1) cohort study design (exposure measured before outcome, with at least two time points with prospective data collection), including nested case-control studies; (2) children under 18 years of age at study baseline, or with separate results reported for children, or for rare diseases, if more than 50% of the study population were children; (3) lower respiratory problems and evaluations of lower respiratory health as outcomes (including respiratory symptoms, test results such as lung function, diagnosis and prognosis) or lower respiratory problems and evaluations of lower respiratory health as exposures (including respiratory symptoms, test results such as lung function, diagnosis, management and prognosis).

We excluded studies with any of the following criteria: (1) reports not in English, (2) published before 1st January 2018 or after 31st December 2018, (3) non-original papers (conference abstracts, editorials and reviews), (4) follow-up time <3 months (to exclude papers on shortterm outcomes of hospitalised patients), and (5) studies with <50 participants to exclude small case series (for rare diseases where smaller sample sizes are expected we excluded if there were <20 participants). If exact sample size was not stated but we could assure that it was greater than our selected limits for paper exclusion, the manuscript was included in the study.

Information sources and search strategy

We searched Medline and EMBASE from 1st January 2018 to 31st December 2018, on April 17th 2019. We used a reference management software (EndNote X8, Thomson Reuters) to import the records and remove duplicates. We provide the full search strategy in the online supplementary information.

Study selection

One reviewer screened titles and abstracts to assess eligibility according to the described criteria. In a second step, a single reviewer screened full-text papers of selected studies and recorded the reasons for exclusion in an Excel form.

Data extraction

We extracted data from the selected papers using a standardised pre-piloted data collection Excel form. We extracted information on the characteristics of the manuscript (author, journal, location and year of publication) and the study (cohort name and size, study design, type of research question, main diseases of interest, source of exposure and outcome data, use of longitudinal analysis, follow-up time and age at baseline). We did not include a risk of bias assessment, as the results were not extracted and evaluated.

Definitions

Journals were classified into thematic categories according to the InCites Journal Citation Report classification. If a journal appeared in two different categories, it was classified as the first in which it appeared in this order: respiratory, allergy, infectious diseases, public health/ epidemiology/ environment, paediatrics, general medicine and any other category (Supplementary Table 1). The diagnoses studied were grouped into: asthma or wheeze, respiratory infectious diseases, rare diseases (defined as occurring in fewer than 1 in 2000

people, and including bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia), lung function in healthy children and other problems (including cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms).

Assessment of reporting quality

We selected a random sample of 100 (27%) of the included papers and assessed how close the manuscript followed the STROBE recommendations for the reporting of cohort studies. We used a standardised data collection Excel form and recorded the adherence to each of the 22 items present in the STROBE checklist for the reporting of cohort studies. The STROBE statement recommends the reporting of all the elements in their checklist. For this reason, we considered insufficient reporting if not all the elements (22) were reported. We did not evaluate the items that are only 'suggested', such as the inclusion of a flow diagram. We defined an item as not reported if it was not present or insufficiently reported. For example, for item 7, if they defined the outcome and main exposure, but not other variables (e.g. confounders and important effect modifiers). To examine characteristics associated with reporting quality, we also extracted information of variables that have been previously associated with reporting: journal's impact factor, percentage ranking, category, reporting recommendations and if it belonged to a scientific society; and the study's location, research question and main diagnosis of interest. We used data from the InCites Journal Citation Report to record the impact factor and ranking of the journal where the manuscript was published, and from the journals' webpages to collect information on whether the journal belonged to a scientific society and on the reporting recommendations (classified into no recommendation (none), recommending to follow any reporting guideline, recommending to follow STROBE reporting guidelines and mandatory attachment of the STROBE checklist at the time of manuscript submission).

Synthesis of results and analysis

We summarised the results (absolute numbers and proportions) of the study characteristics, the journals where they were published and the reporting quality according to the STROBE statement using tables and graphs. We used Poisson regression to study univariable associations between the study's characteristics and the number of items from the STROBE checklist that were reported in the manuscript. We reported the rate ratio with 95% confidence interval, and the p value of the likelihood ratio test. We then applied logistic regression to study univariable associations between the study's characteristics and the reporting of the 4 items from the STROBE checklist that were most poorly reported: item 9 (bias), item 12 (statistics), item 14 (descriptive results) and item 21 (generalisability). We reported the odds ratio with 95% confidence interval for each item separately. For both regression analyses, we included the following factors based on previous findings and plausibility of association with reporting quality: journal's impact factor, ranking, category, reporting recommendations and if it belonged to a scientific society; and the study's location, research question and main diagnosis of interest.

Results

Of the 15 846 records identified through database searching, 890 were selected based on title and abstract and 369 full-text articles were finally included in the systematic review (Figure 1). Of the 521 full-text articles excluded, 77 were not a cohort study and 24 did not include a longitudinal analysis (e.g. used cross-sectional data from a cohort study).

Most studies were located in Europe (161, 44%) or North America (108, 29%), with few from other locations, especially Africa (17, 5%) and South America (12, 3%) (Figure 2). The median sample size was of 746 children (IQR 187-4535). Forty one percent of the studies had a birth or pregnancy cohort design, followed by prospective clinical cohorts (109, 30%) and non-birth

population-based cohorts (56, 15%). Median follow-up time was 5 years (IQR: 1-10 years). A quarter (85, 23%) used linkage with routine datasets and there were very few nested casecontrol studies (7, 2%). The most frequent sources of exposure data were questionnaires/ interviews (128, 35%) or direct examination/ diagnostic tests (134, 36%), while outcomes were normally obtained from questionnaires/ interviews (157, 43%).

The main diagnosis of interest in the included studies was asthma or wheeze (214, 58%) and the main research questions related to aetiology (194, 53%) followed by natural history or prognosis (116, 31%). The research questions varied by diagnosis of interest (Figure 3a). Studies on asthma and lung function answered questions mostly on aetiology or risk factors, while natural history and prognosis was more common in studies of rare diseases and other diagnoses. Disease phenotyping was mostly studied in papers on respiratory infectious diseases or rare diseases. Similarly, sample size of the study population also varied by diagnosis of interest (Figure 3b). More than half of the studies on asthma had more than 1000 participants, while 40% of those on rare diseases had less than 100 participants.

The included cohort studies were mostly published in respiratory (103, 28%) or allergy/immunology journals (88, 24%) (Figure 2). Of the individual journals, those with 10 or more papers were either highly specific (Paediatric pulmonology, Paediatric Allergy& Immunology and Journal of Asthma) or high impact respiratory journals (Journal of Allergy and Clinical Immunology, Thorax and European Respiratory Journal). There was only one general journal (PlosONE) with 10 or more included papers (data not shown). There were some differences in the study design, sample size and research question between journals, though the largest differences were observed in the diagnosis of interest (Supplementary Table 2). Papers on asthma were published mainly in allergy/immunology or respiratory journals and those on respiratory infectious diseases in their respective journals. Papers on other diagnoses were more evenly distributed, with the exception of the allergy/immunology journals that published almost exclusively on asthma.

	ltem No	Recommendation	Ν
Title and	1	All criteria for item 1	81
abstract		(a) Indicate the study's design with a commonly used term in the title or the abstract	83
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	97
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	100
Objectives	3	State specific objectives, including any prespecified hypotheses	97
Methods			
Study design	4	Present key elements of study design early in the paper	93
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	90
Participants	6	(<i>a</i>) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	94
		(b) For matched studies, give matching criteria and number of exposed and	
		unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	
		effect modifiers. Give diagnostic criteria, if applicable	84
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	00
measurement		assessment (measurement). Describe comparability of assessment methods if there is more than one group	96
Bias	9	Describe any efforts to address potential sources of bias	58
Study size	10	Explain how the study size was arrived at	64
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	92
Statistical	12	All criteria for item 12	38
methods		(<i>a</i>) Describe all statistical methods, including those used to control for confounding	92
		(b) Describe any methods used to examine subgroups and interactions	83
		(c) Explain how missing data were addressed	43
		(d) If applicable, explain how loss to follow-up was addressed	59
		(<u>e</u>) Describe any sensitivity analyses	66
Results			
Participants	13*	All criteria for item 13 (except c)	72
		(a) Report numbers of individuals at each stage of study—eg numbers	
		potentially eligible, examined for eligibility, confirmed eligible, included in the	78
		study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	76
		(c) Consider use of a flow diagram	-
Descriptive data	14*	All criteria for item 14	56
		(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	90
		(b) Indicate number of participants with missing data for each variable of interest	59
		(c) Summarise follow-up time (eg, average and total amount)	82
Outcome data	15*	Report numbers of outcome events or summary measures over time	98
Main results	16	All criteria item 16 (except c)	82
		(<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders	84
		were adjusted for and why they were included	0,
		(b) Report category boundaries when continuous variables were categorized	98

Table 1: Number of manuscripts that accurately followed each of the STROBE checklist items for the reporting of cohort studies from a random subsample (N=100)

		(c) If relevant, consider translating estimates of relative risk into absolute risk	_
		for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and	85
		sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	100
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or	94
		imprecision. Discuss both direction and magnitude of any potential bias	94
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	
		limitations, multiplicity of analyses, results from similar studies, and other	96
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	51
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and,	04
		if applicable, for the original study on which the present article is based	84
Colour code for	prop	ortion of manuscripts that reported each item:	

<50%; 50-70%; 70-90%; >90%

Items in white were not evaluated as they are not compulsory but should be only 'considered'. We did not evaluate item 6b as none of the studies included were matched.

The reporting quality of the papers was insufficient (Table 1). Only three (0.8%) of the 369 included papers mentioned the STROBE statement in the text, and none of them stated using any other reporting guideline. Of the 100 subsampled publications, only 15% included all the 22 items mentioned in the STROBE checklist. The median number of elements missing from the checklist was 4 (IQR 1-6). The most frequently missed items were a correct description of the efforts to address potential sources of bias (item 9, missing in 42%), the study size explanation (item 10, missing in 36%), description of the statistical methods (item 12, missing in 62%), of the study participants' characteristics (item 14, missing in 44%), and the discussion of the generalisability of the study findings (item 21, missing in 49%). For the reporting of statistical methods and the descriptive data of the study participants (items 12 and 14), one frequent flaw was the lack of description of the number of participants with missing data for each variable (item 14b, missing in 41%) and the explanation of how the missing data were addressed (item 12c, missing in 57%).

Table 2: Association between studies' and journal's characteristics, and the total score on STROBE reporting recommendations for cohort studies' checklist from a Poisson regression (N=100)

	STROBE score		Poisson regression	
	Median IQR		Crude IRR	Global
			(95% CI)	P value ^{##}
Society journal: Yes	18	16-21	1.0 (0.9-1.1)	0.562
No	18	15-20		
Journal reporting recommendation				
None	17	16-18	(ref)	0.698
Follow any	19	16-21	1.1 (0.9-1.2)	
Follow STROBE	18	15-21	1.0 (0.9-1.2)	
Attach STROBE checklist	19	14-20	1.0 (0.8-1.2)	
Impact factor			1.0 (1.0-1.1)	0.387
Percentage ranking			1.0 (1.0-1.0)	0.279
Journal category [#]				
Respiratory	18	15-20	(ref)	0.762
Allergy	18	16-20	1.0 (0.9-1.2)	
Paediatrics	18	16-20	1.0 (0.9-1.2)	
General medicine	18	14-20	1.0 (0.8-1.2)	
Infectious diseases	15	15-15	0.9 (0.5-1.4)	
Pub health/epidemiology/environment	19	18-21	1.1 (0.9-1.2)	
Other	22	15-22	1.1 (0.9-1.3)	
Continent of study				
Europe	20	17-21	(ref)	0.493
North America	19	16-21	1.0 (0.9-1.1)	
South America	15	14-16	0.8 (0.6-1.1)	
Africa	16	16-18	0.9 (0.7-1.1)	
Asia	18	13-18	0.9 (0.7-1.03)	
Pacific	16	15-18	0.9 (0.8-1.1)	
Several	21	15-21	1.0 (0.8-1.3)	
Research question				
Aetiology	19	17-21	(ref)	0.078
Natural history / prognosis	18	16-20	1.0 (0.9-1.1)	
Diagnosis	14	14-14	0.7 (0.4-1.3)	
Treatment effects	16	15-17	0.8 (0.7-0.97)	
Main diagnosis of interest				
Asthma or wheeze	19	16-21	(ref)	0.825
Respiratory infectious diseases	18	16-18	0.9 (0.8-1.1)	
Rare diseases*	18	15-21	1.0 (0.9-1.1)	
Lung function (healthy children)	20	20-21	1.1 (0.9-1.4)	
Other**	17	16-21	1.0 (0.8-1.2)	

*Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia. **Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms. [#]Categories according to the InCites Journal Citation Report, if a journal appeared in 2 categories, it was classified as the first in which it appears in this order: respiratory, allergy, infectious diseases, public health/epidemiology/environment, paediatrics, general medicine and any other category. ^{##}: Estimated with the likelihood ratio test. IQR: inter-quartile range, RCT: randomized controlled trial.

Table 2 shows the results of the univariable Poisson regression analysis of the factors associated with the number of reported items from the STROBE checklist for cohort studies. None of the studied factors was clearly associated with the STROBE score. The journal's characteristics (belonging to a society, impact factor, percentage ranking and journal category), continent of study and main diagnosis of interest were not associated with the STROBE score. Only studies on treatment effects had a lower score (poorer reporting) when compared to those with an aetiological research question (IRR 0.8, 95% CI 0.7-0.97). Table 3 shows the association between these same characteristics and the reporting of 4 specific items (those that had been reported in less than 60% of the manuscripts). As previously, most tested factors were not associated with the reporting of any of the 4 specific items, except for the location of the study, showing a smaller odds to report these items if the study was undertaken in Africa, Asia or the Pacific, compared to Europe. The study of treatment effects or of natural history of disease/prognosis vs. aetiology, had also a lower odds of reporting 3 of the items. As for the journal reporting recommendations, manuscripts published in journals that recommended following any reporting guideline were more likely to discuss the generalisability of the study findings compared to those published in journals with no recommendations.

		Crude OR (95%CI)	for reporting items	1
	Item 9	Item 12	Item 14	ltem 21
	(Bias)	(Statistics)	(Descriptive)	(Generalisability)
Society journal	1.7 (0.7-3.8)	1.7 (0.7-3.9)	1.0 (0.5-2.3)	1.1 (0.5-2.4)
Journal reporting				
recommendation				
None	(ref)	(ref)	(ref)	(ref)
Follow any guideline	3.0 (0.9-9.5)	1.1 (0.4-3.6)	1.2 (0.4-3.8)	3.7 (1.1-12.1)
Follow STROBE	2.0 (0.6-6.1)	1.1 (0.3-3.4)	0.7 (0.2-2.3)	1.2 (0.4-3.8)
Attach STROBE checklist	1.4 (0.3-5.9)	0.9 (0.2-3.9)	0.7 (0.2-3.1)	1.7 (0.4-7.4)
Impact factor	1.1 (0.96-1.2)	1.1 (0.99-1.2)	1.0 (0.9-1.1)	1.1 (0.99-1.2)
Percentage ranking	1.0 (0.9-1.03)	1.0 (1.0-1.0)	1.0 (1.0-1.0)	1.0 (1.0-1.0)
Journal category*				
Respiratory	(ref)	(ref)	(ref)	(ref)
Allergy	2.3 (0.8-6.7)	1.6 (0.5-5.0)	1.8 (0.6-5.1)	0.6 (0.2-1.8)
Paediatrics	0.9 (0.3-3.4)	1.3 (0.3-5.1)	1.5 (0.4-5.3)	0.4 (0.1-1.6)
General medicine	0.5 (0.08-3.5)	2.6 (0.4-15.9)	1.3 (0.2-7.6)	0.3 (0.05-2.2)
Infectious diseases	-	-	-	-
Pub health/epidemiology/ environment	4.9 (0.9-27.3)	1.5 (0.3-6.6)	2.2 (0.5-9.6)	0.8 (0.2-3.3)
Other	1.3 (0.3-5.4)	4.5 (1.0-20.3)	3.4 (0.7-15.9)	1.2 (0.3-5.1)
Continent of study	· · ·	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	ζ ,
Europe	(ref)	(ref)	(ref)	(ref)
North America	0.4 (0.1-1.03)	0.5 (0.2-1.3)	0.7 (0.3-1.9)	1.4 (0.6-3.7)
South America	0.4 (0.2-6.8)	-	-	-
Africa	0.1 (0.01-0.97)	0.6 (0.9-4.0)	0.8 (0.1-5.7)	0.6 (0.1-4.0)
Asia	0.2 (0.05-0.9)	0.1 (0.01-0.8)	0.5 (0.1-1.8)	0.1 (0.01-0.8)
Pacific	1.3 (0.2-7.6)	0.5 (0.1-2.1)	0.2 (0.02-0.9)	3.1 (0.6-17.2)
Several	0.8 (0.06-9.5)	0.5 (0.04-5.4)	1.1(0.1-13.7)	0.5 (0.04-5.4)
Research question			. ,	
Aetiology	(ref)	(ref)	(ref)	(ref)
Natural history / prognosis	1.0 (0.4-2.4)	0.4 (0.2-0.97)	0.7 (0.3-1.6)	1.0 (0.4-2.4)
Diagnosis	-	-	-	-
Treatment effects	0.2 (0.04-0.7)	-	0.2 (0.07-0.9)	0.4 (0.1-1.3)
Main diagnosis of interest				
Asthma or wheeze	(ref)	(ref)	(ref)	(ref)
Respiratory infectious dis.	1.0 (0.3-3.4)	0.6 (0.2-2.0)	1.1 (0.3-3.6)	0.2 (0.06-0.98)
Rare diseases*	1.2 (0.4-3.7)	0.5 (0.2-1.6)	0.6 (0.2-1.7)	1.2 (0.4-3.5)
Lung function (healthy)	-	2.5 (0.2-28.7)	1.3 (0.1-15.3)	1.6 (0.1-18.9)
Other**	3.0 (0.6-15.9)	0.2 (0.2-1.3)	0.3 (0.07-1.4)	0.7 (0.2-2.7)

Table 3: Association between studies' and journal's characteristics, and reporting of the 4 most poorly reported items (<60% of the manuscripts) from a logistic regression (N=100).

*Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia. **Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms. [#]Categories according to the InCites Journal Citation Report, if a journal appeared in 2 categories, it was classified as the first in which it appears in this order: respiratory, allergy, infectious diseases, public health/epidemiology/environment, paediatrics, general medicine and any other category. IQR: inter-quartile range, RCT: randomized controlled trial.

Discussion

Summary of main findings

This systematic review found that reporting quality of cohort studies on paediatric lower respiratory problems was insufficient; only 15% of the manuscripts included all the recommended items from the STROBE checklist and 42-63% missed specific items such as a correct description of statistical methods. Most published paediatric cohort studies were based in Europe and North America, answering research questions on aetiology and risk factors, and centred on asthma or wheeze. The most frequently used design were birth cohorts with only limited use of alternative strategies that may reduce the costs of cohort studies, such as record linkage or nested case-control studies. Finally, most studies were published in specialised respiratory or allergy journals.

Interpretation of results

During the screening process, we found that one fifth (101) of the 521 excluded full-text papers were actually not cohort studies (77) or did not use a longitudinal analysis (24), despite appearing in a search using specific search terms such as "cohort" or "follow-up", and although we had already excluded papers based on the information in the title or abstract. This was sometimes due to the incorrect use of the word "cohort" and the absence of a clear description of the study design in the abstract or title. This information was still missing in 17% of the included manuscripts. The cohort studies on paediatric lower respiratory problems in 2018 that we analysed, focused mostly on aetiology of asthma and were based in Europe or North America. Lower respiratory infectious diseases, such as pneumonia or tuberculosis, which are a major cause of death in children under 5 years of age worldwide [9], were the focus of only 15% of the studies. This may be because most of the studies are based in high income countries, whereas the burden of respiratory infectious diseases is much higher in low and middle-income countries [9]. The most commonly used design was the birth or pregnancy cohort study. This is

an excellent design to study early life factors and their influence on disease, but also quite expensive as it needs a large sample size to achieve an adequate number of children with a specific outcome and a long follow-up. Adaptations of cohort studies that are cheaper such as case-control studies nested in cohort studies were rarely used (3%). Linking available routine data is often an elegant way to obtain a cohort dataset with little or no selection bias or attrition bias, and achieve large sample sizes at a low cost (even whole population studies)[10]. As a disadvantage, studies based on linked routine data often lack clinically relevant details on exposure and outcome, resulting in measurement bias. This design was used in one quarter (85) of the included studies, and limited to countries with adequate electronic record keeping and unique personal identifiers (such as the social security number) that enables linkage between different datasets.

Even though reporting quality of observational studies improved after the publication of the STROBE statement [6], current studies in different medical fields have shown that adherence to STROBE reporting criteria remains poor or at most moderate [2-7,11-15]. Poor reporting quality does not necessarily imply that the conduct and analysis of the study has been poor. On the other hand, a high STROBE score does not allow to conclude that the study planning and conduct have been excellent. But good reporting is essential, as it enables readers and reviewers to assess the quality and risk of bias of a study. For example, we cannot assess attrition bias if authors do not report how many participants were lost to follow-up in a cohort study. There are multiple tools available to assess the methodological quality or the risk of bias of observational studies [16], such as the Newcastle-Ottawa Scale, an easy tool that assesses the quality of non-randomised studies included in a systematic review based on the selection of the study groups, the comparability of the groups, and the ascertainment of the exposure or outcome of interest [17]. The items we identified as being frequently missed, such as the description of statistical methods, the sample size estimation or the potential sources of bias have been also reported in previous studies [3,6,7,1,1,2,1,4,15]. These items are essential to

enable other researchers to reproduce the study and to evaluate its internal and external validity. The handling of missing information was insufficiently reported in the papers included in this review, both in the methods (43% of papers) and results (59%) section, resulting in a possible source of bias. Missing data and loss to follow up are common limitations of cohort studies, but the implementation of specific statistical strategies, like multiple imputation or inverse probability weighting [18], may attenuate its impact. Reporting bias and confounding is even more important in cohort studies analysing causal associations. Experts recommend specific strategies for adequate variable selection and interpretation of results in causal inference studies, such as the use of Direct Acyclic Graphs to identify possible confounders and mediators [19], and the presentation of effect estimates with their measures of variability (confidence intervals) instead of P values in isolation [20]. These strategies were discussed in a recent editorial by editors of respiratory, sleep, and critical care journals, where they also highlighted the importance of adhering to STROBE guidelines when reporting sources of bias and confounding [21].

A plausible reason for not reporting all the STROBE items may be the limitation of manuscript's length, reducing the amount of information that may be included in the paper. Although most journals offer the possibility of including supplementary online text and tables, they should adjust their policies and guidelines to ensure authors are able to comply with reporting guidelines. For example, to allow longer titles to include the study design, and longer methods sections to encourage a more detailed description of the statistical methods (e.g. handling of missing data and identification of confounders). On the other hand, authors may not be aware of the existence of the STROBE statement [22] or they may deliberately omit certain information such as missing data to increase the publication chances. In this case, it is the journals' responsibility to inform the authors about the different reporting guidelines for each study design. Cohort studies may need to also adhere to other reporting guidelines depending on the aim of the manuscript, such as the TRIPOD (Transparent reporting of a multivariable

prediction model for individual prognosis or diagnosis)[23], or to specific STROBE extensions, such as RECORD (REporting of studies Conducted using Observational Routinely-collected health Data)[24]. There are several other STROBE extensions for specific clinical areas, but these all include additional criteria to the basic STROBE checklist, so the standard criteria remain valid. We did not assess the adherence to any other reporting guideline, but none of the 100 subsampled manuscripts stated using them. These reporting guidelines are all listed in the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network homepage [25]. Journals should promote adherence to reporting guidelines through a compulsory attachment of the reporting checklist at submission and as an online supplement for readers. In addition, journals should implement further measures such as involving reviewers in checking reporting quality or even employing a journal methodologist to check manuscripts substantially before final acceptance. Only by applying this measure in a strict way, as it is done with randomized controlled trials, will the reporting quality of observational studies improve and become standardised.

Quality of reporting was not associated with the characteristics of the journal in our study. It did not depend on the journal's impact factor, percentage ranking, society ownership, category (by subject), or reporting recommendations. Similarly, it was not associated with the study's location, research question or main diagnosis of interest, except for a decreased STROBE score of papers reporting on treatment effects compared to aetiology. Previous studies have found quality of reporting of observational studies to be associated with some of these factors, such as the journal's impact factor [7] and authors guidelines [6], the publication type (peerreviewed vs report) [3,5] or the author's affiliation (public health agency vs academic) [5]. However, these findings are not consistent [15] and are sometimes based on small samples (<80 manuscripts) in specific fields. This shows that reporting quality of cohort studies in paediatric respiratory research needs to be improved globally.

Strengths and limitations

This systematic review is the first to describe the characteristics of cohort studies reporting on paediatric lower respiratory problems published recently and to assess their reporting quality according to the STROBE statement. We collected detailed information on a large number of studies published worldwide. However, the review has some limitations. First, we did not extend our search to specific databases from South America, Africa or Asia and limited the included studies to those published in English. This may have been one of the reasons for the under-representation of these regions of the world. However, the most important and relevant studies are normally published in English and indexed in Medline or Embase to increase accessibility. Second, the large number of studies included precluded a duplicate screening and data extraction. This may be more relevant for the evaluation of the STROBE checklist items, some of which may be rather subjective. However, all assessors were from the same research team; we used well-defined criteria for manuscript inclusion and exclusion, and for the assessment of adherence to each of the STROBE checklist's elements; and papers where the assessor was uncertain, were discussed in the team until agreement was reached.. Third, the criteria we used to evaluate the adherence to each of the STROBE checklist's items were not very strict. For example, when evaluating the information on confounders or reporting of limitations, we only evaluated if confounders were considered or if limitations were mentioned. We did not study in detail each manuscript to assess if the confounders included or the limitations described were correct and complete. Therefore, our evaluation of the reporting quality is quite optimistic and reporting quality may be even poorer.

Conclusion

The findings of this review may inform both authors and editors on how to increase reporting quality of papers of cohort studies reporting on paediatric lower respiratory problems and what areas of research are neglected. Researchers should follow reporting guidelines (either STROBE

or as appropriate) closely when submitting a manuscript and should check these when reviewing other researchers' manuscripts. The use of nested case-control studies, well designed retrospective chart reviews and linkage of routine data with study data should be borne in mind when designing a cohort study to reduce costs. On the other side, editors from international journals should encourage the publication of studies focused on lower respiratory infections and rare diseases, and those based in low and middle-income countries. Journals should not only endorse the STROBE statement for the reporting of cohort studies, but should demand authors to attach the STROBE checklist during the submission process and ask reviewers to report any missing item in the manuscript. Only through a joined effort of editors, reviewers and authors may we improve the reporting quality of paediatric cohort studies on respiratory problems.

Acknowledgements: This paper was motivated by a "Paediatric Year in Review" symposium presentation at the European Society Congress in 2018.

Funding: Swiss National Science Foundation (SNF Grant: 32003B_162820). MO was paid by the Swiss Cancer Research grant (Grant Number: 4157-2017) to CK.

REFERENCES:

1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007;85:867-72.

2. Hendriksma M, Joosten MH, Peters JP, Grolman W, Stegeman I. Evaluation of the quality of reporting of observational studies in otorhinolaryngology-based on the STROBE statement. PloS one 2017;12:e0169316.

3. Huynh N, Baumann A, Loeb M. Reporting quality of the 2014 Ebola outbreak in Africa: A systematic analysis. PloS one 2019;14:e0218170.

4. Papathanasiou AA, Zintzaras E. Assessing the quality of reporting of observational studies in cancer. Ann Epidemiol 2010;20:67-73.

5. Lo C, Mertz D, Loeb M. Assessing the reporting quality of influenza outbreaks in the community. Influenza Other Resp 2017;11:556-63.

6. Swords C, Bhargava EK, Meghji S, Smith ME, Tysome JR. An Assessment of the Change in Compliance of Observational Otology and Audiology Studies With the STROBE Statement Guidelines: A Systematic Review. Otol Neurotol 2019;40:284-91.

7. Tacconelli E, Cataldo MA, Paul M, Leibovici L, Kluytmans J, Schröder W, Foschi F, De Angelis G, De Waure C, Cadeddu C. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ open 2016;6:e010134.

8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.

9. GBD Compare Data Visualization. 2018. (Accessed 07.04.2019, 2019, at <u>http://vizhub.healthdata.org/gbd-compare</u>.)

10. Lodge CJ, Bråbäck L, Lowe AJ, Dharmage SC, Olsson D, Forsberg B. Grandmaternal smoking increases asthma risk in grandchildren: A nationwide Swedish cohort. Clin Exp Allergy 2018;48:167-74.

11. Adams AD, Benner RS, Riggs TW, Chescheir NC. Use of the STROBE Checklist to Evaluate the Reporting Quality of Observational Research in Obstetrics. Obstet Gynecol 2018;132:507-12.

12. Agha RA, Lee S-Y, Jeong KJL, Fowler AJ, Orgill DP. Reporting quality of observational studies in plastic surgery needs improvement: a systematic review. Ann Plas Surg 2016;76:585-9.

13. Hemkens LG, Benchimol EI, Langan SM, Briel M, Kasenda B, Januel J-M, Herrett E, von Elm E. The reporting of studies using routinely collected health data was often insufficient. J Clin Epidemiol 2016;79:104-11.

14. Shawyer AC, Pemberton J, Kanters D, Alnaqi AA, Flageole H. Quality of reporting of the literature on gastrointestinal reflux after repair of esophageal atresia–tracheoesophageal fistula. J Pediatr Surg 2015;50:1099-103.

15. Yolcu Y, Wahood W, Alvi MA, Kerezoudis P, Habermann EB, Bydon M. Reporting Methodology of Neurosurgical Studies Utilizing the American College of Surgeons-National Surgical Quality Improvement Program Database: A Systematic Review and Critical Appraisal. Neurosurgery 2019.

16. Sanderson S, Tatt ID, Higgins J. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. International journal of epidemiology 2007;36:666-76.

17. Wells GA, Tugwell P, O'Connell D, Welch V, Peterson J, Shea B, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. 2015. 18. Perkins NJ, Cole SR, Harel O, Tchetgen Tchetgen EJ, Sun B, Mitchell EM, Schisterman EF. Principled approaches to missing data in epidemiologic studies. American journal of epidemiology 2018;187:568-75.

19. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-25.

20. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol 2016;31:337-50.

21. Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR. Control of confounding and reporting of results in causal inference studies. guidance for authors from editors of respiratory, sleep, and critical care journals. Annals of the American Thoracic Society 2019;16:22-8.

22. Sharp MK, Tokalić R, Gómez G, Wager E, Altman DG, Hren D. A cross-sectional bibliometric study showed suboptimal Journal endorsement rates of STROBE and its extensions. J Clin Epidemiol 2019;107:42-50.

23. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. Ann Intern Med 2015;162:55-63.

24. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sorensen HT, von Elm E, Langan SM. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med 2015;12:e1001885.

25. Enhancing the QUAlity and Transparency Of health Research. 2019. (Accessed 15.12.2019, 2019, at <u>https://www.equator-network.org/</u>".)





Figure 1: Flow diagram of included and excluded studies.

Location		Percentage
Europe	161	44
North America	108	29
Asia	37	10
Pacific	27	7
Africa	17	5
South America	12	3
Several continents	7	2
Sample size (median, IQR) (N= 368)	746 (188-4535)	
Sample size category (N= 368)		
<100	48	13
100 - 999	160	43
1 000 - 9 999	88	24
≥ 10 000	72	20
Study design		
Birth/pregnancy cohort	152	41
Clinical cohort (prospective)	109	30
Population-based cohort (after birth)	56	15
Retrospective chart review	35	9
RCT with continued follow-up	10	3
Nested case-control study	7	2
Linkage with routine data (N = 367)	85	23
Research question	05	23
Aetiology/risk factors / genetics	194	53
Natural history / prognosis / trajectories	116	31
Treatment effects	52	14
Diagnosis	4	1
Disease phenotyping	3	
Main diagnosis of interest	5	1
Asthma or wheeze	214	
Rare diseases*	64	17
Respiratory infectious diseases	55	15
Lung function (healthy children)	14	4
Other diagnoses**	22	6
Source of baseline data (multiple possible)	22	
Questionnaire / interview	128	35
Direct examination /laboratory /diagnostic tests	134	36
Hospital record	91	25
Linkage of routine datasets	66	18
Treatment given	23	6
Source of outcome data (multiple possible)	25	
Questionnaire / interview	157	43
Direct examination /laboratory /diagnostic tests	83	22
· · · -	66	18
Hospital record	63	17
Linkage of routine datasets		17
Follow-up time, years (median, IQR) (N= 361)	5 (1-10)	
lournal category [#] (multiple possible)	4.55	20
Respiratory	103	28
Allergy / Immunology	88	
Paediatrics	57	15
Pub health / epidemiology / environment	37	10
Infectious diseases	14	4
General Medicine	23	6
Other categories	47	13

Fig. 2: Characteristics of cohort studies reporting on paediatric respiratory problems in 2018 (N= 369)

*Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia. **Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms. "Categories according to the InCites Journal Citation Report, if a journal appeared in 2 categories, it was classified as the first in which it appears in this order: respiratory, allergy, infectious diseases, public health/epidemiology/environment, paediatrics, general medicine and any other category. IQR: inter-quartile range, RCT: randomized controlled trial.



A. Research question by diagnosis of interest

B. Sample size by diagnosis of interest




Figure 3: Type of research question (A) and sample size (B) by diagnosis of interest, of cohort studies reporting on paediatric respiratory outcomes or exposures in 2018 (N= 369).

The number inside each bar is the total number of manuscripts for each section.

Supplementary Text

Search terms used for Medline (Ovid)

1. exp cohort studies /

2. (cohort* or prospectiv* or longitudinal* or nested or retrospectiv* or follow*).ti,ab,kw.

3. exp pediatrics/ or exp adolescent/ or exp child/ or exp infant/

4. (toddler* or infan* or child* or schoolchild* or adolescen* or teen* or pediatr* or paediatr*).ti,ab,kw

5. exp "Respiratory Tract Diseases"/ or exp "signs and symptoms, respiratory"/

6. (asthma* or wheez* or bronch* or trache* or laryng* or "vocal cord*" or "primary ciliary dyskinesia" or "cystic fibrosis" or "lung disease*" or "lung infection" or respirat* or cough* or dyspn* or pneumo* or pleura* or pulmonar* or chest or thora* or empyema or "lung abscess" or legionell* or tuberculos* or aspergill* or blastomycos* or "syncytial virus").ti,ab,kw.

7. exp Respiratory Function Tests/

8. ("Airway Resistance" or "Blood Gas Analysis" or Oximetry or Capnography or "Exercise Test*" or "Lung Compliance" or "Lung Volume" or "Lung Capacity" or Plethysmography or "Ventilation-Perfusion" or "forced expiration" or "expiratory flow" or "expiratory volume" or "Maximal Voluntary Ventilation" or "maximal expiratory" or spirometry or "Valsalva Maneuver" or "lung function" or "lung examination" or sputum or "lung biopsy" or "multiple breath washout" or "transthoracic" or "lung angiography" or "lung lavage").ti,ab,kw.

9. exp respiration/

10. (breathing or "breath holding" or exhalation or inhalation or "mucociliary clearance" or "lung clearance" or "lung diffusion" or "lung gas exchange" or "lung mechanics" or "lung ventilation").ti,ab,kw.

11. 1 or 2

12. 3 or 4

13. 5 or 6 or 7 or 8 or 9 or 10

14. 11 and 12 and 13

15. limit 14 to english language

16. limit 15 to year='2018'

TOTAL: 7610 references

Supplementary Table 1: Classification of journals according to the categories used by the In Cites Journal Citation Report.

Paediatrics	Acta Daadiatrica
	- Acta Paediatrica
	- American Journal of Perinatology
	- Archives of Disease in Childhood
	- BMC Pediatrics
	- BMJ Paediatrics Open
	- Clinical Pediatrics
	- Early Human Development
	- Egyptian Pediatric Association Gazette
	- European Journal of Pediatrics
	- International Journal of Pediatrics
	- Jornal de Pediatria
	- Journal of Adolescent Health
	- Journal of Pediatrics
	- Journal of Perinatology
	- Maternal & Child Health Journal
	- Minerva Pediatrica
	- Neonatology
	- Paediatrics & Child Health
	- Pediatric Research
	- Pediatric Research
	- Pediatrics & Neonatology
	- Prenatal Diagnosis
	- Revista Paulista de Pediatria
	- The Lancet Child & Adolescent Health
Infectious diseases	- AIDS Research & Human Retroviruses
	- Antibiotics
	- Clinical Infectious Diseases
	- Emerging Infectious Diseases
	- European Journal of Clinical Microbiology & Infectious Diseases
	- Journal of Infectious Diseases
	- Journal of Medical Virology
	- Journal of Microbiology, Immunology & Infection
	 Journal of Microbiology, Immunology & Infection Open Forum Infectious Diseases
	- Open Forum Infectious Diseases
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight Nature Communications
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight Nature Communications
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight Nature Communications PeerJ
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight Nature Communications PeerJ PLoS ONE
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight Nature Communications PeerJ PLoS ONE Revista Da Associacao Medica Brasileira
General Medicine	 Open Forum Infectious Diseases Pediatric Infectious Disease Journal Vaccine African Health Sciences BioMed Research International Bjgp Open BMJ Open Bosnian Journal of Basic Medical Sciences Colombia Medica Cureus Eastern Mediterranean Health Journal eLife Eurosurveillance International journal of general medicine JAMA Pediatrics Jci Insight Nature Communications PeerJ PLoS ONE Revista Da Associacao Medica Brasileira Sao Paulo Medical Journal = Revista Paulista de Medicina

Other	- Acta Obstatricia at Gynacologica Scandinavica
Uner	 Acta Obstetricia et Gynecologica Scandinavica American Journal of Clinical Nutrition
	- American Journal of Managed Care
	- American Journal of Obstetrics & Gynecology
	- American Journal of Respiratory Cell & Molecular Biology
	- American Journal of Tropical Medicine & Hygiene
	- Annals of Behavioral Medicine
	- Annals of Surgery
	- Arthritis care & research
	- British Journal of Dermatology
	- British Journal of Nutrition
	- CJEM Canadian Journal of Emergency Medical Care - Clinical Nutrition
	- Clinical Otolaryngology
	- ClinicoEconomics and Outcomes Research
	- CMAJ
	- European Journal of Clinical Nutrition
	- European Journal of Obstetrics, Gynecology, & Reproductive Biology
	- European Journal of Psychotraumatology
	- European Radiology
	- Frontiers in Pharmacology
	- Frontiers in Physiology
	- Health Promotion Practice
	- Health Services Insights
	- Hypertension
	- International Journal of Eating Disorders
	- Journal of Laparoendoscopic & Advanced Surgical Techniques.
	- Journal of Pediatric Gastroenterology & Nutrition
	- Journal of Pediatric Nursing
	- Journal of Pediatric Surgery
	- Journal of Racial & Ethnic Health Disparities
	- Journal of Voice
	- Maternal & Child Nutrition
	- Metabolomics
	- Nature Plants
	- Nutrients
	- Oncotarget
	- Orphanet Journal Of Rare Diseases
	- Pediatric Critical Care Medicine
	- Pharmacoepidemiology & Drug Safety
	- Postepy Dermatologii I Alergologii
	- Psychology & Health
<u> </u>	- Ultrasound in obstetrics & gynecology

	Respira- tory (N=103)	Allergy/ Immun (N=88)	Resp. infect dis. (N=14)	PH /epi /envir. (N=37)	Paedia- trics (N=57)	General med. (N=23)	Other (N= 47)
Location							
Europe	45 (44)	40 (45)	3 (21)	17 (46)	23 (40)	6 (26)	27 (57)
North America	31 (30)	21 (24)	6 (43)	9 (24)	23 (40)	6 (26)	12 (26)
South America	2 (2)	3 (3)	0	0	3 (5)	4 (17)	0
Africa	4 (4)	5 (6)	0	3 (8)	1 (2)	3 (13)	1 (2)
Asia	6 (6)	14 (16)	2 (14)	4 (11)	3 (5)	4 (17)	4 (9)
Pacific	10 (10)	4 (5)	3 (21)	3 (8)	4 (7)	0	3 (6)
Several continents	5 (5)	1 (1)	0	1 (3)	0	0	0
Sample size (median, IQR) (N=	564	769	1403	3537	701	432	664
368)	(144-	(250-	(158-	(641-	(145-	(77-	(161-
	3277)	2892)	15504)	23100)	4475)	10476)	9038)
Sample size category (N= 368)							
<100	20 (19)	5(6)	1 (7)	1 (3)	8 (14)	6 (26)	7(15)
100 - 999	42 (41)	46 (52)	5 (36)	11 (30)	26 (46)	8 (35)	22(47)
1 000 – 9 999	28 (27)	25 (28)	4 (29)	11 (30)	10 (18)	3 (13)	7(15)
≥ 10 000	13 (13)	12 (14)	4 (29)	14 (38)	13 (23)	6 (26)	11(23)
Study design							
Birth/pregnancy cohort	44 (43)	42 (48)	2 (14)	20 (54)	22 (39)	5 (22)	17(36)
Population-based (after birth)	12 (12)	10 (11)	2 (14)	10 (27)	8 (14)	6 (26)	8(17)
Clinical cohort (prospective)	31 (30)	28 (32)	9 (64)	6 (16)	14 (25)	7 (30)	14(30)
Retrospective chart review	13 (13)	0	0	0	12 (21)	4 (17)	6(13)
Nested case-control	1 (1)	3(3)	1(7)	0	0	1 (4)	1(2)
RCT with continued follow-up	2 (2)	5 (6)	0	1(3)	1 (2)	0	1(2)
Linkage with routine data (N=	18(18)	19 (22)	5 (36)	10 (27)	13 (23)	5 (22)	15(32)
367)							
Research question							
Aetiology	42(41)	50 (57)	4 (29)	27 (73)	27 (47)	15 (65)	29(62)
Natural history / prognosis	40(39)	28 (32)	7 (50)	4 (11)	20 (35)	4 (17)	13(28)
Diagnosis	4 (4)	0	0	0	0	0	0
Treatment effects	17(17)	8 (9)	3 (21)	5 (14)	10 (18)	4 (17)	5 (11)
Aetiology	0	2 (2)	0	1 (3)	0	0	0
Main diagnosis of interest		. /		. ,			
Asthma or wheeze	56 (54)	72 (82)	1(7)	25 (68)	22 (39)	13 (57)	25(53)
Respiratory infectious dis.	7 (7)	11 (13)	9 (64)	5 (14)	14 (25)	4 (17)	5 (11)
Rare diseases*	27(26)	0	4 (29)	0	16 (28)	4 (17)	13(28)
Lung function (healthy)	7 (7)	1 (1)	0	4 (11)	0	0	2 (4)
Other**	6 (6)	4 (5)	0	3 (8)	5 (9)	2 (9)	2 (4)

Supplementary Table 2: Characteristics of cohort studies reporting on paediatric respiratory outcomes or exposures in 2018, by journal categories (N=369)[#]

_

Figures represent 'n (%)' unless otherwise stated *Rare diseases include: bronchopulmonary dysplasia, diaphragmatic hernia, cystic fibrosis and primary ciliary dyskinesia. **Other diagnoses include: cough, respiratory distress syndrome, pneumothorax and unspecific respiratory symptoms. IQR: inter-quartile range, RCT: randomized controlled trial, CF: cystic fibrosis, PCD: Primary ciliary dyskinesia.

Chapter 8 - Other activities

8.1 Grant applications

Pulmonary function in long-term childhood cancer survivors after hematopoietic stem cell transplantation; Otth M (PI), Kuehni C (Co-PI), Latzin P (Co-PI); Lungenliga Bern 2020; CHF 33'570 (salary funding for primary applicant for 7 month)

8.2 Teaching activities

During my PhD I have participated in the following teaching activities at the Institute of Social and Preventive Medicine at the University of Bern.

Internal teaching	EndNote course at the IPSM, open for all interested employees			
Medical students of the University of Bern	 2019-2020: Writing of multiple choice questions for the exam of medical students 2019: Tutor in Problem Based Learning (PBL) of medical students 			
Co-supervision of Master thesis of medical students (main supervisor: Claudia Kuehni)	 (1st year) at the University of Bern Master student: Morena Elber. Thesis title: Prävalenz abnormer Spirometrie bei ehemaligen Kinderkrebspatienten nach hämatopoetischer Stammzelltransplantation 			
	Master student: Sophie Käser. Thesis title: Prevalence and Severity of Hearing Loss in Childhood Cancer Survivors exposed to Platinum Chemotherapy and/or Cranial Radiation			

8.3 Peer review activity

During my PhD I have contributed to several peer reviews in the cancer and respiratory group of Claudia Kuehni in Thorax, Electronic Journal of General Medicine, and Pediatrics. As invited reviewer, I have performed reviews for PLOS ONE.

8.4 International Guideline Harmonization Group - Metabolic Syndrome

Since May 2018 I am involved in the International Guideline Harmonization Group on metabolic syndrome. I have been mainly involved in evidence extraction and being a second reviewer to assess the extracted evidence by other members.

8.5 Life After Childhood Cancer (LACC) research group



Since January 2019 I am working parttime (20%) as staff physician with focus in research for the newly established Life After Childhood Cancer (LACC) research group at the Kantonsspital Aarau (KSA), under the leadership of Dr. med. Katrin Scheinemann. Research within this group focusses on survivorship care and late effects. We organized an information event for survivors, parents, and health care professionals focusing on survivorship care. We have established the multicenter prospective longitudinal After Childhood Cancer Study (ACCS) to evaluate the transition process from pediatric to adult long-term follow-up care at three different pediatric oncology centers in Switzerland. The project is funded by Cancer Research Switzerland with myself as sub-investigator. We have established the "Young Survivor at KSA" registry, focusing on standardized collection of medical conditions (late effects) in survivors. This registry is supported by a grant from the KSA. Most recently I received a grant from the KSA to perform a study on needs of schools and teachers in reintegrating childhood and adolescent cancer patients into school life during and after completion of treatment.

8.6 Young SIOPE – Essential Medicines project

SI P P

I am actively involved in Young SIOPE, a newly launched group within SIOP Europe in May 2019. Young SIOPE is a group for young members of the European pediatric oncology community and intends to foster a closer community and facilitate involvement of SIOPE's youngest members in research, development and education. I am one of the six board members of Young SIOPE. I have coordinated several pan-European projects, mainly the Essential Medicines project, which aims to:

- 1. provide an evidence based reference list of essential medicines for all pediatric cancer diseases to stakeholders in Europe,
- 2. contribute to the next revisions of the WHO Essential Medicines list for children (EMLc), start proposing new diseases and drugs to be added to the new version in 2021, and
- 3. assess how different European health technology agencies (HTAs) evaluate newly approved expensive anti-cancer medicines for children.

This project was also presented as a poster during the SIOP congress in 2020 and aims to result in several publications.

Appendix A - Questions on pulmonary health and smoking from the SCCSS used in publication I

Have you ever been told by a doctor that you have, or have had	Ever in l	Ever in life?		Currer	Currently?	
	Yes	No		Yes	No	
Chronic Cough (for more than 3 months)			(Year)			
Pneumonia						
If yes, how many in the last two years?						
Pneumonia			(Year)			
Lung fibrosis (scarring of the lung)			(Year)			
Changes on your thorax and/or ribs			(Year)			
Emphysema (Overinflation oft he lungs)			(Year)			
Any other breathing or lung problem?						
If yes, please describe this problem						
			(Year)			

Smoking (version adolescents and adults)

Have you ever smoked cigarettes?

No, I never smoked

No, I stopped smoking since ____ month 🗌

Yes, I smoke irregularly: number ____ of cigarettes per week 🗌

Yes, I smoke regularly: number ____ of cigarettes per week ____

How many hours a day are you exposed to tobacco smoke from other people?

_____ hours and _____ minutes per day (max. 24 hours)

Don't know 🗌

No answer

Smoking (version parents)

Have you ever smoked cigarettes?

Mother

No, never 🗌
Yes, but stopped since years 🗌
Yes, still smoke today 🗌

Father

Yes, but stopped since ____ years 🗌

Yes, still smoke today 🗌

Appendix B - Data extraction sheet used for publication I and publication II

Identification

R Given name:
Date of birth:
First relapse
Date:
Treatment protocol:
Treatment arm (if applicable):
Protocol complete 📋 yes 🗌 no
I
Secondary tumor
Date:
Treatment protocol:
Treatment arm (if applicable):
Protocol complete 🔲 yes 🗌 no

Chemotherapy

Known pulmonary toxicity

Drug	Cumulative dose and unit (e.g. mg/m ² , mg/kg) state if Busulfan is AUC	Way of administration (IV/PO/IM)	Dose quality (1=acc. to protocol 2= intended to treat, 3=incomplete dose 4= no dose available)	Data quality (1=duration acc. to protocol 2=duration application unknown)
Bleomycin				
Busulfan				
BCNU (Carmustine)				
CCNU (Lomustine)				
Cyclophosphamide				

HSCT conditioning regimen or other suspected lung toxic agents

Drug	Cumulative dose and unit (e.g. mg/m ² , mg/kg) state if Busulfan is AUC	Way of administration (IV/PO/IM)	Dose quality (1=acc. to protocol 2= intended to treat, 3=incomplete dose 4= no dose available)	Data quality (1=duration acc. to protocol; 2=duration not acc. to protocol; 3=application unknown)
Fludarabine				
Ifosfamide				

Melphalan		
Other conditioning		

State all chemotherapeutic agents given (also when already mentioned in cumulative doses)

Name	Name	Name	
Alemtuzumab	Etoposide	Mitoxantrone	
(Campath)	(VP-16)		
Asparaginase	Fludarabine	Procarbacine	
Anti-Thymocyte Globulin (ATG,	Idarubicin	Temozolomide	
ATGAM)			
Bleomycin	Ifosfamide	6-Thioguanine	
Busulfan	Lomustine (CCNU)	Thiotepa	
Carboplatin	Mechloretha-mine	Vinblastine	
Carmustin (BCNU)	Melphalan		
Chlorambucil	Methotrexate	Vincristine	
Cisplatin	Methotrexate i.v.	Vindesine	
	(HD = >1g/m ² /Dosis)		
Cyclophosphamide	Methotrexate i.v.	Prednison:	
	(NOT HD)		
Cytarabine (Ara-C)	Methotrexate p.o.	Dexamethason	
Dacarbacine (DTIC)	Methotrexate i.th/i.ventr.	Other:	
Dactinomycin/Actinomycin D	6-Mercapto-purine	Other:	
Daunorubicin		Other	
Doxorubicin	Epirubicin		

MTX IV/PO/IT/Ommaya

Drugs in blue color = calculation of cumulative doses in CCSS

Radiotherapy

Date of start radiotherapy	
Location of radiotherapy	Dose [Gy]
thorax, whole	
thorax, partially	
mantle	
extended mantle	
🔲 mini mantle	
mediastinal	
involved site RT (ISRT)	
involved field RT (IFRT)	
extended field RT (EFRT)	
subtotal lymphoid irradiation (STLI)	
(mantle + paraaortic field)	
□ other	
chest wall (e.g. muscle oft he chest wall, rib)	
□ thoracic spine	
craniospinal axis	
🔲 left kidney	
🔲 right kidney	
whole abdomen	
total body irradiation (TBI)	
total lymphoid irradiation (TLI)	

In case more than one radiotherapy has been performed to the same field: take additional CRF and number the radiotherapy episodes

Modality	Source	
2D conformal	Protontherapy	
3D conformal	Photontherapy	
IMRT		

Surgery

- Biopsy
- □ All other than biopsy

Thoracic wall	Lung	Mediastinal	Thoracic spine
(Rib, scapula, thoracic muscle)	(Thoracotomy, metastasectomy, lobectomy, wedge resection)		(laminectomy)

Exact description of surgery according to surgery protocol: _____

Hematopoietic Stem Cell Transplantation (HSCT)

Date of HSCT	
Time point of HSCT	☐ first remission
	☐ first relapse
	second relapse
	 third relapse for secondary tumor
НЅСТ	autologous marrow (marrow harvest)
	autologous stem cells (apheresis)
	□ allogeneic
	HLA identical sibling
	□ HLA matched other relative
	 HLA matched unrelated HLA mismatch related
	☐ haploidentical
	HLA mismatch unrelated
Source of transplant	□ cord blood
	 peripheral blood / PBSC bone marrow
Procedures before transplantation	□ T cell sorting
	□ T cell depletion
	□ other
Protocol name	unknown/ no data
Conditioning regimen	Busulfan
(Chemotherapeutic doses mentioned in)	Melphalan
(chemotherapeutic doses mentioned in)	□ VP16
	CYC
	Thiotepa
	П ТВІ
HLA- match (e.g. 10/10)	
	🔲 unknown/ no data
CMV status recipient	positive negative
CMV status donor	□ unknown/ no data □ positive □ negative
Gender donor	malefemale
	unknown/ no data
Gender recipient	in male in female
Blood group donor Blood group recipient	
GvHD	
	no yes
	acute
	unknown/no data
	□ location
	🗆 skin
	oral other:
	unknown/ no data

	time point of occurrence (days after HSCT)
	unknown/ no data
	Grade of GvHD
	🗌 unknown/ no data
	Treatment for GvHD
	unknown/ no data
Infectious pulmonary complication during HSCT or during	Pneumonia
follow-up (up to time point of data extraction)	Pulmonary aspergillosis
	CMV pneumonitis
	□ other:
	unknown/ no data/ not mentioned
If at least one infectious pulmonary episode	Date of episode1
occurred fill in this section	
	Hospitalization for episode1
	☐ Yes ☐ No
	□ ICU stay for episode1
	□ Yes □ No
	Treatment for episode1 (e.g. antibiotics, oxygen)
If at least one infectious pulmonary episode	Date of episode2
occurred fill in this section	
occurred his in this section	Hospitalization for episode2
	□ ICU stay for episode2
	□ Yes □ No
	☐ Treatment for episode2 (e.g. antibiotics, oxygen)
	If additional episodes happened, add them on the back of
	this page
Non-infectious pulmonary complication during or after	acute and chronic graft versus host
HSCT when correlation with HSCT	disease (GvHD)
	idiopathic pneumonia syndrome (IPS)
	bronchiolitis obliterans (BO)
	bronchiolitis obliterans organizing
	pneumonia (BOOP)
	🗖 unknown/ no data

In case more than one HSCT has been performed: take additional CRF and number the HSCT episodes

Pulmonary function test results

- ☐ found in archive
- □ found in digital medical record
- not found



Appendix C - Documents for SCCSS-FollowUp

Fragebogen zur Lungengesundheit

Patient sticker

Heutiges Datum: Tag _____ Monat _____ Jahr _____

Das Beantworten des Fragebogens dauert ungefähr 5-15 Minuten.

Bitte nehmen Sie den ausgefüllten Fragebogen mit zum nächsten Arzttermin.

Bei Fragen oder Unklarheiten dürfen Sie sich jederzeit bei folgender Stelle melden:

Anschrift SPOG-Leiter bzw. Sekretariat Poliklinik (Wird vorgängig mit jedem SPOG-Leiter separat abgeklärt)

Anleitung zum Ausfüllen des Fragebogens

Es ist wichtig, dass Sie die Fragen gut durchlesen und wenn immer möglich beantworten. Wenn Sie die Antwort nicht genau wissen, so geben Sie die bestmögliche Antwort an.

Bitte kreuzen Sie das zutreffende Kästchen a	an.			
Beispiel: Machen Sie Sport?	🛛 Ja	🗌 Nein		
Wenn Sie eine Antwort korrigieren möchten,				iz am richtigen Ort.
Beispiel: 🖾 Ja: Fehler zweimal durchstrei	chen	🛛 Nein: Neu ma	rkieren	
Bedeutet, dass Sie etwas reinschreiben	können			
Beispiel: Wie gross sind Sie?	<u>185 (</u> cm) (ohne	Schuhe)		
*Bedeutet, dass Sie diese Frage übersprin	ngen können			
Beispiel: Haben Sie Geschwister?	🗌 Ja 🛛 🖉	Nein	Falls Nein, weiter zu 2.1	N -

- Falls Ihnen bei einer Frage etwas unklar ist, können Sie von Hand einen Kommentar bei dieser Frage anfügen. Falls Sie mehr Platz benötigen, dürfen Sie gerne ein separates Blatt beifügen.

- Im Fragebogen wurde auf eine Aufzählung beider Geschlechter (Arzt/Ärztin) zugunsten der Lesbarkeit verzichtet. Es sind aber immer beide Geschlechter gemeint.

	Atembeschwerden und Erkrankungen von Lunge, Na	se und Ohr	en	
Haben Si	e manchmal Atembeschwerden bei Anstrengung?			
Ja	Nein		F	alls nein, weiter zu Frage 1.2 🇳
	Falls ja, welche Beschwerden haben Sie?			
	•	Ja	Nein	
	Pfeifende oder keuchende Atmung			
	Husten			
	Atemnot oder Engegefühl			
	Raschere Ermüdbarkeit/ Erschöpfung im Vergleich			
	zu Gleichaltrigen			
	Andere Beschwerden			
	Falls andere Beschwerden, welche? (z			srust, Seitenstechen)
	£			
	K			
,	In welchen der folgenden Situationen treten die Ate	mbeschwerd	len auf?	
	Beim Rennen von	Nie	Manchmal	Oft
	Kurzen Strecken (50-100m)			
	Mittellangen Strecken (bis 1km)			
	Langen Strecken (über 1km)			
	Beim Fahrradfahren (schnell)			
	Beim Bergauf gehen/wandern			
	Beim anstrengenden Sportspiel wie Fussball			
	Beim Schwimmen			
	Bei anderen Aktivitäten: welche?			
	<u>£</u>			
	K			
	£41			
laben Sie	manchmal Atembeschwerden in Ruhe bzw. ohne An	strengung?	(z.B. Buch lesen, C	omputer)
] Ja	Nein		F	alls nein, weiter zu Frage 1.3 🍄
]Ja	 Falls ja, welche Beschwerden haben Sie <u>ohne</u> körper 	liche Anstrei		alls nein, weiter zu Frage 1.3 🍣
]Ja	_	liche Anstrei Ja		alls nein, weiter zu Frage 1.3 🌱
]Ja	_		ngung?	alls nein, weiter zu Frage 1.3 ँ⊊ିँ
]Ja	Falls ja, welche Beschwerden haben Sie <u>ohne</u> körper	Ja	ngung?	alls nein, weiter zu Frage 1.3 ँ∽ื
]Ja	Falls ja, welche Beschwerden haben Sie <u>ohne</u> körper Pfeifende oder keuchende Atmung Husten	Ja	ngung?	alls nein, weiter zu Frage 1.3 ँ∽ื
] Ja	 Falls ja, welche Beschwerden haben Sie <u>ohne</u> körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl 	Ja	ngung?	alls nein, weiter zu Frage 1.3 ँ∽ื
] Ja	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden 	Ja 	ngung? Nein 	
] Ja	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden Falls andere Beschwerden, welche? (z 	Ja J J J J J J J J J J J J	ngung? Nein 	
] Ja	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden Falls andere Beschwerden, welche? (z 	Ja	ngung? Nein 	
] Ja	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden Falls andere Beschwerden, welche? (z 	Ja	ngung? Nein 	
] Ja	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden Falls andere Beschwerden, welche? (z 	Ja J J J um Beispiel	ngung? Nein 	Brust, Atempausen)
	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden Falls andere Beschwerden, welche? (z 	Ja D J J J J J J J J J J J J J	ngung? Nein Schmerzen in der B ress, rauchige Umg	Brust, Atempausen)
	 Falls ja, welche Beschwerden haben Sie ohne körper Pfeifende oder keuchende Atmung Husten Atemnot oder Engegefühl Andere Beschwerden Falls andere Beschwerden, welche? (z M	Ja D J J J J J J J J J J J J J	ngung? Nein Schmerzen in der B ress, rauchige Umg	Brust, Atempausen)

Version Deutsch Adult / 11.05.2020

Version 1.0

🗌 Ja	🗌 Nei	n [Weiss nicht					
<u> </u>	Falls ja: Während wel	chen Lebensphasen?	(Mehrere Antwo	rten sind mö	glich)			
	Erste 3	Mit 4-11	Mit 1-3	Jahren	🗌 Mit 4-6 、	Jahren		
	Lebensmonate	Monaten	(Kleinki	nd)	(Kinderg	arten)		
	🗌 Mit 7-10 Jahren 🛛 Mit 11-12 Jah		n 🗌 Mit 13	Jahren oder	später			
	(14. Klasse)	(56. Klasse)						
	Falls ja: Welche der fo	olgenden Situationen h	at bei Ihnen in d	en <u>letzten 12</u>	2 Monaten H	usten oder	pfeifende oder k	euchend
	Atmung ausgelöst? (K	reuzen Sie bitte alle zu	utreffenden Situa	itionen an)				
				Husten		Pfeif	ende/keuchend	le
							Atmung	
			Nie	Manchm	al Oft	Nie	Manchmal	Oft
	Erkältung, Grippe							
	Hausstaub							
	Blütenstaub (Gräser,	Bäume)						
	Kalte Luft oder Nebel	I						
	Wetter- oder Temper	aturwechsel						
	Lautes Lachen							
	Bestimmte Speisen oder Getränke							
	Falls Speisen ode	er Getränke: welche?	Ľ					
Tiere (Katze, Hund, Pferd, Vogel, etc.)								
	Falls Tiere: welch	e? 🖉						
	Andere Situationen							
	Falls andere Situa	ationen: welche? 🖄 _						
Wie viele	Erkältungen hatten Sie	in den <u>letzten 12 Mona</u>	aten?					
🗌 Keine	□ 1-3	4-6	; [7-9	[] 10 oder r	nehr	
Denken S	Sie, dass Sie häufiger hu s	sten als andere Perso	nen im gleichen	Alter?				
_ Ja	L Neir	1						
Hatten Si	e <u>in den letzten 12 Mona</u>	<u>ten</u> jemals einen Hust e	en,					
der länger a	als 3 Wochen am Stück g	gedauert hat?	🗌 Ja 📃	Nein				
der länger a	als 2 Monate am Stück g	edauert hat?	🗌 Ja 📃	Nein				
Husten Si	e auch wenn Sie nicht erl	kältet sind?						
Ja, häuf	īg Ja, ι	manchmal 🗌 Ne	in, nie					
lst Ihr Hu	sten meist trocken (Reiz	zhusten) oder feucht / r	mit Sekret?					

3 Version 1.0

1.9 Hatten Sie in	n den <u>letzten 12 Monaten</u> eine Lungenentzündung , welche	mit einem Antibiotikum behandelt wurde?	
Nein	weiter zu Frage 1.10 🌺		
☐ Ja	Falls ja: Angaben zur letzten Lungenentzündung:		
r	Wie war der Name des Antibiotikums?		
	Mussten Sie wegen dieser Lungenentzündung eine oder i	nehrere Nächte im Snital bleiben?	🗌 Ja 🗌 Nein
$ \longrightarrow $	Falls ja: Hatten Sie mehr als eine Lungenentzündung in d	en letzten 12 Monaten?	
	\Box Ja, mehr als eine; wie viele? 🖄		
	Nein, nicht mehr als eine		
1.10 Hatten Sie in	n den <u>letzten 12 Monaten</u> eine Mittelohrenentzündung (Oti	tis media), welche mit einem Antibiotikum	behandelt wurde?
☐ Nein →→	weiter zu Frage 1.11		
$ \longrightarrow $	Falls ja: Angabe zur letzten Mittelohrenentzündung:		
	Wie war der Name des Antibiotikums?		
	Falls ja: Hatten Sie mehr als eine Mittelohrenentzündung		
	\Box Ja, mehr als eine; wie viele? 🖄		
	Nein, nicht mehr als eine		
1.11 Hatten Sie in behandelt wurde	n den <u>letzten 12 Monaten</u> eine Stirn- oder Nasennebenhöh le?	lenentzündung (Sinusitis), welche mit eine	em Antibiotikum
☐ Nein →→	weiter zu Frage 2.1 🌺		
	Falls ja: Angabe zur letzten Stirn- oder Nasennebenhöhle	nentzündung:	
	Wie war der Name des Antibiotikums?	-	
_			
$ \longrightarrow $	Falls ja: Hatten Sie mehr als eine Stirn- oder Nasenneber	nhöhlenentzündung in den <u>letzten 12 Monat</u>	en?
	\Box Ja, mehr als eine; wie viele? 🖉		
	Nein, nicht mehr als eine		
2. Fragen zu Heus	ischnupfen und Haut		
2.1. Hatten Sie irg	gendeinmal in Ihrem Leben Heuschnupfen?		
🗌 Ja	Nein Weiss	nicht	
F	Falls ja: Haben Sie heute noch Heuschnupfen?	🗌 Nein	
2.2. Hatten Sie in	gendeinmal in Ihrem Leben einen juckenden Hautausschla	ag. der während mindestens 6 Monaten stär	ker oder schwächer
auftrat?			
🗌 Ja	Nein Weiss	nicht	
\longmapsto	Falls ja: Trat dieser juckende Hautausschlag in den letzte	n 12 Monaten auf?	Ja Nein
\longmapsto	Falls ja: Hat Ihnen der Arzt gesagt, dass es sich dabei um	Neurodermitis oder Ekzem handelt?	Ja Nein

Version Deutsch Adult / 11.05.2020

Version 1.0

4

3. Diagnosen zu Erkrankungen der Lunge

3.1. Wurde Ihnen durch einen Arzt gesagt, dass Si	ie an einer der folgenden Ei	rkrankungen der Lunge leiden?
Asthma	🗌 Ja	☐ Nein
Bronchitis	🗌 Ja	☐ Nein
Lungenfibrose (=Vernarbung der Lunge)	🗌 Ja	Nein
Lungenemphysem (=Überblähung der Lunge)	🗌 Ja	Nein
Graft versus Host Disease der Lunge	Ja	Nein
(«Spender-gegen-Empfänger-Reaktion»;		
nur bei transplantierten Patienten möglich)		
Andere Erkrankung der Lunge	🗌 Ja	☐ Nein
Falls ja, welche?	<u>S</u>	
Y	Ŕ	

3.2. Waren Sie schon einmal bei einem Pneumologen (Lungenspezialisten) in Kontrolle/ Behandlung?

🗌 Ja	Nein
	Falls ja, geben Sie bitte an, wann das war und bei wem

Datum der letzten Untersuchung	Ort der Untersuchung	
(Monat/Jahr)	(Name des Arztes und Ort der Klinik oder der Praxis)	
	·	

3.3 Haben Sie in den letzten 12 Monaten ein Medikament für die Lunge oder die Atemwege benötigt (z.B. Spray oder Pulver zum inhalieren oder kortisonhaltige Tabletten)?

🗌 Ja	☐ Nein						
	Falls ja, welches Medikament?	Name		Spray	Pulver	Tablette	Sirup
	Falls ja, wie lange wurde das Medika		r kurzfristig al mindestens 3 Mon	ate oder lä	inger		
4. Fragen zu	ı Lifestyle						
4.1. Haben S	Sie je geraucht?						
🗌 Nein, i	ch habe nie regelmässig geraucht und ra	auche auch zurzeit nicht	weiter zu Frag	ge 4.4 🛸	"		
🗌 Ja, ich	rauche zurzeit, aber nicht regelmässig		weiter zu Frag				
🗌 Ja, ich	rauche zurzeit regelmässig		weiter zu Frag	-			
🗌 Ja, ich	habe früher geraucht und rauche jetzt n	icht mehr	weiter zu Fra	ge 4.3 爷	a		
	Falls Sie bei einer der vier Antwortme	öglichkeiten «ja» gekreuzt	haben: Was rauchen	Sie bzw. v	was haben	Sie geraucht	t?
	«Normale Zigarette»	E-Zigarette	Shisha				
	iQOS oder Ploom (Bei iQOS und Plo	om wird der Tabak erhitzt und	nicht wie bei einer normale	en Zigarette	verbrannt)		
	🗌 Anderes: 🖉						

Version Deutsch Adult / 11.05.2020

5 Version 1.0

4.2. Wie viel rauchen Sie im Moment pro Tag?
 ☐ Weniger als 1 Zigarette pro Tag ☐ 2 – 9 Zigaretten pro Tag ☐ 10 – 19 Zigaretten pro Tag ☐ 1 Päckli pro Tag ☐ Mehr als 1 Päckli pro Tag
Wie alt waren Sie, als Sie mit Rauchen begonnen haben? (Jahre)
4.3. In der Zeit, während Sie am meisten geraucht haben, wie viel haben Sie geraucht?
 ☐ Weniger als 1 Zigarette pro Tag ☐ 2 - 9 Zigaretten pro Tag ☐ 10 - 19 Zigaretten pro Tag ☐ 1 Päckli pro Tag ☐ Mehr als 1 Päckli pro Tag
Wie alt waren Sie, als Sie mit regelmässigem Rauchen begonnen haben? (Jahre)
Vor wie vielen Jahren haben Sie aufgehört? (Jahre) weiter zur Frage 4.4 🧚
4.4. Wie viele Stunden sind Sie täglich dem Tabakrauch von anderen Leuten ausgesetzt (Passivrauchen)?
✓Stunden pro Tag ☐ Weiss nicht ☐ Bin nicht Passivrauchen ausgesetzt
4.5. Treiben Sie Gymnastik, Fitness oder Sport?
□ Ja Welche Sportart?
 □ Nein Haben Sie eine Behinderung oder Erkrankung, die das Ausüben von Sport erschwert? □ Ja □ Nein Was hindert Sie daran Sport zu treiben?

SCCSS-FollowUp – Documentation sheet

Data extraction – Pulmonary follow-up

Identification

Name:	_
Date of birth:	
Institution:	
Date of examination:	

Vital signs

Puls (/min)
Blood pressure (mmHg)
Weight (kg)

□ Height (cm) _____

Current respiratory history

П	Current	resni	ratory	tract	infectior	، ?
	Current	respi	παισιγ	uaci	Intection	

- 🗆 No
- □ Yes
 - Symptoms: _____

□ Respiratory tract infection in the last 4 weeks?

- 🗆 No
- □ Yes

Symptoms, date and duration: ______

□ Intake of bronchodilatators in the last 24 hours?


- 🗆 No
- □ Yes, short-acting (4h)
- □ Yes, long-acting (24h)

If yes, when was the last intake? _____

Which medication has been taken? _____

Clinical examination

Chest wall	
Scars	 No (Do not count scars due to Port-à-Cath) Yes after thoracotomy after thoracoscopy after surgery of the spine after rib resection after surgery to soft tissue (e.g. muscles)
Deformity	 other: No Scoliosis (see picture) Light scoliosis, no referral to orthopedist pronounced scoliosis, referral to orthopedist needed Other:
Inspection	 No signs of shortness of breath present Signs of shortness of breath present tachypnea retractions stridor cyanosis No muscular atrophy/asymmetry thoracic present Muscular atrophy/asymmetry thoracic present Localization: Other:
Auscultation	 Lung auscultation normal pathological If pathological, what do you hear? Attenuated breathing sound Localization (right/left/bilateral/basal/apical):



Clinical signs of scoliosis

SCCSS-FollowUp Study - Study visit (Pulmonary function test)

Identification

Name:	
Date of birth:	
Institution:	
Date study visit:	
Weight (kg):	
Length (cm):	
Ethnicity:	
Nationality:	

Current respiratory history

	Current	respiratory	tract	infection?
--	---------	-------------	-------	------------

- 🗆 No
- 🗆 Yes
 - Symptoms: _____

□ Respiratory tract infection in the last 4 weeks?

🗆 No

🗆 Yes

Symptoms, date and duration: _____

□ Intake of bronchodilatators in the last 24 hours?

🗆 No

□ Yes, short-acting (4h)

□ Yes, long-acting (24h)

Lung function testing

Lung function test performed? (multiple answers possible) None Yes, Spirometry Yes, Body plethysmography Yes, DLCO Yes, Single breath washout test Yes, Multiple breath washout test Quality of Spirometry Bad Acceptable Good

Quality of Body plethysmography

- 🗆 Bad
- □ Acceptable
- 🗆 Good

SCCSS-FollowUp Study - Study visit (Pulmonary function test)

Has the child taken any bronchodilatation on the day lung function test was performed before the test? (not as part of the test)

- 🗆 No
- 🗆 Yes

TLC	
FRC	(Liter, example 3.00)
	(Liter, example 3.00)
RV	(Liter, example 3.00)
FVC	
FEV1	(Liter, example 3.00)
Dtat	(Liter, example 3.00)
Rtot	(kPa/(L/s), example 0.40)
R EX	(kPa/(L/s), example 0.40)
sR eff	
sR tot	(kPa*s, example 1.00)
	(kPa*s, example 1.00)
R mid	(kPa/(L/s), example 0.50)
MEF 75	(Litor oxample 2.00)
MEF 50	(Liter, example 3.00)
MEF 25	(Liter, example 3.00)
	(Liter, example 3.00)

Conclusive results of lung function test

Normal lung function
Obstructive ventilation
mild
severe

Restrictive ventilation

mild
severe

Other result

Comments to the lung function test:



SCCSS-FollowUp Study - Study visit (Pulmonary function test)

Multiple Breath Washout

Quality of multiple washout test Bad Acceptable Good

Was LCI 2.5 or LCI 5 done? LCI 2.5 LCI 5

Lung clearance index (LCI)

Functional residual capacity (FRC)

(Liter, example 2.00)

(Liter, example 2.00)

Moment Ratio (MR)

Sacin

Scond

Comments to the washout test:



Variables in RedCap® for SCCSS-FollowUp

The RedCap[®] database consist of five instruments: three general instrumenst and two project-specific instruments. The two project-specific instruments are specific for the project on pulmonary dysfunction. In the following section I give an overview over the instruments and a short extract of their content.

Overview over Data Collection Instruments

 ata Collection Create a new instrument from scratch Import a new instrument from the official <u>REDCap Share</u> Cupload instrument ZIP file from another project/user or 			: 2
Instrument name	Fields	View PDF	Instrument actions
Patient Data And Eligibility	12	Ø	Choose action 🗢
Medical Data Extraction	250	Ø	Choose action \bigtriangledown
Clinical Visit	9	Ø	Choose action \bigtriangledown
Physical Examination	45	Ø	Choose action 🗢
Clinical Measures (=Pulmonary Function Tests)	23	Ø	Choose action \bigtriangledown

Instrument for "Patient Data And Eligibility"

REDCap ID		
VARIA		
SCCR ID * must provide value		
Patient ID data entered by * must provide value	○ Maria Otth ○ other person	reset
Name of other person * must provide value		
PATIENT DATA AND ELIGEBILITY		
Day of birth		
Month of birth * must provide value		
Year of birth * must provide value	уууу	
Gender * must provide value	~	
Inclusion criteria fullfilled? * must provide value	age at diagnosis 0-21 years diagnosis according to ICCC3 I-XII or LCH must all be fullfilled	
SPOG Patient? * must provide value	○ No ○ Yes	reset
Send date of information letter * must provide value	DD-MM-YYYY	
Send date of reminder letter	DD-MM-YVYY	

Instrument for "Medical Data Extraction" – First questions

REDCap ID		
* must provide value		
Date of data extraction	Today D-M-Y	
* must provide value	DD-MM-YYYY	
Data extracted by	O Maria Otth	
* must provide value	○ other person	reset
Name of other person		
* must provide value		
1.1 CANCER DIAGNOSIS		
	○ leukemias	
	○ lymphomas	
	O central nervous system neoplasms	
	O neuroblastomas	
	O retinoblastomas	
	O renal tumours	
Primary cancer diagnosis (acc. to ICCC-3)	O hepatic tumours	
Primary cancer diagnosis (acc. to iccc-5)	O malignant bone tumours	
	O soft tissue sarcomas	
	O germ cell tumours	
	O other malignant epithelial neoplasms O LCH	
	\odot other specified and unspecified malignant neoplasm	reset
		reset
Detailed primary cancer diagnosis		
* must provide value	detailed cancer diagnosis according to medical letter (e.g. acute lymphoblastic leukemia or alveolar rhabdomyosarcoma)	
Date of primary cancer diagnosis	Today D-M-Y	
	e.g. first day of therapy, date of biopsy	
	🗆 bones	
	bone marrow	
	lymph nodes	
	Central nervous system	
Location of primary cancer (categories)	liver	
	spleen	
	soft tissue	
	□ other	

Information is collected on primary cancer diagnosis, further relapses and secondary malignancy

Did the patient receive chemotherapy?	○ no ○ yes ○ not known	reset
Start of chemotherapy (primary cancer)	Today D-M-Y	
End of chemotherapy (primary cancer)	Today D-M-Y	
Name of protocol (primary cancer)		
Calculations/comments on Busulfan		Expand
Cumulative Busulfan dose	mg/m2	
Way of administration?	NK = Not known	
Quality of cumulative Busulfan data	×	
Quality of data on Busulfan application duration	×	

Instrument for "Medical Data Extraction" – Chemotherapy

Chemotherapeutic agents included: Asparaginase, Anti-Thymocyte Globulin (ATG), Bleomycin, Busulfan, Carboplatin, Carmustin (BCNU), Chlorambucil, Cisplatin, Cyclophosphamide, Cytarabine (Ara-C), Dacarbacine (DTIC), Dactinomycin/ Actinomycin D, Daunorubicin, Doxorubicin, Epirubicin, Etoposide (VP-16), Fludarabine, Idarubicin, Ifosfamide, Lomustine (CCNU), Mechlorethamine, Melphalan, Methotrexate (i.v. low dose, i.v. high dose, p.o, i.th./i.ventr.), 6-Mercaptopurine, Mitoxantrone, Procarbacine, Temozolomide, 6-Thioguanine, Thiotepa, Vinblastine, Vincristine, Vindesine, Other

Instrument for "Medical Data Extraction" – Radiotherapy

Did patient undergo radiation to lung relevant areas?	○ no ○ yes ○ not known reset
First dose radiation	Today D-M-Y
Last dose radiation	Today D-M-Y
Modality of radiation therapy	 2D (Simulator-planned) radiotherapy 3D-conformal radiotherapy IMRT/VMAT (intensity-modulated radiotherapy/volumetric-modulated arch therapy) photon therapy proton therapy not known
	axilla chest wall extended mantle mantle mini mantle hilar lung partial lung whole
Radiation to the lungs and lung relevant areas	TBI (total body irridation)
Dose of radiation to axilla	Gy, 1 decimal

Instrument for "Medical Data Extraction" – HSCT

Did patient undergo HSCT?	⊖yes ⊖no reset
Date of HSCT	Today D-M-Y
Type of HSCT	○ autologous ○ allogeneic reset
Donor type of autologous HSCT	related unrelated HLA-match HLA-mismatched haploidentical
Source of Transplant	○ peripheral stem cells ○ bone marrow ○ cord blood reset
HLA match	e.g. 10/10 or 6/6

Additional information on CMV status of donor and recipient, gender of donor and recipient, blood group of donor and recipient, drugs ued for conditioning, development of graft verus host disease and its degree and affected organ systems

Instrument for "Medical Data Extraction" – Thoracic surgery

Did patient undergo 1st thoracic surgery?	⊖yes ⊖no ⊖not known reset
Date 1st thoracic surgery	Today D-M-Y
Location 1st thoracic surgery	
Description of 1st thoracic surgery	Expand

Instrument for "Clinical Visit"

REDCap ID * must provide value	
Date of the clinical visit * must provide value	DD-MM-YYYY
Age at clinical visit * must provide value	
Signed consent from parents received? * must provide value	v (if under 14 years old)
Signed consent from adolescent received? * must provide value	v if 14 and older
Signed consent from adult received? * must provide value	if 18 and older
Completed questionnaire returned? * must provide value	 ○ no, pending ○ yes, complete ○ yes, incomplete
Date of informed consent * must provide value	DD-MM-YYYY
Additional comments to clinical visit	Expand

Instrument for "Physical examination"

REDCap ID * must provide value		
Date of physical examination	Today D-M-Y	
Physical examination performed by:	O Maria Otth O other person	reset
Name of other person * must provide value		
1. VITALS		
1.1 BLOOD PRESSURE		
Patients should be seated comfortably in a quiet environmer measurements. There should be 3 measurements recorded, readings differ by > 10 mmHg. Blood pressure is recorded as (Guidelines ESH ESC 2018)	1 min apart, and additional measurements if 1. and 2.	
1. Blood pressure: systolic		
* must provide value	systolic in mmHg	

Additional information on heart rate, weight, height, current pulmonary history, clinical examination of the lung including signs of dyspnea and signs of heart failure

Instrument for "Clinical Measures (=Pulmonary Function Test)"

REDCap ID		
* must provide value		
	O White/ European descent	
	O Arab (e.g. Egypt, Iraq, Jordan, Lebanon)	
	O West Asian (e.g. Turkey, Iran, Afghanistan)	
	O Indian subcontinent	
	○ Pakistani/Bangladeshi	
	🔾 Southeast Asian (e.g. Malaysia, Indonesia, Vietnam)	
	O East Asian (e.g. China, Japan, Korea, Taiwan)	
	O African/ African American	
	O Latin American/Hispanic	
Patient's ethnicity	O American Indian/ Alaska Native	
	O Australian aboriginal	
	O Native Hawaiian or other Pacific Islander	
	O Caribbean	
	O Jewish	
	O Roma/ Irish traveler	
	O Other ethnic group	
	O Prefer not to answer	
		reset
Other ethnicity		
Nationality		
1. Lung Function Test		
	O None	
	O Yes, Spirometry	
Lung function test performed	 Yes, Bodyplethysmography Yes, DLCO 	
	O Yes, Single breath washout test	
	\odot Yes, Multiple breath washout test	reset
Reason if no test was performed		
1.1 SPIROMETRY AND BODYPLETHYSMOGRAPHY		
	O bad	
	O acceptable	
Quality of Spirometry	O good	
	O not mentioned	
	O not mentioned	reset
	2	
	○ bad	
	○ acceptable	
Quality of Bodyplethysmography	⊖ good	
	O not mentioned	
		reset
Han the patient taken and been been been been been been been be	Ono	
Has the patient taken any bronchodilatation on the day of the lung function test before the test?	○ yes, short-acting	
the rang runction test before the test?	\bigcirc yes, long-acting	
		reset
Value of TLC (total lung capacity)		
	Liter, 2 decimals	
Value of FRC (functional residual capacity)		
······································	Liter, 2 decimals	

Additional information on RV, FVC, FEV1, resistance, MEF75%, MEF50%, MEF25%

Appendix D - International Guideline Harmonization Group Pulmonary Dysfunction

ЧМ Ч	Who needs surveillance?				
	North American Children's Oncology Group	Dutch Childhood Oncology Group	UK Children's Cancer and Leukaemia Group	Scottish Intercollegiate Guidelines Network	Concordant/ Discordant
At risk	5	5	-		
Allogeneic HSCT	Yes	No	Yes	Not included in guideline	Discordant
Bleomycin	Yes	Yes	?Yes (little evidence of late toxicity in children)	Not included in guideline	Concordant
Busulfan	Yes	Yes	Yes	Not included in guideline	Concordant
Nitrosureas	Yes	Yes	Yes	Not included in guideline	Concordant
Radiotherapy	Yes (≥10 Gy)	Yes	Yes	Not included in guideline	Concordant
Surgery	Yes	Yes	Yes	Not included in guideline	Concordant
High risk					
Allogeneic HSCT	Yes (especially if cGvHD)	No (Not listed separately)	Yes (especially if TBI, busulfan, cGvHD)	Not included in guideline	Discordant
Higher bleomycin dose	Yes (≥400 U/m²)	No (No dose specified)	No (No dose specified)	Not included in guideline	Discordant
Higher busulfan dose	Yes (≥500 mg)	No (No dose specified)	No (No dose specified)	Not included in guideline	Discordant
Higher cumulative dose BCNU	Yes (≥600 mg/m²)	No (No dose specified)	Yes (No dose specified)	Not included in guideline	Discordant
Higher radiotherapy dose	Yes (RT ≥15 Gy; TBI ≥6 Gy single fraction, TBI ≥12 Gy fractionated)	No (No dose specified)	Yes (but: no dose specified)	Not included in guideline	Discordant
Larger radiotherapy	No	No	Yes	Not included in guideline	Discordant

Step 1: Evaluate concordances and discordances of current recommendations

317

treatment volume	(Not mentioned)	(No volume specified)	(but: no volume specified)		
Combinations, others	Yes				
Combinations of above	Busulfan, BCNU combined with chest RT or TBI Belomycin combined with chest RT or TBI Surgery combined with alkylating agents or bleomycin or chest RT or TBI	No (No combinations specified)	No (No combinations specified)	Not included in guideline	Discordant
Combination of radiotherapy and radiomimetic chemotherapy	Yes (doxorubicin, dactinomycin)	No (No combinations specified)	No (No combinations specified)	Not included in guideline	Discordant
Younger age	Yes (bleomycin, radiotherapy no age specified)	No (Not mentioned)	Yes (BCNU <5yrs, radiotherapy)	Not included in guideline	Discordant
Renal dysfunction (bleomycin)	Yes (not further specified)	No (Not mentioned)	No (Not mentioned)	Not included in guideline	Discordant
cGvHD / lmmunosuppress.	Yes	No (Not mentioned)	Yes	Not included in guideline	Discordant
Pulmonary infection (HSCT)	No (Not mentioned)	No (Not mentioned)	Yes	Not included in guideline	Discordant
Tobacco: smoking/ETS/ marijuana	Yes	No (Not mentioned)	No (Not mentioned)	Not included in guideline	Discordant
gend: cGvHD = chronic gr	Legend: cGvHD = chronic graft versus host disease; ETS= environmental Tobacco smoking; HSCT= Hematopoietic stem cell transplantation; TBI = total body Irradiation	ronmental Tobacco smoking	3: HSCT= Hematopoietic stem cell	transplantation: TBI = total bod	v Irradiation

Cyclophosphamide	North American Children's Oncology Group Not included in guideline	Dutch Childhood Oncology Group Not included in guideline	UK Children's Cancer and Leukaemia Group Not included in guideline	Scottish Intercollegiate Guidelines Network Not included in guideline	Concordant/ Discordant
Methotrexate	Not included in guideline	guideline	Not included in guideline	Not included in guideline	
Gemcitabine	Not included in guideline	guideline	Not included in guideline	Not included in guideline	·

Risk factors added by experts and not in current guidelines

	North American Children's Oncology Group	Dutch Childhood Oncology Group	UK Children's Cancer and Leukaemia Group	Scottish Intercollegiate Guidelines Network	Concordant/ Discordant
What surveillance modality should be used?	ality should be used?				
Clinical history	Yes (cough, SOB, DOE, Wheezing)	No (Not mentioned)	Yes (exercise tolerance, smoking)		Discordant
Physical examination	Yes (pulmonary exam)	No (Not mentioned)	Yes (respiratory system)	Not included in guideline	Discordant
Pulmonary function tests	Yes (further specified)	Yes (further specified)	Yes (PFT, not further specified)	Not included in guideline	Concordant
Spirometry	Yes	Yes (flow volume curve)	Not specified	Not included in guideline	Discordant
Bodyplethismography	No (Not mentioned)	Yes (TLC)	Not specified	Not included in guideline	Discordant
DICO	Yes	Yes (DLCocorr/VA)	Not specified	Not included in guideline	Discordant
Radiology examination	Yes	No (Not mentioned)	Yes	Not included in guideline	Discordant
Chest x-ray	No (deleted in version 4.0)	No (Not mentioned)	Yes (if symptomatic or PFT abnormal)	Not included in guideline	Discordant
CT	Yes Discuss for patient for high risk for Lung cancer (chest RT <u>and</u> smoking)	No (Not mentioned)	Yes (HR CT if symptomatic or abnormal)	Not included in guideline	Discordant

Workgroup 2-4:

At what frequency shou	At what frequency should surveillance be performed?	d?			
Physical examination	Yes (Yearly)	No (Not mentioned)	Yes (at LTFU clinic, all patients)	Not included in guideline	Discordant
Clinical history	Yes (Yearly)	No (Not mentioned)	Yes (at LTFU clinic, all patients)	Not included in guideline	Discordant
Pulmonary function tests	At entry into LTFU, at least 2 years after end of cancer treatment, thereafter as clinically indicated in pat with abnormal results or progressive dysfunction	5 and 10 years after diagnosis, then every 5 years if abnormal PFT (<75% predicted)	End of treatment, then after 1 year if symptomatic or abnormal PFT (<2SD below normal)	Not included in guideline	Discordant
Pulmonary function tests post-HSCT	At entry into LTFU, thereafter as clinically indicated	No (Not mentioned)	Pre-HSCT, 1 year post- HSCT, then every 1-3/5 years depending on symptoms and PFTs results	Not included in guideline	Discordant
Radiology examination	Yes Discuss for patient for high risk for Lung cancer (chest RT <u>and</u> smoking)	No (Not mentioned)	Yes (if symptomatic)		Discordant
What should be done w	What should be done when abnormalities are identified?	:ified?			
Consider specialist referral	Yes (if symptomatic or progressive)	Yes (if symptomatic)	Yes (if symptomatic or abnormal PFT)	Not included in guideline	Concordant
Warn anaesthesist about previous bleomycin treatment	Yes (consider repeated PFT before anesthesia if bleomycin busulfan, BCNU, CCNU)	Yes (no exposure to FiO2>30% after bleomycin >400mg/m2 and/or RT to thorax)	Yes (but nothing specified)	Not included in guideline	Concordant

		Yes if			
Preventive measures	Yes	(FEV1/FVC or DLCOcorr/VA <75%predicted or have >20% reduction from baseline) or (recur. infection/ chronic cough)	Yes	Not included in guideline	Partly concordant
Consider pneumococcal and influenza immunization	Yes influenza and pneumococcal	Yes influenza (if abnormalities in PFT as described above)	Yes influenza and pneumococcal (if established lung disease)	Not included in guideline	Partly concordant
Tobacco smoking	Yes (abstain)	Yes (abstain)	Yes (abstain))	Not included in guideline	Concordant
Inhaled drug use (marijuana)	Yes (abstain)	No (Not mentioned)	No (Not mentioned)	Not included in guideline	Discordant
Physical exercise	Yes (get regular physical exercise)	No (Not mentioned)	No (Not mentioned)	Not included in guideline	Discordant
ETS (parents)	Yes (avoid)	No (Not mentioned)	No (Not mentioned)	Not included in guideline	Discordant
Advice on career choice	Yes Follow safety rules, don't' inhale toxic substances (chemicals, solvents, paints) use protective ventilators and report unsafe work conditions	Yes (avoid toxic substances)	No (Not mentioned)	Not included in guideline	Discordant
Scuba diving	Yes	Yes	No	Not included in guideline	Discordant

	(if busulfan, BCNU, CCNU, HSCT, RT to chest, bleomycin get advice from pulmonologist)	(Not mentioned)	(Not mentioned)		
Therapeutic approaches	No (Not mentioned)	No (Not mentioned)	Yes (consider immunosuppression in chronic pulmonary disese wit cGvHD)	Not included in guideline	Discordant
Surveillance modalities a	Surveillance modalities added by experts not included	d in current guidelines for WG2-4	r WG2-4		
	North American Children's Oncology Group	Dutch Childhood Oncology Group	UK Children's Cancer and Leukaemia Group	Scottish Intercollegiate Guidelines Network	Concordant/ Discordant
What surveillance modality should be used?	ality should be used?				
Single Breath/Multiple Breath Washout measurements	No (Not mentioned)	No (Not mentioned)	No (Not mentioned)	Not included in guideline	1
BGA	No (Not mentioned)	No (Not mentioned)	No (Not mentioned)	Not included in guideline	I

1.1

Not included in guideline

i

Not included in guideline Not included in guideline

Not included in guideline

No (Not mentioned)

No (Not mentioned)

What should be done if abnormalities are identified?

No (Not mentioned)

BGA MRI No (Not mentioned)

Not included in guideline

Not included in guideline

High altitudes

Overweight

No (Not mentioned)

No (Not mentioned)

Year	Bibliography	Author
Interst	itial lung disease	
2015	European protocols for the diagnosis and initial treatment of interstitial lung disease in children (Review)	Bush et al
2013	An Official American Thoracic Society Clinical Practice	Kurland et al
2013	Guideline: Classification, Evaluation, and Management of	
		Interstitial lung disease in infants
2000	Childhood Interstitial Lung Disease in Infancy	
2008	Interstitial lung disease guideline: the British Thoracic Society	Wells et al
	in collaboration with the Thoracic Society of Australia and	
2004	New Zealand and the Irish Thoracic Society	
2004	ERS - Task force on chronic interstitial lung disease in	Clement et al
	immunocompetent children	
Chroni	c Obstructive Pulmonary Disease (COPD)	
2020	AWMF - S2k-Leitlinie zur Diagnostik und Therapie von	Vogelmeier et al
	Patienten mit chronisch obstruktiver Bronchitis und	
	Lungenemphysem (COPD)	
2020	The COPD-X Plan: Australian and New Zealand Guidelines for	TSANZ
	the management of Chronic Obstructive Pulmonary Disease	
	2020	
2018	NICE - Chronic obstructive pulmonary disease in over 16s:	NICE
	diagnosis and management	
(Idiana	thic) Pulmonary Fibrosis	
		Dahratal
2019	AWMF – Leitlinie zur Diagnostik der Idiopathischen Lungenfibrose	Behr et al
2018	Diagnosis of Idiopathic Pulmonary Fibrosis An Official	Raghu et al
	ATS/ERS/JRS/ALAT Clinical Practice Guideline	Not include – in primary
		diagnosis only, no information
		on surveillance and treatment
2017	Treatment of idiopathic pulmonary fibrosis in Australia and	Jo et al
-	New Zealand: A position statement from the Thoracic Society	
	of Australia and New Zealand and the Lung Foundation	
	Australia	
2017	French practical guidelines for the diagnosis and management	Cottin et al
-	of idiopathic pulmonary fibrosis – 2017 update	
2015	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline:	Raghu et al
	Treatment of Idiopathic Pulmonary Fibrosis An Update of the	0
	2011 Clinical Practice Guideline	
2013	NICE – Idiopathic pulmonary fibrosis in adults: diagnosis and	NICE
	management	
2011	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic	Raghu et al
2011	-	Raghu et al

Step 2 (WG 2-4): Results of search for clinical practice guidelines

Year	Bibliography	Author
Interst	itial lung disease	
2015	European protocols for the diagnosis and initial treatment of interstitial lung disease in children (Review)	Bush et al
2013	An Official American Thoracic Society Clinical Practice Guideline: Classification, Evaluation, and Management of Childhood Interstitial Lung Disease in Infancy	Kurland et al
2008	Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society	Wells et al
2004	ERS - Task force on chronic interstitial lung disease in immunocompetent children	Clement et al
Chroni	c Obstructive Pulmonary Disease (COPD)	
2020	AWMF - S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)	Vogelmeier et al
2020	The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2020	TSANZ
2018	NICE - Chronic obstructive pulmonary disease in over 16s: diagnosis and management	NICE
(Idiopa	thic) Pulmonary Fibrosis	
2019	AWMF – Leitlinie zur Diagnostik der Idiopathischen Lungenfibrose	Behr et al
2017	Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia	Jo et al
2017	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2017 update	Cottin et al
2015	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: <u>Treatment</u> of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline	Raghu et al
2013	NICE – Idiopathic pulmonary fibrosis in adults: diagnosis and management	NICE
2011	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for <u>Diagnosis and Management</u>	Raghu et al

Guidelines to answer the question on "What surveillance modality should be used?"

No evidence in the guidelines: All guidelines start with symptomatic patients or patients with radiological changes. They do not have an asymptomatic interval where the guidelines already recommend surveillance for.

Guidelines to answer the question on "At what frequency should surveillance be performed? / When should surveillance be initiated?"

Year	Bibliography	Author
Interst	itial lung disease	
2015	European protocols for the diagnosis and initial treatment of interstitial lung	Bush et al
	disease in children (Review)	
2013	An Official American Thoracic Society Clinical Practice Guideline: Classification,	Kurland et al
	Evaluation, and Management of Childhood Interstitial Lung Disease in Infancy	
2008	Interstitial lung disease guideline: the British Thoracic Society in collaboration	Wells et al
	with the Thoracic Society of Australia and New Zealand and the Irish Thoracic	
	Society	
2004	ERS - Task force on chronic interstitial lung disease in immunocompetent	Clement et al
	children	
	c Obstructive Pulmonary Disease (COPD)	
2020	AWMF - S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch	Vogelmeier
	obstruktiver Bronchitis und Lungenemphysem (COPD)	et al
2020	The COPD-X Plan: Australian and New Zealand Guidelines for the management	TSANZ
	of Chronic Obstructive Pulmonary Disease 2020	
2018	NICE - Chronic obstructive pulmonary disease in over 16s: diagnosis and	NICE
	management	
	thic) Pulmonary Fibrosis	I
2019	AWMF – Leitlinie zur Diagnostik der Idiopathischen Lungenfibrose	Behr et al
2017	Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A	Jo et al
	position statement from the Thoracic Society of Australia and New Zealand and	
	the Lung Foundation Australia	
2017	French practical guidelines for the diagnosis and management of idiopathic	Cottin et al
	pulmonary fibrosis – 2017 update	
2015	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: <u>Treatment</u> of Idiopathic	Raghu et al
ļ	Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline	
2013	NICE – Idiopathic pulmonary fibrosis in adults: diagnosis and management	NICE
2011	An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis:	Raghu et al
	Evidence-based Guidelines for <u>Diagnosis and Management</u>	

No evidence in the guidelines: All guidelines start with symptomatic patients or patients with radiological changes. They do not have an asymptomatic interval where the guidelines already recommend surveillance for.

Guidelines to answer the question on "What should be done when abnormalities are found?"

We excluded recommendations on:

Recommendations excluded	Reason
BAL and lung/tissue biopsy	These invasive procedures go beyond tests which would be performed for surveillance
Tests to exclude other systemic disorders (e.g. immunodeficiency, collagen vascular disease), pulmonary infections or allergies.	This is one step further than surveillance and the responsibility of (pediatric) pneumologists.
Pharmacological treatment and oxygen therapy	This is one step further than surveillance
Indications for lung transplantation	This is one step further than surveillance
Diagnosis and management of acute exacerbations	This is one step further than surveillance
Diagnosis and management of comorbidities	This is one step further than surveillance

Abbreviations:

chILD childhood interstitial lung disease

FVC functional vital capacity

HRCT high-resolution computed tomography

ILD interstitial lung disease

IPF idiopathic pulmonary fibrosis

TLCO transfer capacity of the lung for carbon monoxide

For simplicity, the summaries provided in this thesis to not include the grading of level of evidence as this differs between the studies

Recommendations on initial diagnosis and follow-up examinations to extrapolate recommendations for surveillance modality

Interstitial Lung Disease

What should be done when abnormalities are found?	
Clement A et al, ERS Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J, 2004	r Respir J, 2004
Recommendation	Level of evidence
Initial diagnosis	strength of the evidence was not
- Taking family history	assessed (n.a.), more like an
- Chest radiographs: provide limited information	expert opinion
- HRCT as key chest imaging tool, thin sections; the ERS Task Force recommends the use of 120 kVp and 50 mAs	
for performing chest HRCT in paediatric patients	
 Pulmonary function testing represents a useful tool for the diagnosis of ILD 	
Pulmonary function testing represents a useful tool for the management of ILD	strength of the evidence n.a.
- age group 0-2 years: pulse oximetry, BGA with SaO2, SaCO2. Eventually FRC via body plethysmography or by gas	
dilution techniques	
- age group 2–6 years: pulse oximetry, BGA. In addition, SaO2 and/or blood gases may also be determined during	
exercise. If child cooperative perform spirometry	
- children aged >6 years: spirometry, lung volumes by body plethysmography or by gas dilution techniques. Pulse	
oximetry and BGA at room air at rest and during exercise. DLCO whenever possible	
HRCT may also contribute to monitor disease activity and/or severity	strength of the evidence n.a.
Kurland et al, An Official American Thoracic Society Clinical Practice Guideline: Classification, Evaluation, and Management of	ion, and Management of
Childhood Interstitial Lung Disease in Infancy. Am J Respir Crit Care Med, 2013	
Important comments	
Focusing on neonates and infants <2 years of age	
ILD in infants are distinct from those that cause ILD in older children and adults	
Recommendation ¹	Level of evidence
Weak: For infants with ILD, infant pulmonary function testing to better characterize physiologic alterations is suggested	Level of evidence not reported

orotocols to harmonize treatment approaches nclear pediatric radiology oxygen saturation in air awake, oxygen saturation including	Level of evidence ³ Strength of the evidence n.a. Strength of evidence assessed but not clearly provided
chieve a consensus on treatment protocols to harmonize treatment approaches ograph: non specific ion testing: the role in infants is unclear canning in centers experienced in pediatric radiology spiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	I of evidence ³ ngth of the evidence n.a. ngth of evidence assessed but clearly provided
ograph: non specific :ion testing: the role in infants is unclear canning in centers experienced in pediatric radiology spiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	I of evidence ³ ngth of the evidence n.a. ngth of evidence assessed but clearly provided
adiograph: non specific nction testing: the role in infants is unclear .T scanning in centers experienced in pediatric radiology : (respiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	ngth of the evidence n.a. ngth of evidence assessed but clearly provided
diograph: non specific action testing: the role in infants is unclear 5 scanning in centers experienced in pediatric radiology respiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	ngth of evidence assessed but clearly provided
nction testing: the role in infants is unclear 5 scanning in centers experienced in pediatric radiology respiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	ngth of evidence assessed but clearly provided
scanning in centers experienced in pediatric radiology respiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	ngth of evidence assessed but clearly provided
respiratory rate, heart rate, weight, oxygen saturation in air awake, oxygen saturation including	ngth of evidence assessed but clearly provided
oxygen saturation in air awake, oxygen saturation including	clearly provided
overnight while asleep and on exercise, evidence of pulmonary hypertension) and radiologic (chest X-ray, a	
limited cut thin-section HRCT of areas of interest if justifiable) testing	
- In older children, spirometry at each observational monitoring visit, with DLCO and body plethysmography	
recommended as indicated	
ייין איז	
Interstitiation gasease guideline: the british inoracic society in collaboration with the inoracic society of Australia and New	I AUSURALIA AND INEW
Zealand and the Irish Thoracic Society. Well et al, Thorax, 2008	
Recommendation ⁴ Level	Level of evidence ⁵
Initial diagnosis:	
- Taking detailed history to identify respiratory risk factors both past and present [D] .	
- Spirometric and gas transfer (see next section)	
- Maximal exercise data (see next section)	
- HRCT in patients for whom the diagnosis is uncertain after chest radiography and clinical assessment. [C]	
- HRCT is valuable in detecting ILD in patients with a normal chest radiograph. [B]	
Lung function testing:	Level of evidence not explicitly
- All patients with ILD should have resting spirometric and gas transfer measurement at presentation, which	reported for each
everity [C]	recommendation
- Desaturation during the 6-minute walk test at presentation is a stronger prognostic determinant in IPF than	
resting lung function [C] . However, additional studies are required to define the role of exercise testing in routine	
staging and follow-up both in IPF and other ILDs. [C]	
- Maximal exercise data probably add little to resting lung function in assessing the severity of ILD but are	
sometimes usetul, when normal, in excluding clinically significant diffuse lung disease. [C]	

What should be done when abnormances are nound. Vogelmeier C, et al. AWMF - S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und	obstruktiver Bronchitis und
Lungenemphysem (COPD), 2020	
Recommendation ¹	Level of evidence
Strong: COPD should be diagnosed by 1) taking a personal history (including smoking exposure), 2) asking for	Strength of the evidence n.a.
characteristic symptoms (dyspnea, cough, and expectoration), and 3) performing lung function test before and after	
bronchodilatation.	
Strong: Lung function testing should include whole body plethysmography, blood gas analysis, DLCO, imaging (CT	
thorax), and exercise tests.	
Regular follow-up examinations are recommended	
- ask for symptoms (CAT) and exacerbations	
- pulmonary function testing, including diffusion capacity in those with severe disease at rest and with exertion	
- pulse oximetry is suitable for monitoring oxygenation as a progression parameter.	
NICE - Chronic obstructive pulmonary disease in over 16s: diagnosis and management, 2018	
Recommendation	Level of evidence
Use spirometry to monitor disease progression.	Strength of the evidence n.a.
TSANZ - The COPD-X Plan: Australian and New Zealand Guidelines for the management of COPD, 2020	20
Recommendation ²	Level of evidence ³
Strong : Diagnosis of COPD through history and examination and confirmed by presence of persistent airflow limitation	111-2
post-bronchodilator (FEV1/FVC < 0.7).	

Chronic obstructive disease (COPD)

Fibrosis
~
~
nonary
_
_
D
_
\sim
<u></u>
_
-
τ i
g
4
ō
_

Behr J et al., AWMF - S2K Leitlinie zur Diagnostik der Idiopathischen Lungenfibrose, 2019 2019 Important comments	us statement. Level of evidence Strength of the evidence n.a.
decided to adapt the ATS-ERS-JRS-ALAT Guidance 2018 in this consens chnique without X-ray contrast medium in inspiration and supine rong consensus). The diagnostic gold standard in the view of the guideline group al course of the disease: diffusion capacity (TLCO),	ement. of evidence th of the evidence n.a.
decided to adapt the ATS-ERS-JRS-ALAT Guidance 2018 in this consens chnique without X-ray contrast medium in inspiration and supine rong consensus). The diagnostic gold standard in the view of the guideline group al course of the disease: diffusion capacity (TLCO),	ement. of evidence th of the evidence n.a.
ontrast medium in inspiration and supine ird in the view of the guideline group	of evidence th of the evidence n.a.
ontrast medium in inspiration and supine ard in the view of the guideline group	th of the evidence n.a.
ontrast medium in inspiration and supine ard in the view of the guideline group	
ird in the view of the guideline group	
ard in the view of the guideline group	
	Strength of the evidence n.a.
- blood as sublicie at ract and under strace	
- 6 minutes walking test,	
- quality of life (including SGRQ questionnaire or the K-BILD), and	
- imaging techniques (HRCT),	
- cumulative scores (e.g. GAP Index and TORVAN) to assess the severity and the associated prognosis.	
Follow-up exams are usually carried out at 3-4 monthly intervals.	Strength of the evidence n.a.
NICE: Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)	
Recommendation ² Level of	Level of evidence ³
Assess everyone with suspected idiopathic pulmonary fibrosis by:	Recommendation bases on GDG
- taking a detailed history, carrying out a clinical examination (see recommendation 1 for clinical features)	consensus, as evidence was of low
virometry and gas transfer) and	to very low quality due to
- reviewing results of chest X-ray and	limitations in study design and
- performing CT of the thorax (including high-resolution images).	inconsistency across populations
and diag	and diagnostic procedures.
Assess lung function during follow-up appointments of people with idiopathic pulmonary fibrosis	Recommendation bases on GDG
consens	consensus, as no evidence was
retrieve	retrieved to inform this question.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. 2018	ERS/JRS/ALAT Clinical
Recommendation	Level of evidence
Recommendations only about exclusion of differential diagnoses and confirming the diagnosis by performing BAL or biopsy	
Ganesh Raghu et al, An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An	ic Pulmonary Fibrosis An
Update of the 2011 Clinical Practice Guideline, 2015	
Recommendation	Level of evidence
Recommendations only about treatment of IPF	
Ganesh Raghu et al, An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for	ce-based Guidelines for
Diagnosis and Management, 2011	
Recommendation	Level of evidence
Monitoring clinical course	strength of the evidence n.a.
- Objective assessment of dyspnea (e.g. with dyspnea scores/ validated tools; University of California San Diego	
shortness of breath questionnaire)	
- Pulmonary function testing recommended. Combination of FVC and diffusion capacity may be useful in	
assessing progression of disease - Monitor for worsening oxygenation (at rest and with exertion) regardless of symptoms recommended	
Cottin V et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update, 2017	y fibrosis - 2017 update, 2017
Recommendation ⁴	Level of evidence
Workup if pulmonary fibrosis is <u>suspected</u> :	Strength of the evidence n.a.
- It is recommended to consider that a HRCT scan pattern of definite UIP, including honeycombing, is sufficient to	
make the diagnosis of IPF, after ruling out the other causes of UIP (secondary forms).	
Baseline workup if IPF is <u>diagnosed</u> : - It is recommended to assess forred vital ranacity (EVC) and rarbon monovide diffusing ranacity (DLCO)	Strength of the evidence n.a.
It is proposed to also assess total lung capacity, arterial blood gas at rest, and a 6-minute walk test	
Tests used during monitoring after diagnosis:	strength of the evidence n.a.
It is recommended to perform a clinical examination and a pulmonary function test with FVC measurement	
 It is proposed to perform DLco measurement 	
 It is recommended to perform a chest CT scan in special situations (e.g. suspicion of exacerbation, unexplained change in clinical status assessment for lung transclantation) 	

It is proposed to perform annually a CT scan	
Jo HE, et al. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia, 2017	ement from the Thoracic
Recommendation	Level of evidence
No recommendations on diagnostic measures or tests how to follow-up these patients	

What should be done when abnormalities are found?	
Clement A et al, ERS Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J, 2004	r Respir J, 2004
Recommendation	Level of evidence
Response to treatment should be assessed at regular intervals of 3-6 months or more frequently for severely ill patients.	strength of the evidence n.a.
Kurland et al, An Official American Thoracic Society Clinical Practice Guideline: Classification, Evaluation, and Management of	ion, and Management of
Childhood Interstitial Lung Disease in Infancy. Am J Respir Crit Care Med, 2013	
Recommendation	Level of evidence
No information on frequency of follow-up	
Bush et al, European protocols for the diagnosis and initial treatment of interstitial lung disease in children (Review), Thorax, 2015	ildren (Review), Thorax, 2015
Recommendation	Level of evidence ¹
Monitoring with:	Strength of evidence assessed but
- clinical and radiologic (chest X-ray at diagnosis, 6 and 12 months, a limited cut thin-section HRCT of areas of	not clearly provided
interest if justifiable) testing is recommended at months 1, 2, 3, 6, and 12 and annually thereafter.	
- In older children, spirometry at each observational monitoring visit should be recorded, with DLCO and body	
plethysmography recommended as indicated but at least once per year.	
Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New	ety of Australia and New
Zealand and the Irish Thoracic Society. Well et al, Thorax, 2008	
Recommendation ⁴	Level of evidence ⁵
No information on frequency of follow-up	

Recommendations on initial diagnosis to extrapolate for frequency of surveillance

Interstitial Lung Disease

(COPD)
disease
ructive
cobsti
Chronid

What should be done when abnormalities are found?	
Vogelmeier C, et al. AWMF - S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und	obstruktiver Bronchitis und
Lungenemphysem (COPD), 2020	
Recommendation	Level of evidence
No information on frequency of follow-up care	
NICE - Chronic obstructive pulmonary disease in over 16s: diagnosis and management, 2018	
Recommendation	Level of evidence
Primary care F/U:	Strength of the evidence n.a.
- mild/moderate/severe: annual	
- very severe: twice a year	
TSANZ - The COPD-X Plan: Australian and New Zealand Guidelines for the management of COPD, 2020	20
Recommendation ¹	Level of evidence ²
Strong: Severity of COPD should be assessed regularly (no time periods given).	111-2
ldiopathic) Pulmonary Fibrosis	

(Idi

Behr J et al., AWMF - S2K Leitlinie zur Diagnostik der Idiopathischen Lungenfibrose, 2019	
Recommendation ¹	Level of evidence
Follow-up exams are usually carried out at 3-4 monthly intervals.	Strength of the evidence n.a.
NICE: Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)	
Recommendation ²	Level of evidence ³
Consider <u>follow-up</u> of people with idiopathic pulmonary fibrosis:	This recommendation was based
- every 3 months or sooner if they are showing rapid disease progression or rapid deterioration of symptoms or	on GDG consensus, as no evidence
 every 6 months or sooner if they have steadily progressing disease or 	was retrieved to inform this
 initially every 6 months if they have stable disease and then annually if they have stable disease after 1 year. 	question.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. 2018	'ERS/JRS/ALAT Clinical
Recommendation	Level of evidence
Recommendations only about exclusion of differential diagnoses and confirming the diagnosis by performing BAL or biopsy	
Ganesh Raghu et al, An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An	ic Pulmonary Fibrosis An
Update of the 2011 Clinical Practice Guideline, 2015	
Recommendation	Level of evidence
Recommendations only about treatment IPF	
Ganesh Raghu et al, An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for	ce-based Guidelines for
Diagnosis and Management, 2011	
Recommendation ⁴	Level of evidence ⁵
Monitoring clinical course	strength of the evidence n.a.
- A flexible approach to monitoring for disease progression; lower threshold for earlier repetition of FVC and	
DLCO in the presence of progressive dyspnea or other features of a more rapidly progressive course. - Monitor every 4-6 months or sooner as clinically indicated	
Cottin V et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update,	y fibrosis - 2017 update, 2017
Recommendation ⁶	Level of evidence
Monitoring after diagnosis:	strength of the evidence n.a.
- It is recommended to at least perform a clinical examination and a pulmonary function test with FVC	
measurement every 3—6 months in patients with a confirmed diagnosis of IPF.	
- It is proposed to perform DLco measurement every 3—6 months in patients with a confirmed diagnosis of IPF.	
- It is recommended to perform a chest CT scan in case of suspicion of acute IPF exacerbation, unexplained	
change in clinical status, suspicion of lung cancer, and in case of assessment for lung transplantation.	
- ILIS proposed to perform annually a CL scan. When a CL scan is performed, it also allows detecting lung cancer,	
in particular in patients in whom respiratory functional data would allow surgical resection in case of localized	
Jo HE. et al. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic	tement from the Thoracic
Society of Australia and New Zealand and the Lung Foundation Australia. 2017	
	l and of anidoaco
No recommendations on diagnostic measures or tests how to follow-up these patients. Therefore no information on trequency of follow-up	ency of tollow-up

Recommendations on initial diagnosis and follow-up to extrapolate for general management / follow-up care

Interstitial Lung Disease

What should be done when abnormalities are found?	
Clement A et al, ERS Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J, 2004	r Respir J, 2004
Recommendation	Level of evidence
Immunization with influenza vaccine on an annual basis is recommended along with other routine immunizations against major respiratory pathogens	strength of the evidence n.a.
Avoid general anesthesia for high-resolution CT scan and use conscious sedation only if necessary	strength of the evidence n.a.
Kurland et al, An Official American Thoracic Society Clinical Practice Guideline: Classification, Evaluation, and Management of	ion, and Management of
Childhood Interstitial Lung Disease in Infancy. Am J Respir Crit Care Med, 2013	
Recommendation ¹	Level of evidence
All patients with ILD should receive supportive and preventive care such as treatment of hypoxemia, nutritional failure, and comorbidities, as well as interventions to prevent infection.	Strength of the evidence n.a.
Weak: For patients with ILD, thin section CT scanning of the chest using the lowest radiation dose to optimally characterize the nature and distribution of the lung disease is suggested, and if possible, it should be performed at centers with expertise in performing pediatric chest CT	Level of evidence not reported
Strong: For patients with ILD, performing thin-section CT using the lowest radiation dose that provides adequate diagnostic information is recommended	Level of evidence not reported
Bush et al, European protocols for the diagnosis and initial treatment of interstitial lung disease in children (Review), Thorax, 2015	ildren (Review), Thorax, 2015
Recommendation	Level of evidence
 CT scan in patients with suspected ILD should only be performed at centers experienced in pediatric radiology, with a goal to minimize radiation dosage, while maximizing information obtained The optimal CT scan should be a volumetric scan during inspiration, performed in tandem with high-resolution CT (HRCT) fine-cut spaced expiratory scan. Ventilation should be controlled to ensure satisfactory, interpretable, scan output 	strength of the evidence n.a.
 Caretul consideration should be given as to the risk/ benefits of using contrast medium based on anticipated diagnosis, since the administration of contrast medium will make the assessment of ground glass shadowing almost impossible, but the need to assess the pulmonary vasculature will require the use of contrast Faster CT scans without the need for anesthesia are not recommended unless anesthesia is thought to be unsafe 	

Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Well et al, Thorax, 2008	
	of Australia and New
Recommendation ²	Level of evidence ³
- Patients with ILD should have access to a multidisciplinary team based in a regional center with expertise in ILD	Level of evidence not explicitly
[C].	reported for each
- Referral to a regional ILD clinic should be made if there are perceived difficulties in diagnosis and/or	recommendation
management, but a tailored shared care model is advocated. [D]	
- Patients with ILD who are current smokers should receive opportunistic smoking cessation advice from	
healthcare professionals and this advice should be recorded in the clinical notes. [B]	
- Patients with ILD should have access to a local pulmonary rehabilitation program. [D]	
- Best supportive care should be considered a specific and important treatment strategy in all patients with	Level of evidence not explicitly
idiopathic pulmonary fibrosis (IPF). It is a proactive approach to symptomatic treatment and may include oxygen	reported for each
therapy, pulmonary rehabilitation, opiates, anti-reflux therapy, withdrawal of steroids and other	recommendation
immunosuppressants, early recognition of terminal decline and liaison with palliative care specialists. [D]	
- Radiologists with an interest in thoracic imaging and respiratory physicians should meet regularly to evaluate	Level of evidence not explicitly
imaging in patients with ILD. [D]	reported for each
- Radiologists involved with determining the protocol and interpretation of HRCT scans should have expertise in	recommendation
the technique be responsible for quality assurance and ensure that an appropriate radiation dose protocol is	
used. At least one radiologist in any department should have a declared interest and be trained in chest	
radiology and HRCT. [D]	
- Consider to establishing a reference panel of radiologists with particular expertise in HRCT. [D]	

Chronic obstructive disease (COPD)

What should be done when abnormalities are found?	
Vogelmeier C, et al. AWMF - S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und	obstruktiver Bronchitis und
Lungenemphysem (COPD), 2020	
Recommendation ¹	Level of evidence
Additional recommendations on:	Strength of the evidence n.a.
- smoking cessation	
- Weak: influenza vaccination: once per year	
- Strong: pneumococcal vaccination according to STIKO (PSV23 once, then after 6 years again (no more details)	

Level of evidence Strength of the evidence n.a. 0 Level of evidence ³ III-2 I
evel of evidence rength of the evidence n.a. evel of evidence ³ -2
rength of the evidence n.a. evel of evidence ³ -2
evel of evidence ³ -2
evel of evidence ³ -2
-2
-2
wal of avidanca
Level of evidence
Strength of the evidence n.a.
Strength of the evidence n.a.
Level of evidence ³
reng reng

At each stage of the diagnostic care pathway the multidisciplinary team should consist of a minimum of the healthcare professionals, all of whom should have expertise in interstitial lung disease: consultant respiratory physician, consultant radiologist, interstitial lung disease specialist nurse, multidisciplinary team coordinator	Low to moderate quality
Offer best supportive care to people with idiopathic pulmonary fibrosis from the point of diagnosis. Best supportive care should be tailored to disease severity, rate of progression, and the person's preference, and should include if appropriate information and support, symptom relief, management of comorbidities, withdrawal of therapies suspected to be ineffective or causing harm, and end of life care.	This recommendation was partially based on GDG consensus. Very low to moderate quality in studies assessing "best supportive care"
 Assess people with idiopathic pulmonary fibrosis for pulmonary rehabilitation at the time of diagnosis, including 6-minute walk test and a quality-of-life assessment. Repeat the assessment for pulmonary rehabilitation for people with idiopathic pulmonary fibrosis at 6-month or 12-month intervals. 	The GDG considered patient access to pulmonary rehabilitation programmes to be important.
 If appropriate after each assessment, offer pulmonary rehabilitation including exercise and educational components tailored to the needs of people with idiopathic pulmonary fibrosis in general. Pulmonary rehabilitation should be tailored to the individual needs of each person with idiopathic pulmonary fibrosis. Sessions should be held somewhere that is easy for people with idiopathic pulmonary fibrosis to get to and has good access for people with disabilities. 	Studies in QoL with moderate to very low quality. Conflicting findings.
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. 2018	ERS/JRS/ALAT Clinical
Recommendation Recommendations only about exclusion of differential diagnoses and confirming the diagnosis by performing BAL or biopsy	Level of evidence
Ganesh Raghu et al, An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline, 2015	c Pulmonary Fibrosis An
Recommendation Recommendations only about treatment IPF	Level of evidence
Ganesh Raghu et al, An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management, 2011	e-based Guidelines for
Recommendation ⁴ We recommend that a multi-disciplinary discussion should be used in the evaluation of IPF (strong recommendation)	Level of evidence ⁵ ⊕⊕⊖⊖

The recommendation for pulmonary rehabilitation in patients with IPF is weak ; that is, pulmonary rehabilitation should be used in the majority of patients with IPF, but not using pulmonary rehabilitation may be a reasonable choice in a minority	ΘΘΦΦ
Cottin V et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update, 2017	/ fibrosis - 2017 update, 2017
Recommendation ⁶	Level of evidence
 It is recommended to integrate all the data available for the definitive diagnosis of IPF during a multidisciplinary discussion involving multimonologists radiologists and nathologists experienced in the field of ILD. 	Strength of the evidence n.a.
- It is recommended to refer difficult cases, depending on their proximity, to the Reference Center or a regional	
Expertise Center.	
 It is recommended to carry out annual influenza vaccination and pneumococcal vaccination in patients with a confirmed diagnosis of IPF 	Strength of the evidence n.a.
- It is proposed to prescribe a respiratory rehabilitation program to patients with a confirmed diagnosis of IPF and	
with a limited exercise capacity with a significant disability.	
It is recommended to advise patients to quit smoking if they are smokers and to inform them about the smoking	Strength of the evidence n.a.
cessation support services.	
Jo HE, et al. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic	ement from the Thoracic
Society of Australia and New Zealand and the Lung Foundation Australia, 2017	
Recommendation	Level of evidence
Patients with IPF can be successfully managed in existing pulmonary rehabilitation programs and early referral to pulmonary rehabilitation is encouraged.	Strength of the evidence n.a.

Step 3: Literature search

Strategy for re-search for IGHG on pulmonary dysfunction in PubMed, including studies between January 1st 2018 and February 28th 2019

Search	Add to builder	Query	Items found	Time
<u>#43</u>	<u>Add</u>	Search (#41 AND #42)	<u>154</u>	04:08:11
<u>#42</u>	<u>Add</u>	Search ("2018/01/01"[Date - Publication] : "2019/02/28"[Date - Publication])	<u>1522089</u>	04:07:46
<u>#41</u>	Add	Search (#39 NOT #40)	<u>4229</u>	04:05:34
<u>#40</u>	Add	Search (animals[mh] NOT humans[mh])	<u>4553519</u>	04:04:22
<u>#39</u>	Add	Search (#37 OR #38)	<u>4256</u>	04:03:28
<u>#38</u>	<u>Add</u>	Search (#21 AND #27 AND #32 AND #35)	<u>157</u>	04:02:53
<u>#37</u>	<u>Add</u>	Search (#21 AND #26 AND #32 AND #35)	<u>4110</u>	04:00:17
<u>#36</u>	<u>Add</u>	Search (#21 AND #26 AND # 32 AND #35)	<u>2467</u>	03:59:50
<u>#35</u>	<u>Add</u>	Search (#33 OR #34)	<u>1508069</u>	03:56:05
<u>#34</u>	<u>Add</u>	Search ("late effect" OR "late effects" OR "late effect*" OR "late side effect" OR "late side effects" OR "late side effect*" OR "late adverse effect" OR "late adverse effects" OR "late adverse effect*" OR long term effect[tiab] OR long term effect* OR long term adverse effects[mh] OR follow up studie* OR follow up study OR aftercare [mh] OR aftercare* OR after treatment [tiab])	<u>1373864</u>	03:55:30
<u>#33</u>	<u>Add</u>	Search (Survivor OR survivors OR survivor* OR long term survivor OR long term survivors OR long term survivor* OR survivo* OR surviving OR long term survival[tiab] OR survival[mh])	<u>180625</u>	03:55:03
<u>#32</u>	Add	Search (#28 OR #29 OR #30 OR #31)	2254984	03:52:59
<u>#31</u>	<u>Add</u>	Search (respiratory function tests[mh] OR (function test AND (lung OR pulmonary OR respiratory)) OR spirometry OR bronchospasmolysis OR plethysmography OR DLCO OR diffusion capacity OR breath washout OR pulsoxymetry OR therapeutic irrigation[mh] OR broncho alveolar lavage[tiab] OR bronchoscopy OR blood gas analysis OR FEV1 OR forced expiratory volume OR LCI OR lung clearance index OR TLC OR total lung capacity OR FVC OR forced vital capacity OR PEF OR peak expiratory flow OR forced expiratory flow OR FEF OR maximum expiratory flow OR MEF OR KCO OR diffusion capacity OR maximal inspiratory pressure OR maximal expiratory pressure OR respiratory muscle pressure OR ((HR- CT OR MRI OR X-ray OR Biopsy OR lavage) AND (lung OR pulmonary OR chest OR thorax)) OR (transfer factor AND lung))	<u>858054</u>	03:51:23
<u>#30</u>	<u>Add</u>	Search (dyspnea OR cough OR mucus OR sputum OR hypoxia OR oygen requirement[tiab] OR exercise intolerance[tiab] OR respiratory sounds[mh] OR wheeze OR wheeze* OR breathlessness[tiab] OR shortness of breath OR chest pain OR chest discomfort[tiab] OR snore OR snoring OR hemoptysis OR oxygen requirement)	<u>407445</u>	03:50:42
<u>#29</u>	<u>Add</u>	Search (((Pulmonary OR respiratory) AND dysfunction) OR lung diseases, obstructive[mh] OR obstructive lung disease[tiab] OR restrictive lung disease[tiab] OR gas exchange impairment[tiab] OR ((ventilation OR respiration) AND (inhomogeneity OR inhomogeneous OR mismatch)) OR impaired diffusion capacity OR diffusion capacity impairment)	<u>381598</u>	03:50:15

922 Add Search (Pulmonary Fibrosis OR (exarring AND (iung OR lungs)) OR Intersitial lung disease OR acute respiratory distress syndrome (Risho) CR ADS OR respiratory distress syndrome OR shock lung(tial) OR Integration OR COP[tial) OR pnaumonitis[tial) OR ADS OR respiratory distress syndrome OR Shock lung(tial) OR lung neoplasms[m] OR (iung AND (infection OR disease)) OR lung diseases[m] OR (iung AND (infection OR disease)) OR lung diseases[m] OR (iung AND (infection OR disease)) OR lung diseases[m] OR (chost wall AND (ahomanif" OR disease)) OR kyphoscollosis OR Brbrothorax OR bronchitis OR bronchicatis OR appearem OR fibroelex organizing pneumonia[m] OR cryptogenic organizing pneumonia[m] OR cryptogenic organizing pneumonia[m] OR cryptogenic organizing pneumonia[m] OR cryptogenic organizing offect OR apnea OR astman) 110399 03:48:30 #22 Add Search (babacco OR nicotine OR cigarette OR e-cigarette OR cigar OR pipe OR environmental tobacco smoke OR spice OR the OR cannable AND (smoking OR smoke OR spice OR the OR cannable) AND (smoking OR smoke OR spice OR the OR cannable) AND (smoking OR smoke OR spice OR the OR cannable) AND (smoking OR shock OR spice OR the OR cannable) AND (smoking OR claviculae OR scapulae OR muscle tissue on thoraxy)) 03:46:35 #22 Add Search (pulmonary uddge OR lung OR claviculae OR scapulae OR muscle tissue on thransplantation, OR brainsplant 0R) marrow transplantation[m] OR transplantation OR marrow transplantation[m] OR transplantation OR irradiation OR radiation OR radiation OR radiation OR marrow transplantation[m] OR transplantation, OR conditioning(m] OR axilla OR madiestinal OR marties OR suparelabelative agonistic, theory OR brain theore or spadelabelative agonistic, theore orealistore OR irradiation OR radiation OR radiation OR radiation					
cigar OR pipe OR environmental tobacco smoke OR second hand smoke OR ETS OR waterpipe OR narghile OR arghile OR shisha OR hookah OR marjiuana OR joint OR MJ[tiab] OR spice OR the OR cannabis] AND (smoking OR smoke OR smoke') 2020213 03:46:31 #226 Add Search (#22 OR #23 OR #24 OR #25) 2020213 03:46:31 #25 Add Search (pulmonary metastasectomy OR pulmonary lobectomy OR thoracotomy OR sternotomy OR spinal fusion OR (resection tab) OR spinal surgery OR spinal fusion OR (resection AND (pulmonary wedge OR lung OR claviculae OR scapulae OR muscle tissue on thorax))) 210174 03:45:35 #224 Add Search (Stem cell transplant[mh] OR stem-cell transplant OR stem cell transplant*IOn[mh] OR stem-cell transplantation, conditioning[mh] OR fuencel-intensity conditioning regimen OR myeloablative agonists[mh]) 155106 03:45:00 #23 Add Search ((Radiotherapy OR radiation of radiation therapy OR irradiation OR irradiation Sicknesse OR sickness radiation OR radiation sicknesse OR sickness radiation OR radiation Sicknesses OR sickness radiation OR radiation Sicknesse OR sickness radiation OR axilla OR mediastinal OR mantle OR supraciavicular OR susclavicular OR ranial axis OR total axis OR supra clavicular OR susclavicular OR inperted Y[tiab] OR total body OR hole body OR hole holy Whole' OR chest OR lung OR Auilla OR mediastinal OR mantle OR supraciavicular OR susclavicular OR interoplastic Combined Chemotherapy Protocols OR Antineoplastic Combined Chemotherapy Protocols OR Chemotherapy OR Maintenance chemotherapy OR Induction chemotherapy OR Maintenance chemotherapy OR Induction chemotherapy OR Mechloresthamine OR R topotestan OR Chiormes	<u>#28</u>	Add	(lung OR lungs*)) OR interstitial lung disease OR acute respiratory distress syndrome[tiab] OR ARDS OR respiratory distress syndrome OR shock lung[tiab] OR pneumonia OR COP[tiab] OR pneumonitis[tiab] OR pulmonitis[tiab] OR (lung AND (cancer OR carcinoma OR tumor)) OR lung neoplasms[mh] OR (lung AND (infection OR disease)) OR lung diseases[mh] OR (chest wall AND (abnormalit* OR disease)) OR kyphoscoliosis OR fibrothorax OR bronchitis OR bronchiectasis OR emphysema OR fibroelastosis OR Bronchiolitis OR BOS[tiab] OR BOOP OR cryptogenic organizing pneumonia[mh] OR cryptogenic organizing pneumonia[tiab] OR pulmonary disease OR pulmonary disease, chronic obstructive[mh] OR COPD OR pulmonary complications OR OSA OR respiratory tract diseases[mh] OR respiratory disease* OR low infectious respiratory disease OR	<u>1700498</u>	03:49:20
#25 Add Search (pulmonary metastasectomy OR pulmonary lobectomy OR thoracotomy OR sternotomy OR thoracoscopy OR rib resection[tiab] OR spinal surgery OR spinal fusion OR (resection AND (pulmonary wedge OR lung OR claviculae OR scapulae OR muscle tissue on thorax))) 210174 03:45:35 #224 Add Search (Stem cell transplant[mh] OR stem-cell transplant OR stem cell transplant ¹ OR stem cell transplantation, conditioning[mh] OR heme cell transplantation, conditioning[mh] OR reduced-intensity conditioning regimen OR myeloablative agonists[mh]) 155106 03:45:00 #23 Add Search (Radiotherapy OR radiation OR radiation on R radiation OR irradiation OR ingury, radiation OR radiation ingury OR radiation syndrome OR radiation syndromes OR syndrome radiation or radiation OR radiation or syndrome radiation or radiation OR radiation OR radiation OR radiation or supractavicular OR cranial axis OR total axis OR supra diaphragm[tiab] OR abdominal OR Inverted Y[tiab] OR Left Flank OR Hemiabdomen OR Left upper quadrant OR Paraaortic OR Spleen OR cranispinal])) 1642658 03:43:10 #22 Add Search (Antineoplastic Protocols OR Antineoplastic Combined Chemoradiotherapy OR chemotherapy OR manitenance chemotherapy OR chemotherapy OR consolidation OR Antineoplastic agents OR Chemoradiotherapy OR chemotherapy OR Maintenance Chemotherapy OR chemotherapy OR Maintenance Chemotherapy OR chemotherapy OR Maintenance Chemotherapy OR chemotherapy OR Mustine OR Antineoplastic agents OR Chemotherapy OR Chemotherapy OR Mustine OR Chlorethazine OR doxrubici OR Mustine OR Chlorethazine OR doxrubici OR Mustine OR Chlorethazine OR doxrubici OR Mustine OR Chlorethazine OR doxorubici OR Mustine OR Chotorethazine OR doxrubici OR	<u>#27</u>	Add	cigar OR pipe OR environmental tobacco smoke OR second hand smoke OR ETS OR waterpipe OR narghile OR arghile OR shisha OR hookah OR marijuana OR joint OR MJ[tiab] OR spice OR thc OR cannabis) AND (smoking OR smoke OR	<u>119390</u>	03:48:30
OR thoracotomy OR sternotomy OR thoracoscopy OR rib Image: Constraint of the image of the	<u>#26</u>	Add	Search (#22 OR #23 OR #24 OR #25)	<u>2020213</u>	03:46:31
#23Addstem cell transplantation[mh] OR transplantation, conditioning[mh] OR hematopoetic stem cell transplantation[mh] OR reduced-intensity conditioning regimen OR myeloablative agonists[mh])12970203:44:30#23AddSearch ((Radiotherapy OR radiation OR radiation therapy OR irradiation OR irradiat* OR radiation injuries OR injuries, radiation OR indiat* OR radiation oR syndrome oR syndrome oR syndromes OR syndrome radiations syndrome OR radiation sicknesses OR sickness radiation OR radiation * OR irradiation OR radiation Sickness OR sickness radiation oR radiation Sickness OR sickness radiation oR suparachickness OR radiation OR radiations) AND (TBI OR total body OR whole body OR total body* OR body whole* OR chest OR lung OR axilla OR mediastinal OR mantle OR supraclavicular OR susclavicular OR cranial axis OR total axis OR supra diaphragm[tiab] OR abdominal OR Inverted Y[tiab] OR Left Flank OR Hemiabdomen OR Left upper quadrant OR Paraaortic OR Spleen OR craniospinal))164265803:43:10#22AddSearch (Antineoplastic Protocols OR Antineoplastic Combined Chemoradiotherapy Adjuvant OR Consolidation Chemotherapy OR Induction chemotherapy OR Maintenance chemotherapy OR Induction chemotherapy OR Maintenance chemotherapy OR Induction chemotherapy OR Chemotherap* OR busulfan* OR Carmustine OR BCNU OR Chlorembucil OR cyclophospham OR cyclophosphamide OR cyclophospham OR cyclophosphanide OR cyclophospham OR chlorethazine OR doxorubic* OR Mustine OR Chlorethazine OR doxorubic* OR Mustine OR Chlorethazine OR doxorubic* OR bleomycin OR dactinomycin OR gemicitabine OR information or methotrexate OR topotecan OR tacrolimus OR immunotherapy)164265803:43:10	<u>#25</u>	Add	OR thoracotomy OR sternotomy OR thoracoscopy OR rib resection[tiab] OR spinal surgery OR spinal fusion OR (resection AND (pulmonary wedge OR lung OR claviculae OR	<u>210174</u>	03:45:35
#22AddSearch (Antineoplastic Protocols OR Antineoplastic Combined Chemotherapy OR Chemotherapy OR Chemotherapy OR Chorentamine* OR Cyclophosphare OR cytophosphan OR endox* OR Cyclophosphare OR cytophosphan OR dactinomed Result Cyclophosphare OR cytophosphan OR endox* OR Cyclophosphare OR cytophosphan OR gencitabine OR Mustine OR Chlorethamine* OR Chemotherapy OR chemoration OR methorethamine* OR Mustine OR Chorotan OR gencitabine OR innovation OR dactinomycin OR gencitabine OR innovation or distribution or	<u>#24</u>	Add	stem cell transplant* OR stem cell transplantation OR bone marrow transplantation[mh] OR transplantation, conditioning[mh] OR hematopoetic stem cell transplantation[mh] OR reduced-intensity conditioning	<u>155106</u>	03:45:00
Chemotherapy Protocols OR Chemoradiotherapy OR Chemoradiotherapy, Adjuvant OR Chemotherapy, Adjuvant OR Consolidation Chemotherapy OR Induction chemotherapy OR Maintenance chemotherapy OR Chemotherapy, Cancer, Regional Perfusion OR Antineoplastic agents OR chemotherap* OR busulphan OR busulfan* OR Carmustine OR BCNU OR Chlorambucil OR cyclophosphamide OR cyclophosphane OR cytophosphan OR endox* OR cyclophospha* OR Lomustine OR CCNU OR Iomustine* OR Mechlorethamine OR mechlorethamine* OR Chlormethine OR Mustine OR Chlorethazine OR doxorubicin OR doxorubic* OR bleomycin OR dactinomycin OR gemcitabine OR irinotecan OR methotrexate OR topotecan OR tacrolimus OR immunotherapy)	<u>#23</u>	<u>Add</u>	irradiation OR irradiat* OR radiation injuries OR injuries, radiation OR injury, radiation OR radiation injury OR radiation syndrome OR radiation syndromes OR syndrome radiation OR radiation sickness OR radiation sicknesses OR sickness radiation OR radiation* OR irradiation OR radiations) AND (TBI OR total body OR whole body OR total body* OR body whole* OR chest OR lung OR axilla OR mediastinal OR mantle OR supraclavicular OR susclavicular OR cranial axis OR total axis OR supra diaphragm[tiab] OR abdominal OR Inverted Y[tiab] OR Left Flank OR Hemiabdomen OR Left upper quadrant OR	<u>129702</u>	03:44:30
#21 Add Search (#19 AND #20) 577270 03:42:22	<u>#22</u>	<u>Add</u>	Chemotherapy Protocols OR Chemoradiotherapy OR Chemoradiotherapy, Adjuvant OR Chemotherapy, Adjuvant OR Consolidation Chemotherapy OR Induction chemotherapy OR Maintenance chemotherapy OR Chemotherapy, Cancer, Regional Perfusion OR Antineoplastic agents OR chemotherap* OR busulphan OR busulfan* OR Carmustine OR BCNU OR Chlorambucil OR cyclophosphamide OR cyclophosphane OR cytophosphan OR endox* OR cyclophospha* OR Lomustine OR CCNU OR lomustine* OR Mechlorethamine OR mechlorethamine* OR Chlormethine OR Mustine OR Chlorethazine OR doxorubicin OR doxorubic* OR bleomycin OR dactinomycin OR gemcitabine OR irinotecan OR	<u>1642658</u>	03:43:10
	<u>#21</u>	Add	Search (#19 AND #20)	<u>577270</u>	03:42:22

<u>#20</u>	Add	Search (Infan* OR toddler* OR minors OR minors* OR boy OR boys OR boyfriend OR boyhood OR girl* OR kid OR kids OR child OR child* OR children* OR schoolchild* OR schoolchild OR school child[tiab] OR school child*[tiab] OR adolescen* OR juvenil* OR youth* OR teen* OR under*age* OR pubescen* OR pediatrics[mh] OR pediatric* OR paediatric* OR peadiatric* OR school[tiab] OR school*[tiab] OR young adult[mh] OR young adult)	<u>5112271</u>	03:41:56
<u>#19</u>	Add	Search ((leukemia OR leukemi* OR leukaemi* OR (childhood ALL) OR AML OR lymphoma OR lymphom* OR hodgkin OR hodgkin* OR T-cell OR B-cell OR non-hodgkin OR sarcoma OR sarcom* OR sarcoma, Ewing's OR Ewing* OR osteosarcoma OR osteosarcom* OR wilms tumor OR wilms* OR nephroblastom* OR neuroblastoma OR neuroblastom* OR rhabdomyosarcoma OR rhabdomyosarcom* OR teratoma OR teratom* OR hepatoma OR hepatom* OR hepatoblastoma OR hepatoblastom* OR PNET OR medulloblastoma OR medulloblastom* OR PNET* OR neuroectodermal tumors, primitive OR retinoblastoma OR retinoblastom* OR (pediatric oncology OR paediatric oncology) OR (childhood cancer OR childhood tumor OR childhood tumors) OR (brain tumor* OR brain tumour* OR brain neoplasms OR central nervous system neoplasm OR central nervous system neoplasms OR central nervous system tumor* OR central nervous system tumour* OR brain cancer* OR brain neoplasm* OR intracranial neoplasm*) OR (leukemia, lymphocytic, acute) OR (leukemia, lymphocytic, acute*))	<u>1793356</u>	03:41:13

table
an extraction 1
ple of an ext
n - Exam]
Dysfunctio
monary
I: IGHG Pul
Step 4

PICO question: 5, 9a, 12

Main findings: 5 In universite and

 In univariate analysis no significant association between bleomycin exposure and restrictive disease (OR 0.7, 95%CI 0.3-1.6) and DLco abnormalities (OR 0.8, 95%CI 0.4-1.7)
 In univariate analysis no significant association between busulfan exposure and restrictive disease (OR 0.8, 95%CI 0.2-2.9) and DLco abnormalities (OR 0.4, 95%CI 0.4-1.7)
 In univariate analysis no significant association between DSNU or BCNU exposure and restrictive disease (OR 0.1, 95%CI 0.2-2.9) and DLco abnormalities (OR 0.4, 95%CI 0.6-4.7)
 In univariate analysis no significant association between CCNU or BCNU exposure and restrictive disease (OR 1.1, 95%CI 0.3-4.2) and DLco abnormalities (OR 1.4, 95%CI 0.6-4.7)
 In univariate analysis significant association between increasing doses of chest radiation and restrictive disease (20 GY: OR 5.6 (95%CI 1.5-21.0), p<0.05). Significant association between increasing doses of chest radiation and DLCO abnormality (±20 Gy: OR 6.4 (95%CI 1.7-24.4), p<0.01; 20 Gy: OR 11.3 (95%CI 2.6-49.5). p<0.01). Increasing chest radiation doses are significant predictors of decline in DLco longitudinally (20 Gy: OR 24.4 (95%Cl 5.7-38.3), p<0.01).

12. In univariate analysis no significant association between history of smoking and restrictive disease (OR 0.9, 95%CI 0.7-1.9) and DLco abnormalities (OR 0.9, 95%CI 0.2-5.3)

4027. S. H. Armenian, et al. Long-term pulmonary function in survivors of childhood cancer. 2015;33:1592-600. 10.1200/ico.2014;59.8318

4027. S. H. Armenian, et a	I. Long-term pulmonary function in S	402/. S. H. Armenian, et al. Long-term pulmonary function in survivors of childhood cancer. 2015;33:1592-600. 10:12/00/jco.2014:59:8318	2-600. 10.1200/Jco.2014.59.8318	
Study design Treatment era Years of follow-up	Participants	Treatment (= treatment analyzed in the paper)	Main outcomes	Additional remarks
 Cohort Cross-sectional Prospective 	Study population (N) > Original cohort: ? > Eligible cohort: 155 Analysed cohort: 121	 □ 1 HSCT a, b □ 2 Cyclophosphamid □ 3 Methotrexate □ 4 Gemcitabine ○ 5 Bleomycin ○ 5 Bleomycin ○ 6 Busulfan ○ 1 comustin (BCNU) ○ 1 0 Surgery ○ 11 Combinations ○ 12 Tobacco exposure 	 □ Pulmonary diseases □ Pulmonary symptoms ⊠ Pulmonary function test □ Absolute values □ Z-scores ⊠ Percentage predicted □ Percentage pathological tests (e.g. 24% with reduced FEV1) 	 X Longitudinal data available Control group mentioned Reference values stated Not stated Quality check performed Quality check performed Quality check performed Cleaning of lung function data described X Person who analyzed PFT was blinded to the exposure
<u>Centres:</u> Single center, City of Hope Survivorship Clinic <u>Country:</u> USA <u>Treatment era:</u> 1972-2007 <u>Years of Follow-up:</u> Time dx to t2: 17.1 yrs (range 6.3-40.1 urs)	Study population: Eligible at t1 (N): 155 Analysis at t2 (N): 121 Response rate=78.1% General population, age- and sex-matched inclusion criteria: Survivors diagnosed <age 22,<br="">with 22 vrs post diagnosis.</age>	Chemotherapy (median doses) and <u>%any</u> Bleomycin (60 lU/m2), 35% Busulfan (436 mg/m2), 12% BCNU/CCNU (450 mg/m2), 10% Radiotherapy(median doses, range) chest (13.2 Gy, 2-76): 26% no radiotherapy 50% 520 Gy	Pulmonary function assessment: - PFT at baseline (t1) and at follow-up (t2) - Compared with healthy controls (at t2) - PFT parameters measured: TLC, FVC, FEV1, FEV1/FVC, DLco, DLco/Va - %-predicted calculated by using established reference values (reference not stated) - cut-offs: obstructive FEV1/FVC<0.7, FEV1<80% predicted; restrictive TLC<75%, FEV1280% predicted	Analysis: - Cross-sectional and longitudinal analysis - Univariable logistic regression - Multivariable logistic regression, adjusted for , adjusted for race, health insurance status, smoking, heart failure - Single center - Single center - Data collection not clearly prospective/retrospective - Selection bias – only survivors at follow-up at a
	treated with pulmonary-toxic chemotherapy and/or	Surgery	diffusion DLco<75% predicted	tertiary center

 No lung function quality checks reported, no missing values reported Healthy control group not well characterized No baseline PFT before cancer treatment No baseline PFT before cancer Time between t1 and t2 highly variable Time between t1 and t2 highly variable Longitudinal PFT assessment PFT assessment blinded to exposure 			
Comparison survivors – survivors with risk factor analysis (univariable analysis, if sig -> multivariable regression analysis) <u>Bleomycini</u> - no significant association between bleomycin exposure and restrictive disease: univariable OR 0.7, 95%Cl 0.3-1.6 - no significant association between bleomycin exposure and DLCO abnormality: univariable OR 0.8, 95%Cl 0.4-1.7 (no multivariable anaylsis performed because not significant!)	 Busulfan: no significant association between busulfan exposure and restrictive disease: univariable OR 0.8, 95%CI 0.2-2.9 no significant association between busulfan exposure and DLCO abnormality: univariable OR 0.4, 95%CI 0.1-1.6 (no multivariable anaylsis performed because not significant!) BCNU or CCNU: no significant association between BCNU or CCNU 	exposure and restrictive disease: univariable OR 1.1, 95%Cl 0.3-4.2 - no significant association between BCNU or CCNU exposure and DLCO abnormality: univariable OR 1.4, 95%Cl 0.6-4.7 (no multivariable anaylsis performed because not significant!) because not significant!) - no significant association between smoking history	and restrictive disease: univariable OR 0.9, 35%Cl 0.7- 1.9 - no significant association between smoking history and DLCO abnormality: univariable OR 0.9, 95%Cl 0.2- 5.3 (no multivariable anaylsis performed because not significant!)
6% lobectomy, wedge resection or metastasectomy <u>HSCT (53%)</u> Autologous 17% Allogeneic 36%			
radiation and/or allogeneic HCT with cGVHD or pulmonary and/or surgery <u>Cancer diagnoses:</u> HL 34% NHL 6% Leukemia 36% Sarcoma 11% Other 14% (not specified) <u>Age at diagnosis (vrs):</u> Median (range): 16.5 (0.2-21.9)	Age at follow-up (t2) (yrs) <u>:</u> Median (range): 32.2 (14.6- 58.9)		
Time t1 to t2: median of 5 yrs (1-10.3 yrs)			

Chest radiation:	
- significant association (multivariable) between	riable) between
increasing doses of chest radiation and restrictive	on and restrictive
disease:	
- <20 Gy: OR 1.6 (95%Cl 0.5-5.7), not sign.	, not sign.
- >20 Gy: OR 5.6 (95%CI 1.5-21.0), p<0.05), p<0.05
- significant association (multivariable) between	riable) between
increasing doses of chest radiation and DLCO	on and DLCO
abnormality:	
- 520 Gy: OR 6.4 (95%Cl 1.7-24.4), p<0.01), p<0.01
- >20 Gy: OR 11.3 (95%Cl 2.6-49.5). p<0.01	5). p<0.01
Longitudinal comparison t1 – t2 for DLco:	for DLco:
- t1: 89 normal DLco patients	
- t2: 23/89 (25.8%) abnormal DLco test	co test
-> predictors for decline in DLco:	
- <20 Gy: OR 6.4 (95%Cl not stated), not sign.	ed), not sign.
- >20 Gy: OR 24.4 (95%CI 5.7-38.3), p<0.01	3), p<0.01

PICO	Study	No. of participants	Follow-up (median/mean, range) yr	Radiotherapy exposing lung tissue	Pulmonary function Outcomes	Effect size	PFT quality	Risk of bias
8 What is the risk of obstructive abnormalities in CAYA treated with radiotherapy exposing lung tissue compared to CAYA not treated with radiotherapy exposing lung tissue?	0guz 2007	75 Lymphoma survivors	Median 5 (2-13)	Group 1: Chemo and Radio (n=23) Group 2: Chemo only (n=52)	Mean (±5D) of selected % predicted values FEV1 Group 1: 95.43 (± 16.47) Group 2: 105.09 (± 19.01) FEV1/FVC Group 1: 96.43 (± 9.15) Group 2: 99.88 (± 11.93)	Comparison Group I vs Group II (student t- test) p=0.038 p=0.221	 No Yes: References References European Coal and Steel Community; Severity acc. to ATS pulmonary function laboratory guidelines No No No No S. No G. No 	Retrospective cross- sectional SB unclear AB: low risk DB: unclear CF: unclear
	Jenney 1995	70 Leukemia survivors	Median 4.2 (0.6-18.5)	14% (CSI, n=10) 20% (TBI, n=14)	Number of CCS with respective parameter below predicted values 36/69 FEV1 <85% predicted 23/69 FEV1 <80% predicted	Multivariable analysis, CSI (yes/no) leads to reduction in FEV1: p<0.001	6. 1. 4. 8. 2. 1. 4. 8. 6. 7. 8. 8. 6. No 8. NO	Prospective cross- sectional SB: high risk AB: low risk DB: unclear CF: unclear
	Record 2016	143 CCS	Mean 14.1 ±4.8	67.8% (n=97)	Obstructive (EVC, FEV1, FEV1/FVC <80% predicted or FEF25-75% <68%) 25% (13/46) no radiotherapy radiotherapy	Univariable comparison Chi2 radiation yes/no p=0.66	 No Yes: Wang X, Pediatr Pulmonol 2005; Hankinson IJ, Am J Respir Crit Care Med 1999 No Yes Yes Yes 	Retrospective cohort SB: high risk AB: low risk DB: low risk CF: high risk

Appendix D


IGHG Pulmonary Dysfunction - Example of "summary of findings table" for radiotherapy to the lung and obstructive disease as pulmonary

GRADE assessment:	
Study design:	+4 1 retrospective cohort study, 1 retrospective cross-sectional study, 1 prospective cross-sectional study
Study limitations:	-2 Some limitations: Selection bias high in 2/3, unclear in 1/3; Attrition bias low in 3/3; Detection bias low in 1/3, unclear in 2/3; Confounding high in 1/2, unclear in 2/3
<u>Consistency:</u>	-1 No important inconsistency. Two studies show significant effect of radiotherapy exposing lung tissue on FEV1, no significant association for FEV1/FVC and a non-significant inverse effect on "obstructive", where non-exposed CAYA cancer survivors show more often obstructive abnormalities than exposed
Directness:	-1 Population and outcomes broadly generalizable, PFT quality unsure (reference mentioned in 2/3, lung function procedure mentioned in 0/3)
Precision:	-1 Important imprecision, precision cannot be judged as 3/3 report p-values only, 1/3 performed multivariable analysis
Publication bias:	0 Unlikely
Effect size:	0 No large magnitude of effect
Dose-response:	0 Not applicable
Plausible confounding:	0 No plausible confounding
Quality of evidence:	
Conclusion:	Increased risk for obstructive abnormalities (FEV1) after radiotherapy exposing the lung tissue vs. no radiotherapy in CAYA cancer survivors.
	(3 studies; 2 studies significant effect [FEV1], 1 study non-significant effect ["obstructive]; 288 participants; 144 exposed to radiotherapy exposing lung tissue)
Comment:	All studies report their results as p-values only. Outcome assessed differently (FEV1, "obstructive") and cutoff values differ between studies.

Appendix E - Acknowledgements

This PhD has opened my eyes in many ways. In this section I would like to thank a few important people for that.

But first I have to share what a PhD journey can feel like, which also explains why some people become especially important in this phase. Even though I did not expect that doing a PhD would be a straight way, as shown on the left side of the cartoon, it was nevertheless sometime even more turbulent than on the right side. I was told that these turbulent periods can be part of research and most importantly, I have also grown in these challenging situations.



I would like to thank Claudia Kuehni, my supervisor, for giving me the opportunity to do this PhD and the guidance through these three years. I am especially thankful for her critical and valuable feedbacks for research ideas, approaches for analyses, manuscripts, and most importantly for the way of "epidemiological thinking".

I would like to thank Philipp Latzin, my co-supervisor, for the clinical feedback and support in all topics related to pulmonology and pulmonary function testing.

A big "thank you" goes to all my "roommates" at Mittelstrasse and the whole Child and Adolescent Health research group. A special thank goes to the Pediatric Cancer Epidemiology Group for all their inputs on projects, critical reviews of manuscript drafts, and all the coffee breaks before we had to pause them due to COVID19. The trip to St. Jude's Research Hospital with Christina Schindera and Nicolas Waespe, including coffee in the historic "The Peabody" lounge, will remain forever in my memory. This trip also gave me the opportunity to meet and establish an ongoing relationship with Melissa Hudson. An additional thank goes to the Pediatric Respiratory Epidemiology Group, where I received help and support when it came to "respiratory questions". Further I also thank Ben Spycher and Marcel Zwahlen for their statistical support and Beatrice Minder and Doris Kopp for their support in literature search. A big "thank you" goes to Katharina Flandera for all her help in administrative and organizational tasks. Lastly I would like to thank Verena Pfeiffer together with the whole team from the (Swiss) Childhood Cancer Registry and the master student Morena Elber.

When I extend my thanks geographically and leave Bern, I thank all the data manager at the nine SPOG centers who supported me with the data collection. A special thank goes to the pediatric oncologists and transplant specialists who read through the manuscripts critically and provided valuable feedback: Tayfun Güngör, Marc Ansari, Katrin Scheinemann, and Nicolas von der Weid. In addition, I thank all SPOG heads for their critical feedback to the SCCSS-FollwoUp study protocol and DTUA. Similarly, I also thank the pediatric pneumologist Sophie Yammine and the pediatric pulmonology fellow Jakob Usemann.

Some projects and persons I met outside of the official "PhD topic" were very important and supported me in the last three years. First, this is the whole Life After Childhood Cancer (LACC) study group at the Kantonsspital Aarau. I always liked the taste of "hospital air" once per week and working clinically in follow-up care. Second, these are all board members of Young SIOPE, the members of the SIOPE office, and Gilles Vassal, who initiated the Essential Medicines Project, and all participating members.

And last, but most importantly, I thank my wife, my mother and sisters who supported me through this turbulent time and were very supportive.

Appendix F - Curriculum vitae and list of publications

Curriculum vitae Maria Otth

Working address	University of Bern Institute of Social and Preventive Medicine (ISPM) Mittelstrasse 43 CH – 3012 Bern phone: 0041 31 631 39 75 email: maria.otth@ispm.unibe.ch
Date of birth Nationality	15.06.1985 Switzerland
Education Degrees 2017 2011	Board certification in General Pediatrics (FMH), Switzerland Doctoral thesis "Organ donation in Switzerland: a survey on marginal or extended criteria donors (ECD) from 1998 to 2009", University of Berne,
2004-2010	Switzerland Medical school, Berne, Switzerland

Professional Career

Clinical education

Since 01/2019	Research associate and staff physician Pediatric Oncology-Hematology,
	Kantonsspital Aarau
Since 01/2018	PhD candidate at ISPM, University of Bern
01/2017 - 12/2017	Fellow Pediatric Hematology/ Oncology, Children's Hospital
	Zurich, Switzerland
04/2014 - 12/2016	Resident General Pediatrics, Children's Hospital Lucerne, Switzerland
04/2013 - 03/2014	Resident General Pediatrics, Children's Hospital Wildermeth,
	Biel/Bienne, Switzerland
11/2012 - 03/2013	Resident Internal Medicine, Hospital STS AG, Zweisimmen,
	Switzerland
11/2011 - 10/2012	Resident Surgery, Hospital STS AG, Zweisimmen, Switzerland
11/2010 - 10/2011	Resident Internal Medicine, Hospital STS AG, Zweisimmen,
	Switzerland

Courses relevant for pediatric oncology

11/2020	SIOPE Neuro-oncology course (virtual)
01/2017	German School of Pediatric Oncology and Hematology III (GsoPOH),
	Oberstdorf, Germany
03/2016	Course in developmental pediatrics, Childrens Hospital, Zurich, Switzerland
01/2016	German School of Pediatric Oncology and Hematology II (GsoPOH),
	Oberstdorf, Germany
12/2015	Good Clinical Practice (Modul 1 and 2), Clinical Trial Center, University
	Hospital Zurich, Switzerland
11/2015	20th Course for clinical hemostaseology, Giessen, Germany

10/2015	5th Symposium for integrative oncology and research, focus on integrative pediatric oncology, Hospital St. Gallen, Switzerland
10/2015	Pediatric Update Refresher, Zurich, Switzerland
10/2014	Pediatric Update Refresher, Interlaken, Switzerland
02/2014	Basic in pediatric sonography, Blaubeuren, Germany
11/2013	SGDV Course in pediatric dermatology, University Hospital Basel,
	Switzerland
02/2013	PALS, University Hospital Basel, Switzerland

Courses relevant to perform science

08/2017	Introduction to Probability and Data (an online non-credit course authorized
	By Duke University and offered through Coursera)
02/2017	Understanding Clinical Research: Behind the Statistics, Coursera (an online non-credit course authorized by University of Cape Town and offered through
	Coursera)
01-03/2018	Course Biostatistics II, Prof. M. Zwahlen, ISPM, University of Bern
06/2018	Project Management for Researchers, Dr. Dimitrije Krstic, University of Bern
09/2018	Using DAGs for Causal Inference, Dr. J. Textor, University of Lucern
11/2018	Fundamental Concepts in Epidemiology, Prof. A. Hofman, University of Bern
11-12/2018	An introduction to systematic reviewing: From literature search to meta- analysis, University of Basel
01/2019	Statistical analysis with missing data using multiple imputation and inverse
	probability weighting, Prof. J. Carpenter, Swiss Epidemiology Winter School,
	University of Bern
01/2019	Causal Inference in Observational Epidemiology, Prof. M. Hernan, Swiss
	Epidemiology Winter School, University of Bern
03/2019	Applied logistic regression, Prof. S. Lemeshow, University of Bern
03/2019	Writing a journal article and getting it published, Prof. Dr. C, Kühni,
	University of Bern
11/2019	Qualität und Sicherheit im Gesundheitswesen, Prof. Dr. D. Schwappach,
	University of Bern
01/2020	Tools to Assess RIsk of Bias in Randomized and Non-Randomized Studies:
	Cochrane ROB2 and ROBINS-I, Prof. Jonathan Sterne, Prof. Julian Higgins;
	Swiss Epidemiology Winter School, University of Bern
02/2020	Soziokulturelle Kontexte, Migration und gesundheitliche Chancengleichheit,
	Prof. T. Abel, Universit of Bern
08/2020	Policy Options on Mental Health; Prof. E. Albanese, Prof. B. Saraceno, Dr.
	M. Fada, Dr. D. Krupchanka; SSPH+ Lugano Summer School
08/2020	Multisectorial Approaches for Health: Implications for Policy and Practice;
	Prof. C. Williams, N. Valentine; SSPH+ Lugano Summer School

Publications (ORCID: 0000-0002-2839-502X)

Peer reviewed

- Otth M, Greiner-Lang J, Scheinemann K; Médecine intégrative en oncologie pédiatrique (Integrative medicine in pediatric oncology); Rev Med Suisse. 2020 Nov 25;16(716):2293-2296
- Otth M, Schindera C, Güngör T, Ansari M, Scheinemann K, Belle FN, Latzin P, von der Weid N, Kuehni CE; Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a cohort study; Bone Marrow Transplant 2020 Nov 25. doi: 10.1038/s41409-020-01137-1

- Visscher H, Otth M, Feijen EAM, Nathan PC, Kuehni CE; Cardiovascular and pulmonary challenges after treatment for Childhood Cancer; Pediatr Clin North Am. 2020 Dec;67(6):1155-1170. doi: 10.1016/j.pcl.2020.07.007
- 4. Otth M*, Denzler S*, Koenig C, Koehler H, Scheinemann K; Transition from pediatric to adult follow-up care in childhood cancer survivors a systematic review; J Cancer Surviv 2020 Jul 16. doi: 10.1007/s11764-020-00920-9
- Denzler S*, Otth M*, Scheinemann K; Aftercare of Childhood Cancer Survivors in Switzerland – the ACCS Switzerland Project: Protocol for a Prospective Multicenter Observational Study; JMIR Res Protoc 2020 Aug 26;9(8):e18898. doi: 10.2196/18898
- 6. **Otth M**, Denzler S, Schmid S, Setz B, Scheinemann K; Perception of inpatient oncologic rehabilitation in children, adolescents and young adults diagnosed with cancer in Switzerland; Klin Padiatr 2020; 232: 1–6. DOI https://doi.org/10.1055/a-1210-2599
- Ardura-Garcia C, Mouzon R, Pedersen E, Otth M, Mallet M, Goutaki M, Kuehni CE; Paediatric cohort studies on lower respiratory diseases and their reporting quality: systematic review of the year 2018; Eur Respir J; 2020 May 26; 2000168. doi: 10.1183/13993003.00168-2020.
- Belle F, Beck Popovic M, Ansari M, Otth M, Kuehni CE, Bochud M; Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study; JMIR Res Protoc. 2019 Nov 18;8(11):e14427. doi: 10.2196/14427.
- Schindera C, Weiss A, Hagenbuch N, Otth M, Diesch T, von der Weid N, Kuehni CE; Physical activity and screen time in children who survived cancer – A report from the Swiss Childhood Cancer Survivor Study; Pediatr Blood cancer. 2020 Feb; 67(2):e28046. doi: 10.1002/pbc.28046. Epub 2019 Nov 20.
- Otth M, Scheinemann K; Surveillance imaging for high-grade childhood brain tumors: what to do ten years after completion of treatment?; Pediatr Blood Cancer. 2018 Nov;65(11):e27311. doi: 10.1002/pbc.27311. Epub 2018 Jul 15
- Otth M, Rödder S, Immer FF, Marti HP; Organ donation in Switzerland: a survey on marginal or extended criteria donors (ECD) from 1998 to 2009; Swiss Med Wkly. 2011;141:w13230

Not peer reviewed

- 1. **Otth M**, Pfeiffer V, Kuehni CE, Scheinemann K; Kinderkrebs in der Schweiz; Paediatrica; Vol 31-1/2020
- 2. Denzler S, **Otth M**, Scheinemann K; Spätfolgen und Langzeit-Nachsorge nach einer Krebserkrankung im Kindes- und Jugendalter; Paediatrica; Vol 31-1/2020
- Otth M, Denzler S, Merki R, Janthur WD, Janz I, Klein-Franke A, Wechsler P, Scheinemann K; Childhood Cancer Suvivors: Transition into Adulthood; Swiss Cancer Bulletin; Issue 01/2019

Submitted

1. **Otth M**, Wechsler P, Denzler S, Koehler H, Scheinemann K; Determining transition readiness in Swiss childhood cancer survivors – a feasibility study; BMC Cancer

Ongoing research projects Bern

- 1. International Guideline Harmonization Group (IGHG) Recommendations for pulmonary guidelines; function as co-coordinator
- 2. Pulmonary function in Swiss childhood cancer survivors after hematopoietic stem cell transplantation a retrospective study
- 3. Lung function in Swiss childhood cancer survivors- a retrospective study

Ongoing research projects Aarau (LACC study group)

- 1. Aftercare of Childhood Cancer Survivors in Switzerland –a Prospective Multicenter Observational Study
- 2. Educational attainment in Swiss childhood cancer survivors treated for central nervous system tumors
- 3. "Young Survivors at KSA" Registry A Standardized Assessment of Long-Term and Late-Onset Health Events in Survivors of Childhood and Adolescent Cancer

Fundraising

- 1. Back to school after childhood cancer; **Otth M** (PI), Scheinemann K (Co-PI); Forschungsprojekt 1410.000.135 KSA 2020; CHF 7'000
- Pulmonary function in long-term childhood cancer survivors after hematopoietic stem cell transplantation; Otth M (PI), Kuehni C (Co-PI), Latzin P (Co-PI); Lungenliga Bern 2020; CHF 33'570
- Young Survivors at KSA a cohort study to assess chronic late effects following childhood cancer; Scheinemann K (PI), Otth M (Co-PI), Denzler S (Co-PI); Forschungsprojekt 1410.000.113 KSA 2020 – 2021; CHF 57'717.00
- 4. Aftercare of childhood cancer survivors in Switzerland the ACCS Switzerland project; Scheinemann K (PI), Diesch T (Co-PI), Eisenreich B (Co-PI), **Otth M** (Co-PI); Grant HSR-4359-11-2017, Krebsforschung Schweiz 01.07.2018 – 30.06.2021; CHF 183'100

Presentations

Poster

- 1. **Otth M**, Schoot R, Brack E, Ocokoljic M, Kozhaeva O, Vassal G, and the Essential Medicines Group. «The SIOPE Essential Anticancer Medicines Project Creating an evidence based list of essential anticancer medicines to treat childhood cancer in Europe». SIOP Congress. October 2020.
- Otth M, Schindera C, Güngör T, Ansari M, Belle FN, Scheinemann K, Latzin P, Kuehni CE. «Pulmonary late effects in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a report from the Swiss Childhood Cancer Survivor Study». Swiss Public Health Conference, Winterthur. August 2019
- Otth M, Schindera C, Güngör T, Ansari M, Belle F, Scheinemann K, Latzin P, Kuehni C. «Pulmonary late effects in Swiss childhood cancer survivors after hematopoietic stem cell transplantation – a report from the Swiss Childhood Cancer Survivor Study». North American Symposium on Late Complications After Childhood Cancer (NSALCCC), Atlanta, USA. June 2019
- Scheinemann K, Otth M, Duckworth J, Stein NR, Whitton A, Greenspoon J, Singh S. "Radiation necrosis in children – an underreported problem?!" ?" International Society of Pediatric Oncology: 47th Congress, Cape Town, South Africa. October 2015.
- 5. Scheinemann K, **Otth M**, Duckworth J, Stein NR, Singh S. "Early post-operative MRI following a resection of a pediatric brain tumor what is the right timepoint?" International Society of Pediatric Oncology: 47th Congress, Cape Town, South Africa. October 2015
- 6. **Otth M**, Hartmann K, Rischewski J, Dirnhofer S, Klapper W, Scheinemann K. Generalized lymphadenopathy and B- symptoms it's not always cancer" Swiss Pediatric Society, Interlaken, Switzerland, June 2015
- Gut Eberle D, Otth M, Rischewski J, Hartmann K, Schmitt Mechelke T, Berger T, Hürlimann S, Gähler A, Scheinemann K. "Status asthmaticus – not always what it looks like" Swiss Pediatric Society congress, Interlaken, Switzerland, June 2015

Oral presentations

Local

- 1. Case presentation Children's Hospital Zurich, Switzerland, 03/2017
- 2. Cardiotoxicity in pediatric oncology, Children's Hospital Lucerne, Switzerland, 04/2016
- 3. Aftercare in Pediatric Oncology, Children's Hospital Lucerne, Switzerland, 06/2016
- 4. Bone density in long-term survivors of Cancer in Childhood, Children's Hospital Lucerne, Switzerland, 01/2016
- 5. Tumor predisposition syndrome, Children's Hospital Lucerne, Switzerland, 03/2016
- 6. Emergencies in Pediatric Oncology, Children's Hospital Lucerne, Switzerland, 01/2015
- 7. Brain tumors in childhood, Children's Hospital Lucerne, Switzerland, 01/2015

National

- 1. Educational achievement in childhood cancer survivors treated for a tumor of the central nervous system, SPOG meeting, Lugano, Switzerland, 01/2020
- 2. Pulmonary disease in childhood cancer survivors after hematopoietic stem cell transplantation, SPOG meeting, Lugano, Switzerland, 01/2019
- 3. Pulmonary late effects in childhood cancer survivors after HSCT, Annual meeting Swiss Society of Pneumology, Montreux, Switzerland, 05/2019
- 4. Pulmonary dysfunction after childhood cancer: diagnosing early stage disease, SPOG meeting, Lugano, Switzerland, 01/2018

International

- 1. Pulmonary disease in childhood cancer survivors after hematopoietic stem cell transplantation, PanCare meeting, Basel, 11/2019
- 2. Perception of inpatient oncologic rehabilitation in children, adolescents and young adults diagnosed with cancer in Switzerland, PanCare meeting, Basel, 11/2019
- 3. Pediatric Palliative Care in Switzerland GSoPOH, Oberstdorf, Germany, 01/2017
- 4. Offspring in female CCS in Switzerland, PanCare meeting, Lübeck, 10/2017
- 5. Follow up after brain tumors, GSoPOH, Oberstdorf, Germany, 01/2016

Invited speech

- 1. "Good or bad How to read an epidemiological paper", Hematology-Oncology-Weekend, Children's Hospital Zurich, Switzerland, 03/2019
- 2. Pulmonary late effects in childhood cancer survivors, Cancer Survivorship, University Cancer Center Inselspital, 05/2019
- 3. "Follow-up after childhood cancer", Hematology-Oncology-Weekend, Children's Hospital Zurich, Switzerland, 03/2018

Professional organizations

- Member of SIOP Europe, since 2020
- Board member of Young SIOPE, since May 2019
- Member of Young SIOPE (European Society for Paediatric Oncology), since July 2018
- Member of PanCare (Pan-European Network for Care of Survivors after Childhood and Adolescent Cancer), since 2018
- Member of the International Guideline Harmonisation Group (IGHG) Pulmonary Dysfunction, since February 2018
- Member of the International Guideline Harmonisation Group (IGHG) Metabolic Syndrome, since May 2018

Appendix G - Declaration of originality

Declaration of Originality

Last name, first name: Otth, Maria

Matriculation number: 04-132-486

I hereby declare that this thesis represents my original work and that I have used no other sources except as noted by citations.

All data, tables, figures and text citations which have been reproduced from any other source, including the internet, have been explicitly acknowledged as such.

I am aware that in case of non-compliance, the Senate is entitled to withdraw the doctorate degree awarded to me on the basis of the present thesis, in accordance with the "Statut der Universität Bern (Universitätsstatut; UniSt)", Art. 69, of 7 June 2011.

Place, date

Biberstein, 13.12.2020

Signature

